B3f16c75f05e47bfa5b2e99905baa7d1

CURRICULUM VITAE MINESH P MEHTA, MD, FASTRO ADDRESS:

6406 Brandywood Trail Sun Prairie, WI, 53590 Tel: 608-695-6714 E-mail: mineshpmehta@gmail.com

PERSONAL:

Birthdate:

LICENSURE:

California, Illinois, Maryland, Ohio, Wisconsin

22 S Greene Street Baltimore, MD, 21201 410-328-2325 mmehta@umm.edu

December 14, 1957

BOARD CERTIFICATION: 1988-Current 2011-Current

Radiation Oncology, American Board of Radiology United Council for Neurologic Subspecialties, Neuro-Oncology

ACADEMIC EDUCATION:

1981 1978

M.B.Ch.B., University of Zambia B.Sc. (Human Biology) with Distinction, U. Zambia

POSTGRADUATE TRAINING: 1984-1988

PG 1-4 & Chief Resident, Radiation Oncology, University of Wisconsin

1981-1983

PG 1-2, Ndola Central Hospital, Zambia

PROFESSIONAL SOCIETIES: American Society for Therapeutic Radiology and Oncology; American Society of Clinical Oncology; International Association for the Study of Lung Cancer; International Stereotactic Radiosurgery Society; Society of Neuro-Oncology Previous Memberships: American Brachytherapy Society, American Medical Association; American Radium Society, Association of Community Cancer Centers, Indo American Cancer Congress, Society for Cancer Research and Communication, State Medical Society of Wisconsin, Wisconsin Society of Radiation Oncologists, Zambian Medical Society FACULTY APPOINTMENTS: 2012-Current

Professor, Radiation Oncology, University of Maryland

2012-Current

Director, Maryland Proton Treatment Center

2012-Current

Co-Director of Clinical Reserach, Radiation Oncology, University of Maryland

2010-2012

Professor, Radiation Oncology, Northwestern U, Feinberg School of Medicine

2010-2012

Co-Director, Radiation Oncology Residency Training, Northwestern U, Feinberg School of Medicine

2007-2010

Eric Wolfe Professor, Human Oncology, UW-Madison Medical School

2002-2007

Professor, Human Oncology, UW-Madison Medical School

2002-2010

Professor, Neurological Surgery, UW-Madison Medical School

1997-2007

Chairman, Human Oncology, UW-Madison Medical School

1998-2002

Associate Professor, Neurological Surgery, UW-Madison

1996-1997

Vice-Chairman, Human Oncology, UW Madison Medical School

1994-2002

Associate Professor, Human Oncology, UW-Madison Medical School

1994-1997

Director, Radiation Oncology Residency Training, UW-Madison

1988-1994

Assistant Professor, Human Oncology, UW-Madison Medical School

07/88-10/88

Instructor, Radiation Oncology, University of Wisconsin

HOSPITAL APPOINTMENTS: 2012-Current

University of Maryland Hospital, Baltimore, MD

2010-2012

Northwestern University Hospital, Chicago, IL

2010-2012

Childrens’ Memorial Hospital, Chicago, IL

2010-2010

OSUMC and the James Cancer Hospital, Columbus, OH

2005-2010

Mercy Medical, Appleton, WI

2005-2010

Mercy Medical, Oshkosh, WI

2003-2010

Riverview Hospital, Wisconsin Rapids, WI

1998-2010

Meriter Hospital, Madison, WI

1998-2008

Holy Family Hospital, Manitowoc, WI

1994-2010

Freeport Memorial Hospital, Freeport, IL

1992-2002

St. Clare Hospital, Monroe, WI

1991-2010

Wausau Regional Hospital, Wausau, WI

1989-2010

Beloit Memorial Hospital, Beloit, WI

1988-2010

UW Hospital and Clinics, Madison, WI

1988-2010

William S. Middleton Veterans' Hospital, Madison

TEACHING EXPERIENCE: 2013-Present

Research Mentor, Michael Chuong, MD, U Maryland: 1) Phase I evaluation of IPdR with WBRT for brain metastases 2) Proton vs photon therapy outcomes analysis for Ca Esophagus

2013-Present

Research Mentor, Mark Mishra, MD, U Maryland: 1) Worldwide Proton Clinical Trials.

2) PCORI, patient-focused evaluation of proton and photon therapy for head and neck cancer.

3) CER, proton vs photon therapy, Ca Esophagus.

2013-Present

Research Mentor, Andrew Hanna, Med 3, U Maryland: Developing a model to predict risk factors for developing post-SRS edema

2013-Present

Research Mentor, JW Snider, MD, U Maryland: The Evolving Role of Prophylactic Cranial Irradiation in and Beyond Small Cell Lung Cancer.

2013-Present

Research Mentor, Neha Bhooshan, MD, U Maryland: Proton Therapy for Cancer of the Esophagus: A propensity score matched comparative acute toxicity analysis between photon and proton radiotherapeutic techniques, with comparative effectiveness analysis.

2013-Present

Research Mentor, Nicholas Dye, Med 4, U Maryland: 1) Whole Brain Radiotherapy for Brain Metastasses with a focus on Cognitive Sparing Strategies.

2) Dosimetric analysis of pediatric cancer patients.

2013-Present

Research Mentor, Kruti Patel, MD, U Maryland: 1) Coronary vessel-specific dosimetric analysis of IMPT versus IMRT versus 3DCRT techniques for left sided breast cancer with or without IM node targeting.

2) Dosimetric analysis of pediatric cancer patients.

2013-Present

Research Mentor, Alex Engelman, MD, U Maryland, 1) Pilot Study of The Safety and Efficacy of Combined NovoTTF-100A, Bevacizumab, and Hypofractionated Stereotactic Irradiation For Recurrent Glioblastoma; 2) Dosimetric analysis of pediatric cancer patients.

2013-Present

Research Mentor, Adam Reese, MD, U Maryland, Stereotactic Radiosurgery plus Lapatinib and Capecitabine in HER2-positive Breast Cancer with Brain Metastasis: a Non-Randomized Phase II Study (Vail ASCO Project).

2012-Present

Research Mentor, Hunter Boggs, MD, U Maryland: 1) A Multi-institutional Database Analysis of Factors Predictive of Brain Failure Following SRS Alone.

2) Temozolomide prophylaxis in non small cell lung cancer to prevent brain metastases 3) Evaluating post-SRS edema risk factors and developing preventive strategies

4) Principles and Practice of Proton Therapy, Textbook 5) Glyburide to Prevent Post-Radiosurgery Edema 2012-Present

Resident/Medical Student Education, University of Maryland.

2012-Present

Research Mentor, Tamer Rafat (MD, Radiation Oncology Research Asst), Northwestern University: 1) RTOG Brain Tumor Trials Practice Changing Results 2) NFkB prediction of post-Radiotherapy Outcome for NSCLC.

2012-Present

Research Mentor, Michelle Kim (PGY 4, Radiation Oncology), MD Anderson Cancer Center, Houston, TX, Multi-Institutional Pilot Study Evaluating Applied Mathematics of Glioma Proliferation and Invasion to Optimize Radiation Treatment Planning for Newly Diagnosed Glioblastoma. 2012 Research Resident/Fellow Grant Application

2012-2013

Research Mentor, Anuj Shah (Medical Student), Northwestern University: 1) Meningioma with Metastastic Potential 2) Second Malignancies in Thymoma, a Cohort-Controlled Analysis

2012-Present

CNS Tumor Education Foundation, an independent 501(c)(3) nonprofit educational foundation, www.cnsteducationfound.org, Secretary/Treasurer

2011-Present

Research Mentor, K Kalakota, MD, Northwestern University: Breast Cancer Brain Metastases Research Projects: 1) CHART 11R45: Validation Of The Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) And The Survival Nomogram For Patients With Breast Cancer With Brain Metastases 2) Prospective Study of Neurocognitive Outcomes following Whole-Brain Radiotherapy for Newly Diagnosed Brain Metastasis in Breast Cancer Patients 3) Patterns of Failure Analysis Following Gamma-Knife Radiosurgery for Patients with Resected Single Brain Metastases.

2011-2013

Research Mentor, H Yoon, MD, Northwestern University: Patients

with

G2/3

Meningioma

With

or

Outcomes of

Without

Adjuvant

Research Mentor, H Saeed, Med 4, Chicago Medical School:

Predictive

Radiotherapy/Radiosurgery Following Resection.

2011-2012

Variables for Development of Brain Metastases in Patients with LocoRegionally Advanced Non-Small Cell Lung Cancer.

2010-2012

Resident/Medical Student Education, Northwestern University.

2008-2011

Research Mentor, V Gondi, MD, University of Wisconsin:

Hippocampal

Sparing Whole Brain Radiotherapy for Brain Metastases.

2011

Research Mentor, H Shirazi, MD, Northwestern University: Evidence-Based Management Strategies for “Difficult Cases� in Neuro-Oncology.

2011

Research Mentor, A Diavolitsis, MD, Northwestern University: Phase II Trial of Temozolomide, Bevacizumab and re-Irradiation for Recurrent Malignant Glioma.

2010

Research Mentor, T Kruser, MD, University of Wisconsin: 1) L-19131-SIP in Lung Cancer Brain Metastases 2) Pseudoprogression in Malignant Glioma, Literature Review

2009-2010

Research Mentor, J. Li, MD, MDACC, RTOG RPA for GBM: Revised Models.

2009-2010

Research Supervisor, P Karthikeyan, MD, University of Wisconsin, NeuroOncology Translational Research (SNPs for temozolomide sensitivity, Avastin and re-XRT for recurrent GBM)

2009-2010

Research Mentor, Disha Patel, B.S., Ohio State University, Radiotherapy and Anti-Angiogenic Agents for Malignant Glioma.

2009

Research Mentor, Zulehya Akgun, MD, Radiation Oncologist, Turkey, NeuroOncology Translational Research: ML-10 Apoptosis Imaging for GBM.

2009-2010

Research Mentor, Sayana Thomas, MD, Radiation Oncology Resident, PGY3, Neuro-Oncology Translational Research: 1) ML-10 Apoptosis Imaging for Brain Metastases 2) Driving Restrictions in Brain Tumor Patients.

2009-2010

Research Mentor, Allison Quick, MD, Ohio State University: Targeted Therapies and Their Role in Malignant Glioma, in Combination with Radiation Therapy.

2008-2010

Research Mentor, M Siker, MD: Young Age as a Prognostic Variable in GBM.

2008-2010

Research Mentor, D McHaffie, MD: MGd plus SRS and WBRT for Brain Metastases.

2008-2010

Research Mentor, A Bhatt, MD: Application of GPA in Outcomes Analysis of Brain Metastases Patients.

2007-2009

Research Mentor, J Adkison, MD: Hypofractionated Helical Tomotherapy for NSCLC, Outcomes.

2007-2008

Research Mentor, G Cannon, MD: Hypofractionated Helical Tomotherapy for NSCLC, Toxicities.

2007-2010

Research Mentor, B Anderson, MD: SRS and FSRT for Vestibular Schwannoma.

2007

Research Mentor, N Hafez, Med 3, Metabolomics in Cancer.

2006-2010

Research Mentor, T Kruser, AVM SRS; PET-CT in RT Planning.

2006-2007

Research Mentor, K Hazienga, Cutaneous Radioprotective Compounds.

2006

Research Mentor, W Hodge, MD: Stereotactic Body Radiotherapy.

2006

Research Mentor, N Mahommed Med 4, Set-up Variability in Tomotherapy.

2006

Research Mentor, V Gondi, Med 4, PET-CT in Radiotherapy Planning.

2006

Research Mentor, A Ghia, MD: The Hippocampus and Whole Brain Radiotherapy for Brain Metastases.

2006

Research Mentor, P Chinnaiyan, MD: Novel Radioprotective Compounds; HDAC Inhibitors in Glioma; Metabolomics in Glioma.

2005-2006

Research Mentor, J. Li, Med 4, Neurocognitive Decline, Radiographic Progression, Quality of Life and Survival in Brain Metastases.

2005

Research Mentor, E Soisson, MS: IMRT vs. Tomotherapy for Skull Base Tumors.

2005

Research Mentor, G Richards, MD: Anaplstic Glioma

2005

Research Mentor, Malika Siker., Med 4, Volumetric Regression of Lung Cancer During Tomotherapy.

2004-2005

Research Mentor, H. Aayoma, MD: Research Sabbatical Protons vs.

Tomotherapy.

2004

Research Mentor, A Howard, MD: PET-CT Planning for Esophageal and Lung Cancer.

2004

Co-Director, UW Neoplasia Course.

2004-2005

Research Mentor, S. Dubey, Clinical Investigator Preparatory Program.

2003-2007

ASTRO Refresher Course: CNS Tumors.

2002

Research Mentor, T Zhang, Ph D: Motion Control for IMRT.

2003

Research Mentor, T. Hong, MD: Patterns of failure in Childhood PNET; Tomotherapy for lung cancer.

2003

Research Mentor, R. Manon, MD: Impact of breath-hold patterns on thoracic radiotherapy delivery.

2002

Research Mentor, H Jaradat, Ph D: Multimodality Image Planning for RT.

2002

Research Mentor, R Patel, MD: Physiologic Imaging for RT Planning.

2002-2003

Research Mentor, K. Bradley, MD: Tomotherapy; CT-PET based treatment planning for radiotherapy.

2002

Research Mentor, S Chadha, MD: Her2neu in Oligodendroglioma.

2002

44th Annual ASTRO, Panel Moderator: State of the Art in Lung Cancer.

2002

Research Mentor: J Merchant, MD: Carboplatin, Paclitaxel, Thalidomide and RT for NSCLC.

2002-2007

NCI K12 CA87718 Training Grant Committee Advisor.

2001

Research Mentor, R Rao, MD: Acute side effects of SRS.

2001

Research Mentor, J Kapatoes, Ph D: Gating Tomotherapy.

2001

Research Mentor, A Forouzannia, MD: Isometric Regression of Brain Metastases.

1999-2000

Research Mentor, A. Miranpuri (undergraduate): Vestibular schwannoma: Evaluation of radiobiological parameters.

1999-2000

Research Mentor, R Scrimger, MD: Tomotherapy.

1999-2000

Research Mentor, Ivo Tremont, MD : Brain Mets

1999

Research Mentor, R Skrupky (med student): SRS for Recurrent GBM

1999

Research Mentor, M Herman (med student): QOL for CNS tumors

1998-1999

Research Mentor, S Sanghavi, MD: Radiosurgery for Brain Metastases.

1998

Research Mentor, C Kesslering, MD: MGd Retention in Brain Metastases.

1998-2001

UW ADAC Radiosurgery Course

1998-1999

Research Mentor, S. Miranpuri (undergraduate): Methods for evaluating responses in CNS tumors

1997-1999

UWCCC Associate Director for Education.

1997-1998

Research Mentor: R Orth, Graduate Student: MR-based RT planning.

1997

Research Mentor, P Nguyen, MD: Response Analysis for CNS Tumors.

1997

Research Mentor, T Boyd, MD: Hyperfractionated RT for Medulloblastoma.

1997

Research Mentor, C Schultz, MD: Continuous Infusion IUdR for GBM.

1996-1998

ASTRO Refresher Course: HDR Brachytherapy (Lung/Esophagus).

1996

Research Mentor, J Berlin, MD: NSCLC Radiosensitization with Topotecan.

1996

Research Mentor, R Auchter, MD: Radiosurgery for Brain Mets.

1996

Research Mentor, J Lamond, MD: Topotecan as a Glioma Radiosensitizer.

1995-2004

University of Florida LINAC Radiosurgery Teaching Faculty.

1995-1996

Research Mentor, S Tannehill, MD: WR 2721 in NSCLC.

1995

Research Mentor, P Kesava, MD: MRA for AVM Radiosurgery.

1995

Research Mentor, M Yao, MD: Failure in high-risk childhood PNET.

1995

Research Mentor: Eva Baker (Med 4, MD/PhD ): AVM Radiosurgery.

1995

Research Mentor: W Noyes, MD: Cost-Effectiveness of Radiosurgery.

1995

UCSD Gamma Knife Workshop.

1994

Research Mentor: J Sarkaria, MD: Radiosurgery.

1994

Mentor: Scott Bornstein, Skidmore College (Premed).

1993-1996

Annual UCLA Hands-On Radiosurgery Workshop.

1993

Research Mentor: J Masciopinto, MD: Glioma Radiosurgery.

1992

Research Mentor: R Rodriguez, MD: Glioma Radiosensitization.

1992

Research Mentor: M Khorsand, MD: MRS in Gliomas.

1991-1992

Research Mentor: D Petereit, M.D.: Brachytherapy Applications.

1991-1992

Research Mentor: K Bastin, M.D.: Optic Nerve Radiotolerance.

1991-1992

Research Mentor: P Mahler, M.D.: Tumor Hypoxia.

1991

UW Stereotactic Radiotherapy Workshop.

1990-1999

Co-Director, UW Medical School Neoplasia Course.

1990-1998

Oncology Instructor, UW Radiation Therapy Technology School.

1990-1996

Director, Neuro-Oncology Tumor Board.

1990-1994

UW Radiation Therapy Technology School, Director.

1990

Research Mentor: M Harmon, M.D.: Endobronchial Brachytherapy.

1990

Research Mentor: M Steinmetz, M.D.: Radiosurgery.

1989-1999

Health Line Reviewer.

1989

Research Mentor: T Shanahan, M.D.: Bowel Sparing Techniques.

1989

Research Mentor: J Stephenson, M.D.: Pelvic Brachytherapy.

1988-2006

UW Medical School Neoplasia Course Faculty.

1988-2006

UW Lecturer for Advanced Medical Physics Course.

1988-1994

Reference Source for American College of Radiology.

1988-1990

UW Radiation Oncology Course, Chief Instructor.

1987-1997

Cancer Education Committee Summer Assistantship Program.

1987-1990

Consultant, ACS: WI/IA Cancer Information Service.

1986-1988

Anatomy Instructor, UW Radiation Therapy Technology School.

1984-2010

Resident/Medical Student Education, University of Wisconsin.

AWARDS AND HONORS: 2011

Award for Excellence in Clinical Research, Society for Neuro-Oncology (Gilbert M, et al, for RTOG 0525: A Randomized Phase III Trial Comparing Standard Adjuvant Temozolomide (TMZ) with a Dose-Dense (dd) Schedule in Newly Diagnosed Glioblastoma (GBM))

2011

Award for Excellence in Translational Research, Society for Neuro-Oncology (Aldape K, et al, for RTOG 0525: Clinical Utility of G-CIMP and IDH1 Status as Dual Prognostic Markers in Glioblastoma)

2011

Award for Excellence in Quality of Life Research, Society for Neuro-Oncology (Armstrong T, et al, for Clinical Utility of Quality of Life (QOL) and Symptom Assessment as Prognostic Factors for Survival and Measures of Treatment Effects on RTOG 0525)

2008-2011

Young Investigators’ Roundtable Mentor, Society of NeuroOncology

2010

American Board of Radiology, Lifetime Service Award

2009-2010

Best Doctors in America

2009

Fellow of the American Society for Therapeutic Radiation Oncology

2009

The Association of Residents in Radiation Oncology Teacher of the Year Award for the Academic Year 2008-2009

2008

Radiological Society of North America, Annual Meeting Orator

2007-2010

Eric Wolfe Professorship in Human Oncology

2007

Ladies’ Home Journal Health Breakthrough Award

2007

Founding Member, Brain Research Academy International for Neoplasia

2006

Award for Excellence in Quality of Life Research, Society for Neuro-Oncology (Jing L, et al, Relationship Between Neurocognitive Function and Quality of Life Following Whole Brain Radiation Therapy in Patients with Brain Metastasis)

2005-2010

America’s Top Doctors for Cancer, (Castle-Connelly)

2003

“Best Physicians”, Madison (Madison Business Magazine)

2002-2010

Top Docs, Madison (Madison Magazine)

2002

The Pancer Lecture, University of Toronto & Princess Margaret Hospital

2001

The 15th Annual Simon Kramer Lecture, Thomas Jefferson University

1998-2013

ASTRO/ARRO: “Meet the Professors”

1999

Nick Khadiwala Award for Excellence in Neuro-Oncology

1989-2001

AMA Physicians’ Recognition Award

1996-99

The Best Doctors in America: Midwest Region

1998

ASTRO Presidential Categorical Course

1996

"Radiotherapy Teacher of the Year," University of Wisconsin

1995

Year Book of Oncology

1994

Dean's Teaching Award, University of Wisconsin

1993

"Most important papers", International Monitor in Oncology

1992

"Outstanding Article in the Field", Respiratory Diseases Digest

1992

ASTRO Travel Research Award: Karolinska Institute, Sweden

1990

"Radiotherapy Teacher of the Year," University of Wisconsin

1989

1990 Year Book of Otolaryngology

1981

Raymond Radunski Prize: Best Overall Graduate, School of Medicine, University of Zambia, School of Medicine

1981

Merck, Sharpe and Dohme Prize: Best Graduate, Internal Medicine, University of Zambia, School of Medicine

1981

Upjohns Prize: Best Graduate, Pediatrics, University of Zambia, School of Medicine

1981

Hassim Lucas Prize: Best Graduate, Obstetrics and Gynecology, University of Zambia, School of Medicine

1980

Billingsley Award: Best 6th Year Medical Student, University of Zambia

1978

Highest Scoring B.Sc., School of Natural Sciences, University of Zambia

1975

Wildlife Conservation Prize: Best Biology Freshman, University of Zambia, School of Natural Sciences

1975

Kerry Gill Prize: Best Chemistry Freshman, University of Zambia, School of Natural Sciences

GRANTS: 1. 2013-2014

Novelos: 1344GCC: Pilot Study Of Combined NovoTTF-100A, Bevacizumab, And Hypofractionated Stereotactic Irradiation For Bevacizumab-Naiive, Recurrent Glioblastoma, $279,314, PI: Mehta MP

2. 2013-2014

Bierman Foundation Grant: Treatment Planning Comparative Analyis for Pediatric Tumors, $25,000, PI: Mehta MP

3. 2009-2014

RTOG CA 21661-36-41: RTOG: PI: Curran W, Brain Tumor Committee Chair: Mehta M, ~$60,000,000, 5% effort and salary. (Institute proposal number 13053781).

4. 2011-2012

Dixon Translational Research Grant: Developing nano-RNAi-based inhibitors of lipogenic and Bcl-2 signaling as anti-glioma therapeutics, Co-Investigator: Mehta MP (PI: Stegh A).

5. 2011-2012

SP0015614 Project ID 60029168 (Abbott Laboratories) A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in combination with Whole Brain Radiation Therapy in Subjects with Brain Metastases. PI: Mehta M: $123,134.

6. 2006-2011

Brain Tumor Funders’ Collaborative Grant: Identifying and Overcoming Resistance Mechanisms in Glioblastomas: A Joint EORTC-RTOG Effort 5%, PI: Mehta MP, $2,000,000.

7. 2010-2010

U10 CA021076-: ECOG Wisconsin Studies, PI: Kahl, B, Study Chair, and Thoracic Committee and CNS Working Group: Mehta MP.

8. 2009-2010

MSN104756 (American College Of Radiology, RTOG Award), Mehta MP, PI

9. 2009-2010

CA62421 Consortium Therapeutic Studies of Primary CNS Malignancies PI: Mehta MP.

10. 2009-2010

University of Wisconsin DHO Seed Grant: Prediction of Response of Brain Metastases to WBRT using Diffusion-Weighted MRI. Co- Principal Investigator: Mehta MP: $18,000.

11. 2008-2010

MSN101404: 533300/233: Breast Brachytherapy Education. PI: Mehta MP, $3527.99.

12. 2008-2010

NCI P30 CA14520-39: UW Comprehensive Cancer Center Support Grant. PI: Wilding G, Imaging and Radiation Sciences Program, Program Leader: Mehta M, 10% effort and salary, ~$ 15,000,000.

13. 2008-2010

MSN111459, Project #PRJ12GD (Glaxo Smith Kline). A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer HYT105962. PI: Mehta M: $3826.63

14. 2008-2010

MSN116018, Project #PRJ12TA (Abbott Laboratories Sponsor Reference #: M10-128) A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in combination with Whole Brain Radiation Therapy in Subjects with Brain Metastases. PI: Mehta M: $29,119.72

15. 2005-2010

K12 CA87718-01: Academic Clinical Oncologist Training Program, PI: Albertini, Trainer: Mehta MP

16. 2004-2010

U10 CA021076-30: ECOG Wisconsin Studies, PI: Kahl B, Study Chair, and Thoracic Committee and CNS Working Group: Mehta MP.

17. 2002-2008

MSN104756 (American College Of Radiology, RTOG Award), Mehta MP, PI, Total Project Budget: $596,011.

18. 2002-2008

RTOG CA 21661-27-34: RTOG: PI: Curran W, Brain Tumor Committee Chair: Mehta M, ~$86,000,000, 5% effort and salary.

19. 2004-2008

CA62421 Consortium Therapeutic Studies of Primary CNS Malignancies PI: Mehta MP, $1,353,020.

20. 2007

Herman Shapiro Research Program Grant: Metabolomics in Cancer, Mentored Research Project. Mentee: Naved Hafez, Effort 1%, PI: Mehta MP, $20,772.

21. 2005-2006

RTOG TRP Glioma Grant: Impact of HDAC 1 expression in malignant glioma.

Effort 2%, PI: Mehta MP, $15,000.

22. 2005-2006

Metaphore Pharmaceuticals: Examination of the in vivo radioprotective capacity of the superoxide dismutase mimetic M40403, Protocol M01756-3-0606 PI: Chinnaiyan, Co-PI: Mehta, $75,000.

23. 2004-2006

UWCCC Collaborative Grant: Lung Cancer Pre-SPORE: Project #2 Evaluation of I-124 NM404 as a Novel CT-PET Imaging Agent Co-PI: Mehta MP, $ 300,000.

24. 2004-2005

NCCF (subcontract from NIH): COG 09712 PI Grant PI: Mehta MP, $12,492.

25. 2003-2005

Pharmacyclics Grant to evaluate M-Gd as a radiosensitizer for lung cancer patients with brain metastases. PI: Mehta MP, $180,000.

26. 2002-2005

GE CT-PET for Radiotherapy Treatment Planning. Principal Investigator: Mehta MP, $220,000, 5% effort.

27. 2002-2004

UWCCC Pilot Project: Subcellular localization of Gd for GdNCT. Co-Project Leader: Mehta MP, $100,000, 5% effort.

28. 2002-2003

Schering-Plough Phase II randomized trial of Whole Brain Radiotherapy plus Temozolomide or Placebo for Patients with Brain Metastases. PI: Mehta MP, $10.000, unrestricted funds.

29. 2001-2007

P01 CA88960-01-05: Improving Cancer Outcome with Adaptive Helical Tomotherapy. PI, Project and Core Leader: Mehta MP, 20% effort and salary, $10,538,675.

30. 2001-2007

NCI P30 CA14520-33: UW Comprehensive Cancer Center Support Grant. PI: Wilding G, Imaging and Radiation Sciences Program, Program Leader: Mehta M, 10% effort and salary, $ 17,302,845.

31. 2001-2004

NCI P20 CA01010-1-3: Wisconsin Interdisciplinary Molecular Imaging Center Grant. PI: Grist T, Collaborator, Steering Committee Member & Project Leader (Tomotherapy based on Functional MRI, Positron Emission Tomography and Chemical Shift Imaging and Cell proliferation: Molecular Affects of Radiation Therapy): Mehta MP, 2% effort, 0% salary, $ 1,212,102.

32. 2001-2002

Pharmacyclics Phase II Motexafin Gadolinium for GBM. Mehta M, $202,520.

33. 2001-2002

NCI R43 AR47728-01: ProDermaCel: Topical Protector Against Chemo/Radiotherapy. PI: Fahl W, Collaborator & Consultant: Mehta MP, 5% effort, $ 99,475.

34. 2001-2006

NCI K12 CA87718-01: Training Grant, PI: Schiller J, Co-investigator: Mehta, M (Trainer), 5% effort, $1,250,000

35. 2001-2002

UW Grad School: Subcellular localization of a novel Gd compound for Gadolinium Neutron Capture Therapy (GdNCT), PI: DeStasio, Coinvestigator: Mehta, M, 2% effort, $30,000.

36. 2001-2001

RTOG Pilot Grant to Evaluate C-erb-B2 Expression in Malignant Glioma. PI: Mehta M, 2% effort.

37. 1999-2004

ECOG-WI 5U10 CA-21076-24-29: PI: Stewart J, Study Chair & Committee Vice Chair (Thoracic & CNS Working Group): Mehta M, 5% effort, $1,959,420.

38. 1999-2002

UWCCC Pilot Grant: Staging disease in patients with lung cancer using CT and PET. PI: Perlman S, Co-PI: Mehta M, 2% effort, $15,252.

39. 1999-2002

RTOG CA 21661-24-26: PI: Curran W, Brain Tumor Committee Chair: Mehta M, 5% effort and salary, $8,459,153.

40. 1999-2002

UWCCC Pilot Grant: Advanced imaging technologies for brain tumor treatment planning. PI: Meyerand B, Co-PI: Mehta M, 2% effort, $20,000.

41. 1999-2000

UIR Industrial & Economic Development Research Fund: Development of a system for fractionated Stereotactic Radiotherapy/Tomotherapy to allow online patient repositioning. PI: Tome W, Co-PI: Mehta M, 2% effort, $29,902.

42. 1999-2000

Varian: Multi-institutional analysis of radiosurgically treated brain metastases patients stratified by RTOG RPA Class, PI: Mehta M, 1% effort, $10,000.

43. 1999-2000

NABTC: Novel Telomerase Inhibitors for Brain Tumor Therapy. PI: Mehta M, 5% effort, $30,010.

44. 1999-2000

Bristol Myers Grant: Temozolomide and cis-retinoic acid for malignant glioma. PI: Mehta M, $15,000.

45. 1999

UWCCC GCRC Summer Research Grant: QOL tools for patients with brain metastases. PI: Mehta M, $7,500.

46. 1998-2003

NCI UO1 CA62421-05-10: Consortium Therapeutic Studies of Primary CNS Malignancies. PI: Mehta M, 10% effort, $352,952.

47. 1998-2002

NCI UO1 CA-62491: Phase I Clinical Trials of Novel Anti-Cancer Therapies.

PI: Wilding G, Co-PI: Mehta M, 5% effort, $1,519,820.

48. 1998-2001

NCI P30 CA14520-26-29: UW Comprehensive Cancer Center Support Grant: PI: Niederhuber J, Radiation Oncology and Physics Program Leader: Mehta M, 10% effort and salary, $10,393,187.

49. 1998-2000

NCI RO1 CA48902-09-11: Optimized Planning and Delivery of Radiotherapy.

PI: Mackie TR, Co-Investigator Mehta M, 5% effort and salary, $1,158,388.

50. 1998-2000

ADAC Technology Development Grant. PI: Tome W, Co-Investigator; Mehta MP, 1% effort, $75,000.

51. 1998-2000

Pharmacyclics Grant PCI-P120-9801: Phase III Randomized Trial of Gadolinium Texaphyrin. PI: Mehta M, 10% effort, $210,443.

52. 1998-1999

American Society for Therapeutic Radiology and Oncology Research Training Fellowship Grant PI: Mehta M: $35,000.

53. 1998-1999

UW School of Medicine Educational Research and Development Grant: Development of WWW-based modules for Oncology Grand Rounds. Co-PI: Mehta M, $5000.

54. 1998-1999

Eli Lilly & Co Research Grant: Phase I study of Gemcitabine plus palliative radiation therapy for advanced lung cancer. PI: Mehta M, $9,000.

55. 1998-1999

Pharmacyclics Research Grant: A Field Test of Brain Quality of Life Tools. PI: Mehta M, $7920.

56. 1998

Bristol Myers Squibb Education Grant: Post-Mastectomy Radiation Therapy, ASTRO Consensus Conference, PI: Mehta M, $4500.

57. 1997-2007

UW Radiotherapy Research & Development Fund. Various agencies and Individuals. PI: Mehta M. >$30,000.

58. 1997-1999

Laaitinen Corporation Grant: Fractionated radiosurgery frame and phantom development. PI: Mehta M, equipment grant $15,000.

59. 1997-1998

UW DoIt Technology Development Grant: Enhancement of WWW-aided Educational Tools for Neoplastic Diseases Course. PI: Mehta M, $750.

60. 1997-1998

UW School of Medicine Educational Research and Development Grant: Impact of WWW-aided Educational Tools on Neoplastic Diseases Course Learning. PI: Mehta M, $5000.

61. 1997-1998

UW DHO XRT Technology Development Grant: Utilization of MRI and MRA in Radiosurgery Treatment Planning. PI: Mehta M, $23,000.

62. 1997-1998

Pharmacyclics: Phase Ib/II study of Gd-Texaphyrin and cranial radiation for brain metastases. PI: Mehta M, $80,058.

63. 1997

ADAC Corporation Grant: Comparison of MRA and angiographic localization for AVM radiosurgery. PI: Mehta M, Digitizer, equipment grant $5,000.

64. 1996-1997

SmithKline Beecham Grant: Kytril in Radiation Emesis, PI: Mehta M. $8000.

65. 1994-1997

NCI U01 CA-62421 01-04: Therapeutic Studies of Primary CNS Malignancies in Adults. PI: Mehta M, $111,000.

66. 1995-1996

ACS Clinical Oncology Training Fellowship Grant: PI: Mehta M, $10,000.

67. 1994-1998

ECOG-WI 5U10 CA-21076-19-23: PI: Stewart J, Study Chair & Committee Vice Chair: Mehta M, $1,709,675.

68. 1993-1998

NCI UO1 CA-62492 Clinical trials of Novel Anti-Cancer Therapies.

Stewart J, Co-PI: Mehta M, $877,634.

PI:

69. 1993-1998

NCI CCG-WI 5U10 CA-05436. PI: Gaynon P, Co-PI: Mehta M, $1,022,645.

70. 1993-1995

U.S. Biosciences UW133-W172: Nursing and Clinical Research Fellowship, PI: Schiller J, Co-PI: Mehta M, $10,000.

71. 1990-1995

U.S. Biosciences UW133-R860: A Phase II Study of Cisplatin/Vinblastine and WR 2721 Plus Radiotherapy and WR 2721 in Patients with Locally Advanced Non-Small Cell Lung Cancer, PI: Schiller J, Co-PI: Mehta M, $90,000.

72. 1992-1993

Amgen Grant: Effects of rh-GCSF on Neutropenia Induced by Whole Abdominal Radiation Therapy, PI: Mehta M, $10,000.

73. 1992

American Society for Therapeutic Radiation Oncology Travel Research Grant: Radiosurgery, Karolinska Hospital, Stockholm, Sweden, Mehta M, $5,000.

74. 1990-1992

Alpha Therapeutics Grant: Fluosol as an Adjuvant to Combination Whole Brain Radiation Therapy and Stereotactic Radiosurgery in the Treatment of Metastatic Brain Tumors, PI: Mehta M, $50,000.

75. 1989-1992

U.S. Biosciences UW133-N931: Pilot Study of Cisplatin/Vinblastine and WR 2721 Plus Radiotherapy and WR 2721 in Locally Advanced Lung Cancer, PI: Schiller J, Co-PI: Mehta M, $10,500.

76. 1991

Radionics: MRA for AVM Radiosurgery Planning, PI: Mehta M, equipment grant, $6,000.

77. 1990

American Medical Association Grant: Bronchioalveolar Lavage in RadiationAssociated Pneumonitis, PI: Jarjour N, Co-PI: Mehta M, $40,000.

78. 1990

Hoechst-Roussel Pharmaceutical Grant: Pentoxyfilline for Radiation Myelitis, PI: Rodriguez R, Co-PI: Mehta M, $8,000.

75. 1989-2010

UW Brain Tumor Research Fund, Various agencies/Individuals. PI: Mehta M, >$200,000.

76. 1989-1990

COTA Biotech Grant: COTA Monoclonal Antibody for Early Detection of Colorectal Cancer, PI: Mehta M, $5,000.

77. 1988-1990

Alpha Therapeutics Grant: Phase III Randomized Fluosol Head and Neck Study, PI: Mehta M, $26,000.

78. 1988

Alpha Therapeutics: Oxygen Probe Study, PI: Mehta M, $5,000.

79. 1987-1988

Carrington Industries: Acute Skin Reaction Study, PI: Mehta M, $10,000.

80. 1986

ACS 1N-35-28-13: Radiolabeled Monoclonal Dosimetry, PI: Mehta M, $10,000.

CONSULTANT TO GRANTS: 1.

1995

GE CRD 5520.008 for Army BAA on Breast Cancer Research: Low-cost, solidstate positron emission tomography imager for detection, diagnosis and staging of breast cancer. PI: Ishaque AN.

2.

2002-2008

NCI: Disparities in Radiation Oncology Access/Technology for Underserved Populations. PI: Dan Petereit.

3.

2010

NCI: Disparities in Radiation Oncology Access/Technology for Underserved Populations. PI: Dan Petereit.

4.

2011-2016

NCI RO1: NM-404 for Accurate Delineation of Brain Tumor Invasiveness. PI: Lance Hall.

GRANTS in REVIEW and SUBMISSION: 1. 2013-2014

NIH NCI RO1: A Targeted Approach Utilizing Stem Cells for the Treatment of Brain Tumors.

Co-Investigator; Mehta MP, 5% effort. PI: Balyasnikova (University of Chicago) (submitted 1/15/2013).

2. 2013-2018

NIH NCI U10: UMGCC Lead Academic Participating Site for NCTN. Co-PI; Mehta MP, 5% effort. Co-PI: Martin Edelman (U Maryland), $2,389,117 (submitted 1/15/2013).

3. 2013-2018

NIH NCI U10: Evaluation of Tumor Evolution in Clinical Trials of Glioblastoma. Co-Investigator; Mehta MP, 3% effort. PI: Rameen Beroukhim (MIT, Broad Institute) (submitted 1/15/2013).

4. 2013-2018

NIH NCI U10: NRG Oncology Co-operative Group Grant. Brain Tumor Committee Chair, 5% effort. PI: N Wolmark (submitted 1/15/2013).

5. 2013-2018

NCI NIH SPORE: Development of Personalized Care Strategies for Glioblastoma, Using RTOG Clinical, Biorepository and Statistical Resources PI: Mehta MP, 15% effort, (submitted May 2012; targeted resubmission for 2013).

6. 2013-2015

UMB-UMCP Collaborative Innovation Grant: Achieving an Optimal Patient Flow Configuration and Operational Schedule in Multi-Room Proton Centers via Discrete-Event Simulation and Optimization, Hao Zhang, PhD, PI, Investigator: Mehta MP, 5% effort, (submitted March 2013)

PATENTS:

1.

P05246US Patent Number 8,114,914: "Topical Vasoconstrictor Preparations And Methods For Protecting Cells During Cancer Chemotherapy And Radiotherapy" Co-inventor (William Fahl, Arnold Ruoho, and Minesh Mehta), US Application No: 11/471,047, Filed 6/19/2006 and expanded in 2011.

2.

P06226US: “Gadolinium Synchrotron Stereotactic Radiotherapy� Co-inventor (Gelsominio de Stasio and Minesh Mehta), 2007.

CLINICAL PROTOCOLS: (Closed to accrual) 1. HSRC 86-832-198 (1986-89): MR spectroscopy of intracranial neoplasms. Co-Investigator.

2.

87-832-138 (1987-88): Carrington Gel vs. no treatment, and Carrington Gel vs. aloe vera 98% gel in the prophylactic treatment of skin in patients receiving radiation therapy. Principal Investigator.

3.

RO 8798 (1987-89): A prospective randomized study to evaluate the role of laser and/or conventional dose rate endobronchial irradiation (EBRT) for malignant airway obstruction.

Principal Investigator.

4.

CO 8852 (1988-89): A pilot study of Cisplatin/Vinblastine and WR 2721 plus radiotherapy and WR 2721 in patients with locally advanced non-small cell lung cancer. Co-Principal Investigator.

5.

RO 8832: (1988-89) Fluosol-DA 20% as an adjuvant or radiation therapy in the treatment of advanced squamous cell carcinomas of the head and neck Phase III trial. Principal Investigator.

6.

RO 8833 (1988-89): A prospective evaluation of intratumor oxygen tension prior to and during therapy with Fluosol-DA 20%. Principal Investigator.

7.

RO 8993 (1989-90): Phase I testing of SEM-TEST and COTAKIT. Principal Investigator.

8.

HSC 89-936-445 (1989-96): Evaluation of preoperative chemoradiotherapy in soft tissue sarcoma of the extremities. Co-Principal Investigator.

9.

ATC 90-15 (1990-91) Fluosol as an adjuvant to stereotactic radiosurgery in the treatment of solitary brain metastases, a controlled Phase II Study. Study Chairman and QA Physician.

10. RO 9188 (1991-92) A Phase II trial to assess the effects of recombinant human gCSF in neutropenia induced by whole abdominal radiation therapy. Co-Principal Investigator.

11. WIN 59080-006 (1992-94): A Phase II open label multicenter study with Sprodiamide injection in patients with malignant brain tumors following treatment with surgery, radiation and/or chemotherapy for the detection of viable tumor. Co-Investigator.

12. CO 9042 (NCI: T94-0099) (1995-99): Phase I study of topotecan and thoracic radiation.

Radiotherapy Chair.

13. CO 9052 (1991-95): A Phase II study of Cisplatin/Vinblastine and WR 2721 radiotherapy and WR 2721 (ethyol) in patients with locally advanced non-small cell lung cancer. Co-Principal Investigator.

14. CO 9392 (NCI: T93:0059) (1998-99): A Phase I study of iododeoxyruidine and accelerated hyper-fractionated radiotherapy for high grade gliomas. Study Chairman.

15. ECOG 2393 (1995): Phase II study of continuous infusion BCNU and cisplatin and external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme. Radiotherapy Co-Chair.

16. ECOG E4593 (1993-95): Phase II study of hyperfractionated accelerated radiation therapy for advanced unresectable non-small cell lung cancer. Principal Investigator.

17. NABTC 9401 (NCI T93-0057) (1994-95): A Phase II study of taxol chemotherapy for recurrent malignant glioma. Co-Investigator.

18. ECOG R9402 (1994-02): Phase III intergroup randomized comparison of radiation alone vs pre-radiation chemotherapy for pure and mixed anaplastic oligodendroglioma. ECOG Study Coordinator.

19. NABTC-9402 (NCI T94-0087) (1995): A Phase II trial of phenylacetic acid (PAA) for recurrent malignant glioma; a clinical and pharmacokinetics study of the North American Brain Tumor Consortium. Co-Investigator.

20. ECOG E2394 (1996-99): A Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation therapy with radiation therapy and concurrent adjuvant BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme.

Radiotherapy Co-Chair.

21. NABTC 9403 (NCI T94-0184) (1995-98): A Phase I/II study of Paclitaxel (Taxol) chemotherapy for recurrent malignant glioma. Co-Investigator.

22. NABTC 9404 (NCI T95-0034) (1996-97): A Phase I trial and pharmacokinetic study of the sequential administration of Carmustine (BCNU) and Temozolomide in patients with CNS or systemic tumors refractory to standard chemotherapy. Co-Investigator.

23. CCG 0952 (1995-98): Phase I study of topotecan and involved field radiation therapy for intrinsic pontine glioma of childhood. Radiation Therapy Chair and Study Vice-Chair.

24. RO 9632 (1996-97): A double-blind, parallel, multicenter study comparing the safety and efficacy of Kytril (granisetron hydrochloride) tablets 2 mg once daily with placebo in the prophylaxsis of nausea and emesis in patients receiving fractionated upper abdominal radiotherapy for malignancy. Co-Investigator.

25. CCG 9951 (1995-97): A pilot study of radiosurgery for recurrent brain tumors. Co-Investigator.

26. CCG 9931 (1994-97): A group-wide pilot study of neoadjuvant chemotherapy followed by craniospinal hyperfractionated radiotherapy in patients with newly diagnosed high-risk primitive neuroectodermal tumors (PNET). Co-Investigator.

27. NCNSC 96-213 (1998): A Phase II trial of Bryostatin in patients with recurrent high grade astrocytomas or mixed gliomas. Institutional Chair.

28. Pharmacyclics PCI-P120-9501 (1996-98): A Phase IB/II study of Gadolinium Texaphyrin and cranial radiation in patients with brain metastases. Institutional Chair.

29. NABTC 9701 (NCI T96-0082) (1998-99): A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas. Co-Investigator.

30. NABTC 9702 (NCI T96-0103) (1997-01): A Phase I trial of Pre-Surgical O6–Benzylguanine for malignant glioma. Co-Investigator.

31. ECOG 2597 (1998-01): Induction Paclitaxel and Carboplatin followed by standard radiotherapy (64 Gy/7 weeks) vs. continuous hyperfractionated accelerated radiotherapy (57.6 Gy/2.5 weeks) for patients with unresectable stage IIIA and IIIB non small cell lung cancer. Co-Chair.

32. NABTC 9705 (1998-99): A Phase II Trial of Thymidine and Carboplatin for recurrent malignant gliomas. Co-Principal Investigator.

33. RO 98305 (1998-99): A Field Test of Brain Quality of Life Tools. Study Chair.

34. PCI-P120-9801 (1998-01): Randomized Phase III Trial of Gadolinium Texaphyrin (Gd-Tex) as a Radiation Sensitizer for Patients with Brain Metastases Undergoing Whole Brain Radiation, Co-Chair.

35. INT 9802 (1999-02): A Phase II study of observation in favorable low-grade glioma and a Phase III study of radiation with or without PCV chemotherapy in unfavorable low-grade glioma. ECOG Radiation Oncology Chair.

36. NABTC 9704 (1997-98): Phase II evaluation of Flavopiridol for treatment of recurrent or progressive malignant gliomas. Co-Investigator.

37. NABTC 9801 (1999-02): Phase I/II trial of lrinotecan (CPT-11) for recurrent malignant glioma.

Co-Investigator.

38. CO 99501 (NCI T98-0093) (1999-2000): Pilot and Safety Trial of Carboplatin, Paclitaxel and Thalidomide followed by definitive radiotherapy in Advanced Non-small Cell Lung Cancer.

Co-Chair.

39. HSC 199-268 (1999-2002): University of Wisconsin Lung Cancer Working Group: Staging Disease in Patients with Lung Cancer Using CT and PET. Co-Chair.

40. NABTC 9803 (1999): Phase II evaluation of Temodar and 13-Cis-Retinoic acid for progressive and recurrent malignant gliomas. Co-Investigator.

41. NABTC 9902 (1999): A Phase I/II trial, SU5416, in patients with recurrent high grade astrocytoma or mixed gliomas. Co-Investigator.

42. NABTC 9904 (1999): A Phase II evaluation of temzolomide and thalidomide for treatment of recurrent and progressive glioblastoma multiforme. Co-Investigator.

43. G-P02143-02 (2001-02): A Phase II Pilot Randomized Double-Blind Placebo Controlled Trial of Temozolomide and Radiation Therapy in the Treatment of Non-small Cell Lung Cancer Brain Metastasis. Chair.

44. PCYC-0205 (2001-02): Phase II trial of Motexafin Gadolinium and Cranial Irradiation in the treatment of newly diagnosed glioblastoma multiforme. Chair.

45. RTOG 0021 (2001-02): A Phase II trial of high dose tamoxifen for the treatment of newly diagnosed supratentorial glioblastoma multiforme (GBM). Radiotherapy Chair.

46. NABTC 9905 (2001-02): A Phase II evaluation of Fenretinide as a single agent in the treatment of adult patients with recurrent malignant glioma. Co-Investigator.

47. RO-00502 HSC 2000-197 (2001-03): A Pilot Study Investigating the Potential Value of Respiratory-Gated Radiotherapy in Lung Cancer: A University of Wisconsin Tomotherapy Group Study. Chair.

48. HSC 2002-059 (2002-03): UW MegaVoltage Computed Tomograpy for Lung Cancer: A Feasibility Study. Investigator.

49. ECOG 6397 (1998-2003): A Phase II study of radiosurgery for patients with 1-3 newly diagnosed brain metastases from melanoma, renal cell carcinoma or sarcoma. Study Chair.

50. B9E-MC-I135 (Eli Lilly) (1998-2003): Phase I study of Gemcitabaine plus palliative radiation therapy for advanced lung cancer. Study Chair.

51. CCG-09712 (1999-2004): A Phase I study of Gadolinium Texaphyrin and cranial radiation in children with brainstem glioma. Study Chair.

52. ECOG N9371 (1999-2001): Phase II Trial of Chemotherapy Plus Radiotherapy for Management of Primary Central Nervous System Non-Hodgkin’s Lymphoma (PCNSL). Co-Chair.

53. ECOG 4397 (1999-2004): A Phase II trial of preradiation multiagent chemotherapy for adults with “poor risk” medulloblastoma, PNET, and disseminated ependymoma. Radiotherapy Chair.

54. NABTC 9901 (2000-2004): Phase I/II trial of R115777 in patients with recurrent malignant glioma. Co-Investigator.

55. COG (2001-03): Phase I Study of Concurrent Cereport and Carboplatin with Radiation Therapy for Children with Newly-Diagnosed Brain Stem Gliomas (BSG). COG Radiotherapy Chair 56. NABTC 9908 (2001-04): A Phase I/II trial of STI-571 in patients with recurrent malignant glioma and meningioma. Co-Investigator.

57. CCG 99701 (2001-04): An intergroup study of concurrent carboplatin, vincristine and radiotherapy followed by adjuvant chemotherapy in patients with newly diagnosed high-risk central nervous system primitive neuroectodermal tumors, A COG Phase I/II study, ViceChair.

58. ECOG 8597 (2001-03): Phase I pilot trial of adenovirus p53 and radiotherapy on nonsmall cell lung cancer. Co-Chair.

59. NABTC 9907 (2001-05): A Phase I/II trial of CPT-11 and temzolomide in patients with recurrent malignant glioma. Co-Investigator.

60. PCYC-0208 (2002-03): A Phase I Dose Escalation Study of Motexafin Gadolinium with Radiation and Chemotherapy for Inoperable Locally Advanced Non-Small Cell Lung Cancer.

Co-Chair.

61. NABTC 0001 (2002-2004): A Phase I/II trial of ZD 1839 in patients with recurrent malignant glioma. Co-Investigator.

62. NABTC 0101 (2002-04): A Phase I/II trial of weekly infusion CCI-779 in patients with recurrent malignant glioma. Co-Investigator.

63. ECOG E1FO1 (2002-2004): A Phase II Study to Evaluate the Effect of DalteparinÂŽ (5,000 IU Subcutaneously) on clinically relevant Thromboembolic events and Survival When Administered Daily to Patients with Newly Diagnosed Glioblastoma Multiforme Receiving Radiation as Initial Therapy. Study co-chair.

64. NABTC 0102 (2002-2003): A Phase I/II trial of ZD 1839 and temozolomide in patients with recurrent malignant glioma. Co-Investigator.

65. NABTC 0103 (2002-2005): A Phase I/II Trial of OSI-774 in Patients with Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy. Co-Investigator.

66. RO 02303 (2002-2005): Pilot Study of Helical Tomotherapy for the Palliative Treatment of Bone Metastases. Investigator.

67. HSC#2002-422 (2003) CT/PET Feasibility Study: Investigator

Database of Patients’ Demographics.

68. RO 02301 (2003-2004): Phase II study of Rofecoxib for the treatment of glioma associated edema. Investigator.

69. SB 104864/535 (RO 02509) (2003-2004): A Phase II trial of twice daily oral topotecan as a radiation sensitizer with twice-daily radiotherapy for newly diagnosed small cell lung cancer.

Chair.

70. RO 02512 (2003-04): A Pilot Study of Reduced Treatment Time in Patients with Non-Small Cell Lung Cancer Using 3-D Conformal Radiation. Chair 71. NABTC 0108 (2003-2005) Phase II Trial of STI571 for Patients with Recurrent Meningioma.

Co-Investigator.

72. PCYC 0211 (2003-2005): Randomized Phase III trial of Xcytrin (Motexafin gadolinium) injection for the treatment of brain metastases patients with non-small cell lung cancer undergoing whole brain radiation therapy. Co-chair.

73. NABTC 0106 (2003-2005) A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma. Co-Investigator.

74. NABTC 0105 (2004-2005) Phase II Trial of Poly-ICLC for Glioblastoma. Co-Investigator.

75. HSC RO 03507 (2004-2005): Investigation of a New Thoracic Neoplasm Radiotherapy Planning Technique: A Pilot Study. Study Chair.

76. HSC RO 2005-0400 (2005-06): Determination of Metabolites of Motexafin Gadolinium in Cancer Patients being Treated with MGd as a Single Agent Therapy. Study Chair.

77. ECOG E3598 (2000-06): Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, with or without Thalidomide, in patients with Stage III NSCLC. Co-Chair.

78. PCYC-0224 (2005-06): Phase II Trial of Motexafin Gadolinium with Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients with Brain Metastases. Chair.

79. ECOG/RTOG 9813 (2000-07): A Phase I/II randomized study of radiation therapy and temozolomide versus radiation therapy and BCNU versus radiation therapy and temozolomide and BCNU for anaplastic atrocytoma. ECOG Radiotherapy Chair.

80. PCI-P120-9801B (2001-07): An Observational Follow-Up Trial to Collect Survival Data on Patients Enrolled in Clinical Study PCIP1209801. Chair.

81. NABTC 0202 (2003-07) Phase I Trial of R115777 with Radiation Therapy and Temozolomide in Patients with Newly Diagoned Glioblastoma Multiforme. Co-Investigator.

82. HSC RO 03305 (2004-07): A Trial Comparing CT-based to CT/PET-based Radiation Treatment Planning. Study Chair.

83. ECOG E1F03 (2005-07): A Phase II Study of Temodar (Temozolomide) and radiation therapy in Patients with Brain Metastases from Non-small Cell Lung Cancer (NSCLC). Study co-chair.

84. NABTC 0401 (2005-2008) A Biomarker and Phase II Study of GW 572016 in Recurrent Malignant Glioma. Co-Chair.

85. NABTC 0303 (2005-2008): A Phase I/II Trial of Depsipeptide for Recurrent Glioblastoma: CoInvestigator.

86. NABTC 0302 (2005-2008): A Phase I/II Trial of EMD 121974 for Recurrent Glioblastoma: A Clinical Trial with Tissue Correlates of Response. Co-Investigator.

87. RTOG/EORTC 0525 (2006-2008): Phase III Trial Comparing Concurrent Radiation with Temozolomide followed by Conventional Adjuvant Temozolmide with Concurrent Radiation and Temozolomide followed by Dose-intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma. Study Co-Chair.

88. NABTC 0107 (2003-2009) A Prospective National Study to Molecularly and Genetically Characterize Human Glioma. Co-Investigator.

89. RO 05311 CEPO906A2227 (2005-2009): An open-label, multi-center, Phase II study to evaluate the activity of Patupilone (EPO906), in the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer. Co-Investigator.

90. RTOG 0320 (2005-2009): A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus with Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Brain Metastases. Study Co-Chair.

91. NABTC 0402 (2005-2009): Phase I/II Study of Erlotinib (OSI-774) & Temsirolimus (CCI-779) in Patients with Recurrent Glioblastoma Multiforme. Co-Investigator.

92. NABTC 0403 (2005-2009): “A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas. CoInvestigator.

93. NABTC 0501 (2005-2009): Phase II Study of Rituximab & Temozolomide in recurrent Primary CNS Lymphoma. Co-Investigator.

94. NABTC 06-01 (2007-2009): Phase II Single Arm Trial of VEGF-Trap in Patients with Recurrent Temozolomide-Resistant Glioblastoma Multiforme. Co-Investigator.

95. RO 06314 (2007-2009): Phase I Trial of Helical Tomotherapy Simultaneous Boost (SIB) Treatment for Patients with Brain Metastases. Study Chair.

96. RO 06316 (2007-2009): Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique. Study Chair.

97. NABTC 0602 (2007-2009): Phase II Trial of GW786034 (Pazopanib) in Subjects with Recurrent Glioblastoma. PI. 98. HSC #2000-484 (2001-2010): A pilot study investigating the use of advanced imaging techniques in glioblastoma: Investigator.

99. RO 04502 (2004-2010): The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Non-Small Cell Lung Cancer: Chair.

100. NABTC 05-02 (2007-2010): Phase I/II Studies of BAY43-9006 (sorafenib) in Combination with OSI-774 (erlotinib), R115777 (tipifarnib) or CCI-779 (temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma. Co-Investigator.

101. RO 05503 (2007-2010): Phase I Study of Image Guided Stereotactic Body Radiotherapy for Small Lung Malignancies. Study Chair.

102. RO 06309 (2007-2010): 61CuATSM-PET Imaging in Cancer Patients. Investigator.

103. RO 06310 (2007-2010): 18F-FLT-PET Imaging in Cancer Patients. Investigator.

104. RO 07324 (2008-2010): Phase I Study Evaluation the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination with Whole Brain Radiation Therapy in Subjects with Brain Metastases Glioblastoma. PI, University of Wisconsin.

105. RO 06317 (2008-2010): Randomized, Phase III, Open Label Study of Oral Topotecan plus Whole-Brain Radiation Therapy (WBRT) Alone in Patients with Brain Metastases from NonSmall Cell Lung Cancer. PI. 106. RTOG 0825 (2009-2011): A Phase III Double Blind Placebo Controlled Trial of Conventional Concurrent ChemoRadiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. Study Co-Chair.

107. RTOG 0933 (2011-2012): A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases. Study Co-PI. 108. M10-128 (2011-2012): Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ABT-888 in Combination with Whole Brain Radiation Therapy in Subjects with Brain Metastases Gl. PI, Northwestern University.

CLINICAL PROTOCOLS: (Open to accrual) 1.

E3FO5 (2009-): ECOG Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low- Grade Gliomas. Radiation Oncology Co-Chair: Minesh Mehta.

2.

NU 11C02 (2011-): A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas, PI.

3.

NU DF11B07 (2011-): Prospective Study of Neurocognitive Outcomes following Whole Brain Radiotherapy for Newly Diagnosed Brain Metastasis in Breast Cancer Patients. PI, Northwestern University.

4.

NU (2012-) Phase 2 HSPPC-96 Vaccine with Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme. Sub-I, Northwestern University.

5.

NU (2012-) A Phase II Multicenter Open Label Study Evaluating the Efficay and Safety of GRN 1005 in Non Small Cell Lung Cancer Patients with Brain Metastases. Sub-I, Northwestern University.

6.

NU (2012-) A Phase II Multicenter Open Label Study Evaluating GRN 1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases. Sub-I, Northwestern University

7.

GCC 1344 (2013-): Pilot Study Of Combined NovoTTF-100A, Bevacizumab, And Hypofractionated Stereotactic Irradiation For Bevacizumab-Naiive, Recurrent Glioblastoma. PI

8.

GCC 1345 (2013-) A Phase II Study of Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis. PI.

COMMITTEES: A. National: 1.

1992

ASTRO ad-hoc Radiosurgery Advisory Committee

2.

1994

ECOG Scientific Advisory Committee

3.

1993-1996

ECOG Brain Tumor Working Group, Co-Chairman

4.

1994-1999

Childrens’ Cancer Group Glioma Working Group

5.

1997-1999

ASTRO Membership Committee

6.

1991-2000

Childrens’ Cancer Group Brain Tumor Strategy Group

7.

1991-2000

Childrens’ Cancer Group Radiation Therapy Strategy Group

8.

1999-2000

ABS Nominations Committee

9.

2000

NIH Brain Tumor Progress Review Group

10.

1993-2000

ABS Clinical Research Committee Vice-Chairman

11.

1994-2000

Childrens’ Cancer Group Radiotherapy Steering Committee

12.

1997-2001

FDA Technology Assessment Committee ad hoc member

13.

1996-2002

ECOG Brain Tumor Committee, Vice-Chairman

14.

2000-2002

AANS Joint Section on Tumors: Malignant Glioma Guidelines Committee.

15.

2002

ASTRO Scientific Program Committee

16.

1997-2003

ISRS Executive Committee

17.

2001-2003

ISRS By-Laws Committee

18.

2001-2003

Patterns of Care Outcomes Committee

19.

2003

FDA/ASCO Lung Cancer Endpoints Development Committee

20.

2003

SNO, 8th Annual Meeting, Scientific Program Committee.

21.

1998-2004

ASTRO Education Committee Vice Chair ASTRO Symposium

22.

1999-2004

ACRIN–RTOG Committee

23.

2002-2004

ASTRO Nominations Committee

24.

2001-2005

FDA Radiological Devices Panel Chair & member

25.

2003-2005

ASTRO Technology Assessment Task force (Radiosurgery)

26.

2004-2005

ASCO Bylaws Committee

27.

2004-2005

ASTRO IGRT Workgroup

28.

2004-2005

ASTRO MOC/CME Committee

29.

2004-2005

ASTRO Corporate Relations Committee, Vice Chair

30.

2001-2006

RTOG Outcomes Committee Brain Tumor Liaison

31.

2001-2007

American Board of Radiology Examinations Committee

32.

2003-2007

ECOG Lung Committee Radiation Oncology Co-Chair

33.

1996-2008

ECOG Radiotherapy Toxicity Monitor

34.

1990-2010

ECOG Lung Core Committee

35.

1992-2010

ECOG Radiotherapy Committee

36.

1999-2010

Pediatric Brain Tumor Consortium, External Reviewer.

37.

2001-2010

Childrens’ Oncology Group CNS Tumor Committee

38.

2004-2010

SNO: Board of Directors

39.

2006-2010

ASTRO Board of Directors

40.

2009-2010

ASTRO/ACR Stereotactic Radiosurgery Guidelines Committee

41.

2009-2011

ASTRO Nominating Committee

42.

1998-Present

RTOG Brain Tumor Committee, Chairman

43.

2000-Present

American Joint Committee on Cancer (AJCC) CNS Task Force Committee

44.

2001-Present

American Brain Tumor Association Scientific Advisory Council

45.

2003-Present

American College of Surgeons, Commission on Cancer, Brain Site.

46.

2008-Present

UCSF Brain Tumor SPORE EAB

47.

2010-Present

NIH/NCI/CTEP Brain Tumor Steering Committee

48.

2012-Present

National Brain Tumor Society Medical Advisory Board

49.

2013

ASTRO/ACR Practice Guideline for the Performance of Stereotactic Body Radiation Therapy.

50.

2013

PCG (Proton Collaborative Group) Board of Directors

51.

2013

Specialist External Consultant, Tata Memorial Cancer Center, National Hadron Facility

B. Regional:

1.

1989-1992

Midwestern Neuro-Oncology Group Committee

2.

1996-2008

WI State Medical Society Governmental Affairs Commission

1.

1988-1998

Neuro-Oncology and Radiosurgery, University of Wisconsin

2.

1988-1991

PhD. Thesis Committee (Med Physics) Doug Simpkins, Uni of WI

3.

1989-1997

Radiation Oncology Special Procedures, University of Wisconsin

4.

1989-1991

Radiation Oncology Quality Assurance, University of Wisconsin

C. Local:

5.

1990-1991

Radiation Oncology CT Committee, University of Wisconsin

6.

1990-1994

Radiation Therapy Technology School Committee & Director

7.

1990-1996

UWCCC Surgical Oncology Committee

8.

1990-2000

Combined Lung Cancer Committee, University of Wisconsin

9.

1991-1996

UWCCC Immunology and Biotherapeutics Committee

10.

1991-1998

COMS Group, University of Wisconsin

11.

1993-1995

Group Practice Steering Committee

12.

1993-1997

Ph.D. Committee (Medical Physics) Todd McNutt, Uni of WI

13.

1994-1996

Medical Board, University of Wisconsin Hospital and Clinics

14.

1994-2007

Mentor Committee, Peter Mahler, MD, Human Oncology

15.

1994-2007

Mentor Committee, Darryl Barton, MD, Human Oncology

16.

1995-1996

University of Wisconsin Hospital Council of Faculty

17.

1995-1997

UW Hospital Council of Residency Program Directors

18.

1995-2000

Mentor Committee, Judy Stitt, MD, Human Oncology

19.

1995-2000

Department of Human Oncology Computer Committee

20.

1996-1997

University of Wisconsin, Radiology Chair Search Committee

21.

1996-1997

Department of Human Oncology, R&D Committee Chair

22.

1997-2010

UWCCC Senior Leaders’ (Executive) Committee

23.

1997-2000

UW Medical School 1st and 2nd year Course Directors’ Committee

24.

1997-2007

Medical Board, University of Wisconsin Hospital and Clinics

25.

1997-1999

Radiation Oncology Technology Development Committee

26.

1997-1999

UW Ambulatory Cancer Center Strategic Planning Committee

27.

1997-1998

UW Ambulatory Cancer Center Multidisciplinary Clinics Planning Committee

28.

1997-1998

UW Ambulatory Cancer Center Rad Oncology Planning Committee

29.

1997

UW Department of Radiology Chair Search Committee

30.

1997-1999

UWCCC Associate Director for Education

31.

1997-2007

University of Wisconsin Hospital Council of Chairs

32.

1997-2005

Mentor Committee, Behnam Badie, MD, Neurosurgery

33.

1998-1999

Dean’s Teaching Award Selection Committee

34.

1998-2010

UW Department of Neurological Surgery Executive Committee

35.

1998-2000

Mentor Committee, William Hunter, M.D., Neurosurgery

36.

1998-2005

Mentor Committee, Rupak Das, Ph.D., Human Oncology

37.

1998-2006

Mentor Committee, Wolfgang Tome, Ph.D., Human Oncology

38.

1998-2005

Mentor Committee, Steven Howard, M.D., Ph.D., Human Oncology

39.

2000-2010

Meriter Hospital Tumor Board, Committee Co-Chair

40.

2000-2010

UWCCC Lung Cancer Disease Oriented Working Group

41.

2000-2008

UWCCC Brain Cancer Disease Oriented Working Group, Leader

42.

2000

Ph.D. Thesis Committee (Med Phys) Jeff Kapatoes, Uni of WI

43.

2001

PhD Thesis Committee (Med Phys): Chaun Wu, Uni of WI

44.

2001-2002

UW Hospital Credentials Committee

45.

2001-2002

UW Vet School Search Committee

46.

2001-2002

Dean’s Committee on Strategic Planning for Cancer

47.

2001-2007

Mentor Committee, James Welsh, M.D., Human Oncology

48.

2002-2007

Mentor Committee, Nihal Ahmed, Ph.D., Dermatology

49.

2002-2005

UW Dept of Ob/Gyn Chair Search Committee

50.

2002-2004

UWCCC Director Search Committee

51.

2003

PhD Thesis Committee (Med Phys): Tiezhi Zhang, Uni of WI

52.

2003

PhD Thesis Committee (Med Phys): Stewart Becker, Uni of WI

53.

2003-2004

UWCCC Compliance Support Committee

54.

2004-2008

Mentor Committee, Rakesh Patel, MD, Human Oncology

55.

2004-2009

Mentor Committee, Kristin Bradley, MD, Human Oncology

56.

2004-2005

UW Dept of Radiology Chair Search Committee

57.

2005

UW GCRC Director Search Committee Chair

58.

2005-2010

Mentor Committee, John Kuo, MD, Neurosurgery

59.

2006-2007

PhD Thesis Committee (Med Phys): Alonso Gutierrez, Uni of WI

60.

2007-2010

Mentor Committee, Toby Campbell, M.D., Medicine

61.

2008-2009

PhD Thesis Committee (Med Phys): Emilee Soisson, Uni of WI

62.

2008-2010

Mentor Committee, Deepak Khuntia, MD, Human Oncology.

63.

2009-2010:

UW School of Medicine and Public Health Tenure Track Promotions Committee.

64.

2008-2010

UWCCC Brain Tumor Disease Oriented Working Group.

65.

2009

PhD Thesis Committee (Med Phys), Keisha McCall, Uni of WI

66.

2009

PhD Thesis Committee (Med Phys), Ed Bender, Uni of WI

67.

2009-2010

Mentor Committee, Neha Patel M.D., Pediatrics

68.

2009-2010

Mentor Committee, Lance Hall M.D., Radiology

69.

2010-Present

Northwestern University, Brain Tumor Institute Advisory Board

70.

2013-2014

University of Maryland Medical Executive Committee

D.

Corporate/Private:

1.

1990

Alpha Therapeutics Corporation: Oncology Advisory Board

2.

1992-1998

Editorial Board, Advanced Medical Publishing

3.

1998-2000

ALZA Radiation Oncology Advisory Board

4.

1999-2007

Schering-Plough, Temodar Advisory Board

5.

2000-Present

ProCertus BioPharm Advisory Board

6.

2001-2008

Chair, Medical Advisory Board, TomoInc

7.

2001-2002

MedImmune Radiation Oncology Advisory Board

8.

2001-2003

Ultravisual Medical Advisory Board

9.

2001-2005

Philips Radiation Oncology Systems Medical Advisory Board

10.

2002-2007

RMI-Gammex, Advisory Board

11.

2006-2008

Allos Therapeutics, Advisory Board

12.

2006-2010

Colby Pharmaceutical, CMO

13.

2007-2010

Radiate Hope, Executive Board Member

14.

2008-2010

Compact Particle Accelerator Corporation Scientific Advisory Board

15.

2008-Present

Pharmacyclics, Board of Directors

16.

2008-Present

Stemina Biomarker Inc., Scientific Advisory Board Member

17.

2010-2012

Apogenix Data Safety Monitoring Committee

18.

2011-2012

Center for Developmental Therapeutics (CDT) of the Chemistry of Life Processes Institute and the Innovation and New Venture Office (INVO), Northwestern University, Board of Directors

E.

Invited Journal Reviewer:

1. American Journal of Neuroradiology 2. Annals of Neurology 3. Archives of Ophthalmology 4. Cancer 5. Cancer Journal from Scientific American 6. Cancer Letter 7. Chest 8. Childrens' Cancer Group and Childrens' Oncology Group Manuscripts 9. Endocurietherapy Hyperthermia Oncology

10. Experimental Lung Research 11. Expert Review of AntiCancer Therapy 12. International Journal of Cancer 13. Journal of the National Cancer Institute 14.Journal of Neuro-Oncology 15. Journal of Technology in Cancer Research and Treatment 16. Lung Cancer 17. Neuro-Oncology 18. Neurosurgery 19. New England Journal of Medicine 20. Oncology: International Journal of Cancer Research and Treatment 21. Radiation Oncology Investigations 22. Radiation Therapy Oncology Group Publications 23. Radiology

F.

Editorial Board Member of Journal:

1. Asia-Pacific Journal of Oncological Medicine 2. Cancer Management and Research 3. Clinical Lung Cancer 4. The Cancer Journal: The Journal of Principles and Practice of Oncology 5. International Journal of Cancer Research 6. International Journal of Radiation Oncology Biology Physics 7. Journal of Cancer Research and Therapeutics 8. Journal of Clinical Oncology 9. Journal of Neuro-Oncology 10. Journal of Oncology 11. Journal of Radiosurgery 12. Journal of Radiosurgery and SBRT 13. Neurotherapeutics 14. World Science

G.

Invited Reviewer/Moderator/Examiner:

1.

Allegheny-Singer Research Institute Grant Reviewer, Pittsburgh, PA (April 1992).

2.

Fourth International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison, WI (September 16-19, 1992).

3.

Scientific Session (Stereotactic CNS Techniques) Moderator, 36th Annual Meeting of American Society for Therapeutic Radiology and Oncology, San Francisco, CA, October 3 1994.

4.

Scientific Session (Stereotactic CNS Techniques) Moderator, 37th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Miami, FL, October 9 1995.

5.

American Board of Radiology, Clinical Exam Writing Task Force, Thoracic Tumors, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003.

6.

American Board of Radiology, Clinical Exam Writing Task Force, CNS Tumors, 1996.

7.

Scientific Panel (Stereotactic Radiation) Moderator, 38th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Los Angeles, CA, October 1996.

8.

American Board of Radiology, Oral Board Examiner, Thoracic Tumors/Sarcomas, 1997, 2001.

9.

Fifth International Conference on Dose, Time and Fractionation in Radiation Oncology, Session Moderator and co-Chair, Madison, WI (September 10-13, 1997).

10.

Scientific Poster Panel (Stereotactic Radiation) Moderator, 39th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Orlando, FL, October 1997.

11.

American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Breast Cancer), Convener, Pittsburgh, PA, September 1998.

12.

Scientific Poster Panel (Stereotactic Radiosurgery) Moderator, 40th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Phoenix, AZ, October 1998.

13.

American Society for Therapeutic Radiology and Oncology, Scientific Panel Presidential Categorial Course: CNS Tumors (Brain Metastases), Phoenix AZ, October 1998.

14.

Scientific Poster Panel (Radiobiology) Moderator, Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA, November 1998.

15.

American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Lung Cancer), Convener, Washington, DC, September 1999.

16.

Medical Research Council of Canada, Clinical Trials Grant Peer Reviewer, 2000.

17.

American Society of Clinical Oncology, Discussant (Lung Cancer), New Orleans, LA, May 2000.

18.

American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Endovascular Brachytherapy), Convener, New York, NY, September 2000.

19.

Society for Neuro-Oncology, Annual Meeting, Scientific Program Chair, Chicago, IL, November 2000.

20.

Society for Neuro-Oncology, Annual Meeting, Scientific Session Moderator (Epidemiology and Prevention), Chicago, IL, November 2000.

21.

Society for Neuro-Oncology, Annual Meeting, Abstract Reviewer, 1999, 2000, 2002, 2003.

22.

American Society of Clinical Oncology 2001 Education Editor: Abstract review on Current Research on Treatment of Non-Small Cell Lung Cancer.

23.

American Society of Clinical Oncology, Poster Discussion Leader (CNS Tumors), San Francisco, CA, May 2001.

24.

Sixth International Conference on Dose, Time and Fractionation in Radiation Oncology, Co-Chair, Madison, WI (September 23-26, 2001).

25.

American Brain Tumor Association, Peer Grant Reviewer, 2001-08.

26.

American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Pelvic Cancers), Convener, San Francisco, CA, September 2001.

27.

American Association for Cancer Research Neuro-Tumor Club, 2002 Convener.

28.

National Brain Tumor Foundation, Peer Grant Reviewer, 2002-08.

29.

Johns Hopkins CNS Tumors Spore Grant External Consultant, 2002, 2003.

30.

National Pediatric Brain Tumor Consortium External Consultant, 2002, 2003, 2004

31.

St. Judes’ Childrens’ Hospital Radiation Oncology Program External Reviewer, 2002.

32.

American Society for Therapeutic Radiology and Oncology, Annual Meeting Abstract Reviewer (Lung Cancer), 2002, 2003, 2004.

33.

National Brain Tumor Foundation Research Reviewer for the Charles B. Wilson Brain Tumor Research Excellence Grant, 2003.

34.

American Society of Clinical Oncology: Brain Tumor Poster Session Discussant, 2003.

35.

International Stereotactic Radiosurgery Congress: Moderator, Brain Tumors, 2003.

36.

International Stereotactic Radiosurgery Congress: Reviewer, Young Investigator Award, 2003.

37.

American Brain Tumor Association Annual Meeting, Chair, Q & A Session: Malignant Brain Tumors, Lincolnshire, IL, July 2003.

38.

10th World Congress of the International Association for the Study of Lung Cancer, Moderator, Proferred Papers Session, August 2003.

39.

European Cancer Conference ECCO 12, Satellite Symposium Chair (Optimizing Radiation Therapy: Cytoprotection and Chemotherapy), Copenhagen, Denmark, September 2003.

40.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Plenary Session Discussant (Cord Compression), Salt Lake City, UT, October 2003.

41.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Poster Review with the Professor (CNS Tumors), Salt Lake City, UT, October 2003.

42.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Satellite Symposium Chair (Advances in the Management of Gliomas), Salt Lake City, UT, October 2003.

43.

Society for Neuro-Oncology, Annual Meeting, Moderator, Radiation Therapy Session, Keystone, CO, November 2003.

44.

Society for Neuro-Oncology, Annual Meeting, Satellite Symposium Co-Chair (Controversies in Primary Brain Tumor Management). Keystone, CO, November 2003.

45.

NIH, NCI Cancer Center Core Grant Reviewer, 2004.

46.

NCI, RO1 Special Emphasis Panel, 2004.

47.

Avon-NCI Progress for Patients" (PFP) Awards Program Grant Reviewer, 2004.

48.

American Society for Therapeutic Radiology and Oncology, 2004 ASTRO Symposium Chair (Brain Tumors: Evidence –Based Decision Making for the New Millenium), Washington DC, May 2004.

49.

Invited Member and Reviewer, Neuro-Oncology Section Evaluation Board, Faculty of 1000 Medicine (www.f1000medicine.com) 2004, 05, 06, 07, 08, 09, 10, 11.

50.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Satellite Symposium Chair (Is Combination Chemo-Radiotherapy the New “Gold Standard” in Managing Gliomas?), Atlanta, GA, October 2004.

51.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Satellite Symposium Chair (WBRT for the Management of Brain Metastases: Novel Approaches to Improve the Therapeutic Index.), Atlanta, GA, October 2004.

52.

World Federation of Neuro-Oncology, Satellite Symposium Co-Chair (Optimizing Combined Modality Treatment for First-Line High-Grade Gliomas), Edinburgh, Scotland, May 2005.

53.

Radiation Therapy Oncology Group, Brain Tumor Symposium Co-Chair (Brain Tumors: What Does the New Millenium Promise?), Philadelphia, PA, June 2005.

54.

Radiation Therapy Oncology Group, Brain Tumor Workshop Co-Chair (Overcoming Resistance to Temozolomide), Philadelphia, PA, June 2005.

55.

NIH, NCI, CSR, Developmental Therapeutics Section, Grant Reviewer, June 2005.

56.

NIH, NCI, RO1 Cooperative Groups Grants Review Panel, July 2005.

57.

International Stereotactic Radiosurgery Society 2005 Congress, Scientific Program Committee, and Session Chair, Brussels, Belgium, September 2005.

58.

Seventh International Conference on Dose, Time and Fractionation in Radiation Oncology: Physical, Chemical and Biological Targeting in Radiation Oncology, Organizing and Program Committee, Madison, WI, September 2005.

59.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Panel Chair (Primary Brain Tumors – Practical Problems), Denver, CO, October 2005.

60.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Satellite Symposium Chair (New Century, New Treatments: Today’s Innovative Therapies for Metastatic Brain Tumors), Denver, CO, October 2005.

61.

American Society for Clinical Oncology, Annual Meeting, Satellite Symposium CoChair, Atlanta, GA, June 2006.

62.

NIH, NCI, Cooperative Groups Grants Review Panel, Subcommittee H, July 2006.

63.

NIH, NCI, SPORE Grants Review Panel (Brain Tumors and Lymphomas), September 2006.

64.

United Council for Neurologic Subspecialties, Neuro-Oncology Written Board Exam Preparation Team, 2006-09.

65.

Society of Neuro-Oncology, Annual Meeting, Panel Moderator (Impact and Significance of 1p19q Deletion Status), Orlando, FL, November 2006.

66.

Brain Tumor Grand Rounds National Progam Development, Co-Chair, MCM Communications, CME AKH Inc, 2007.

67.

NIH, NCI Cancer Center Core Grant Reviewer, 2007.

68.

2007 Symposium on Gliomas and Secondary Brain Tumor Tumors, Progam Director, PER, New York, NY, September 2007.

69.

Society of Neuro-Oncology, Annual Meeting, Satellite Symposium (Controversies in Neuro-Oncology: A Case-Based Discussion on Managing Primary & Metastatic Brain Tumors), Co-Chair, MCM Communications, CME AKH Inc, Dallas, TX, November 2007.

70.

Moderator, Brain Metastases Research: NCI Workshop on the Biology of Brain Metastases, Bethesda, MD, January 2008.

71.

2008 ASTRO Image Guided Radiotherapy (IGRT III) Symposium, Moderator, Newport Beach, CA, March 2008.

72.

Burroughs Welcome Award in Clinical Translational Research, UW Internal Review Team, 2008.

73.

MD Anderson Cancer Center IGRT Retreat, External Advisor, 2008.

74.

Moderator, Breast Cancer Brain Metastases Research: NCI Tele-Conference on the Clinical Research Priorities in Brain Metastases from Breast Cancer, September 2008.

75.

American Society for Therapeutic Radiology and Oncology, Annual Meeting, Poster Review with the Professor (CNS Tumors), Boston, MA, September 2008.

76.

Second Annual Symposium on Gliomas and Secondary Brain Tumor Tumors, Progam Director, PER, Washington DC, November 2008.

77.

NCI, RO1 Special Emphasis Panel Review Leader, November, 2008.

78.

Society of Neuro-Oncology, 13th Annual Meeting, Sunrise Session (Advanced radiotherapy Technologies): Chair, Las Vegas, NV, November 2008.

79.

NIH/RTOG/Komen Foundation Brain Metastases in Breast Cancer Workshop (NCI/RTOG/Komen Foundation), Co-leader, Arlington, VA, February 2009.

80.

Third Annual Symposium on Gliomas and Secondary Brain Tumor Tumors, Progam Co-Director, PER, Philadelphia, PA, November 2009.

81.

Indian Society of Neuro-Oncology: Molecular Biology and Emerging Therapeutic Targets in Gliomas, Chair, Mumbai, India, November 2009.

82.

NIH, NCI, ART-RIM (Advanced Radiation Therapeutics-Radiation Injury Mitigation) Panel, January 2010.

83.

NIH, NCI Cancer Center Core Grant Reviewer, 2010.

84.

Tomotherapy North American Users’ Group Meeting Moderator, San Diego, CA, 2010.

85.

Tomotherapy European Users’ Group Meeting Moderator, Malaga, Spain, 2010.

86.

ASCO 2010 Education Session Chair: Supportive Care in Patients with Non-Small Cell Lung Cancer, Chicago, IL, 2010

87.

NIH, NCI Special Protocol Advisory Group, 2010.

88.

NIH, NCI, Advanced Imaging in Cancer Innovation Grants Review Panel, 2010.

89.

NIH, NCI Cancer Center Core Grant Reviewer, 2011.

90.

ASCO Educational Book Reviewer, 2012, 2013.

PUBLICATIONS: 1.

Shahabi S, Mehta MP: The role of computerized tomography in dosimetric evaluation of endobronchial implants. Endocurie/Hypertherm Oncol 4:187-191, 1988.

2.

Wiley Jr AL, Wirtanen GW, Mehta MP, Shahabi S, Ramirez G: Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5Fluorouracil infusion and radiation therapy. Acta Oncol 27:377-381, 1988.

3.

Mehta MP, Langeland P, Bertelrud KL: Adult Wilms' tumor: Role of combined modality treatment. Acta Oncol 28:647-650, 1989.

4.

Mehta MP, Goetowski P, Kinsella TJ: Radiation induced thyroid cancer, 1920-87: A vanishing problem? Int J Radiat Oncol Biol Phys 16:1471-1475, 1989.

5.

Mehta MP, Shahabi S, Thomadsen BR, Uehling D, Kinsella TJ: A three-dimensional model for treatment planning of interstitial implants. Endocurie/Hypertherm Oncol 5:227-230, 1989.

6.

Mehta MP: Normal tissue response: summary. American Association of Physicists in Medicine Proceedings 7:154-157, 1989.

7.

Mehta MP, Shahabi S, Jarjour N, Kinsella TJ: Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys 17:847-851, 1989.

8.

Shahabi S, Mehta MP, Wiley Jr AL, Gehring MA, Olsen KJ, Vainio PA: Computed tomographic dosimetric planning for optimization of pelvic interstitial implants.

Endocurie/Hypertherm Oncol 6:47-52, 1990.

9.

Mehta MP, Shahabi S, Jarjour N, Steinmetz MC, Chosy L: Effect of endobronchial radiation therapy on malignant bronchial obstruction. Chest 97:662-665, 1990.

10.

Frank L, Rowley L, Shanahan TG, Mehta MP: Technical aspects in the use of "belly boards" for small bowel minimization. Medical Dosimetry, 15:13-16, 1990.

11.

Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank L, Gehring MA, Kubsad SS, Utrie PC, Kinsella TJ: Minimization of small bowel volume within treatment fields using customized "belly board" mold. Int J Radiat Oncol Biol Phys 19:469-476, 1990.

12.

Mehta MP, Kubsad SS, Fowler JF, Verma AK, Hsieh JT, Kinsella TJ: 90Y•B72.3 against pancreatic cancer: Therapeutic, dosimetric and biological analysis. Int J Radiat Oncol Biol Phys 19:627-631, 1990.

13.

Kubsad SS, Mackie TR, Gehring MA, Paliwal BR, Mehta MP, Kinsella TJ: Monte Carlo and convolution dosimetry for stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 19:1027-1035, 1990.

14.

Mehta MP: Endobronchial irradiation: Is HDR better? Int J Radiat Oncol Biol Phys 19:1629, 1990.

15.

Thomadsen BR, Shahabi S, Mehta MP, Buchler DA, Giese WL: Differential loadings of brachytherapy templates. Endocurie/Hypertherm Oncol 6:197-202, 1990.

16.

Gehring MA, Mackie TR, Kubsad SS, Paliwal BR, Mehta MP, Kinsella TJ: A threedimensional volume visualization package applied to stereotactic radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 21:491-500, 1991.

17.

Shahabi S, Mehta MP, Kubsad SS, Robertson S, Giese WL: Technical modification of perineal templates to reduce rectal mucosal dose from pelvic interstitial brachytherapy. Endocurie/Hypertherm Oncol 7:57-61, 1991.

18.

Bertelrud KL, Mehta MP, Shanahan TG, Utrie PC, Gehring MA: An immobilization and bowel displacement device for abdomino-pelvic radiotherapy. Radiologic Technology 62:284-287, 1991.

19.

Rozental JM, Levine RL, Mehta MP, Kinsella TJ, Levin AB, Algan O, Mendoza M, Hanson JM, Schrader D, Nickles RJ: Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 20:1053-1060, 1991.

20.

Mehta MP, Mackie TR, Levin AB, Gehring MA, Kubsad SS, Rozental JM, Kinsella TJ: Radiosurgery for brain metastases. Contemporary Oncology 1:12-19, 1991.

21.

Mehta MP, Bastin KT, Wiersma SR: Treatment of Wilms' Tumor: Current recommendations. Drugs 42:766-780, 1991.

22.

Mehta MP, Petereit DG, Chosy L, Harmon MW, Fowler JF, Shahabi S, Thomadsen BR, Kinsella TJ: Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. Int J Radiat Oncol Biol Phys 23:133-139, 1992.

23.

Mehta MP: Endobronchial brachytherapy: Wither prescription point? Int J Radiat Oncol Biol Phys 23:251, 1992.

24.

Bastin KT, Mehta MP: Lung cancer mortality in Wisconsin: Year 2001, the therapeutic challenge. Wisconsin State Medical Journal 91:343-347, 1992.

25.

Rieger J, Mehta MP, Paliwal BR, Kubsad SS: Weight consideration in the use of cerrobend beam blocks. Medical Dosimetry 17:141-143, 1992.

26.

Mehta MP, Rozental JM, Levin AB, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Defining the role of radiosurgery in the management of brain metastases. Int J Radiat Oncol Biol Phys 24:619-625, 1992.

27.

Bastin KT, Mehta MP: Meningeal hemangiopericytoma: Defining the role for radiation therapy. J Neuro Oncology 14:277-287, 1992.

28.

Petereit DG, Mehta MP, Turski PA, Levin AB, Strother CM, Mistretta CA, Mackie TR, Gehring M, Kubsad SS, Kinsella TJ: Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. Int J Radiat Oncol Biol Phys 25(2):309-313, 1993.

29.

Petereit DG, Mehta MP, Buchler DA, Kinsella TK: A retrospective review of nodal treatment for vulvar cancer. American Journal of Clinical Oncology 16:38-42, 1993.

30.

Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ: Acute changes in glucose metabolism after treatment: The effects of Carmustine (BCNU) on human glioblastoma multiforme. J Neuro Oncology 15:57-66, 1993.

31.

Bastin KT, Mehta MP, Kinsella TJ: Thoracic volume radiation sparing following endobronchial brachytherapy. Int J Radiat Oncol Biol Phys 25:703-707, 1993.

32.

Mehta MP, Petereit DG, Kubsad SS, Turski PA, Levin AB, Kinsella TJ: Radiosurgery for arteriovenous malformations based on magnetic resonance angiography. AMPI Medical Physics Bulletin 18:25-28, 1993.

33.

Mehta MP, Petereit DG, Turski PA, Kinsella TJ: Magnetic resonance angiography: A three-dimensional database for assessing arteriovenous malformations. J Neurosurg 79:289-293, 1993.

34.

Mehta MP, Kinsella TJ: Cavernous sinus cranial neuropathies: Is there a doseresponse relationship for radiosurgery? Int J Radiat Oncol Biol Phys 27:477-480, 1993.

35.

Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Inguino femoral radiation of N0N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 27:963-967, 1993.

36.

Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Groin node radiation for vulvar cancer: Treatment planning must do more than scratch the surface: Nodal control sustained at greater than 90% with 40 months median follow-up. Int J Radiat Oncol Biol Phys 27:991, 1993.

37.

Nag S, Abitbol A, Anderson L, Blasko J, Flores A, Harrison L, Hilaris B, Martinez A, Mehta MP, Nori P, Porter A, Rossman K, Speiser BL, Stitt JA, Syed N, Vikram B: Consensus guidelines for high dose rate remote brachytherapy (HDR) in cervical, endometrial and endobronchial tumors. Int J Radiat Oncol Biol Phys 27:1241-1244, 1993.

38.

Larson DA, Bova FJ, Eisert D, Kline R, Loeffler JS, Lutz W, Mehta MP, Palta J, Schewe F, Schultz CJ, Shaw E, Wilson JF: Current radiosurgery practice: Results of an ASTRO survey. Int J Radiat Oncol Biol Phys 28:523-526,1994.

39.

Larson DA, Bova FJ, Eisert D, Kline R, Loeffler JS, Lutz W, Mehta MP, Palta J, Schewe F, Schultz CJ, Shaw E, Wilson JF, Lunsford LD, Alexander E, Chapman P, Coffey R, Friedman W, Harsh G, Maciunas R, Olivier A, Steinberg G, Walsh J: Consensus statement on stereotactic radiosurgery quality improvement. Int J Radiat Oncol Biol Phys 28:527-530, 1994.

40.

Lunsford LD, Alexander E, Chapman P, Coffey R, Friedman W, Harsh G, Maciunas R, Olivier A, Steinberg G, Walsh J, Larson DA, Bova FJ, Eisert D, Kline R, Loeffler JS, Lutz W, Mehta MP, Palta J, Schewe F, Schultz CJ, Shaw E, Wilson JF: Consensus statement on stereotactic radiosurgery quality improvement. Neurosurgery 34:193195, 1994.

41.

Mehta MP, Masciopinto JE, Rozental JM, Levin AB, Chappell RJ, Bastin KT, Miles J, Turski PA, Kubsad SS, Mackie TR, Kinsella TJ: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541-549, 1994.

42.

Mehta MP: Glioblastoma multiforme: "Who should receive stereotactic boost therapy?" Int J Radiat Oncol Biol Phys 30:746, 1994.

43.

Auchter RM, Mehta MP, Peters NE, Kitchen R, Thomadsen BR, Kinsella TJ: An original technique for surface mold high dose rate brachytherapy for Kaposi's sarcoma of the penis. Endocurie/Hypertherm Oncol 10:193-198, 1994 .

44.

Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotactic radiosurgery for glioblastoma multiforme. Streotactic & Functional Neurosurg 63:233-240, 1994.

45.

Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotaxic radiosurgery for glioblastoma: A final report of 31 patients. J Neurosurg 82:530-535, 1995.

46.

Mehta MP, Noyes WR, Mackie TR: Linear accelerator configurations for radiosurgery.

Seminars in Radiation Oncology 5:203-212, 1995.

47.

Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Kinsella TJ: Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 32:931-942, 1995.

48.

Mehta MP, Schiller JH: Prognosis with asymptomatic pulmonary nodules. JAMA 274:358, 1995.

49.

Mehta MP, Kinsella TJ: The physical, biological and clinical basis of radiosurgery.

Current Problems in Cancer 19: 267-329, 1995.

50.

Mehta MP, Kinsella TJ, Harari PM, Mahler PA, Petereit DG, Ritter MA, Steeves RA, Stitt JA: Manpower issues and training program directions in radiation oncology. Int J Radiat Oncol Biol Phys 34:970, 1996.

51.

Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell RJ, Friedman W, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP: A multi-institutional outcome and prognostic factor analysis of radiosurgery (RS) for resectable single brain metastases:. Int J Radiat Oncol Biol Phys 35:27-35, 1996.

52.

Thomas AM, Ryner LN, Mehta MP, Turski PA, Sorenson JA: Localized 2-D J-resolved 1H MR spectroscopy of human brain tumors in vivo. JMRI 6:453-459, 1996.

53.

Prados MD, Schold CS, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM: Phase II study of Paclitaxel in patients with recurrent malignant glioma. J Clin Onc 14:2316-2321, 1996.

54.

Lamond JP, Mehta MP, Boothman DA: The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation. J Neuro Oncology 30:1-6, 1996.

55.

Kesava PP, Baker EH, Mehta MP, Turski PA: Staging of arteriovenous malformations using three-dimensional time-of-flight MR angiography and volume-rendered displays of surface anatomy. Am J Roentgenol 167:605-609, 1996.

56.

Tannehill SP, Mehta MP, Kinsella TJ: Amifostine (WR 2721) and radiation therapy: Past, present and future. Sem Oncol 23:69-77, 1996.

57.

Kesava PP, Perl J, Mehta MP, Warner T, Graves VB, Strother CM: Thorotrastassociated oropharyngeal hemorrhage-treatment by means of carotid occlusion with use of flow arrest and fibered coils. J Vasc Intervent Radiol 7:709-712, 1996.

58.

Mehta MP, Kinsella TJ: What's New In Radiation Oncology? Wisc Med J 96:4249,1997.

59.

Mehta MP: External beam radiation therapy: an effective tool to manage painful bone metastases. Cancer Pain Update 66:3-4, 1997.

60.

Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella T, Schiller JH: Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: results of a Phase II trial. J Clin Oncol 15:2850-2857, 1997.

61.

Mehta MP, Noyes WR, Craig B, Lamond JP, Auchter RM, French MC, Johnson MN, Levin AB, Badie B, Robins HI, Kinsella TK: A cost-effectiveness and cost-utility analysis of radiosurgery versus resection for single brain metastases. Int J Radiat Oncol Biol Phys 39:445-454, 1997.

62.

Yao MS, Mehta MP, Boyett JM, Li H, Donahue B, Rorke LB, Zeltzer PM. The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A Phase III study in a high-risk patient population. Int J Rad Onc Biol Phys 38:469-476, 1997.

63.

Mehta MP, Boyd T, Sinha P: The status of stereotactic radiosurgery for cerebral metastases in 1997. J Radiosurg 1:17-30, 1998.

64.

Chappell R, Miranpuri S, Mehta M: Dimension in defining tumor response.

Oncol, 16:1234, 1998.

65.

Bastin KT, Mehta MP, Rogers P, Miles J, Gilchrest K: Spectrum of radiosurgically induced histopathologic changes correlated with radiographic changes, J Radiosurg, 1:201-211, 1998.

J Clin

66.

Chang SM, Kuhn JG, Rizzo J, Robins IH, Schold SC Jr, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados M: Phase I study of paclitaxel in patients with recurrent malignant glioma. A North American Brain Tumor Consortium Report. J Clin Oncol 16:2188-2194, 1998.

67.

Mehta MP: Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine. Sem Radiat Oncol 8:14-16, 1998.

68.

Mehta MP, Sinha P, Kanwar K, Inman A, Albanese M, Fahl, W: Evaluation of Internetbased Oncologic Teaching for Medical Students. J of Cancer Education 13:197-202, 1998.

69.

Mehta MP, Tannehill SP, Adak S, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D: Phase II trial of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer: Results of Eastern Cooperative Oncology Group trial 4593. J Clin Oncol, 16:3518-3523, 1998.

70.

Kesava P, Mehta MP: MR demonstration of arterial thrombosis following radiosurgery for cerebral AVMs. J Radiosurgery, 1:291-295, 1998.

71.

Mackie TR, Balog J, Ruchala K, Shepard D, Aldridge S, Fitchard E, Reckwerdt P, Olivera G, Mehta M: Tomotherapy. Sem Rad Oncol, 9:108-117; 1999.

72.

Chang SM, Kuhn JG, Robins HI, Schold CS, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD: Phase II study of Phenylacetate in patients with recurrent malignant glioma. A North American Consortium Report. J Clin Oncol, 17:984-990, 1999.

73.

Mehta MP: Amifostine and combined-modality therapeutic approaches. Sem Oncol 26:95-101,1999.

74.

Corn BW, Mehta MP, Buatti JM, Wolfson AH, Greven KM, Kim RY, Dunton CJ, Loeffler JS. Stereotactic Irradiation: potential new treatment method for brain metastases resulting from ovarian cancer. Amer J Clin Onc 22:143-146, 1999.

75.

Mehta MP, Sanghavi S: Management Trends for Lung Cancer. WI Med J, 98:37-42, 1999.

76.

Robins I, Tutsch K, Katschinski D, Jacobson E, Mehta M, Olsen M, Cohen J, Tiggelaar C, Arzoomanian R, Albert D, Feierabend C, Wilding C: A Phase I Trial of Intravenous Thymidine and Carboplatin in Patients with Advanced Cancer. J Clin Oncol 17:29222931, 1999.

77.

Sanghavi S, Skrupsky R, Badie B, Robins H, Tome W, Mehta M: Recurrent malignant gliomas treated with radiosurgery. J Radiosurgery 2:119-125, 1999.

78.

Miranpuri SS, Schulz CA, Chappell RJ, Kesava PP, Nguyen PH, Olsen MA, McNutt TR, Mehta MP: Comparison of methods for response analysis of central nervous system neoplasms. J Radiosurgery 2:153-162, 1999.

79.

Boyd TS, Mehta M: Stereotactic radiosurgery for brain metastases. Oncology 13:13971407, 1999.

80.

Orth RC, Sinha P, Madsen EL, Frank G, Korosec FR, Mackie TR, Mehta MP: Development of a unique phantom to assess the geometric accuracy of magnetic resonance imaging for stereotactic localization. Neurosurgery 45(6): 1423-1429, 1999

81.

Gentry J, Boyd T, Mehta M: Use of digital technology improves patient documentation and decreases costs in radiation oncology. J Oncology Mgmt, 8:10-13, 1999.

82.

Boyd T, Mehta MP: Radiosurgery for brain metastases: Neurosurgery Clinics of North America 10(2): 337-350, 1999.

83.

Schold Jr SC, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium Study. NeuroOncology 2:34-39, 2000.

84.

Tome W, Mehta M, Paliwal B: From Roots to Realizations–Radiosurgery. Advance for Imaging and Oncology Administrators, 10: 45-50, 2000.

85.

Robins HI, Howard SP, Mehta MP: Validity of Datasets Questioned in Gliadel Study.

Letters to the Editors, Managed Care & Cancer, pp 10-11,July/Aug 2000.

86.

Mehta M, Tome W, Olivera G: Neruo-Oncology: Radiotherapy of Brain Tumors.

Current Oncology Reports, 2:438-446, 2000

87.

Merchant JJ, Kim K, Mehta MP, Ripple GM, Larson ML, Brophy DJ, Hammes LC, Schiller JC: Pilot and Safety Trial of Carboplatin, Paclitaxel and Thalidomide in Advanced Non-Small Cell Lung Cancer, Clinical Lung Cancer 2:48-52, 2000.

88.

Gentry J, Steeves R, Paliwal B, Mehta M: The operational impact of a program to measure and monitor radiation dose to external beam patients. J Oncology Mgmt, 9:10-15, 2000.

89.

Mehta MP: The Contemporary Role of Radiation in the Management of Lung Cancer: Surgical Oncology Clinics of North America, 9(3): 539-561, 2000.

90.

Chang SM, Kuhn JG, Rizzo J, Robbins IH, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Gilbert M, Funton D, Rankin C, Prados MD: A phase I study of paclitaxel (Taxol) in patients with recurrent malignant glioma. A North American Brain Tumor Consortium Report. Classic Papers and Current Comments (5) 2:265272, 2000

91.

Gilbert M, O’Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, Hellman R: A Phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: An Eastern Cooperative Oncology Group Study (E2393). J Neuro Oncol 47:145-152, 2001.

92.

Mehta M, Scrimger R, Mackie TR, Paliwal B, Chappell R, Fowler J: A New Approach to Dose Escalation in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 49:2333, 2001.

93.

Chang SM, Kuhn JG, Robins, HI, Schold Jr. SC, Spence AM, Berger MS, Mehta MP, Pollack I, Rankin C, Prados MD: A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. A North American Brain Tumor Consortium Report, Cancer, 91:417-422, 2001.

94.

Schulz CA, Harari PM, Mehta MP: Multiple daily fractionation radiotherapy schedules in lung cancer. Current Oncology Reports, 3:179-184, 2001.

95.

Carde P, Timmerman R, Mehta M, Koprowski C, Ford J, Tishler R, Miles D, Miller R, Renschler M: Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients with Brain Metastases. J Clin Oncol, 19: 2074-2083, 2001.

96.

Rao R, Robins HI, Mehta MP: An unusual case of liver metastases from GBM following radiosurgery. J Radiosurgery 3: 165-167, 2001.

97.

de Stasio G, Casalbore P, Gilbert B, Mercanti D, Ciotti MT, Larocca LM, Rinelli A, Perret D, Mogk DW, Perfetti P, Mehta MP, Pallini R: Gadolinium in human glioblastoma cells for Gadolinium Neuton Capture Therapy (GdNCT). Ca Res 61:4272-77, 2001.

98.

Auchter R, Scholtens D, Adak S, Wagner H, Cella D, Mehta MP: Quality of Life Assessment in Advanced Non-Small Cell Lung Cancer Patients Undergoing an Accelerated Radiotherapy Regimen: Report of ECOG Study 4593. Int J Radiat Oncol Biol Phys, 50: 1199-1206, 2001.

99.

Sanghavi S, Miranpuri S, Chappell R, Buatti J, Mabanta S, Suh J, Regine W, Weltman E, Sneed P, Goetsch S, Breneman J, Sperduto P, Freedman W, Mehta,M: Survival of brain metastases patients treated with radiosurgery and stratified by Recursive Partitioning Analysis: A Multi-institutional study. Int J Radiat Oncol Biol Phys, 51: 426-434, 2001.

100. Miranpuri AS, TomĂŠ W, Paliwal B, Kesslering C, Mehta M: An Assessment of Operator-Induced Error for a Non-Invasive Frame for Fractionated Stereotactic Radiotherapy. Int J Ca, Radiat Oncol Invest, 96: 320-325, 2001.

101. Tome WA, Meeks SL, McNutt TR, Buatti JM, Bova FJ, Friedman WA, Mehta M: Optically guided intensity modulated radiotherapy. Radiother Oncol 61:33-44, 2001.

102. Rao R, Robins I, Mehta M: Late recurrence of a primitive neuro-ectodermal tumor.

Oncology 61:189-191, 2001.

103. Mehta M, Yung A, Bullard D, Barger G, Choucair A, Gillin M, Grossman S, Guha A, Hammond E, Michalski J, Prados M, Provins S, Scott C, Zamorano L: Radiation Therapy Oncology Group Research Plan 2002-2006, Brain Tumor Committee. Int J Rad Oncol Biol Phys 51 (S2): 11-18, 2001.

104. Hammond ME, Ang K, Byhardt R, Campbell B, Chapman JD, Eisenberg B, Greven K, Harris J, Hoffman J, Lange C, McCormick B, Mehta M, Sandler H, Trotti, A, Willet C, Wolfson A, Furness A, Jensen T, Grignon D, Okunieff P. Radiation Therapy Oncology Group Research Plan 2002-2006. Tumor Utilization Committee. Int J Radiat Oncol Biol Phys. 51(S2): 103-9, 2001.

105. Mehta MP: Book Review: “Combined Modality Therapy of Central Nervous System Tumors” eds Brady, Heilmann and Molls, Springer, Berlin, Oncology, 61:255-6, 2001.

106. Liu Z, Salamat MS, Hafez GR, Mehta M, Robins HI, Amoli RS, Tomic S: Pineal sarcoma. Acta Neurochirur 144:89-92, 2002.

107. Robins HI, Lui G, Hayes L, Mehta M: Trestuzumab for Breast Cancer Carcinomatous Meningitis. Clinical Breast Cancer 2:316, 2002.

108. Robins HI, Chang S, Prados MD, Yung A, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Cloughesy T, Junck L, Mehta M: A Phase II Trial of Thymidine and Carboplatin for Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Neuro-Oncol 4:109-114, 2002.

109. Mehta M: Retrospective vs. randomized data: The prevalence of bias, in response to Drs. Millar and Lapierre. Int J Rad Oncol Biol Phys, 53:252-3, 2002.

110. Tomé W, Mehta M, Meeks S, Buatti J: Fractionated Stereotactic Radiotherapy: A Short Review. Technology in Cancer Research And Treatment, 1:153-173, 2002.

111. Patel R, Mehta MP: 3-D conformal radiation therapy for lung cancer: Promises and pitfalls. Current Oncology Reports, 4:347-353, 2002.

112. Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, Regine WF, Weltman E, King VJ, Breneman JC, Sperduto PW, Mehta MP: A Multi-Institutional Review Of Radiosurgery Alone Vs. Radiosurgery With Whole Brain Radiotherapy As The Initial Management Of Brain Metastases. Int J Radiat Oncol Biol Phys, 53:519-526, 2002.

113. Packer RJ, Mehta M: Neurocognitive Sequelae of Cancer Treatment (Editorial).

Neurology 59:8-10, 2002.

114. Regine WF, Sperduto PW, Mehta MP: What is the Appropriate Primary Endpoint for Clinical Trials for Patients With Brain Metastases: In Response to Dr. Burri and Asher.

Int J Radiat Oncol Biol Phys 53:1394, 2002.

115. Mehta MP, Shapiro W, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith J, Miller R, and Renschler MF: Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole Brain Radiation for Patients with Brain Metastases: Centralized Assessment of MRI, Neurocognitive and Neurologic Endpoints. J Clin Oncol 20:3445-53, 2002.

116. De Stasio G, Frazer BH, Gilbert B, Sobderegger B, Richter K, Salt C, P Casalbore, Howard S, Rajesh D, Fowler J, Mehta MP, R Pallini, Mercanti D. New criteria for GdNCT agents. Proceedings of the 10th International Congress on Neutron Capture Therapy, Essen, Germany, Sep. 8-13, 2002, in "Research and Development in Neutron Capture Therapy", W. Sauerwein, R. Moss and A. Wittig Eds., Monduzzi, Bologna, p.

813-817, 2002.

117. Mehta M, Scrimger R, Mackie TR, Paliwal B, Chappell R, Fowler J: A New Approach to Dose Escalation in Non-Small Cell Lung Cancer. Biological and Physical Basis of

IMRT and Tomotherapy, Procedings of the 6th International Conference on Dose, Time and Fractionation, pp 275-291, 2002.

118. Welsh J, Patel R, TR Mackie, L Forrest, P Harari, B Paliwal, M Ritter, M Mehta: Tomotherapy. Technology In Cancer Research And Treatment, 1:311-316, 2002.

119. Sanghavi S, Needle M, Krailo M, Geyer R, Ater J, Mehta MP: CCG 0952; A Phase I Study of Topotecan, as a Radiosensitizer, for Brainstem Glioma of Childhood. J Neurooncol 5:17-22, 2003.

120. Scrimger RA, Tome WA, Olivera G, Reckwerdt PJ, Mehta MP, Fowler JF: Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. Am J Clin Oncol 26:70-78, 2003.

121. Harari P, Mehta M, Ritter M, Petereit D: Clinical Promise versus Clinical Reality in the Delivery of Concurrent Chemoradiotherapy. Sem Radiat Oncol 13:3-12, 2003.

122. Abrey L, Mehta MP: Treatment of Brain Metastases: A Short Review of Current Therapies and the Emerging Role of Temozolomide. Clin Adv Heme Oncol 1:231-238, 2003.

123. Grossman S, O’Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R: A phase III study comparing three cycles of infusional BCNU/Cisplatin followed by radiation therapy with radiation therapy and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394). J Clin Oncol 21:1485-91, 2003.

124. Mackie TR, Kapatoes J, Ruchala K, Lu W, Wu C, Olivera G, Forrest L, Tome W, Welsh J, Jeraj R, Harari P, Reckwerdt P, Paliwal B, Ritter M, Keller H, Fowler J, Mehta M: Image-Guidance for Precise Conformal Radiotherapy. Int J Radiat Oncol Biol Phys 56:89-105, 2003.

125. Stieber V, Bourland JD, Tome W, Mehta M: Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery. Technology In Cancer Research And Treatment, 2:79-86, 2003.

126. Thomadsen B, Howard S, Mehta MP: Supine Craniospinal Setup for Pediatric Radiotherapy. Medical Dosimetry 28:35-38, 2003.

127. Herman M, Tremont-Lukats I, Meyers CA, Trask DD, Froseth C, Renschler M, Mehta M: Neurocognitive and Functional Assessment of Patients with Brain Metastases: A Pilot Study. AmJ Clin Oncol 26: 273-9, 2003.

128. Mehta MP: Book Review: Controversies in Neuro-Oncology. Frontiers of Radiation Therapy and Oncology, Vol. 33, Edited by T. Wiegel, W. Hinkelbein, M. Brock, and T. Hoell. S. Karger, Basel, 1999, 380 pp., ISBN 38055-6834-7 NeuroOncol 5:221-2, 2003.

129. Jaeckle KA, Hess KR, Yung WKA, Greenberg H, Fine H, Schiff D, Pollack IE, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang SM, Prados M: A phase II evaluation of temozolomide (SCH52365) and 13-cis-retinoic acid (Isotretinoin; cRA)

for the treament of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium (NABTC) study. J. Clin Oncol 21:2305-11, 2003.

130. Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M: RSR 13 plus cranial radiation therapy in patients with brain metastases: comparison to the Radiation Therapy Oncology Group recursive partitioning analysis brain metastases database. J Clin Oncol 21:2364-2371, 2003.

131. Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller R, Renschler M: Survival And Neurologic Outcomes In A Randomized Trial Of Motexafin Gadolinium And Whole Brain Radiation Therapy In Brain Metastases. J Clin Oncol, 21:2529-36, 2003.

132. Robins HI, Peterson C, Mehta MP: Combined Modality Treatment for Brain Tumors.

Seminars in Oncology, 30:11-22, 2003.

133. Hong T, Mehta MP: Brain Metastases: Contemporary Management and Practice.

Contemp Oncol 2:1-8, 2003.

134. Hong T, Mehta MP: Book Review: Cancer in the Nervous System 2nd edition, Victor A Levin (ed), Oxford University Press, Neuro-Oncol, 5:275-6, 2003.

135. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Pollack I, Gilbert M, Prados MD: A study of a different dose-intense infusion schedule of Phenylacetate in patients with recurrent primary brain tumors. Investigational New Drugs 21:429-33, 2003.

136. Yawn BP, Wollan PC, Schroeder C, Rocca L, Mehta M: Temporal Trends in Brain Metastases Associated with Breast and Lung Cancer. Minn Med 86:32-37, 2003.

137. Meyers CA, Bezjak A, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg P, Meerwaldt J, Siemers R, Carrie C, Curran W, Mehta MP, Phan SC, Renschler MF, Miller RA, Smith JA: Neurocognitive Function and Progression in Patients with Brain Metastases Treated with Whole Brain Radiation and Motexafin Gadolinium (MGd): Results of a Randomized Phase III Trial. J Clin Oncol 22:157-165, 2004.

138. Harari PM, Ritter MA, Mehta MP, Petereit DG: Chemoradiation for Upper Aerodigestive Track Malignancies: Balancing Clinical Trials Evidence and Individual Patient Recommendations. Epithelial Malignancies. Current Problems in Cancer 28:7-40, 2004.

139. Schold SC Jr, Kokkinakis DM, Chang S, Berger M, Hess K, Schiff D, Robins I, Mehta M, Fink KL, Davis RL, Prados M: O6-Benzylguanine suppression of O6-alkylguanineDNA alkyltransferase in anaplastic gliomas, Neuro-Oncol 6:28-32, 2004.

140. Prados MD, Yung WKA, Fine H, Greenberg H, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C: Phase 2 study of BCNU and Temozolomide for Recurrent Glioblastoma Multiforme: North American Brain Tumor Consortium Study. Neuro-Oncol 6:33-37, 2004.

141. Prados MD, Yung WKA, Jaeckle K, Robins HI, Mehta M, Fine H, Wen P, Cloughsey T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J: Phase 1 Trial of Irinotecan (CPT-11) in Patients with Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Neuro-Oncol 6:44-54, 2004.

142. Chakravarti A, Dicker A, Mehta M: The Contribution of Epidermal Growth Factor Receptor (EGFR) Signaling Pathways to Radioresistance in Human Gliomas: A Review of Preclinical and Correlative Clinical Data. Int J Radiat Oncol Biol Phys 58:927-31, 2004.

143. Regine WF, Schmitt FA, Scott C, Patchell RA, Nichols RC, Gore E, Franklin RL, Suh J, Mehta M: Feasibility study of neurocognitive outcomes evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 58: 1346-1352, 2004.

144. Forouzannia A, Schiller JH, Hutson PR, Boothman DA, Storer B, Berlin J, and Mehta MP: A Phase I Study of Topotecan, as a Radiosensitizer for Thoracic Malignancies.

Lung Ca 44:111-119, 2004.

145. Brat DJ, Seiferheld W, Perry A, Hammond EH, Murray KJ, Schulsinger A, Mehta M, Curran W: Analysis of 1p, 19q, 9p, and 10q as Prognostic Markers for High-Grade Astrocytomas Using Fluorescent In-Situ Hybridization on Tissue Micro-arrays from RTOG Trials. NeuroOncol 6:96-103, 2004.

146. Welsh J, Bradley K, Ruchala K, Mackie TR, Manon R, Patel R, Lock M, Weiderholt P, Hui S, Mehta MP: Megavoltage Computed Tomography Imaging: a Potential Tool to Guide and Improve the Delivery of Thoracic Radiotherapy. Clinical Lung Cancer.

5:303-6; 2004.

147. Chang SM, Prados MD, Yung WKA, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink K, Jaeckle KA, Kuhn J, Hess K, Schold C: Phase II study of neoadjuvant 1, 3bis (2-chloroethyl)-1-nitrosourea and Temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer 100:1712-1716, 2004.

148. Andrews DW, Scott C, Sperduto PW, Flanders AE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Gaspar LE, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ: Phase III randomized trial comparing whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Results of the RTOG 9508 trial. Lancet 363: 1665-1673, 2004.

149. Manon R, Hui S, Chinnaiyan P, Suh J, Chang E, Timmerman R, Phan S, Das R, Mehta M: The Impact of Mid-Treatment MRI on Defining MRI Boost Volumes. Technology In Cancer Research And Treatment, 3:303-307, 2004.

150. Bradley KA, Tome WA, Resnick DK, Mehta MP: Treatment of Trigeminal Neuralgia Using Linear Accelerator-Based Radiosurgery. Radiosurgery 5:171-180, 2004.

151. Hong TS, Tome WA, Hayes L, Yuan Z, Rao R, Badie B, Rao R, Mehta M: Acute sequalae of radiosurgery. Radiosurgery 5:38-45, 2004.

152. Schulz C, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ: Continuous 28-Day Iododeoxyuridine Infusion and Hyperfractionated accelerated radiotherapy for Malignant Glioma: A Phase I Trial Clinical Study. Int J Radiat Oncol Biol Phys 59:1107-1115, 2004.

153. Chang S, Seiferheld W, Curran W, Share R, Atkins J, Choucair A, Kresl J, Thoron L, Cairncross G, Gilbert M, Bahary J-P, Dolinskas C, Louis D, Bushunow P, Buckner J, Barger G, Mehta M: Phase I Study Pilot Arms of Radiotherapy and Carmustine with Temozolomide for Anaplastic Astrocytoma (Radiation Therapy Oncology GroupRTOG 9813): Implications for Studies Testing Initial Treatment of Brain Tumors. Int J Radiat Oncol Biol Phys, 59:1122-1126, 2004.

154. Nieder C, Grosu AL, Mehta MP, Andratschke N, Molls M: Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents, Expert Reviews in Neurotherapeutics 4: 691-703, 2004.

155. Hong T, Mehta MP, Donohue B, Zeltzer P, Boyett JM: Patterns-of-failure in supratentorial primitive neuro-ectodermal tumors treated on CCG 921, a Phase III combined modality study. Int J Radiat Oncol Biol Phys, 60:204-213, 2004.

156. Souhami L, Scott CB, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran, WJ: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys, 60: 853-860, 2004.

157. Fowler JF, TomĂŠ WA, Fenwick J, Mehta MP: Stereotactic Body Radiotherapy: A Challenge to Conventional Radiation Oncology. Int J Radiat Oncol Biol Phys, 60: 1241-1256, 2004.

158. Bradley K, Mehta MP: Management of Brain Metastases. Sem in Oncol 31:693-701, 2004.

159. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA: American Society for Therapeutic Radiology and Oncology and American College of Radiology Practice Guidelines for the Performance of Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 60: 1026-32, 2004.

160. Puduvalli VK, Yung AW, Hess KR, Kuhn JG, Groves M, Levin VA, Zwiebel J, Chang SM, Cloughesy T, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert M, Meyers CA, Liu V, Mehta MP, Nicholas K, Prados M: Phase II Study of Fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium Study. J Clin Oncol 22: 4282-89, 2004.

161. Petereit D, Rogers D, Govern F, Coleman N, Osburn CH, Howard S, Kaur J, Burhansstipanov L, Fowler J, Chappell R, Mehta MP: Increasing Access to Clinical Cancer Trials and Emerging Technologies for Minority Populations: The Native American Project. J Clin Oncol 22: 4452-55, 2004.

162. Hui SK, Das RK, Kapatoes J, Oliviera G, Becker S, Odau H, Fenwick JD, Patel R, Kuske R, Mehta M, Paliwal B, Mackie TR, Fowler JF, Welsh J: Helical Tomotherapy as a Means of Delivering Accelerated Partial Breast Irradiation. Tech Ca Res Treat 3: 639-46, 2004.

163. Khuntia D and Mehta MP: Motexafin Gadolinium: A Clinical Review of a Novel Radioenhancer for Brain Tumors. Expert Rev Anticancer Ther 4: 981-9, 2004.

164. Mehta MP, Suh J: Novel Radiosensitizers for Tumors of the Central Nervous System.

Current Opinion Investig Drugs 5: 1284-91, 2004.

165. Forrest LJ, Mackie TR, Ruchala K, Turek M, Kapatoes J, Jaradat H, Hui S, Balog J, Vail DM, Mehta M: The Utility of Megavoltage Computed Tomography Images from a Helical Tomotherapy System for Set-up Verification Purposes. Int J Radiat Oncol Biol Phys 60:1639-44, 2004.

166. Mehta MP, Fowler JF: Accelerated Hypofractionation. Int J Radiat Oncol Biol Phys, 61:299, 2005.

167. Manon R, Mehta M: Strategies for Enhanced Radiation Delivery in Patients with Lung Cancer. Expert Opin Drug Deliv, 2:103-113, 2005.

168. Hong TS, TomĂŠ WA, Chappell RJ, Chinnaiyan P, Mehta MP, Harari PM: The Impact of Daily Set-up Variation on Head and Neck Intensity Modulated Radiotherapy. Int J Rad Oncol, Biol, Phys 61:779-788, 2005.

169. Petereit D, Rogers D, Burhansstipanov L, Kaur J, Govern F, Howard S, Osburn CH, Coleman N, Fowler J, Chappell R, Mehta MP: Walking Forward: The South Dakota Native American Project. J Ca Educ 20: 65-70, 2005.

170. Souhami L, Mehta MP, Brachman D, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L: Lack of Survival Benefit After Stereotactic Radiosurgery Boost for Glioblastoma Multiforme: In Response to Drs. Vordermark and Kolbl. Int J Radiat Oncol Biol Phys, 62: 297, 2005.

171. Chakravarti A, Seiferheld W, Tu X, Wang H, Zhang HZ, Ang KK, Hammond E, Curran W, Mehta M: Immunohistochemically Determined Total Epidermal Growth Factor Receptor Levels Not of Prognostic Value in Newly-Diagnosed Glioblastoma Multiforme: Report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 62:318-327, 2005.

172. Souhami L, Mehta MP, Brachman D, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L: Lack of Survival Benefit After Stereotactic Radiosurgery Boost for Glioblastoma Multiforme: In Response to Dr. Kondziolka, et al. Int J Radiat Oncol Biol Phys, 62: 615-6, 2005.

173. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M: Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients with Unresectable Stage IIIA & B Non-Small Cell Lung Cancer. J Clin Oncol, 23:3753-3760, 2005.

174. De Stasio G, Rajesh D, Casalbore P, Daniels MJ, Erhardt RJ, Frazer BH, Wiese LM, Richter KL, Sonderegger BR, Gilbert B, Schaub S, Cannara R, Crawford JE, Gilles MK, Tyliszczak T, Fowler JF, Larocca LM, Howard S, Mercanti D, Mehta MP, Pallini R: Are Gadolinium Contrast Agents Suitable for Gadolinium Neutron Capture Therapy?

Neurol Res 27: 387-398, 2005.

175. Mehta MP: Gliomas: Setting New Standards and Developing New Therapeutic Approaches. Cancer Abstracts and Summaries 6: 1-2, 2005.

176. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L: The American Society for Therapeutic Radiology and Oncology (ASTRO) Technology Assessment on the Role of Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys, 63: 37-46, 2005.

177. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L: The American Society for Therapeutic Radiology and Oncology (ASTRO) Technology Assessment on the Role of Radiosurgery for Malignant Glioma. Int J Radiat Oncol Biol Phys, 63: 47-55, 2005.

178. Mehta M, Manon R: Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non Small Cell Lung Cancer: Combined Modality Treatment? Sem Oncol 32 (Suppl 3): 25-34, 2005.

179. Langer C, Mehta MP: Systemic Therapy for Brain Metastases. JCO 23:6207-6219, 2005.

180. Hong T, Mehta MP, Boyett JM, Donohue B, Rorke LB, Zeltzer P: Patterns of Treatment Failure in Infants with Primitive Neuro-ectodermal Tumors who were Treated on CCG 921, a Phase III Combined Modality Study. Pediatr Blood Ca 45:676-682, 2005.

181. Cloughsey TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M: Phase I Trial of Tipifarnib in Patients with Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. J Clin Oncol 23: 6647-6656, 2005.

182. Mehta MP, Khuntia D: Current Strategies in Whole Brain Radiation Therapy for Brain Metastases. Neurosurg 57(S4): 33-44, 2005.

183. Manon RR, Jaradat H, Patel R, Zhang T, Fenwick J, Tome W, Fowler J, Paliwal B, Soisson E, Yuan Z, Mehta MP: Potential for Radiation Therapy Technology Innovations to Permit Dose Escalation for Non Small Cell Lung Cancer. Clin Lung Ca 7:107-113, 2005.

184. Welsh JS, Mehta M, Mackie TR, Orton N, Jaradat H, Khuntia D, TomĂŠ W: Helical tomotherapy as a means of delivering scalp-sparing whole brain radiation therapy.

Technology in Cancer Research and Treatment 4:661-662, 2005.

185. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca J, Chiba A, Reaman G: Phase 1 Study of Concurrent RMP-7 and Carboplatin with Radiation Therapy for Children with Newly-Diagnosed Brain Stem Gliomas. Cancer 104:12811287, 2005.

186. Manon R, O’Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert, Mehta M: A Phase II Trial of Radiosurgery (RS) for 1 to 3 Newly Diagnosed Brain Metastases from Renal Cell, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397). J Clin Oncol 23: 8870-8876, 2005.

187. Bradley KA, Hong TS, Tomé WA, Hayes LL, Peng L, Resnick DK, Mehta MP: Linear Accelerator-based Radiosurgery in the Treatment of Trigeminal Neuralgia: A Preliminary Report. Neurosurg 57: 1193-1200, 2005.

188. Fisher B, Seiferheld W, Schultz C, DeAngelis L, Nelson D, Schold SC, Curran W, Mehta M: Secondary Analysis of Radiation Therapy Oncology Group Study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma. J NeuroOncol 74: 201-205, 2005.

189. Mehta MP, Bradley K: Radiation Therapy for Leptomeningeal Cancer. Cancer Treat Res 125: 147-158, 2005.

190. Richards GM, Bradley KA, Tome WA, Bentzen SM, Resnick DK, Mehta MP. Linear accelerator radiosurgery for trigeminal neuralgia. Neurosurgery 57:1193-1200, 2005.

191. Robins HI, Won M, Seiferheld W, Schultz C, Choucair A, Brachman D, Demas W, Mehta M: Phase II Trial of Radiation Plus High Dose Tamoxifen for Glioblastoma Multiforme: RTOG Protocol BR-0021. Neuro Oncol 8: 47-52, 2006.

192. Khuntia D, Brown P, Li J, Mehta MP: Whole Brain Radiotherapy in the Management of Brain Metastases. J Clin Oncol, 24: 1295-1304, 2006.

193. Richards GM, Tsao MN, Mehta MP: Summary of the American Society for Therapeutiv Radiology and Oncology (ASTRO) Evidence-Based Review of the Role of Radiosurgery for Brain Metastases. Am J Oncol Rev 5: 58-61, 2006.

194. Aoyama H, Westerly DC, Mackie TR, Olivera G, Bentzen S, Patel RR, Jaradat H, Tome WA, Ritter M, Mehta M: Integral Radiation Dose to Normal Structures with Conformal External Beam Radiation. Int J Radiat Oncol Biol Phys, 64: 962-967, 2006.

195. Khuntia D, Jaradat H, Orton N, Tomé W, Mehta MP, Welsh JS: Helical tomotherapy as a means of administering total or partial scalp irradiation. Int J Radiat Oncol Biol Phys, 64:1288-9, 2006.

196. Prados MD, Lamborn K, Yung WKA, Jaeckle K, Robins HI, Mehta M, Fine H, Wen P, Cloughsey T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J: A Phase-2 Trial of Irinotecan (CPT-11) in Patients with Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Neuro-Oncol, 8:189-193, 2006.

197. De Stasio G, Rajesh D, Ford JM, Daniels MJ, Erhardt RJ, Frazer BH, Tyliszczak T, Gilles MK, Conhaim RL, Howard SP, Fowler JF, Esteve F, Mehta MP: Motexafin-Gadolinium Taken Up in Vitro by >90% of Glioblastoma Cell Nuclei. Clin Ca Res 12: 206-13, 2006.

198. Soisson ET, Richards GM, Mehta MP, Tomé WA: Comparison of Linac Based Fractionated Stereotactic Radiotherapy and Tomotherapy Treatment Plans for SkullBase Tumors. Radiother & Oncol, 78: 313-21, 2006.

199. Siker M, Mehta M: Results of Bhatnagar et al., Stereotactic Radiosurgery For Four of More Intracranial Metastases: Implications and Future Directions, Am J Oncol Radiol 5:316-318, 2006.

200. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W: Phase III Trial of Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol, 24:2707-2714, 2006.

201. Aoyama H, Mackie TR, Bentzen S, Olivera G, Westerly DC, Mehta M: Caution and Diligence are Critical in our Application of New Technologies: In Response to Dr. Peñagarícano. Int J Radiat Oncol Biol Phys, 65:1274-5, 2006.

202. Mehta MP: Models Support Prophylactic Cranial Irradiation. J Clin Oncol, 24:3524-25, 2006.

203. Cloughesy TF, Wen P, Robins I, Chang S, Groves, M, Fink KL, Junck L, Schiff D, Abrey L, Gilbert M, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer J, Yung WKA, Aldape K, Lamborn KR, Prados M: Phase II Trial of Tipifarnib in Patients with Recurrent Malignant Glioma either Receiving or not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study, J Clin Oncol, 24:3651-56, 2006.

204. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M: A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boost for Supratentorial Glioblastoma Multiforme.

RTOG-0023. Int J Radiat Oncol Biol Phys, 65:1422-1428, 2006.

205. Chakravarti A, Erkkinen MG, Nestler U, Mehta, M, Black PM, Loeffler JS: Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. Clin Ca Res, 12:4738-4746, 2006.

206. Welsh JS, Lock M, Harari P, Tomé W, Fowler J, Mackie TR, Ritter M, Kapatoes J, Forrest L, Chappell R, Paliwal B, Mehta MP: Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy, Technology in Cancer Research and Treatment, 5:1-15, 2006.

207. Hodge W, Tomé W, Jaradat H, Khuntia D, Traynor A, Weigle T, Mehta MP: Feasibility Report of Stereotactic Body Radiotherapy with TomoTherapy for Early Stage Medically Inoperable Lung Cancer Using Extreme Hypofractionation, Acta Oncologica, 45:890-896, 2006.

208. Fenwick JD, Tomé WA, Soisson ET, Mehta MP, Mackie TR: Tomotherapy and Other Innovative IMRT delivery systems. Sem Rad Oncol, 16:199-208, 2006.

209. Robins HI, Traynor A, Mehta MP: Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer Group, J Thorac Oncol, 1:732-733, 2006.

210. Gondi V, Mehta M, Bradley K, Tome W, Paliwal B, Burkhamer M, Howard A, Pola Y, Perlman S, Turski P: Adoption of a Hybrid CT/PET Scanner in a Radiotherapy

Department: The University of Wisconsin Experience.

Nov/Dec 2006.

Oncology Issues, 26-31,

211. Tome WA, Fenwick JD, Mehta MP: How Can tumor Effect and Normal Tissue Effect Be Balanced in Stereotactic Body Radiotherapy. Radiosurgery, 6: 86-97, 2006.

212. Tewatia D, Zhang T, Paliwal B, Mehta M: Clinical Implementation of Target Tracking

by Breathing Synchronized Delivery (BSD), Med Phys, 33: 4330-36, 2006.

213. Siker M, Chakravarti A, Mehta M: Should Concomitant and Adjuvant Treatment with Temozolomide be Used as Standard Therapy in Patients with Anaplastic Glioma?

Critical Reviews in Oncology/Hematology, 60:99-111, 2006.

214. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM: The Memorial Sloan Kettering Cancer Center Prognostic Model for Primary Central Nervous System Lymphoma, J Clin Oncol, 24:5711-15, 2006.

215. Siker ML, TomĂŠ WA, Mehta MP: Tumor Volume Changes on Serial Imaging with Megavoltage CT for Non-Small Cell Lung Cancer During Intensity Modulated Radiotherapy: How Reliable, Consistent and Meaningful is the Effect? Int J Radiat Oncol Biol Phys, 66:135-141, 2006.

216. Colman H, Berkey B, Maor M, Groves MD, Schultz C, Vermeulin S, Nelson D, Mehta M, Yung WKA: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-Ă&#x; for supratentorial glioblastoma- Results of RTOG 9710. Int J Radiat Oncol Biol Phys, 66:818-24, 2006.

217. Wen PY, Yung WKA, LamborN KR, Dahia P, Peng B, Wang Y, Abrey L, Raiser J, Cloughesy T, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves M, Puduvalli VK, Levin V, Conrad C, Maher EA, Kuhn J, Aldape K, Hayes M, Capdeville R, Kaplan R, Murgo A, Stiles C, Prados MD: Phase I/II Study of Imatinib Mesylate (Gleevec) For Patients With Recurrent Malignant Gliomas. Clin Ca Res, 12:4899-4907, 2006.

218. Richards GM, Khuntia D, and Mehta MP: Therapeutic Management of Metastatic Brain Tumors. Critical Reviews in Oncology/Hematology, 61:70-78, 2007.

219. Gondi V, Bradley K, Mehta M, Howard A, Khuntia D, Ritter M, Tome W: Impact of Hybrid Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography on Radiotherapy Planning in Esophageal and Non-Small-Cell Lung Cancer, Int J Radiat Oncol Biol Phys, 67:187-195, 2007.

220. Chang JE, Robins HI, Mehta MP: Therapeutic Advances in the Treatment of Brain Metastases, Clinical Advances in Hematology & Oncology, 5:54-64, 2007.

221. Siker M, Mehta M: Resection versus Radiosurgery for Patients with Brain Metastases, Future Oncology, 3:95-102, 2007.

222. Robins HI, Chang S, Butowski N, Mehta M: Therapeutic Advances for Glioblastoma Multiforme: Current Status and Future Prospects, Curr Oncol Reports, 9:66-70, 2007.

223. Richards GM, Mehta MP: Motexafin Gadolinium in the Treatment of Brain Metastasis, Expert Opinion on Biol Ther, 8:351-9, 2007.

224. Li J, Bentzen SM, Renschler M, Mehta M: Regression of Brain Metastases After Whole Brain Radiation Therapy Correlates with Survival and Improved Neurocogntive Function with Brain Metastases, J Clin Oncol, 25:1260-66, 2007.

225. Forouzannia A, Richards GM, Khuntia D, Mehta MP: Motexafin gadolinium: A Novel Radiosensitizer for Brain Tumors. Expt Rev Anticancer Ther 7:785-794, 2007.

226. Chakravarti A, Tyndall E, Palanichamy K, Mehta M, Aldape K, Loeffler J: Impact of Molecular Profiling on Clinical Trial Design for Glioblastoma, Current Oncol Reports, 9:71-79, 2007.

227. Berk L, Berkey B, Rich T, Hrushesky W, Blask D, Gallagher M, Kudrimoti M, McGarry R, Suh J, Mehta M: Randomized Phase II Trial of High Dose Melatonin and Radiation Therapy for RPA Class 2 Patients with Brain Metastases (RTOG 0119) Int J Radiat Oncol Biol Phys 68:852-857, 2007.

228. Patel R and Mehta MP: Brain Metastases: Targeted Therapies Reveal a Sanctuary Site: Implications for CNS-specific Therapy, Clinical Cancer Research (CCR) Focus Series Biol Phys, 13: 1675-1683, 2007.

229. Ghia A, Tome W, Thomas S, Kuo J, Cannon G, Mehta M: Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation, Int J Radiat Oncol, Biol Phys, 68:971-977, 2007.

230. Hodge CW, Tomé WA, Mehta MP: Image-Guided Radiotherapy for Early Stage Medically Inoperable Non-Small Cell Lung Cancer Study, Touch Briefings, 1:44-46, 2007.

231. Zhang T, Mackie TR, Keller H, Olivera G, Lu W, Jeraj R, Mehta MP, Paliwal B: Breathing Synchronized Delivery (BSD): A Potential Four Dimensional Tomotherapy Treatment Technique. International Journal of Radiation Oncology, Biology, Physics, 68:1572-78, 2007.

232. Li J, Bentzen SM, Renschler M, Mehta M: “Strategies to improve compliance and reduce bias in patient-reported outcomes in metastatic disease” Reply to “Avoiding bias in the prospective evaluation of patient with brain metastases”. J Clin Oncol Biol Phys, 25: 4024-25, 2007.

233. Stieber V, Mehta MP: Advances in Radiation Therapy for Brain Tumors, Neurologic Clinics, 25: 1005-1034, 2007.

234. Chang JE, Khuntia D, Robins HI, Mehta MP: Radiotherapy and Radiosensitizers in the Treatment of Glioblastoma Multiforme, Clin Adv Heme Oncol, 5:894-915, 2007.

235. Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC: Results of the Phase I Dose Escalating Study of Motexafin Gadolinium with Standard Radiation Therapy in Patients with Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys, 69:831-838, 2007.

236. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM: Reply to Everything Should be Made as Simple as Possible, but not Simpler, J Clin Oncol, 25:4324-4325, 2007.

237. Hong TS, Welsh JS, Ritter MA, Harari PM, Jaradat H, Mackie TR, Mehta MP: Megavoltage Computer Tomography: An Emerging Tool For Image-Guided Radiotherapy. Am J Clin Oncol, 30:617-623, 2007.

238. Siker M, Mehta MP: Radiation for Brain Metastases, Cancer Treat Res, 136:91-115, 2007.

239. Rogers L, Mehta MP: Role of Radiation Therapy in Treating Intracranial Meningiomas: Neurosurg Focus, 23(4) E4, 2007.

240. GutiĂŠrrez AN, Westerly DC, TomĂŠ WA, Jaradat HA, Mackie TR, Bentzen S, Khuntia D, Mehta MP: Whole Brain Radiation Therapy with Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. Int J Radiat Oncol Biol Phys, 69:589-97, 2007.

241. Tome WA, Jaradat HA, Nelson IA, Ritter M, Mehta M: Helical Tomotherapy: Image Guidance and Adaptive Dose Guidance, Fron Radiat Ther Oncol, 40:162-178, 2007.

242. Thomas RS, Khuntia D, Mehta M: Current Therapeutic Strategies for Metastatic Brain Tumors, Touch Briefings European Oncology Review, European Oncological Disease, 1:7-9, 2007.

243. Loghin ME, Prados M, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Mehta M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins HI, Aldape KD, Yung WKA: Phase I study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Clin Ca Res, 13:7133-7138, 2007.

244. Flynn RT, Kissick MW, Jeraj R, Mehta MP, Olivera GH, Mackie TR: The Impact of Linac Output Variations in Helical tomotherapy. Phys Med Biol, 53: 417-430, 2008.

245. Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W: A New Prognostic Index and Comparison to Three Other Indices for Patients with Brain Metastases: An Analysis of 1960 Patients in the RTOG Database. Int J Radiat Oncol Biol Phys, 70:510-14, 2008.

246. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Kink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD: Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma. Clin Ca Res, 13:7401-6, 2008.

247. Li J, Bentzen SM, Li J, Renschler M, Mehta MP: Relationship Between Neurocognitive Function and Quality of Life Following Whole Brain Radiation Therapy in Patients with Brain Metastasis, Int J Radiat Oncol Biol Phys, 71:64-70, 2008.

248. Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W: A New Prognostic Index and Comparison to Three Other Indices for Patients with Brain Metastases: An Analysis

of 1960 Patients in the RTOG Database. In Reply to Dr. Weltman. Int J Radiat Oncol Biol Phys, 70:1292-3, 2008.

249. Bentzen SM, Harari PM, Tome WA, Mehta MP: Radiation Oncology Advances: An Introduction, Cancer Treat Res 139:1-4, 2008.

250. Wong G, Mehta MP: Combined Chemoradiotherapy Advances, Cancer Treat Res 139:281-305, 2008.

251. Corn B, Moughan J, Knisley J, Fox SW, Chakravarti A, Yung WK, Curran WJ, Robins HI, Brachman DG, Henderson RH, Mehta MP, Movsas B: Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients with Multiple Brain Metastases Receiving Whole Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. Int J Radiat Oncol Biol Phys, 71:71-78, 2008.

252. Knisley J, Berkey B, Chakravarti A, Yung WK, Curaan WJ, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta M: A Phase III Study of Conventional Radiation Therapy plus Thalidomide versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). Int J Radiat Oncol Biol Phy, 71:79-86, 2008.

253. Giannini C, Burger PC, Berkey BA, Cairncross GJ, Jenkins RB, Mehta M, Curran WJ, Aldape K: Anaplastic Oligodendroglial Tumors: Refining the Correlation Among Histopathology, 1p 19q Deletion and clinical Outcome in Intergroup Radiation Therapy Oncology Group trial 9402. Brain Pathol, 18:360-369, 2008.

254. Lamborn K, Yung A, Chang S, Wen P, Cloughesy T, DeAngelis L, Robins HI, Lieberman F, Fine H, Fink K, Junck L, Abrey L, Gilbert M, Mehta M, Kuhn J, Aldape K, Hibberts J, Peterson P, Prados M: Progression Free Survival: An Important Endpoint in Evaluating Therapy for Recurrent High Grade Gliomas. Neuro Oncol, 10:162-170, 2008.

255. Nieder C, Astner ST, Mehta MP, Grosu Al, Molls M: Improvement, Clinical Course and Quality of Life after Palliative Radiotherapy for Recurrent Glioblastoma. Am J Clin Oncol, 31:300-305, 2008.

256. Chang SM, Lamborn KR, Kuhn JG, Yung AWK, Gilbert MR, Wen PY, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins HI, Abrey LE, Prados MD: Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium (NABTC). Neuro Oncol 10: 631-642, 2008.

257. Robins HI, O’Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B, Mehta M: Effect of Dalteparin and Radiation on Survival and Thromboembolic Events in Glioblastoma Multiforme: A Phase II ECOG Trial, Ca Chemo Pharmacol, 62:227-233, 2008.

258. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR: Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. J Clin Oncol, 26:4189-4199, 2008.

259. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W, Mehta MP: The Prognostic Value of Nestin Expression In

Newly Diagnosed Glioblastoma: Report From The Radiation Therapy Oncology Group. Radiation Oncology, 3:1-8. 2008.

260. Choi B, Robins HI, Schiller J, Mehta M: A Phase I Study of Gemcitabine plus Palliative Radiation Therapy for Advanced Lung Cancer. Ca Chemo Pharmacol 63:175-179, 2008.

261. Adkison JB, Khuntia D, Bentzen SM, Cannon GM, Tome WA, Jaradat H, Walker W, Traynor A, Weigel T, Mehta MP: Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. J Ca Res Technol, 7:441-448, 2008.

262. Arvidson NB, Mehta MP, Tomé WA: Dose Coverage Beyond GTV for Various Sterotactic Body Radiotherapy (SBRT) Planning Techniques Reporting Similar Control Rates for Stage I Non-Small-Cell Lung Cancer. Int J Radiat Oncol, 72:1597-1603, 2008.

263. Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W: The Validation of the Graded Prognostic Assessment Index for Patients with Brain Metastases. In Reply to Dr. Nieder. Int J Radiat Oncol Biol Phys, 72:1619, 2008.

264. Bradley KA, Pollack I, Reid J, Adamson PC, Ames M, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP: Motexafin Gadolinium and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood: A Childrens’ Oncology Group Phase I Study, J Neuro Oncol, 10:752-758, 2008.

265. Buatti J, Ryken TC, Smith MC, Sneed P, Suh JH, Mehta M, Olson JJ: Radiation Therapy of Pathologically Confirmed Newly Diagnosed Glioblastoma in Adults. J Neuro-Oncol, 89:313-337, 2008.

266. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, M. R. Gilbert MR, Mehta M: Recurrence Following NeurosurgeonDefined Gross Total Resection of Adult Supratentorial Low-Grade Glioma, J Neurosurg, 109:835-841, 2008.

267. Blumenthal DT, Won M, Mehta MP, Curran W, Souhami L, Michalski J, Rogers L, Corn B: Short Delay in Initiation of Radiotherapy May Not Affect the Outcome of Patients with Glioblastoma. A Secondary Analysis from the Radiation Therapy Oncology Group Database, J Clin Oncol, 27:733-739, 2009.

268. Kruser TJ, Bradley KA, Bentzen SM, Anderson BM, Gondi V, Khuntia D, Perlman S, Tome WA, Chappell R, Walker W, Mehta MP: The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. Tech Ca Res Treat, 8:149-158, 2009.

269. Nieder C, Mehta MP: Prognostic Indices for Brain Metastases – Usefulness and Challenges. Rad Oncol, 4:10, 2009.

270. Schubert LK, Westerly DC, Tomé WA, Mehta MP, Soisson ET, Mackie TR, Ritter M, Harari PM, Paliwal BR: A Comprehensive Assessment of Patient Setup using Daily MVCT Imaging by Tumor Site from More than 3,800 Helical Tomotherapy Treatments, Med Phys, 73:1260-1269, 2009.

271. Vogelbaum MA, Berkey B, Peereboom D, MacDonald D, Giannini C, Suh J, Jenkins R, Herman J, Brown P, Blumenthal D, Biggs C, Schultz C, Mehta M: Phase II Trial of PreIrradiation and Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligoastrocytomas: RTOG BR0131. Neuro Oncol, 11:167-175, 2009.

272. Khuntia D, Tome WA, Mehta MP: Radiation Techniques in Neuro-Oncology.

Neurotherapeutics, 6: 487-499, 2009.

273. Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF: Motexafin Gadolinium Combined with Prompt Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in NonSmall-Cell Lung Cancer Patients with Brain Metastases: Results of a Phase 3 Trial. Int J Radiat Oncol Biol Phys, 73:1069-76, 2009.

274. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Robins I, Junck L, Chang SM: A North Amercian brain tumor consortium (NABTC01-06) phase II study of Poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neuro Oncol, 91:183-9, 2009.

275. Allen J, Donahue B, Mehta M, Miller D, Rorke L, Jakacki R, Roberston P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW: A Phase II Childrens’ Cancer Group Study (CCG 9931) of Pre-Radiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High Risk Medulloblastoma/PNET. Int J Radiat Oncol Biol Phys, 74:1397-1404, 2009.

276. Mehta M, Hoban P, Mackie TR: Commissioning and Quality Assurance of RapidArc Radiotherapy Delivery System: In Regards to Ling et al (Int J Radiat Oncol Biol Phys 2008;72;575-581): Absence of Data Does Not Constitute Proof; The Proof is in Tasting the Pudding. Int J Radiat Oncol Biol Phys, 75: 4-6, 2009.

277. Tsien C, Moughan J, Michalski JM, Gilbert M, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP: Phase I 3D Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: RTOG 9803. Int J Radiat Oncol Biol Phys, 73:699-708, 2009.

278. Francis D, Richards GM, Forouzannia A, Mehta MP, Khuntia D: Motexafin Gadolinium: A Novel Radiosensitizer for Brain Tumors. Expert Opin Pharmacother, 10:2171-2180, 2009.

279. Corn BW, Wang M, Fox S, Michalski J, Purdy J, Simpson J, Kresl J, Curran WJ, Diaz A, Mehta MP, Movsas B: Health Related Quality of Life and Cognitive Status in Patients with Glioblastoma Receiving Escalating Doses of Conformal Three Dimensional Radiation on RTOG 98-03. J Neuro-Oncol, 95:247-257, 2009.

280. Nieder C, Mehta MP, Jalali R: Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol, 21:515-524, 2009.

281. Wen PY, Yung WKA, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Fink K, DeAngelis LM, Mehta M, Robins HI, Di Tomaso E, Drappatz J,

Kesari S, Ligon K, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II Study of Imatinib Mesylate (Gleevec®) For Recurrent Meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-Oncology, 6:853-860, 2009.

282. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, Deangelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS: EGFR Signaling Through an Akt/SREBP1 Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to AntiLipogenic Therapy. Science Signaling, 2 (101), ra82, 2009.

283. Bender ET, Mehta MP, Tomé WA: On the estimation of the location of the hippocampus in the context of hippocampal avoidence whole brain radiotherapy (HA-WBRT) treatment planning. Tech Ca Res Treat 8:425-432, 2009.

284. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WKA, Gilbert MR, Fine HA, Mehta M, DeAngelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II Trials of Erlotinib or Gefitinib in Patients with Recurrent Meningioma, J Neuro-Oncology, 96:211-217, 2010.

285. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA: American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy, Int J Radiat, Oncol, Biol, Physics 76: 2, 326-32, 2010.

286. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M: Current Therapeutic Paradigms in Glioblastoma, 5:14-27, 2010.

287. Gutiérrez AN, Tomé WA, Ghia A, Thomas S, Cannon G, Khuntia D, Kuo J, Mehta M: Simultaneously Integrated Boost to Multiple Brain Metastases during Whole Brain Radiation Therapy-Hippocampal Avoidance (WBRT-HA) ISRS 2007, Radiosurgery, 7:247-257, 2010.

288. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:17-32, 2010.

289. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Linskey ME: The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:33-44, 2010.

290. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN: The role of stereotactic radiosurgery in the management of newly diagnosed brain metastases: a

systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:45-70, 2010.

291. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN: The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:71-84, 2010.

292. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN: The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:85-96, 2010.

293. Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Olson JJ, Ryken TC, Patchell RA, Kalkanis SN: The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:97-102, 2010.

294. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN: The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:103-114, 2010.

295. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, M, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN: The role of emerging and investigational therapies for metastastatic brain tumors: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncology, 96:115-142, 2010.

296. Hodge CW, Tome W, Fain SB, Bentzen S, Mehta MP: On the use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy. Med Dos, 35: 297-303, 2010.

297. Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, Mehta MP: Angiogenic Blocade and Radiotherapy in Hepatocellular Carcinoma, Int J Radiat Oncol, Biol, Phys 78: 188-193, 2010.

298. Platta CS, Khuntia D, Mehta MP, Suh JH: Current Treatment Strategies for Brain Metastasis and Complications from Therapeutic Techniques: A Review of Current Literature. Am J Clin Oncol, 33:398-407, 2010.

299. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen A, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash J, Chiang V, Knisely J, Sperduto CM, Mehta M: Diagnosis-Specific Prognostic Factors, Indices and Treatment Outcomes for Patients with Newly-Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4259 Patients, Int J Radiat Oncol Biol Phys, 77:655-661, 2010.

300. Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W: Cognition and Quality of Life after Chemotherapy plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402, Int J Radiat Oncol Biol Phys, 77:662-669, 2010.

301. PMID: 20150367. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross GJ, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K: A Multigene Predictor of Outcome in Glioblastoma. Neuro-Oncol, 12(1):49-57, January 2010.

302. PMID: 20150371. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD: A Phase I Trial of Erlotinib in Patients with Non-progressive Glioblastoma Multiforme Post Radiation Therapy, and Recurrent Malignant Gliomas and Meningiomas: NeuroOncol, 12(1):8794, January 2010.

303. PMID: 20150372. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD: A Phase II Trial of Erlotinib in Patients with Recurrent Malignant Gliomas and Non-progressive Glioblastoma Multiforme Post Radiation Therapy, NeuroOncol, 12(1):95-103, January 2010.

304. PMID: 20379203. Mehta MP: Gangliogliomas: What is the Appropriate Management Strategy? Nature Reviews Neurol, 6(4):190-191, April 2010.

305. PMID: 20410395. Adkison JB, Mehta M: Radiographic Pneumonitis Patterns and Low Pulmonary Toxicity After Helical Tomotherapy. Am J Roentgenol. 194(5):W459; author reply 194 (5):W460, May 2010.

306. PMID: 20392503. Gondi V, Tome W, Marsh J, Struck A, Ghia A, Turian JV, Bentzen SM, Kuo JS, Khuntia D, Mehta MP: Estimated Risk of Perihippocampal Disease Progression after Hippocampal Avoidance during Whole-Brain Radiotherapy: Safety Profile for RTOG 0933. Radiother Oncol, 95(3):327-331, June 2010.

307. PMID: 20200024. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, DeAngelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA: Phase II Trial of Pazopanib (GW786034), an Oral Multi-Targeted Angiogenesis Inhibitor, for Adults with Recurrent Glioblastoma (North American Brain Tumor Consortium Study 06-02), NeuroOncol, 12(8):855-861, August 2010.

308. PMID: 20973393. Lawrence JA, Forrest LJ, Turek MM, Miller PE, Mackie TR, Jaradat HA, Vail DM, Dubielzig RR, Chappell R, Mehta MP: Proof of Principle of Ocular Sparing in Dogs with Sinonasal Tumors Treated with Intensity-Modulated Radiation Therapy, Vet Radiol Ultrasound, 51(5):561-570, September 2010.

309. PMID: 20809249. Gondi V, Tome WA, and Mehta MP: Fractionated Radiotherapy for Intracranial Meningiomas. J Neuro Oncol, 99(3):349-356, September 2010.

310. PMID: 20835750.

Vogelbaum MA, Rogers CL, Linskey MA, Mehta MP: Opportunities for Clinical Research in Meningioma. J Neuro Oncol, 99(3):417-22, September 2010.

311. PMID: 20970214. Gondi V, Tomé WA, Mehta MP: Why Avoid the Hippocampus: A Comprehensive Review, Radiother Oncol, 97(3):370-376, October 2010.

312. PMID: 20970038. Mehta MP, Khuntia D: Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy and Helical Tomotherapy: In Regard to Song et al., Int J Radiat Oncol, Biol, Phys, 78(4):1281, November 2010.

313. PMID: 20859206. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, Khuntia D, Tome WA: Hippocampal-Sparing Whole Brain Radiotherapy: A “HowTo” Technique, Utilizing Helical Tomotherapy and LINAC-based Intensity Modulated Radiotherapy, Int J Radiat Oncol Biol Phys, 78(4):1244-1252, November 2010.

314. PMID: 20859206. Gondi V and Mehta MP: Novel Insights into the Management of Brain Metastases, Current Opinion in Neurology, 23(6):556-562, December 2010.

315. Lawrence YR, Wang M, Dicker A, Andrews D, Curran WJ, Michalski JM, Souhami L, Yung WKA, Mehta M: Acute Neurological Toxicity (NT) and Long-Term Outcomes in High-grade Glioma RTOG Trials, Bodine Journal: Vol. 3: Iss. 1, Article 6, 2010.

316. Gondi V, Tolakanahalli R, Mehta MP, Tomé WA: In Response to Dr. Knisely and Colleagues, Int J Radiat Oncol, Biol, Phys, 79 (3), 958, 2011.

317. PMID: 21135269. Mehta M: “The Dandelion Effect: Treat the Whole Lawn or Weed Selectively?” Journal of Clinical Oncology, 29 (2), 121-4, Jan 2011.

318. PMID: 20938339. Sylvester RK, Steen P, Tate J, Mehta M, Petrich RJ, Berg A, Kolesar J: Temozolomide-induced severe myelosuppression: analysis of clinically-associated polymorphisms in two patients, Anti-Cancer Drugs, 22:104-110, Jan 2011.

319. PMID: 21295876. Tome WA, Bender ET, Gondi V, Mehta MP: In response to “The distribution of brain metastases in the perihippocampal region (Regarding Gondi et al., Radiother Oncol 2010; 95:327–331) by van Kesteren et al, Radiother Oncol, 98:284, Feb 2011.

320. PMID: 21310734. Reardon DA, Galanis E, DeGroot JF, Cloughesy TM, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY: Clinical Trial End Points for High-Grade Glioma: The Evolving Landscape. NeuroOncol, 13:353-361, Mar 2011.

321. PMID: 21112157. Nieder C, Mehta MP: Advances in Translational Research Provide a Rationale for Clinical Re-evaluation of High-dose Radiotherapy for Glioblastoma, Med Hypotheses, 76:410-413, Mar 2011.

322. PMID: 21487410. Lawrence YR, Wang M, Dicker A, Andrews D, Curran WJ, Michalski JM, Souhami L, Yung WK, Mehta M: Early Toxicity Predicts Long-Term Survival in High-Grade Glioma, Br J Cancer, 104:1365-71, Apr 2011.

323. PMID: 21622124. Choucair A, Moughan J, Schultz C, Schulsinger A, Mehta M, Curran W: Prognostic Value of h-mlh1 After Adjusting for RPA Class in GBM Patients. Front BioSci, 3:1182-91, Jun 2011.

324. PMID: 21477946. Vogelius IR, Westerly DC, Cannon GM, Mackie TR, Mehta MP, Sugie C, Bentzen SM: Intensity Modulated Radiotherapy Might Increase Pneumonitis Risk Relative toThree-Dimesional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: a Modeling Study of Dose Dumping.

Int J Radiat Oncol Biol Phys, 80:893-899, Jul 2011.

325. PMID: 20972603. Thomas S, Mehta M, Kuo J, Robins I, Khuntia D: Current Practices of Driving Restriction Implementation for Patients with Brain Tumors. J NeuroOncol, 103:641-647, Jul 2011.

326. PMID: 21632852. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, DeAngelis L, Camphausen K, Chen A, Yung WKA, Prados M, Wen PY, Heymach JV: Myeloid Biomarkers Predict Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept , Clin Ca Res, 17:4872-81, Jul 2011.

327. PMID: 21606416. de Groot JF, Lamborn KL, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson E, Lieberman F, Robins HI, Mehta MP, DeAngelis LM, Yung WK, Chen AP, Prados MD, Wen PY: Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. J Clin Oncol.

29:2689-95, Jul 2011.

328. PMID: 20539207. Chi A, Tome WA, Fowler J, Komaki R, Nguyen NP, Mehta MP, Welsh JS: Stereotactic Body Radiation Therapy in Non-Small-Cell Lung Cancer: Linking Radiobiological Modeling and Clinical Outcome, Am J Clin Oncol, 34:432-41, Aug 2011.

329. PMID: 20805738. Soisson ET, Mehta MP, Tomé WA: A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases. Am J Clin Oncol, 34:388-394, Aug 2011.

330. PMID: 21221714. Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, Souhami L, Chakravarti A, Yung AWK, DelRowe J, Coughlin CT, Mehta MP: Age as an Independent Prognostic Factor in Patients with Glioblastoma: A Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base Comparison, J NeuroOncol, 104:351-356, Aug 2011.

331. PMID: 21316783. Schubert LK, Gondi V, Sengbusch E, Westerly DC, Soisson ET, Paliwal BR, Mackie TR, Mehta MP, Patel RR, Tomé WA, Cannon GM: Dosimetric Comparison of Left-sided Whole Breast Irradiation with 3DCRT, Forward-planned IMRT, Inverse-planned IMRT, Helical Tomotherapy, and Topotherapy, Radiother Oncol, 100:241-246, Aug 2011.

332. PMID: 21768451. Wen PY, Schiff D, Cloughsey TF, Reardon DA, Batchelor TT, Chabner B, Flaherty K, DeGroot J, Gilbert MR, Galanis E, Chang SM, Peereboom D, Mehta M, Yung WKA, Grosman S, Praos MD, DeAngelis LM: It Is Time To Include Brain Tumors in Phase I Trials in Oncology, J Clin Oncol, 29:3211-3213, Aug 2011.

333. PMID: 21767173. Vogelius IR, Westerly DC, Aznar MC, Cannon GM, Korreman SS, Mackie TR, Mehta MP, Bentzen SM: Estimated Radiation Pneumonitis Risk after Photon versus Proton Therapy Alone or Combined with Chemotherapy for Lung Cancer. Acta Oncol. 2011 50:772-6, Aug 2011.

334. PMID: 21955197. Alexander BM, Mehta MP: Role of Isocitrate Dehydrogenase in Glioma. Expt Rev Neurotherapeutics 11:1399-409, Oct 2011.

335. PMID: 21813511. Clarke JL, Ennis MM, Yung WKA, Chang S, Wen PY, Cloughsey TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD: Is Surgery at Progression a Prognostic Marker for Improved 6-month Progression-free Survival or Overall Survival for Patients with Recurrent Glioblastoma? Neuro-Oncol, 10:1118-1124, Oct 2011.

336. PMID: 22059152. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Iwanami A, Tanaka K, Gini B, DeJesus J, Lisiero D, Huang T, Prins R, Wen PY, Robbins IH, Prados MD, DeAngelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS: An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent Pathway, Cancer Discov, 1: 442-456, Oct 2011. Erratum in: Cancer Discov, 2:290-1, Feb 2012. PMID: 22059152.

337. PMID: 22655242. Shirazi HA, Grimm S, Raizer J, Mehta MP: Combined Modality Approaches in the Management of Adult Glioblastoma, Front Oncol, 1:36-47, Oct 2011.

338. PMID 20888136. Li J, Wang M, Won M, Shaw E, Coughlin C, Curran WJ, Mehta M: Validation and Simplification of the Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) Classification for Glioblastoma (GBM), Int J Radiat Oncol Biol Phy, 81:623-630, Nov 2011.

339. PMID: 23251128. Leal T, Chang JE, Mehta M, Robins HI: Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Am J Clin Oncol 7:319-327, Nov 2011.

340. PMID: 21523486. McHaffie D, Chabot P, Dagnault A, Suh J, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, Schultz C, Werner-Wasik M, Gaspar L, Suh J, Brachman D, Mody T, Mehta MP: Safety and Feasibility of Motexafin Gadolinium Administration with Whole Brain Radiation Therapy and Stereotactic Radiosurgery Boost in the Treatment of < 6 Brain Metastases: A Multi-Institutional Phase II Trial, J Neurooncol, 105:301-308, Nov 2011.

341. PMID: 22162886. DeCamp MM and Mehta MP: Pro: Lung Cancer in 2011: A Time for Optimism and Investment in New Approaches and Technologies with a Commitment to Produce Evidence-Based Data, Am J Respir Crit Care Med, 184:1231-1234, Dec 2011.

342. PMID: 20934264. Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Lee PM, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, CloughesyTF: A phase I trial of Tipifarnib with Radiation Therapy, with and without Temozolomide, for Newly Diagnosed Glioblastoma Patients, Int J Radiat Oncol, Biol, Phys, 81: 1422-1427, Dec 2011.

343. PMID: 24048799. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H: Presentation, Patterns of Care and Survival in Patients with Brain Metastases: What Has Changed in the Last 20 Years? Cancer, 117(11):2505-2512, June 1 2011.

344. Koneru R, Mehta MP: Brain Metastases: Clinical Trials and Techniques of Radiotherapy, J Clin Oncol (ASCO Edu Supplement), 94-97, 2011.

345. TomĂŠ WA, Hodge CW, Mehta MP, Bentzen SM: Incidence of Rib Fractures after Stereotactic Body Radiotherapy for Peripheral Lung Lesions: Clinical Experience and Dose Response Estimation, Journal of SRS and SBRT, 1:155-161, 2011.

346. Sperduto, P. W.; Chao, S. T.; Suh, J.; Sneed, P. K.; Luo, X.; Roberge, D.; Bhatt, A.; Mehta, M.P.; Jensen, A. W.; Brown, P. D.; Shih, H.; Kirkpatrick, J.; Gaspar, L. E.; Fiveash, J. B.; Chiang, V.; Knisely, J.; Sperduto, C. M. Reply to drs. Mulvenna and holt.

Int J Radiat Oncol Biol Phys 81:1194-1195, 2011.

347. Hodge CW, Tome W, Weigle T, Traynor A, Mehta MP: Initial Clinical Experience with Stereotactic Lung Radiotherapy, Based on a Biological Model-Driven Prescription Method. J Radiosurg SBRT, 1:221-229, 2011.

348. Kruser TJ, Tome WA, Seo S, Kuo J, Turski P, Chappell RJ, Scrimger RA, Mehta MP: Prognostic Factors for Complete Obliteration of Arteriovenous Malformations Treated with LINAC-based Stereotactic Radiosurgery, J Radiosurg SBRT, 3:203-211, 2011.

349. PMID: 21739168. Gilbert MR, Kuhn J, Lamborn K, Lieberman F, Wen P, Mehta M, Cloughsey T, Lassman AB, DeAngelis L, Chang S, Prados M: Cilengitide in Patients with Recurrent Glioblastoma: the Results of NABTC 03-02, a Phase II Trial with Measures of Treatment Delivery. J NeuroOncol, 106(1):147-153, Jan 2012.

350. PMID: 22203767. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin NL, Mehta M: Summary Report on The Graded Prognostic Assessment: an Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients with Brain Metastases, J Clin Oncol, 30(4):419-25, Feb 2012.

351. PMID: 22212630. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta M, Winkler F, Wick W, von Deimling A: Brain Metastases: Pathobiology and Emerging Targeted Therapies, Acta Neuropathol, 123(2): 205-22, Feb 2012.

352. PMID: 22271472. Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH: Randomized Phase III Study of Thoracic Radiation in Combination with Paclitaxel and Carboplatin with or without Thalidomine in Patients

with Stage III Non-Small Cell Lung Cancer: the ECOG 3598 Study, J Clin Oncol, 30(6):616-22, Feb 2012.

353. PMID: 22123260. Tsao MN, Khuntia D, Mehta MP: Brain Metastases: What’s New With an Old Problem? Curr Opin Support Palliat Care, 6(1):85-90, Mar 2012.

354. PMID: 22380400. Tome W, Gondi V, Mehta MP: In Regards to Kirby et al, Physics Strategies for Sparing Neural Stem Cells During Whole-Brain Radiation Treatments, Med Phys 39(3):1677-8, March 2012.

355. PMID: 21497451. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M: Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients with Breast Cancer and Brain Metastases, Int J Radiat Oncol Biol Phys, 82(5):2111-17, April 2012.

356. PMID: 22426925. Ogiwara H, Kalakota K, Rakhra SS, Helenowski IB, Marymont MH, Kalapurakal JA, Mehta MP, Levy RB, Chandler JP: Intracranial Relapse Rates and Patterns, and Survival Trends Following Post-resection Cavity Radiosurgery for Patients with Single Intracranial Metastases, J Neurooncol, 108(1):141-6, May 2012.

357. PMID: 22588883. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda M, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan C, Heguy A, Liau L, Lieberman F, Yung WKA, Gilbert M, Reardon D, Drppatz J, Wen P, Lamborn K, Chang S, Prados M, Fine H, Horvath S, Wu N, Lassman A, DeAngelis L, Yong W, Kuhn J, Mischel P, Mehta M, Cloughesy T, Mellinghoff IK: Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors, Cancer Discov 2(5):458-71, May 2012.

358. PMD: 22594900. Caine C, Mehta MP, Laack NN, Gondi V: Cognitive Function Testing in Adult Brain Tumor Trials: Lessons from a Comprehensive Review. Expert Rev Anticancer Ther, 12(5):655-667, May 2012.

359. PMID: 22544733. Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW: A Nomogram for Individualized Estimation of Survival among Patients with Brain Metastasis, Neuro Oncol, 14(7):910-8, July 2012.

360. PMID: 22851558. Shaw EG, Wang M, Coons SW, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert M, Mehta M: Randomized Trial Of Radiation Therapy Plus Procarbazine, Lomustine And Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802, J Clin Oncol, 30(25):3065-70, July 2012.

361. PMID: 22665539. Jakacki RI, Burger P, Zhou T, Holmes E, Kocak M, Onar A, Goldwein J, Mehta M, Packer R, Tarbell N, Fitz C, Vezina G, Hilden J, Pollack I: Outcome of Children with Metastatic Medulloblastoma Treated with Carboplatin During Craniospinal Radiotherapy: A Children’s Oncology Group Phase I/II Study, J Clin Oncol, 30(21):2648-53, July 2012.

362. Sperduto P, Kased NW, Roberge D, Xu Z, Shanley R, Luo X, Sneed P, Chao S, Weil R, Suh J, Bhatt A, Jensen A, Brown P, Shih H, Kirkpatrick J, Gaspar L, Fiveash J, Chiang V, Knisely J, Sperduto C, Lin N, Mehta M: Reply to Chamberlain et al, J Clin Oncol, 30:3316-17, September 2012.

363. PMID: 23028253. Nieder C, Grosu AL, Mehta MP: Brain Metastases Research 19902010: Pattern of Citation and Systematic Review of Highly Cited Articles, Scientific World J, Article ID 721598, pp1-9, http://dx.doi.org/10.1100/2012/721598, October 2012.

364. PMID: 23078894. Sperduto PW, Sneed PK, Roberge D, Shanley R, Luo X, Luo X, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Knisely JPS, Lin N, Mehta M: In Regard to Yamamoto, et al. Int J Radiat Oncol Biol Phys, 84(4):875-6, November 2012.

365. PMID: 23099651. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WKA, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY: Phase I/II Study of Sorafenib in Combination with Temsirolimus for Recurrent Glioblastoma or Gliosarcoma: North American Brain Tumor Consortium Study 05-02, Neuro Oncol, 14(12):1511-8, December 2012.

366. PMID: 23180870. Wang M, Dignam JJ, Zhang QE, Degroot J, Mehta MP, Hunsberger S, Integrated Phase II/III Clinical Trials in Oncology: A Case Study, Clin Trials, 9:741747, December 2012.

367. PMID: 23071247. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M: Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402, J Clin Oncol, 31:337-43, January 2013.

368. PMID: 23086432. Alexander B, Wang M, Yung WK, Fine HA, Donahue BA, Tremont IW, Richards RS, Kerlin KJ, Hartford AC, Curran WJ, Mehta MP: A Phase II Study of Conventional Radiation Therapy and Thalidomide for Supratentorial, Newly Diagnosed Glioblastoma (RTOG 9806). J Neuro Oncol 111(1):33-39, January 2013.

369. PMID: 23646269. Lall RR, Shafizadeh SF, Lee KH, Mao Q, Mehta M, Raizer J, Bendok BR, Chandler JP: Orbital Metastasis of Pituitary Growth Hormone Secreting Carcinoma Causing Lateral Gaze Palsy: Case Report, Pathology Review, and Review of the Literature. Surgical Neurology International, 4(1):59 Apr 18 2013.

370. PMID: 23312272. Gondi V, Herman B, Mehta MP, Tome WA: Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors, Int J Radiat Oncol Biol Phys, 85(2):348-54, February 2013.

371. PMID: 23748827. Choi M, Hayes J, Mehta MP, Swisher A, Small WJ, Mittal BB, MacVicar GR, Kalapurakal JA, Sejpal SV: Using Intensity Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report, Tumori 99(2):38e-42e, Mar-Apr 2013.

372. PMID: 23182702. Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M: RTOG 0211: A Phase 1/2 Study of Radiation Therapy with Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients, Int J Radiat Oncol Biol Phys, 85(5):1206-11, April 2013.

373. PMID: 23391814. Sperduto PW, Wang M, Robins HI, Schell M, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski M, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry GA, Suh JH, Mehta MP: A Phase III Trial of Whole Brain Radiation Therapy (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus WBRT and SRS with Temozolomide (TMZ) or Erlotinib for Non-Small Cell Lung Cancer and 1-3 Brain Metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85(5):1312-1318, April 2013.

374. PMID: 23545054. Kruser T, Robins HI, Mehta MP: Pseudoprogression after Glioma Therapy: A Comprehensive Review, Expert Rev Neurother, 13(4):389-403, April 2013.

375. PMID: 23544937. Raparia K, Villa C, Decamp M, Patel JD, Mehta M: Molecular Profiling in Non Small Cell Lung Cancer: A Step Towards Personalized Medicine, Arch Pathol Lab Med, 137(4):481-91, April 2013.

376. PMID: 23462853. Sperduto PW, Kased N, Roberge D, Chao S, Stanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisley JP, Sperduto CM, Lin N, Mehta, M: The Effect Of Tumor Subtype On The Time From Primary Diagnosis To Development Of Brain Metastases And Survival In Women With Breast Cancer. J Neuro Oncol 112(3):467-72, May 2013.

377. PMID: 23503600. Lin S, George T, Ben-Josef E, Bradley J, Choe K, Edelman M, Guha C, Krishnan S, Lawrence T, Quynh-Thu L, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver M, C. Coleman CN, Vikram B, Yoo S, Chung C: Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy, JNCI 105(10):686-93, May 2013.

378. Robins HI, Oâ&#x20AC;&#x2122;Neil A, Mehta M, Grossman S: A Phase III Trial of Whole Brain Radiation Therapy (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus WBRT & SRS with Temozolomide (TMZ) or Erlotinib for Non-Small Cell Lung Cancer and 13 Brain Metastases: Radiation Therapy Oncology Group 0320 Int J of Radiation Oncol Biol Phys, 86(5):809-810, September 2013.

379. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Henson JW, F. Hodi S, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff DS, Sneed PK, Soffietti R, Suh J, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY: Response Assessment in Neuro-Oncology (A Report of the RANO Group): Challenges Relating To Solid Tumor Brain Metastases in Clinical Trials, Part 1: Patient Population, Response, and Progression, Lancet Oncol, 14:e407-16, September 2013.

380. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh J, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi S, Macdonald DR, Wen PY: Response Assessment in Neuro-Oncology (A Report of the RANO Group): Challenges Relating To Solid Tumor Brain Metastases in Clinical Trials, Part 2: Neurocognitive,

Neurological, and Quality of Life Outcomes, Lancet Oncol, 14:e407-16, September 2013.

381. PMID: 24252135. Krauze AV, Won, M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA.: Predictive Value of Tumor Recurrence using Urinary Vascular Endothelial Factor Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme, Biomark Res, 1(1):29-34, Oct 31 2013.

382. Gilbert MR, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Janzer R, Blumenthal D, Mahajan A, Schultz CJ, Erridge S, Brown P, Miraminoff R, Chakravarti A, Curran WJ, Mehta MP: Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: a Randomized Phase III Clinical Trial. J Clin Oncol, 31 (32):4085-90, Nov 10 2013.

383. Armstrong T, Wefel J, Wang M, Gilbert M, Won M, Bottomley A, Mendoza T, Coens C, Werner-Wasik M, Brachman D, Choucair A, Mehta M: Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma, J Clin Oncol, 31 (32):4076-84, Nov 10 2013.

384. PMID: 23357968. Kruser TJ, McCabe BP, Mehta MP, Khuntia D, Campbell TC, Geye HM, Cannon GM: Reirradiation for Locoregionally Recurrent Lung Cancer: Outcomes in Small Cell and Non-small Cell Lung Carcinoma, Am J Clin Oncol (epub ahead of print Jan 24 2013).

385. PMID: 23388565. Refaat T, Choi M, Gaber G, Kiel K, Mehta M, Gradishar W, Small W: Markov Model and Cost effectiveness analysis of Bevacizumab in HER 2-negative metastatic breast cancer, Am J Clin Oncol, 2012(epub ahead of print Feb 5 2013).

386. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D: Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (WBRT): First Report of RTOG 0614, a Placebo-Controlled, DoubleBlind, Randomized Controlled Trial, Neuro-Oncol, 15(10):1429-1437, October 2013 (advance e aaccess as of 08/16/2013).

387. Gorlia T, Wu W, Wang M, Baumert BG, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den Bent M: New Validated Prognostic Models and Prognostic Calculators in Patients with Low Grade Gliomas Diagnosed by Central Pathology Review: A Pooled Analysis of EORTC/RTOG/NCCTG Phase III Clinical Trials, Neuro-Oncol, 2013. (advance e access as of 09/18/2013).

388. Anderson BM, Khuntia D, Hayes LL, Bentzen SM, Kuo J, Baskaya M, Badie B, Basvatia A, Pyle M, TomĂŠ WA, Mehta MP: Single Institution Experience Treating 104 Vestibular Schwannomas With Fractionated Stereotactic Radiation Therapy or Stereotactic Radiosurgery, J NeuroOncol, (online access as of 10/20/13).

389. Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, TomĂŠ WA, Chappell R, Tolakanahalli R, Bentzen SM, Cannon GM: Dose Limiting Toxicity Following Hypofractionated Dose-Escalated Radiotherapy in Non-Small Cell Lung Cancer, J

Clin Oncol, Published 10.1200/JCO.2013.51.5353.

Ahead

of

Print

on

October

21,

2013

as

390. Chinnaiyan PC, Won M, Wen P, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW, Mehta MP: RTOG 0913: A Phase I Study of Daily Everolimus (RAD001) In Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma, Int J Radiat Oncol Biol Phys (in press as of 4/17/2013).

391. Cairncross G, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W: Benefit from PCV in Oligodendroglial Tumors is Associated with Mutation of IDH, J Clin Oncol, (accepted 10/8/13).

392. Prabhu RS, Won M, Shaw EG, Wang M, Brachman DG, Mehta MP: The Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients with Low Grade Glioma: Secondary Analysis of RTOG 98-02, JCO, 2013 (accepted 10/15/13).

393. Wen PY, Chang SM, LambornKR, Kuhn J, Norden AD, Cloughesy TF, Robins HI, Lieberman F, Gilbert MR, Mehta M, Drappatz J, Groves M, Santagata S, Ligon A, Yung WKA, Wright J, Dancey J, Aldape K, Prados MD, Ligon KL: Phase I/II Study of Erlotinib and Temsirolimus for Patients with Recurrent Malignant Glioma: North American Brain Tumor Consortium (NABTC) Trial 04-02, Neuro-Oncology (accepted 11/15/2013).

394. Erkkinen MG, Palanichamy K, Saia GL, Siedow M, Stupp R, Mehta M, Aldape K, Colman H, Gilbert MR, Loeffler JS, Calvert HA, Plummer RE, Mischel P, Robe P, Chakravarti A: Poly(ADP-ribose) Polymerase-1 Inhibition-Mediated Enhancement of Radiation and Temozolomide in Glioblastoma: Underlying Mechanisms. Clin Ca Res, 2011 (submitted) 395. Mukherjee N, Robe PA, Mukherjee S, McL Black P, Loeffler JS, Carroll RS, Aldape K, Mischel PS, Hegi M, Mehta M, Stupp R, Chakladar A, Chakravarti A: GSEA and ASSESS transcriptome analysis identify biochemical pathways of prognostic significance in malignant gliomas. Clin Ca Res, 2011 (submitted).

396. Moots PL, O’Neill A, Londer H, Mehta M, Blumenthal DT, Barger GR, Grunnet ML, Gilbert M, Grossman S, Schiff D: A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults with “Poor Risk” Medulloblastoma, PNET and Disseminated Ependymoma: A Trial Coordinated by the Eastern Cooperative Oncology Group E4397, Neuro Oncol, 2012 (submitted 07/12).

397. Platta CS, Kruser TJ, Weigel TL, Tomé WA, Das RK, Geye HM, Khuntia K, Mehta MP Cannon GM: Sublobar Resection with Intraoperative 125I Brachytherapy vs Stereotactic Body Radiation Therapy for Treatment of Clinical Early Stage Non-Small Cell Lung Cancer in Patients not Eligible for Lobectomy, Int J Radiat Oncol Biol Phys, 2012 (submitted 10/12).

398. Feliciano J, Feigenberg S, Mehta M: Chemoradiation for Definitive, Pre-operative, or Post-Operative Therapy of Locally Advanced Non-Small Cell Lung Cancer, Ca J (submitted 2/13).

399. Jakacki RI, Burger PC, Kocak M, Boyett JM, Goldwein J, Mehta M, Packer RJ, Tarbell N, Pollack IF: Outcome And Prognostic Factors For Children With Supratentorial Primitive Neuroectodermal Tumors (Spnet) Treated With Carboplatin During Craniospinal Radiotherapy: A Report From The Childrenâ&#x20AC;&#x2122;s Oncology Group, JCO (submitted July 2013).

400. Wang M, Dignam J, Curran W, Mehta M, Gilbert M: Variation over time and interdependence between disease progression and death among patients with Glioblastoma (GBM) on RTOG 0525, 2013, Neuro Oncol (submitted August 2013).

401. Peereboom D, Lin N, Sperduto, P, Mehta MP: An Overview of New Approaches to Outcome Measures and Clinical Trial Designs for Brain Metastases, Int J Surg Oncol, 2013 (in submission).

402. Gondi V, Eickhoff J, Tome WA, Kozak KR, Kuo J, Robins HI, Mehta MP: Assessing the Survival Benefit of Early Adjuvant Radiotherapy for Resected Supratentorial Grade II Glioma in Adults using the Surveillance, Epidemiology, and End Results Database, Int J Radiat Oncol Biol Phys, 2013 (in submission).

403. Palanichamy K, Patel D, Gordon N, Erkkinen M, Reardon Z, Noda S, Robe PA, Bredel M, Chiocca AE, Mehta MP, Chakravarti A: Towards Personalizing Therapy in Gliomas: Gene Status Determines the Radio-sensitizing Effect of Akt Kinase Inhibitor in Malignant Gliomas, Clin Ca Res, 2013 (in submission).

404. Lieberman FS, Wang M, Tsien C, Curran WJ, Werner-Wasik M, Smith RP, Grossheim LD, Hartford AC, Robins HI, Mehta M: Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma Multiforme: Radiation Therapy Oncology Group Trial 0420, 2013 (in submission).

405. Mehta MP, Refaat T, Choi M, Wang M, Gilbert M, Vogelbaum M, Aldape K, Chakravarti A, Corn B, Pajak T, Scott C, Seiferhald W, Machtay M, Curran W: Radiation Therapy Oncology Group Brain Tumor Committee: History and Achievements, 2013 (in submission).

406. Liu FF, Okunieff P, Bernhard EJ, Stone H, Yoo S, Coleman CN, Vikram B, Brown M, Buatti J, Guha C, Mehta MP, and Workshop Participants: Lessons Learned from Radiation Oncology Clinical Trials, 2013 (in submission).

407. Shah A, Kalakota K, Bit-Ivan EN, Gallagher T, Bigio EH, Mehta M: Case Report of Disseminated Osseous Metastases of Intracranial Meningioma with Literature Review (in submission 2013).

408. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal D, Vogelbaum MA, Aldape K, Colman H, Chakravarti A, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Atkins JN, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Curran WJ, Mehta MP: Bevacizumab for newly diagnosed glioblastoma: A placebo controlled, double-blinded, randomized phase III clinical trial (in submission 2013).

409. Yoon H, Perumal K, Helenowski IB, Chappell RJ, Akture E, Lin Y, Marymont MH, Chandler J, Bendok B, Rosenow J, Salamat S, Raizer J, Baskaya MK, Mehta MP: Prognostic factors and outcome of atypical and anaplastic meningioma with and without radiation (in submission 2013).

410. Brachman DG, Wang M, Ashby LS, Thomas TA, Dunbar EM, Rockhill JK, Khuntia D, Bovi JA, Macher MS, Mehta MP: Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM): Final Results of RTOG 0513. (in submission, August 2013) 411. Niyazi M, Weller M, Mehta MP, Chakravarti A, NN, Goldbrunner R, Combs SE: State of the Art Glioma Therapy. (in submission, September 2013) 412. Vogelbaum MA, Wang M, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP: Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligoastrocytomas: Long Term Results of RTOG BR0131 (in submission, October 2013) 413. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP: Preservation of Memory with Conformal Avoidance of the Hippocampal Neural Stem Cell Compartment during Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase 2 Multi-Institutional Trial (in submission, December 2013) PUBLICATIONSâ&#x20AC;&#x201C;ABSTRACTS: 1.

Wiley Jr AL, Wirtanen GW, Mehta MP, Ramirez G: Prophylactic liver therapy with intra-arterial 5-FU and X-ray therapy. Proceedings of the 3rd International Conference on Advances in Regional Cancer Therapy. Neu-Ulm, West Germany, pp 40, 1987.

2.

Thomadsen BR, Shahabi S, Buchler DA, Giese WL, Mehta MP: Differential loading of the brachytherapy template. Radiology 165(P):69, 1987.

3.

Wiley Jr AL, Wirtanen GW, Mehta MP, Ramirez G: Prophylactic combined hepatic artery 5-Fluorouracil infusion and hepatic X-ray therapy for pancreatic carcinoma.

Digestive Diseases and Sciences 32:1190, 1987.

4.

Mehta MP, Kubsad SS, Verma AK, Kinsella TJ: An in vivo model for dosimetric analysis of radiolabeled monoclonal antibodies. American Association of Cancer Research Proceedings 29:429, 1988.

5.

Goetowski P, Mehta MP, Stephenson J, Kinsella TJ: Radiation-induced thyroid cancer, 1920-1987: a vanishing phenomenon? Int J Radiat Oncol Biol Phys 15 (S1):139, 1988.

6.

Mehta MP, Goetowski P, Shahabi S, Kinsella TJ: Endobronchial brachytherapy for malignant airway obstruction. Int J Radiat Oncol Biol Phys 15(S1):119, 1988.

7.

Wiley Jr AL, Mehta MP, Wirtanen GW, Ramirez G: Chemoradiotherapy for unresectable biliary carcinoma. Int J Radiat Oncol Biol Phys 15 (S1):240, 1988.

8.

Shahabi S, Mehta MP: The physics of endobronchial brachytherapy and the role of CT planning for 3-D dosimetry. Phys Med Bio 33(1):130, 1988.

9.

Shahabi S, Kubsad SS, Mehta MP, Stephenson J, Kinsella TJ: A technique for partial shielding in pelvic interstitial implants. Med Phys 16:474 (P3-1), 1989.

10.

Shahabi S, Mehta MP, Thomadsen BR, Kinsella TJ: Use of computerized tomographic dosimetric planning for optimization of pelvic interstitial implants. Med Phys 16:474 (P-3-2), 1989.

11.

Mackie TR, Kubsad SS, Mehta MP, Misisco D, Sohn W, Gehring MA, Paliwal BR, Loper D, Thomadsen BR, Shahabi S: Physical aspects of stereotactic radiotherapy using a linear accelerator. Med Phys 16:460 (E-7), 1989.

12.

Shanahan TG, Mehta MP, Gehring MA, Buchler DA, Kubsad SS, Kinsella TJ: Minimization of small bowel volume utilizing customized "belly board" mold. Int J Radiat Oncol Biol Phys 17(S):187-18, 1989.

13.

Gehring MA, Mackie TR, Kubsad SS, Paliwal BR, Mehta MP, Kinsella TJ: An improved ray casting technique for surface-shaded display: applications in radiation treatment planning. Int J Radiat Oncol Biol Phys 17(S):126, 1989.

14.

Kubsad SS, Mackie TR, Gehring MA, Paliwal BR, Mehta MP, Kinsella TJ: Monte Carlo and convolution dosimetry for stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 17(S):196, 1989.

15.

Mehta MP, Kubsad SS, Fowler JF, Kinsella TJ: Radioimmunotherapy: dosimetric and biological analysis. Int J Radiat Oncol Biol Phys 17(S):21, 1989.

16.

Shahabi S, Mehta MP, Kubsad SS, Thomadsen BR, Kinsella TJ: Direct computerized tomographic (CT) dosimetry of endobronchial implants. Int J Radiat Oncol Biol Phys 17(S):239, 1989.

17.

Mehta MP, Goetowski PG, Kinsella TJ: Radiation-induced thyroid neoplasms, 19201987: A vanishing problem? Oncology Review: Late sequelae of cancer therapy in children and adolescents, pp 56, October 1989.

18.

Mehta MP, Steinmetz MC, Harmon MW, Kubsad SS, Gehring MA, Mackie TR: Brain tumor response following stereotactic radiotherapy. American Society of Clinical Oncology Proceedings 9:91, 1990.

19.

Harmon MW, Mehta MP, Shahabi S, Steinmetz MC, Thomadsen BR, Fowler JF: Conventional versus hyperfractionated high dose rate endobronchial radiation. Int J Radiat Oncol Biol Phys 19(S):232-233, 1990.

20.

Mehta MP, Steinmetz MC, Harmon MW, Kubsad SS, Mackie TR, Gehring MA, Levin AB, Kinsella TJ: Stereotactic radiation: Evaluation of brain tumor response. Int J Radiat Oncol Biol Phys 19(S):269, 1990.

21.

Mehta MP, Petereit DG, Harmon MW, Shahabi S, Thomadsen BR, Fowler JF: Hyperfractionated high dose rate endobronchial radiation. Endocurie/Hypertherm Oncol 7:81, 1991.

22.

Mehta MP, Schiller JH, Bastin KT, Kinsella TJ: Pilot study of WR 2721/CDDP/VLB and sequential TRT/WR 2721 in Stage III NSCLC: Preliminary results. American Society of Clinical Oncology Proceedings 10:263, 1991.

23.

Mehta MP, Shanahan TG: "Belly board" for radiotherapy. Contemporary Oncology 1:60, 1991.

24.

Gehring MA, Mackie TR, Sanders CL, Reckwerdt PJ, Kubsad SS, Mehta MP: 3-D visualization tools for stereotactic radiosurgery treatment planning. Med Phys 18:602 (E-1), 1991.

25.

Thomadsen BR, Shahabi S, Buchler DA, Mehta MP, Paliwal BR: Anatomy of two high dose rate misadministrations. Med Phys 18:645 (P-45), 1991.

26.

Mackie TR, Gehring MA, Reckwerdt PJ, Sanders CL, Mehta MP, Kubsad SS: A fast algorithm for dose computation and arc weighting for stereotactic radiosurgery. Med Phys 18:646 (P-48), 1991.

27.

Harmon MW, Petereit DG, Mehta MP, Fowler JF, Shahabi S, Thomadsen BR, Kinsella TJ: Sequential comparison of LDR and hyperfractionated HDR EBRT for MAO. Int J Radiat Oncol Biol Phys 21(S):137-138, 1991.

28.

Petereit DG, Mehta MP, Turski PA, Strother CM, Levin AB, Mackie TR, Gehring MA, Kinsella TJ: The role of magnetic resonance angiography in the radiosurgical management of arteriovenous malformations. Int J Radiat Oncol Biol Phys 21(S):196, 1991.

29.

Mehta MP, Levin AB, Rozental JM, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 21(S):172, 1991.

30.

Bastin KT, Mehta MP, Levin AB, Rozental JM, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Radiosurgery for gliomas. Radiology 181(P):139, 1991.

31.

Bastin KT, Mehta MP, Kinsella TJ: Quantitative analysis of lung sparing following endobronchial boost in Stage III non-small cell lung carcinoma treated curatively.

Endocurie/Hypertherm Oncol 7:225, 1992.

32.

Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Is inguino-femoral irradiation as effective as lymphadenectomy for N0, N1 vulvar disease? Int J Radiat Oncol Biol Phys 24(S):145-146, 1992.

33.

Mehta MP, Petereit DG, Harmon MW, Shahabi S, Thomadsen BR, Fowler JF: Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. Respiratory Diseases Digest 1:16-17, 1993.

34.

Bastin KT, Mehta MP, VerHoeve JN, Chandra B, Thomadsen BR, Lipman R, Knudson K, Kinsella TJ: Selective optic nerve irradiation simulating radiosurgery: An animal model. Proceedings of the 41st Annual Meeting of Radiation Research Society, pg. 172 P-33-8, 1993.

35.

Mehta MP, Thomas AM, Levin AB, Kinsella TJ: Preliminary analysis of multivoxel 1H MR spectroscopic imaging for CNS neoplasms. Proceedings of 41st Annual Meeting of Radiation Research Society, pg. 132 P-24-7, 1993.

36.

Mehta MP, Storer B, Schiller JH: Phase II study of WR 2721/Cisplatin/Vinblastine, followed by thoracic radiation (TRT) and WR 2721, in Stage III non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Proceedings 12:359, 1993.

37.

Mehta MP, Werwie S, Levin AB, Kinsella TJ: Surgery vs radiosurgery for brain metastases. Acta Neurochirurgica 122:Fasc. 1-2, 157-158, 1993.

38.

Levin AB, Mehta MP, Masciopinto JE, Rohde B: Stereotactic radiosurgery for glioblastoma multiforme. Acta Neurochirurgica 122:Fasc. 1-2, 154, 1993.

39.

Bastin KT, Mehta MP, Rogers P, Miles J, Kinsella TJ: Correlation of post-radiosurgical tumor histopathology with radiographic changes. Int J Radiat Oncol Biol Phys 27 (S):152, 1993.

40.

Mehta MP, Masciopinto JE, Bastin KT, Levin AB, Chappell RJ, Miles J, Kinsella TJ: Glioblastoma treated with external beam radiotherapy and stereotactic radiosurgery boost. Int J Radiat Oncol Biol Phys 27 (S):153, 1993.

41.

Thomas AM, Khorsand M, Miles J, Levin AB, Sebree L, Bianco JA, Mehta MP, Puccetti DM, Turski PA, Javid MJ: 1H and 31P MR spectroscopy of human brain tumors in vitro. Radiology 189 (P): 393, 1993.

42.

Schiller JH, Mehta MP, Larson M, Storer B, Reynolds R, Capizzi R: Amifostine, cisplatin and vinblastine for advanced non-small cell lung cancer. Lung Cancer 11:178, 1994.

43.

Mehta MP, Storer B, Larson M, Kinsella TJ, Schiller JH: High response rate for advanced non-small cell lung cancer with amifostine, cisplatin, vinblastine and radiation. Proceedings of the American Society of Clinical Oncology 13:349,1994.

44.

Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Kinsella TK: Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 30:164-5, 1994.

45.

Mehta MP, Rozental JM, Levin AB, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Defining the role of radiosurgery in the management of brain metastases. The International Monitor in Oncology, 1994.

46.

Schiller JH, Storer B, Berlin JD, Wittenkeller J, Larson M, Pharo L, Larson M, Mehta MP, Reynolds R, Capizzi R: Amifostine, plus chemotherapy for advanced non-small cell lung cancer. Cancer Investigation 13 (Supplement 1):9-12, 1995.

47.

Mehta MP, Larson M, Storer B, Schiller JH: Phase II clinical trial of amifostine, cisplatin, vinblastine (ACV) and radiation therapy (RT) for unresectable Stage III nonsmall cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, 14:373,1995.

48.

Prados M, Schold C, Spence A, Berger M, McAllister L, Mehta M, Gilbert M, Fulton D, Chang S: Phase II study of Taxol in patients with recurrent glioma: North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology, 14:146,1995.

49.

Baker EH, Sorenson JA, Mehta MP: Segmentation of the AVM nidus for radiosurgery planning. Proceedings of the 2nd Congress of the International Stereotactic Radiosurgery Society, 2:87-88, 1995.

50.

Noyes WR, Mehta MP, Auchter RM, Lamond JP, Levin AB, Alexander E, Loeffler JS: Radiosurgery for single brain metastases: Outcome and cost analysis. Proceedings of the 2nd Congress of the International Stereotactic Radiosurgery Society, pp 57-58, 1995.

51.

Mehta MP: An overview of the current status of outcomes measures in therapeutic radiology. Medical Physics 22:954, 1995.

52.

Tannehill SP, Mehta MP, Larson M, Storer B, Schiller JH: Phase II clinical trial of amifostine (WR 2721), cisplatin (C), vinblastine (V) (ACV) and thoracic radiation therapy (RT) for unresectable Stage III non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 32:196, 1995.

53.

Yao-Long M, Mehta MP, Donohue B, Zeltzer P, Boyett JM, Kinsella TK: Patterns-offailure in CCG 921, a Phase III study of chemoradiotherapy in high-risk intracranial PNET. Int J Radiat Oncol Biol Phys 32:182, 1995.

54.

Baker EH, Mehta MP, Sorenson JA: Definition of AVM nidus for radiosurgery using segmentation tools. Int J Radiat Oncol Biol Phys 32:285, 1995.

55.

Mehta MP: Stereotactic radiosurgery: Metastatic brain lesions. Proceedings of the UCLA Fifth Annual Workshop on Minimally Invasive Therapy of the Brain pp 117120, Santa Monica, CA, 1995.

56.

Mehta MP, Masciopinto JE, Rozental JM, Levin AB, Chappell RJ, Bastin KT, Miles J, Turski PA, Kubsad SS, Mackie TR, Kinsella TJ: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Year Book of Oncology, 1995.

57.

Kesava PP, Baker EH, Mehta MP, Turski PA: Pre-radiosurgery classification of AVMs using MRI 3-D time-of-flight MRA, anatomic surface rendering and phase contrast flow analysis. Proc Am Roentgen Ray Soc 95:81, 1995.

58.

Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell RJ, Friedman W, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP: A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastases. Int J Radiat Oncol Biol Phys 35:27-35, 1996.

59.

Donahue B, Mehta MP, Prados MD, Allen J, Wara W, Newall J: Absence of radionecrosis following high-dose posterior fossa hyperfractionated radiotherapy for primitive neuroectodermal tumors. Proceedings of the 64th Annual Meeting of the American Association of Neurological Surgeons pp 212, 1996.

60.

Chang SM, Schold CS, Spence AM, Berger MS, McAllister L, Mehta MP, Gilbert MR, Fulton D, Prados MD: Phase I/II study of Paclitaxel chemotherapy for recurrent malignant glioma: Preliminary report. North American Brain Tumor Consortium.

Proceedings of the American Society of Clinical Oncology 15:153, 1996.

61.

Prados MD, Spence AM, Schold CS, Robins HI, Mehta MP, Berger MS, Kuhn J, Rector D, Chang SM, Gilbert MR: A Phase II trial of phenylacetic acid for recurrent malignant glioma: Preliminary report of the North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology 15:156, 1996.

62.

Berlin JD, Schiller JH, Hutson PR, Feierabend C, Simon K, Alberti D, Arzoomanian RZ, Boothman DA, Planchon S, Wuerzberger S, Glen V, Mehta MP, Wilding G: Phase I clinical and pharmacokinetic study of daily topotecan with thoracic irradiation.

Proceedings of the American Association of Cancer Research 37:164, 1996.

63.

Fahl WE, Holt RW, Mehta MP: Cancer education: Past, present and future. The preclinical oncology educational program at the University of Wisconsin. J Cancer Education 11:17, 1996.

64.

Tannehill SP, Froseth C, Wagner H, Petereit DP, Mehta MP: A multi-institutional Phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer: Initial report of ECOG 4593. Int J Radiat Oncol Biol Phys 36:207, 1996.

65.

Mehta MP: The current status of radiosurgery. Int J Radiat Oncol Biol Phys 36:112, 1996.

66.

Mehta MP: Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. Int J Radiat Oncol Biol Phys 36:142, 1996.

67.

Mehta MP, Rozental JM, Puccetti DM, Robins HI: Sequential combination chemotherapy and radiotherapy of malignant brain tumors in children and adults.

Cancer Invest 15:10-11, 1997.

68.

Tannehill SP, Mehta MP, Froseth C, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D: Phase II trial of hyperfractionated accelerated radiation therapy (HART) for unresectable non-small cell lung cancer(NSCLC): preliminary results of ECOG 4593. Proceedings of the American Society of Clinical Oncology 16: 446a,1997.

69.

Schulz CA, Mehta MP, Robins HI, Badie B, Arzoomanian RZ, Simon K, Alberti D, Feierabend C, Kinsella TJ, Wilding G: A Phase I study of iododeoxyuridine and accelerated hyperfractionated radiotherapy for malignant gliomas. Proceedings of the American Society of Clinical Oncology 16:249a, 1997.

70.

Kuhn JG, Rizzo J, Chang SM, Schold C, Spence AM, Berger MS, Robins HI, Mehta MP, Bozik ME, Fulton D, Rector D, Prados MD: Effects of anticonvulsants (ACs) on the pharmacokinetics (PK) and metabolic profile of paclitaxel. Proceedings of the American Society of Clinical Oncology 16: 224a, 1997.

71.

Mehta MP, Tannehill SP, Martin L, Froseth C, Wagner H, Johnson D: ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for non-small cell lung cancer (NSCLC): Early results and RT quality assurance (QA). Lung Cancer 18:123, 1997.

72.

Nag S, Abitbol A, Erickson B, Fontanessi J, Hilaris BS, Martinez A, Mehta M, Nori D, Orton C, Porter AT, Speiser B, Stitt J, Young D: Survey of brachytherapy practice for carcinoma of the cervix in the United States-a report of the American Brachytherapy Society (ABS). 19th Annual Brachytherapy Society Meeting Proceedings, pg 7, 1997.

73.

Mehta MP: Radiation Pneumonitis: Clinical spectrum, molecular pathophysiology, treatment and prevention. 5th International Conference on Dose, Time and Fractionation in Radiation Oncology Meeting Proceedings, pg 29, 1997.

74.

Schulz CA, Mehta MP, Robins HI, Badie B, Arzoomanian R, Simon K, Alberti D, Feierabend C, Kunugi KA, Wilding G, Kinsella TJ: Continuous 28 day iododeoxyuridine (IudR) and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: a phase I clinical and thymidine replacement study. Int J Radiat Oncol Biol Phys 37:139, 1997.

75.

Boyd T, Mehta MP, Donohue B, Prados M, Allen J: Feasibility & acute toxicities of craniospinal hyperfractionated radiotherapy (CHFRT) for high-risk intracranial primitive neuroectodermal tumors (HRPNET); CCG 9931; a groupwide Phase II study of intensive chemoradiotherapy (CT) and CHFRT. Int J Radiat Oncol Biol Phys 37:144, 1997.

76.

Mehta MP, Adak S, Wagner H, Cella D: Experience with the functional assessment of cancer therapy-lung (FACT-L) in ECOG 4593, a Phase II hyperfractionated accelerated radiation therapy (HART) trial. Int J Radiat Oncol Biol Phys 37:232, 1997.

77.

Bastin KT, Mehta MP: Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: a rabbit model using visual evoked potentials, fundoscopy and histology. Int J Radiat Oncol Biol Phys 37:226, 1997.

77.

Mehta MP: Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. Int J Radiat Oncol Biol Phys 37:123, 1997.

78.

Mehta MP: Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on Amifostine. Proceedings of Advances in Therapy: Protecting against the toxicities of radiotherapy, pg 12, 1997.

79.

Mehta MP, Sinha P, Fahl W, Kanwar K, Inman A: A randomized assessment of the value of Web-based education for teaching second year medical students. J Cancer Education 12 (S):27, 1997.

80.

Mehta MP: Book Review: Principles and Practice of Radiation Therapy: Introduction to Radiation Therapy, CM Washington and DT Leaver (eds). Med Phys 24:929,1997.

81.

Chang S, Kuhn J, Schold C, Spence A, Berger M, Mehta M, Bozik M, Gilbert M, Robins I, Fulton D, Rankin C, Prados M: Phase I study of Paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Report. Proceedings of the Society of Neuro-Oncology, 1997.

82.

Prados M, Rankin C, Kuhn J, Bozik M, Gilbert M, Spence A, Berger M, Mehta M, Robins I, Schold C, Chang S: Phase II study of Phenylacetate (PAA) in patients (pts) with recurrent malignant glioma (MG): a North American Brain Tumor Consortium report. Proceedings of the Society of Neuro-Oncology, 1997.

83.

Nguyen P, Miranpuri S, Olsen M, Kesava P, Badie B, Mehta MP: Comparative assessment of response analysis techniques for CNS neoplasms. Proceedings of the Congress of Neurological Surgeons, 1997.

84.

Carde P, Timmerman B, Koprowski D, Arwood J, Ford J, Larner J, Mehta M, Tishler R, Rosenthal D, Engel J, Miller M, Renschler M: Gadolinium-Texaphyrin (Gd-Tex) radiation sensitizer: improved survival in a Phase IB/II trial in patients with brain metastases. Proceedings of the American Society of Clinical Oncology 17:379a, 1998.

85.

Kesslering C, Renschler M, Vanel D, Mathews V, Rosenthal D, Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Miller R, Mehta M. Selective uptake and retention of the radiation sensitizer Gadolinium Texaphyrin (Gd-Tex) in tumors demonstrated

by MRI in Phase I and Phase II clinical trials. Int J Radiat Oncol Biol Phys 42:263, 1998.

86.

Sanghavi S, Krailo M, Needle M, Geyer J, Ater J, Mosher R, Mehta M. Topotecan, as a radiosensitizer, for brainstem glioma (BSG) of childhood: First report of CCG 0952, a Phase I study. Int J Radiat Oncol Biol Phys 42:357, 1998.

87.

Schulz C, Miranpuri S, Chappell R, Kesava P, Nguyen P, Olsen M, McNutt T, Mehta M. Comparison of methods for response analysis of central nervous system neoplasms. Int J Radiat Oncol Biol Phys 42:261, 1998.

88.

Egorin M, Miles D, Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Mehta M, Miller R, Renschler M. Pharmacokinetics of the radiation sensitizer Gadolinium Texaphyrin in a Phase IB/II trial for patients with brain metastases receiving whole brain radiation. Int J Radiat Oncol Biol Phys 42:263, 1998.

89.

Timmerman B, Carde P, Koprowski C, Arwood D, Ford J, Mehta M, Tishler R, Larner J, Miller R, Koffler-Horovitz S, Hoth D, Renschler M. Phase IB/II trial of the radiation sensitizer Gadolinium Texaphyrin (Gd-Tex) for patients with brain metastases: Final results. Int J Radiat Oncol Biol Phys 42:198, 1998.

90.

Schold C, Kuhn J, Chang S, Bosik M, Mehta M, Robins IH, Fink KL, Spence A, Fulton D, Rector D, Prados MD. A Phase I Trial of BCNU + Temozolomide: A North American Brain Tumor Consortium Study. Proceedings of the Society for NeuroOncologyâ&#x20AC;&#x2122;s 3rd Annual Scientific Meeting, 1998.

91.

Harari PM, Kanwar K, Inman A, Kesslering C, Boyd T, Sanghavi S, Sinha P, Mehta M. Web-based multi-media modules for oncology grand rounds: Preliminary evaluation of listener satisfaction and knowledge gain. AACE 32nd annual meeting. J Ca Edu, 13:18, 1998.

92.

Mehta M, Ford J, Carde P, Timmerman R, Renschler M. Gadolinium Texaphyrin (GdTex), a tumor selective radiation sensitizer for primary and metastatic brain tumors.

Neuro-Oncology 1:540, 1999.

93.

Sanghavi S, Skrupky R, Badie B, Robins, I, Mehta M. Recurrent malignant gliomas treated with radiosurgery. Proceedings of the American Association of Neurological Surgeons 4th Annual Meeting, New Orleans, LA, # 1427, pg 245, April 1999.

94.

Mehta MP: Pediatric Brain Tumors: Innovative therapeutic approaches-radiotherapy.

Proceedings of the 4th International Symposium on Special Aspects of Radiotherapy: Controversies in Pediatric Oncology, Berlin, Germany, April 1999.

95.

Needle MN, Mehta M, Krailo M, Geyer JR, Ater JL, Mosher R; The Childrens’ Cancer Group, Arcadia, CA. Phase I Study of Topotecan as a Radiosensitizer Prior to Daily Involved Field Irradiation in Children with Intrinsic Pontine Glioma. A Childrens’ Cancer Group Study. Proceedings of the American Society of Clinical Oncology, 18:558A, 1999.

96.

Berlin JD, Schiller JH, Mehta MP, Hutson PR, Boothman DA, Alberti DB, Feierabend CA, Kehrli NJ, Binger KA, Kavka JE, Pomplun ML, Wahamaki AS, Storer B, Arzoomanian RZ, Wilding G: Phase I study of topotecan and thoracic radiation.

Proceedings of the American Society of Clinical Oncology, 18:175A, 1999.

97.

Sanghavi SN, Miranpuri SS, Chappell R, Mabanta S, Suh JH, Regine WF, Weltman E, Sneed PK, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Buatti JM, Mehta MP: Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification. Int J Radiat Oncol Biol Phys 45:171, 1999.

98.

Mehta MP, Meyers CA, Renschler MF, Eisenberg PD, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Arwood D, Cmelak AJ, Rao A, Brereton H, Timmerman RD, Phan SC, DeVault AR, Curran WJ, Gaspar L. Clinical trial of Gadolinium Texaphyrin (Gd-Tex) in patients with brain metastases. Int J Radiat Oncol Biol Phys 45:320, 1999.

99.

Sanghavi S, Miranpuri SS, Chappell R, Buatti JM, Suh JH, Regine WF, Weltman E, Sneed PK, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Mehta M: Multiinstitutional analysis of survival outcome for radiosurgery treated patients with brain metastases, stratisfied by RTOG RPA classification. Neuro-Oncology 1:337, 1999.

100. Robins IH, Mehta M, Chang S, Yung A, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Trask D, Prados MD. A Phase II Trial of Thymidine and Carboplatin for Recurrent Malignant Glioma: A North American Brain Tumor Consortium (NABTC) Study. Proceedings of the Society for Neuro-Oncology’s 4th Annual Scientific Meeting, Scottsdale, AZ, November 1999.

101. Meyers CA, Mehta M, Eisenberg P, Schultz CJ, Ford JM, Roa W, Leibenhaut M, Phan SC, Renschler MF. Neurocognitive impairment in brain metastasis patients. NeuroOncology 1:326, 1999.

102. Mehta MP, Eisenberg P, Schultz CJ, Ford JM, Roa W, Leibenhaut M, Sze G, Einstein S, Renschler MF, Phan SC. Computer assisted masked MRI analysis of volumetric response: Implementation for a Phase III protocol of gadolinium texpaphyrin (GdTex) in patients with brain metastases. Neuro-Oncology 1:325, 1999.

103. Sanghavi SN, Mehta M: Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification.

Proceedings of the 85th Scientific Assembly and Meeting of RSNA, Chicago IL, December, 1999.

104. Sanghavi S, Miranpuri S, Chappel R, Mabanta S, Regine W, Weltman E, Sneed P, Goetsch J, Breneman J, Sperduto P, Scott C, Buati J, Mehta M: Multi-institutional analysis of prognostic factors and survival outcome for radiosurgery treated patients with brain metastases, stratified by RTOG RPA classification. Proceedings of the LINAC Radiosurgery Annual Scientific Meeting, pg 37, Orlando, FL, December 1999 105. Mehta MP, Sanghavi SN, Miranpuri, SS, Chappell, R, Mabanta SR, Suh JH, Regine WF, Weltman E, Sneed PK, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Buatti JM: A Multi-Center database analysis predicting survival benefit for brain metastases patients treated with radiosurgery. Cancer J, 6:408, 2000.

106. Grossman SA, Oâ&#x20AC;&#x2122;Neil A, Grunnet M, Mehta M, Pearlman J, Wagner H, Gilbert M, Newton H, Hellman R: Phase III study comparing three cycles of infusional BCNU/Cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394SWOG 9503). Proceedings of the American Society of Clinical Oncology, 19:158a, 2000.

107. Robins HI, Prados MD, Rao DR, Chang S, Yung A, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Mehta MP. A Phase II trial of thymidine and carboplatin for recurrent malignant gliom: A North American Brain Tumor Consortium (NABTC) study. Proceedings of the American Society of Clinical Oncology 19:166a, 2000.

108. Schulz C, Mehta M, Robins HI, Badie B, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Wilding G, Kinsella T, et. al.: Continuous 28-day iododeoxyuridine (IudR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A Phase I Trial. Proceedings of the American Society of Clinical Oncology 19:194a, 2000.

109. Shaw E, Scott C, Stea B, Suh J, Kadish S, Hackman J, Pearlman A, Gerber M, Murray K, Gaspar L, Mehta M, Curran W: Survival improvement with RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison to the radiation therapy oncology group recursive partitioning analysis brain metastases database.

Proceedings of the American Society of Clinical Oncology, 19:159a, 2000.

110. Merchant J, Hammes L, Brophy D, Larson M, Ripple G, Mehta M, Kim K, Schiller JH: Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology 19:541a, 2000.

111. Mehta M, Meyers C, Schultz C, Ford J, Roa W, Leibenhaut M, Eber D, Phan S, Renschler M: Neurocognitive function (NF) predicts outcome in patients with brain

metastases (BM) treated with whole brain radiation (WBRT) and Xyctrin. Proceedings of the American Society of Clinical Oncology 19:164a, 2000.

112. Mehta MP, Meyers CA, Curran WJ, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Cmelak AJ, Rao A, Timmerman RD, Gaspar L, Phan SC, Eber D, Renschler MF: Xcytrin™ (Motexafin Gadolinium) and Whole Brain Radiation for Patients with Brain Metastases: Lead-In Phase to Randomized Trial – Final Results. Int J Radiat Oncol Biol Phys 48:204, 2000.

113. Shaw E, Scott C, Stea B, Suh J, Kadish S, Hackman J, Pearlman A, Gerber M, Murray K, Gaspar L, Mehta M, Curran W: RSR13 plus cranial radiation therapy improves survival in patients with brain metastases compared to the RTOG recursive partitioning analysis brain metastases database: Update of a Phase II trial. Int J Radiat Oncol Biol Phys 48:203, 2000.

114. Allen J, Prados M, Donahue B, Mehta M, Robertson P, Jakacki R, Sposto R: Phase I/II Study for Newly Diagnosed High Risk PNET Consisting of Neoadjuvant Chemotherapy (CHT) Followed by Hyperfractionated Radiotherapy (RT) – Preliminary Results of CCG Protocol 9931. Neuro-Oncology 2(4):247, 2000.

115. Prados MD, Yung WKA, Fine H, Greenberg H, Junk L, Chang S, Nicholas MK, Robins HI, Mehta MP, Fink K, Schiff D, Jaeckle KA, Kuhn J, Hess K, Schold C: A Phase II Study of BCNU and Temozolomide for Recurrent Glioblastoma Multiforme: A North American Brain Tumor Consortium Study. Neuro-Oncology 2(4):287, 2000.

116. Scrimger RA, Mehta MP, Chappell RC, Tome WA: Spetzler grade and minimum dose are the most important prognostic factors in AVMs treated with stereotactic radiosurgery. Proceedings of the LINAC Radiosurgery Annual Scientific Meeting, pg 74-75, December 2000.

117. Forrest LJ, Vail DM, Smilowitz JB, Mackie TR, Olivera GH, Reckwerdt P, Mehta MP. Helical Tomotherapy. Vet Radiol Ultrasound 2000;41:573, 2000.

118. Mehta MP, Larson M, Schiller J: Phase I Trial of Gemcitabine as a Radiosensitizer for Non-Small Cell Lung Cancer. 5th Annual US Gemzar Investigators Meeting, Orlando, FL, March 2001.

119. Mehta M, Ames M, Reid J, Vezina G, Kuttesch J, LaFond D, Pollack I, Reaman G, Shaw D, Timmerman R, Krailo M: Phase I study of Motexafin-Gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): A Childrens’ Oncology Group study. Proceedings of the American Society of Clinical Oncology 20: 62a(# 243), 2001.

120. Forouzannia A, Mehta MP, Schiller JH, Hutson PR, Alberti DB, Feierabend CA, Kehrli NJ, Binger KA, Howard S, Pomplun ML, Wahamaki AS, McFarland T, Arzoomanian RZ, and Wilding G: Phase I Study Of Topotecan and Thoracic Radiation. Proceedings of the American Society of Clinical Oncology 20: 269b(# 2826), 2001.

121. Scott C, Seiferheld W, Prados M, Mehta M, Curran W: Is time to tumor progression (TTP) an appropriate endpoint for clinical trials in anaplastic astrocytomas (AA)?

Analysis of Radiation Therapy Oncology Group (RTOG) study 9404. Proceedings of the American Society of Clinical Oncology 20: 51a(#200), 2001.

122. Sze G, Mehta M, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Cmelak AJ, Rao A, Timmerman RD, Gaspar L, Curran WJ, Phan SC, DeVault A, Renschler MF: Radiologic Response Evaluation Of Brain Metastases: Uni-Dimensional (1d) W.H.O. Recist Vs. Bi-Dimensional (2d) Or 3-Dimensional (3d) Criteria. Proceedings of the American Society of Clinical Oncology 20: 59a(# 234), 2001.

123. Mehta MP: Activities of the RTOG Brain Tumor Committee, 1996-2001. Neuro-Oncol 3:S26 (abstract 108), 2001.

124. Shaw E, Scott C, Stea B, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M: Phase II study of RSR13 + cranial radiation therapy in patients with brain metastases. Neuro-Oncol 3:S40 (abstract 166), 2001.

125. Miller RA, Renschler MF, Phan SC, Mehta MP: Motexafin Gadolinium: A tumor selective radiation enhancer for treatment of brain metastases. Radiation Research P26-349, 165, 2001.

126. Mehta MP: Lung Cancer: Dose Escalation Matters. Proceedings of the Sixth International Conference on Time Dose and Fractionation, pg 43-45, 2001.

127. Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz CJ, Timmerman R, Illidge T, Meyers CA, Curran WJ, Phan SC, Smith J, Renschler MF: Impairment of neurocognitive function in brain metastases patients: baseline results from the Phase III trial with Motexafin Gadolinium. Int J Rad Oncol Biol Phys 51:135 (abstract 242), 2001.

128. Forouzannia A, Sze G, Mehta M, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Rao A, Cmelak AJ, Timmerman RD: Brain Metastases Regress Isometrically Following Radiation Therapy, Allowing the use of 1D W.H.O. RECIST Criteria for Adequate Response Evaluation. Int J Rad Oncol Biol Phys 51:250 (abstract 2048), 2001.

129. Rodrigus P, Mehta MP, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz CJ, Timmerman R, Illidge T, Curran WJ, Phan SC, Smith J, Renschler MF: Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with Motexafin Gadolinium.

Int J Rad Oncol Biol Phys 51:410 (abstract 2349), 2001.

130. De Stasio G, Frazer BH, Gilbert B, Schaub S, Mercanti D, Casalbore P, Larocca LM, Rinelli A, Mehta MP, Pallini R: Tumor-Specific Intracellular Delivery of Gadolinium for Glioblastoma. Int J Rad Oncol Biol Phys 51:251 (abstract 2050), 2001.

131. Kapatoes JM, Olivera GH, Schloesser EA, Pearson DW, Balog JP, Ruchala KJ, Schmidt R, Reckwerdt P, Mehta MP, Mackie TR: Gating-by-Rotation: A Solution to the Problem of Intratreatment Motion in Helical Tomotherapy. Int J Rad Oncol Biol Phys 51:95 (abstract 169), 2001.

132.

Mehta MP, Seiferheld W, Delrowe J, MacDonald D, Langer C, Scott C, Curran W, Yung A: Glioblastoma Multiforme: The Phase II RTOG Experience. Neuro-Oncol 3:350 (abstract 332), 2001.

133. Mehta M, Hayes L, Robins HI, Badie, B, Rao R: Acute Side Effects of Radiosurgery.

Neuro-Oncol 3:351 (abstract 333), 2001.

134. Chadha S, Salamat M Sh, Mehta M: Lack of Correlation between HER2/neu Expression, Histologic Parameters, and Cell Proliferation Indices in Oligodendrogliomas. Neuro-Oncol 3:326 (abstract 243), 2001.

135. De Stasio G, Frazer BH, Gilbert B, Schaub S, Mercanti D, Casalbore P, Larocca LM, Rinelli A, Mehta MP, Pallini R: Tumor-Specific Intracellular Delivery of Gadolinium in Glioblastoma. Neuro-Oncol 3:348 (abstract 322), 2001.

136. MP Mehta, P Rodrigus, C Terhaard, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, and MF Renschler. Impaired Neurocognitive Function (Ncf) In Brain Metastasis (Bm) Patients (Pts) Is Strongly Correlated With Worse Quality Of Life (Qol): Baseline Results From The Phase III Trial Of Motexafin Gadolinium (MGD).

Neuro-Oncol 3:292-3 (abstract 292), 2001.

137. Passe SM, Law ME, Cairncross JG, Curran WJ, Scott CB, Mehta M, Scheithauer BW, Jenkins RB: A Pilot Analysis of 1p and 19q Deletions in Anaplastic Oligodendrogliomas and Mixed Oligoastrocytomas from RTOG Trial 94-02. NeuroOncol 3:332 (abstract 263), 2001.

138. Cloughsey T, Kuhn J, Robins I, DeAngelis L, Chang S, Schiff D, Wen P, Yung A, Gilbert M, Fink K, Junck L, Abrey L, Leiberman F, Mehta M, Reizer J, Prados M: Phase I trial of R115777 in patients with recurrent malignant glioma taking enzyme inducing antiepileptic drugs (EIAED). North American Brain Tumor Consortium. NeuroOncol 3:357 (abstract 358), 2001.

139. Cloughsey T, Kuhn J, Wen P, Chang S, Schiff D, Greenberg H, Junck L, Robins I, DeAngelis L, Yung A, Fink K, Abrey L, Leiberman F, Mehta M, Reizer J, Hess K, Prados M: Phase II trial of R115777 in patients with recurrent malignant glioma not taking enzyme inducing antiepileptic drugs (EIAED). North American Brain Tumor Consortium. Neuro-Oncol 3:357 (abstract 359), 2001.

140. Heiner J, Mehta M, Bailey H, Fowler J, Kinsella T, Lamson M, Storm FK: Neoadjuvant adriamycin and twice daily radiotherapy in adult soft tissue sarcoma. Proceedings of the Connective Tissue Oncology Society (abstract 22), 2001.

141. W Seiferheld, MP Mehta, J Delrowe, D MacDonald, C Langer, C Scott, W Curran, A Yung: Five Years of Glioblastoma Multiforme (GBM) Phase II Trials at the Radiation Therapy Oncology Group (RTOG). Proceedings of the American Society of Clinical Oncology 21: 71a(# 281), 2002.

142. Wagner LI, Rue M, Fisch M, Cleeland C, Bonomi PD, Schiller JH, Mehta MP, Petereit D, DeVore RF, Johnson DH, Cella D. Neuropsychiatric Symptoms During Cancer Treatment: An Examination of Quality of Life Data from Two ECOG Lung Cancer Trials. Proceedings of the American Society of Clinical Oncology 21: 357a(#1426), 2002.

143. Cloughesy T, Kuhn J, Wen P, Chang S, Schiff D, Greenberg H, Junck L, RobinsI, DeAngelis LM, Yung A, Fink K, Abrey L, Lieberman F, Mehta M, Reizer J, Hess K and

Prados M. Phase II Trial of R115777 in Patients with Recurrent Glioma not taking Enzyme Inducing Antiepileptic Drugs (EIAED). A Preliminary Report.

North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology 21: 80a(#317), 2002.

144. PY Wen, WKA Yung, K Hess, S Silberman, M Hayes, D Schiff, F Lieberman, T Cloughesy, LM DeAngelis, S Chang, L Junck, H Fine, K Fink, I Robbins, J Raiser, L Abrey, M Mehta, E Maher, PM Black, R Capdeville, R Kaplan, A Murgo, C Stiles, MD Prados. Phase I Study of STI571 (Gleevec) For Patients With Recurrent Malignant Gliomas and Meningiomas (NABTC 99-08). Proceedings of the American Society of Clinical Oncology 21: 73a(#288), 2002.

145. Kuhn J, Prados M, Robins I, DeAngelis LM, Chang S. Schiff D, Wen P, Yung A, Gilbert M, Fink K, Greenberg H, Junck L, Abrey L, Lieberman F, Mehta M, Reizer J, Hess K, and Cloughesy T. Phase I Trial of R115777 (Zarnestra) in Patients with Recurrent Malignant Glioma taking Enzyme Inducting Antiepileptic Drugs (EIAED). A North American Brain Tumor Consortium (NABTC) Report. Proceedings of the American Society of Clinical Oncology 21: 86a(#342), 2002.

146. J Suh, E Chang, R Timmerman, J Yamada, L Gaspar, M Leibenhaut, A Rao, S Phan, WK A Yung, M Mehta. Phase II Trial of Motexafin Gadolinium (MGd, XcytrinR) and Cranial Radiation in Newly Diagnosed Glioblastoma Multiforme. Proceedings of the American Society of Clinical Oncology 21: 74b(#2108), 2002.

147. P Rodrigus, MP Mehta, C Terhaard, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, and MF Renschler. Impaired Neurocognitive Function in Brain Metastasis Patients is Strongly Correlated with MRI Tumor Volume and Tumor Histology: Baseline Results from the Phase III Trial of Motexafin Gadolinium.

Proceedings of the American Society of Clinical Oncology 21: 74a(# 292), 2002.

148. DR Miles, JM Ford, MP Mehta, C Schultz, P de Brouwer, H Dehnad, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, SJ Hutcheson, G Boswell, S Phan, and M Renschler. An evaluation of gender, alkaline phosphatase, and cytochrome P450 on Motexafin Gadolinium pharmacokinetics in Patients with brain tumors using a population pharmacokinetic analysis. Proceedings of the American Society of Clinical Oncology 21: 119a(#474), 2002.

149. C Terhaard, MP Mehta, P Rodrigus, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, and MF Renschler. Quality of Life (QOL) in Patients (Pts) with Brain Metastases (BM) is Strongly Related to MRI Tumor Volume and Neurocognitive Function (NCF): Baseline Results from the Phase III Trial of Motexafin Gadolinium (MGd). Proceedings of the American Society of Clinical Oncology 21: 73a(# 290), 2002.

150. MP Mehta, P Rodrigus, C Terhaard, A Rao, J Suh, W Roa, WR Shapiro, MJ Glantz, RA Patchell, MA Weitzner, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, RA Miller, and MF Renschler. Results from the Phase III Trial of Motexafin Gadolinium (MGd) in Brain Metastases. Proceedings of the American Society of Clinical Oncology 21: 72a(# 286), 2002.

151. Mehta MP, Larson M, Schiller J. Phase I Trial of Gemcitabine as a Radiosensitizer for Non-Small Cell Lung Cancer. Proceedings of the Third International Lung Cancer Conference. Abstract #6, 2002.

152. RA Miller, MP Mehta, W Curran, S Phan, MF Renschler. Motexafin Gadolinium (MGd) Prolongs Time to Neurologic Progression in Lung Cancer Patients with Brain Metastases: Results of a Randomized Phase III Trial. Proceedings of the Third International Lung Cancer Conference. Abstract #5, 2002.

153. Tremont-Lukats IW, Herman MA, Meyers CA, Mehta MP, Renschler MF, Trask DD, Froseth C: Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Neuro-Oncol 4 (S1): S 98 (abstract 418), 2002.

154. Ruchala K, Olivera G, Forrest L, Mehta M, Kapatoes J, Welsh J, Mackie T. Megavoltage CT for image-guided radiotherapy. Radiother & Oncol 64 (S1): S12 (abstract 37), 2002.

155. Welsh J, Mehta M, Olivera G, Forrest L, Forouzannia A, Kapatoes J, Ruchala K, Lu W, Reckwerdt P, Mackie T. Helical tomotherapy: an innovative technology for delivery of intensity modulated radiotherapy. Radiother & Oncol 64 (S1): S211 (abstract 697), 2002.

156. Patel RR, Tome WA, Tannehill SP, Harari PM, Paliwal BR, Mehta MP: Optically Guided Intensity Modulated Radiotherapy for the Head and Neck. Radiother & Oncol 64 (S1): S248 (abstract 835), 2002.

157. Kapatoes JM, Olivera GH, Mehta MP, Mackie TR, Lu W, Ruchala KJ, Jeraj R, Reckwerdt PJ, Balog JP. Breath-hold tomotherapy. Radiother & Oncol 64 (S1): S257-8 (abstract 869), 2002.

158. Tome WA, Jaradat JA, McNutt TR, Meyerand ME, Paliwal BP, Mehta MP. On the use of multimodality imaging in radiation therapy planning of brain tumors. Radiother & Oncol 64 (S1): S298-9 (abstract 1018), 2002.

159. Welsh J, Fowler J, Burkhamer M, Mehta M, Howard S. Radiation dose-rate considerations with intensity modulated radiation therapy. Radiother & Oncol 64 (S1): S312 (abstract 1073), 2002.

160. Paliwal B, Balog J, Tome W, Das R, Richardson S, Mackie R, Mehta M. Tomotherapy: Initial University of Wisconsin experience. Radiother & Oncol 64 (S1): S22 (abstract 68), 2002.

161. Regine WF, Schmitt, FA, Scott C,, Dearth CS, Patchell RA, Nichols RC, Jr. Gore E, Franklin RL III, Suh J, Mehta M. Feasibility of Neurocognitive Evaluations in Patients with Brain Metastases in a Multi-Institutional Cooperative Group Setting: Results of Radiation Therapy Oncology Group (RTOG) Trial BR-0018. Int J Radiat Oncol Biol Phys 54:49 (abstract 79), 2002.

162. M P Mehta, P Rodrigus, C Terhaard, A Rao, J Suh, W Roa, WR Shapiro, M J Glantz, RA Patchell, MA Weitzner, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W J Curran, S Phan, J Smith, A DeVault, R Miller, M F Renschler. Motexafin Gadolinium Prolongs Time to Neurologic Progression in

Lung Cancer Patients with Brain Metastases: Results of a Randomized Phase III Trial.

Int J Radiat Oncol Biol Phys 54:92 (abstract 154), 2002.

163. W Curran, M P Mehta, C Terhaard, A Rao, J Suh, W Roa, WR Shapiro, M J Glantz, RA Patchell, MA Weitzner, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W J Curran, S Phan, J Smith, A DeVault, R Miller, M F Renschler. Predictors of Survival for Patients with Brain Metastases: Results of a Randomized Phase III Trial. Int J Radiat Oncol Biol Phys 54:93 (abstract 155), 2002.

164. L Souhami, C Scott, D Brachman, E Podgorsak, M Werner-Wasik, R Lustig, CJ Schultz, W Sause, P Okunieff, J Buckner, L Zamorano, M Mehta, W Curran.

Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): Report of RTOG 93-05 protocol. Int J Radiat Oncol Biol Phys 54:94 (abstract 158), 2002.

165. W. Seiferheld, A. Chakravarti, K. Ang, E. Hammond, W Curran, M. Mehta.

Overexpression of the Epidermal Growth Factor Receptor (EGFR), as Determined by EGFR Immunostaining on Tissue Microarrays, fails to Demonstrate Independent Prognostic Value for Patients with Glioblastoma Multiforme: A Report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602, and 9806. Int J Radiat Oncol Biol Phys 54:96 (abstract 161), 2002.

166. Tomé WA, Jaradat HA, McNutt TR, Meyerand ME, Mehta MP. Application of multimodality imaging to radiation therapy treatment planning of brain tumors. Int J Radiat Oncol Biol Phys 54:240-1 (abstract 2052), 2002.

167. R Manon, P Chinnaiyan, S Hui, S Phan, J Suh, E Chang, R Timmerman, S Phan, R Das, M Mehta. The Impact of a Mid-Treatment MRI on Defining GBM Boost Volumes. Int J Radiat Oncol Biol Phys 54:245 (abstract 2060), 2002.

168. Suh J, Mehta M, Chang E, Timmerman R, Yamada J, Gaspar L, Leibenhaut M, Rao A, Yung W, Phan S. Phase II Trial of Motexafin Gadolinium (MGd, Xcytrin®) and Cranial Radiation in Newly Diagnosed Glioblastoma Multiforme (GBM). Int J Radiat Oncol Biol Phys 54:245 (abstract 2061), 2002.

169. Bradley K, Hong T, Hayes L, Tomé W, Reznick D, Mehta M. LINAC-based Radiosurgery in the Treatment of Trigeminal Neuralgia: a Preliminary Report. Int J Radiat Oncol Biol Phys 54:303-4 (abstract 2162), 2002.

170. Olivera G, Kapatoes JM, Mehta MP, Ruchala KJ, Reckwerdt P, Jeraj R, Lu W, Mackie TR. Defining the Impact of Beam Parameters in Breath-Hold Tomotherapy. Int J Radiat Oncol Biol Phys 54:315-6 (abstract 2183), 2002.

171. Forrest L, Mackie TR, Ruchala KJ, Mehta MP. Megavoltage CT Images from a Helical Tomotherapy System. Int J Radiat Oncol Biol Phys 54:333-4 (abstract 2211), 2002.

172. Chakravarti A, Seiferheld W, Ang KK, Tu X, Hammond E, Curran W, Mehta M. Epidermal growth factor receptor overexpression, as determined by EGFR immunostaining on tissue microarrays, fails to demonstrate prognostic value for patients with glioblastoma multiforme: a report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602, and 9806. Neuronocol 4:341 (abstract 126), 2002.

173. R Manon, S Hui, P Chinnaiyan, J Suh, E Chang, R Timmerman, S Phan, R Das, M Mehta. Changes in GBM Boost Treatment Volumes with the Implementation of Midtreatment MRI. Neuronocol 4:355 (abstract 174), 2002.

174. Mehta MP, Rodrigus P, Terhaard C, Suh J, Roa W, Souhami L, Bezjak A, Komaki R, Schultz C, Timmerman R, Curran WJ, Meyers C, Phan S, Smith J, Miller R, Renschler MF. Neurocognitive (NC) Changes Following Whole Brain Radiation Therapy (WBRT) for the Treatment of Brain Metastases (BM). Neurooncol 4:355 (abstract 175), 2002.

175. J Michalski, K Winter, M Arquette, J Purdy, D Brachman, W Curran, J Simpson, M Mehta Preliminary Toxicity Report on RTOG 9803, a Prospective Dose Escalation Trial Using 3D Conformal Radiation Therapy (3DCRT) in Glioblastoma Multiforme.

Neurooncol 4:356 (abstract 177), 2002.

176. Patel RR, Jaradat HA, Tome WA, McNutt TR, Meyerand EM, Mehta MP. The influence of physiologic imaging on target volume definition in radiotherapy for brain tumors. Neuroncol 4:357 (abstract 181), 2002.

177. Chang S, Seiferheld W, Curran W, Sharo R, Atkins J, Choucair A, Brachman D, Thoron L, Cairncross G, Gilbert M, Bahary JP, Dolinskas C, Louis D, Bushurnow P, Buckner J, Barger G, Mehta M: Results of the Phase I study pilot arm of radiation therapy and BCNU and Temozolomide for anaplastic astrocytoma (RTOG 9813).

Neurooncol 4:366 (abstract 211), 2002.

178. Chang S, Wen P, Greenberg H, Schiff D, Fine H, Yung A, Fink K, Mehta M, Kuhn J, Cloughesy T, De Angelis L, Hess K, Dancey J, Prados M. Phase I study of CCI-779 in patients with recurrent malignant glioma (MG) on enzyme inducing antiepileptic drugs (EIAEDs). Neurooncol 4:367 (abstract 214), 2002.

179. Meyers CA, Mehta MP, Rodrigus P, Terhaard C, Suh J, Roa W, Souhami L, Bezjak A, Komaki R, Schultz C, Timmerman R, Curran WJ, Meyers C, Phan S, Miller R, Renschler M, Smith J. Motexafin Gadolinium (MGd) Delays Neurocognitive (NC) Progression in Patients with Brain Metastases (BM) from Lung Cancer: Results of a Randomized Phase III Trial. Neurooncol 4:372-3, (abstract 235), 2002.

180. Shapiro, WR, Glantz, MJ, Patchell, RA, Weitzner, MA, Mehta, MP, Suh, J, Souhami, L, Smith, JA, Renschler, MF, Phan, S. Assessment of Time to Neurologic Progression in a Randomized Trial of Brain Metastases Patients. Neurooncol 4:377, (abstract 250), 2002.

181. J Suh, M P Mehta, W J Curran, P Rodrigus, C Terhaard, A Rao, W Roa, L Souhami, A Bezjak, R Komaki, C Schultz, R Timmerman, C Meyers, S Phan, J Smith, R Miller, M F Renschler. Neurocognitive Function at Presentation with Brain Metastases Predicts Survival. Neurooncol 4:377-8, (abstract 253), 2002.

182. Bradley KA, Hong TS, Tome WA, Hayes LL, Peng L, Resnick DK, Mehta MP: Linacbased Radiosurgery in the Treatment of Trigeminal Neuralgia: A Preliminary Report.

Proceedings of the LINAC Radiosurgery Annual Scientific Meeting, pgs 39-40, December 2002.

183. Forouzannia A, Mehta M, Mackie TR, Welsh J. Helical Tomotherapy: An Innovative Technology and Approach for the Delivery of Intensity Modulated Radiation Therapy. Radiology (supplement) 225 (p): 711 (abstract 0541RO-e), 2002.

184. Forrest L, Vail D, Mackie T, Ruchala KJ, Olivera GH, and Mehta M. Helical tomotherapy: Conformal Avoidance and Megavoltage CT Imaging. Vet Radiol Ultrasound 2003; 44:109.

185. MP Mehta: Treatment of Brain Metastases. Proceedings of the VIIIth Congreso de la Sociedad Espanola de Radiocirugia, pgs 22-24, March 2003.

186. McMillan KM, Rogers BP, Tome W, Jaradat HA, Mehta MP, Meyerand ME: MRI Biological Maps to Target Radiation Proceedings of ISMRM 11th Scientific Meeting, 2003.

187. Turek MM, Forrest LJ, Mackie TR, Kapatoes JM, Ruchala KJ, Mehta MP: Helical Tomotherapy: 3-D Set-up Verification and Dose Delivery Implementation in Dogs with Spontaneous Tumors. AACR Proceedings 44:1027 (#4485), 2003.

188. Sebti SM, Paquette S, Kuhn JG, Prados M, Robins HI, DeAngelis LM, Chang SM, Schiff D, Wen P, Yung YKA, Gilbert M, Fink K, Greenberg H, Junck L, Abrey LE, Liberman FS, Mehta MP, Raizer JJ, Hess K, Cloughsey TF: Inhibition of Farnesyltransferase (not Geranylgeranyltransferase I) Enzyme Activity and the Processing of HDJ-2 (not Rap1) in Peripheral Blood Monocytes of Patients with Recurrent Malignant Glioma Treated with Zarnestra in Phase I/II Clinical Trials.

AACR Proceedings 44:1117 (#4871), 2003.

189. Gilbert MR, Wen P, Lieberman F, Robins I, Mehta M, Yung A, Chang S, Junck L, Cloughsey T, Prados M: Phase I/II study of Combination Temozolomide and Irinotecan (CPT-11) for Recurrent Malignant Gliomas: A North American Brain Tumor Consortium (NABTC) Study. ASCO Proceedings 22:103 (#410), 2003.

190. Chang S, Yung A, Kuhn J, Schiff D, Fine H, Mehta M, Robins I, Junck L, Hess K, Prados M: Phase II study of Neoadjuvant BCNU and Temozolomide for Newly Diagnosed Anaplastic Glioma (AG). North American Brain Tumor Consortium.

ASCO Proceedings 22:103 (#413), 2003.

191. Lieberman FS, Cloughsey T, DeAngelis L, Fine H, Fink K, Junck L, Kuhn J, Mehta M, Wen P, Prados M: Phase I-II Study of ZD1839 for Recurrent Malignant Gliomas and Meningiomas Progressing after Radiation Therapy. ASCO Proceedings 22:105 (#421), 2003.

192. Ford J, W. Seiferheld, M. Mehta, S Phan, and W. Curran: Comparison of survival of patients in the phase I study of Motexafin Gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma data base. ASCO Proceedings 22:106 (#425), 2003.

193. Renschler M, Mehta MP, Donald DM, Fondrie P, Phan SC, Whitten TG: Treatment Intent for Brain Metastases: Surveys of Medical and Radiation Oncologists Indicate that Maintaining Neurologic and Neurocognitive Function is more Important than Prolonging Survival. ASCO Proceedings 22:552 (#2222), 2003.

194. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M: Induction Chemotherapy Followed by Standard Thoracic Radiotherapy (Std.Trt) Vs. Hyperfractionated Accelerated Radiotherapy (HART) for Patients with Unresectable Stage IIIA & B Non-Small Cell Lung Cancer (NSCLC): Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597). ASCO Proceedings 22:622 (#2503), 2003.

195. Mehta MP: Radiosurgery Update; Brain and Body. Proceedings of the 6th International Stereotactic Radiosurgery Society Congress, pg 57, abstract# SL-IV 2003.

196. Mehta MP: Radiosurgery for Brain Metastases: Where are we today and where next?

Proceedings of the 6th International Stereotactic Radiosurgery Society Congress, pg 69, abstract# GSS III-1 2003.

197. Tomé W, Bradley K, Hong T, Hayes L, Peng L, Resnick D, Mehta M: LINAC-based Radiosurgery in the Treatment of Trigeminal Neuralgia: A Preliminary Report.

Proceedings of the 6th International Stereotactic Radiosurgery Society Congress, pg 90, abstract# OSS I-A-4, 2003.

198. Hong TS, Tomé WA, Hayes L, Badie B, Mehta MP: Acute Toxicities of Stereotactic Radiosurgery. Proceedings of the 6th International Stereotactic Radiosurgery Society Congress, pg 101, abstract# OSS II-11, 2003.

199. Belani CP, Wang W, Johnson D, Wagner H, Schiller J, Veeder M, Mehta M: Induction Chemotherapy Followed by Standard Thoracic Radiotherapy Vs. Hyperfractionated Accelerated Radiotherapy for Patients with Unresectable Stage IIIA & B Non-Small Cell Lung Cancer: Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597). Proceedings of the Fourth International Lung Cancer Conference, June 2003.

200. Bradley K, Mañon R, Patel R, Henderson D, Wiederholt P, Mehta M, and Welsh J. Megavoltage CT Imaging for Image-guided Lung Cancer Intensity Modulated Radiation Therapy (IMRT). Proceedings of the 10th World Conference on Lung Cancer, 41(suppl 2): S10 (abst #O-22), 2003.

201. Mehta M, Suh J, Rodrigus P, Sagar S, Kunkler I, Meerwaldt J, Siemers R, Carrie C, Smith J, Renschler M, Phan S: Impact of Whole Brain Radiation Therapy (WBRT) and Motexafin Gadolinium (MGd) on Neurologic and Neurocognitive Progression in Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases: Results of a Randomized Phase III Trial. Proceedings of the 10th World Conference on Lung Cancer, 41(suppl 2): S22 (abst #O-66), 2003.

202. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M: Induction Chemotherapy Followed by Standard Thoracic Radiotherapy (Std.Trt) Vs. Hyperfractionated Accelerated Radiotherapy (Hart) for Patients with Unresectable Stage IIIA & B Non-Small Cell Lung Cancer (NSCLC): Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597). Proceedings of the 10th World Conference on Lung Cancer, 41(suppl 2): S39 (abst #O-125), 2003.

203. Suh J, Mehta M, Rodrigus P, Sagar S, Kunkler I, Meerwaldt J, Siemers R, Carrie C, Renschler M, Phan S: Differences in Baseline Characteristics Between Non-Small Cell Lung Cancer and Breast Cancer Patients with Brain Metastases, 41 (suppl 2): S208 (abst #P-465), 2003.

204. Mehta M, Tome W, Scrimger R, Welsh J, Chappell R, Fowler J, Mackie T: An Innovative Technological Radiation Therapeutic Approach for Lung Cancer.

Proceedings of the 10th World Conference on Lung Cancer, 41 (suppl 3): S67-8 (abst #E-53), 2003.

205. Mehta M, Wang W, Johnson D, Wagner H, Schiller J, Veeder M, Belani CP: Induction Chemotherapy Followed by Standard Thoracic Radiotherapy Vs. Hyperfractionated Accelerated Radiotherapy for Patients with Unresectable Stage IIIA & B Non-Small Cell Lung Cancer: Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597). Int J Radiat Oncol Biol Phys 57 (S): S141 (abst # 29), 2003.

206. Brat DJ, Seiferheld W, Perry A, Hammond E, Byhardt R, Schulsinger A, Mehta M, Curran W: FISH Analysis of Genetic Markers of Prognosis for High Grade Astrocyotmas using Tissue Micro-arrays from RTOG Clinical Trials. Radiation Therapy Oncology Group Translational Research Program. Int J Radiat Oncol Biol Phys 57 (S): S135 (abst # 19), 2003.

207. Shaw EG, Seiferheld W, Scott C, Coughlin C, Leibel S, Curran W, Mehta M: Reexamining the Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) for Glioblastoma Multiforme (GBM) Patients. Int J Radiat Oncol Biol Phys 57 (S): S135-6 (abst # 20), 2003.

208. Manon RR, Patel R, Henderson D, Tomé W, Zhang T, Paliwal B, Fenwick J, Mehta M: CT-based Analysis of Free-Breathing (FB) vs. Maximum Inspiratory Breath Hold (MIBH) Techniques for 3-D Conformal Radiation Therapy (3-D CRT) and Intensity Modulated Radiation Therapy (IMRT) in Lung Cancer, and the Potential for DoseEscalation. Int J Radiat Oncol Biol Phys 57 (S): S417 (abst # 2124), 2003.

209. Zhang T, Keller H, Jeraj R, Manon R, Welsh J, Patel R, Fenwick JD, Mehta M, Mackie TR Paliwal B: Breathing Synchronized Delivery – A New Technique for Radiation Treatment of the Targets with Respiratory Motion. Int J Radiat Oncol Biol Phys 57 (S): S185 (abst # 103), 2003.

210. Song S, Tome W, Mackie TR, Mehta MP, Harari PM: Emphasizing Conformal Avoidance Versus Target Definition for IMRT Planning in H&N Cancer. Int J Radiat Oncol Biol Phys 57 (S): S299 (abst # 1065), 2003.

211. Kumar P, Mehta MP, Rodrigus P, Suh J, Sagar S, Kunkler I, Carrie C, Smith JA, Phan SC, Renschler MF: Motexafin Gadolinium (MGd) Overcomes Adverse Survival Effect of Anemia in Brain Metastasis (BM) Patients Treated with Whole Brain Radiation Therapy (WBRT): Analysis of a Phase III Randomized Trial. Int J Radiat Oncol Biol Phys 57 (S): S133 (abst # 16), 2003.

212. Chakravarti A, Seiferheld W, Robins HI, Guha A, Sperduto P, Choucair A, Brachman D, Mehta M: Phase I Results from RTOG BR-0211, a Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), with Radiation Therapy in Glioblastoma Multiforme (GBM). Int J Radiat Oncol Biol Phys 57 (S): S329 (abst # 1113), 2003.

213. Welsh JS, Bradley K, Manon R, Lock M, Patel R, Ruchala K, Mackie TR, Mehta M: Megavoltage CT Imaging for Adaptive Helical Tomotherapy of Lung Cancer. Int J Radiat Oncol Biol Phys 57 (S): S429 (abst # 2146), 2003.

214. Shaw EG, Seiferheld W, Scott C, Coughlin C, Leibel S, Curran W, and Mehta M: Ethnic Differences in Survival of Glioblastoma (GBM): A Secondary Analysis of the Radiation Therapy Oncology Group Recursive Partitioning Analysis (RPA) Database.

Neuro-Oncol 5: 296 (abstract # EP 14), 2003.

215. Brat DJ, Seiferheld W, Perry A, Hammond EH, Murray KJ, Schulsinger A, Mehta M, Curran W: Fluorescence In Situ Hybridization Analysis of 1p, 19q, 9p, and 10q as Prognostic Markers for High-Grade Astrocytomas Using Tissue Micro-arrays from RTOG Trials. Neuro-Oncol 5: 324 (abstract # PA 02), 2003.

216. Cloughesy TF, Kuhn J, Wen P, Chang SM, Schiff D, Greenberg H, Junck L, Robins I, DeAngelis LM, Yung A, Groves M, Fink K, Abrey LE, Lieberman F, Mehta MP, Raizer JJ, Lamborn K, Prados M: Two Phase II Trials of R115777 (Zarnestra) in Patients with Recurrent Glioblastoma Multiforme (GBM): a Comparison of Patients on Enzyme Inducing Anti-epileptic Drugs (EIAED) and not on EIAED at Maximum Tolerated Dose Respectively: a North American Brain Tumor Consortium (NABTC) report.

Neuro-Oncol 5: 349 (abstract # TA 10), 2003.

217. Chang S, Kuhn J, Wen P, Greenberg H, Schiff D, Fine H, Yung A, Fink K, Mehta M, Cloughesy T, DeAngelis L, Hess K, Dancey J, Prados M: Phase I/Pharmacokinetic Study of CCI-779 in Patients with Recurrent Malignant Glioma on Enzyme-Inducing Antiepileptic Drugs (EIAEDS). Neuro-Oncol 5: 377 (abstract # 19), 2003.

218. Zhang T, Keller H, Jeraj R, Manon R, Welsh J, Patel R, Fenwick J, Mehta M, and Mackie T. Radiation Treatment of the Targets with Respiratory Motion Using Breathing Synchronized Delivery (BSD) Technique â&#x20AC;&#x201C; A Feasibility Study. Proceedings of the 7th Biennial ESTRO Meeting on Physics and Radiation Technology for Clinical Radiotherapy, Geneva, Switzerland 13 - 18 September 2003.

219. Turek M, Forrest L, Mackie TR, Hui S, Jaradat H, Henderson D, Kapatoes J, Das R, Mehta M: Helical tomotherapy: 3-D set-up verification and treatment implementation in dogs with spontaneous nasopharyngeal tumors. RSNA Proceedings abstract 049PH-p, pgs 157-8, 2003.

220. Hong TS, TomĂŠ WA, Chappell RJ, Chinnaiyan P, Mehta MP, Harari PM: Dosimetric and Clinical Implications of Daily Set-up Variation on the Quality of Head and Neck IMRT. RSNA Proceedings abstract 045PH-p, pg156, 2003.

221. Welsh J, Forouzannia A, Ritter M, Hui S, Kapatoes J, Mackie T, Mehta M: Helical Tomotherapy Planning and Treatment of Patients with Painful Bone Metastases.

RSNA Proceedings abstract 711, pg 478, 2003.

222. Hong TS, Puccetti D, Bradley KA, Iskandar B, Salamat SM, Mehta M. Combined Modality Therapy in the Management of Pediatric Disseminated Primary Anaplastic Ependymoma of the Spinal Cord. International Society for Pediatric NeuroOncology, 2004.

223. Packer RJ, Krailo M, Mehta M, Allen J, and Reaman GA. Phase I Study of Concurrent Cereport and Carboplatin with Radiation Therapy for Children with NewlyDiagnosed Brain Stem Gliomas (BSG). International Society for Pediatric NeuroOncology, 2004.

224. Manon, R, Oâ&#x20AC;&#x2122;Neill A, Mehta M, Knisely J, Werner-Wasik M, Lazarus H, Wagner H, Gilbert M: A Phase II Trial of Radiosurgery (RS) for 1 to 3 Newly Diagnosed Brain Metastases from Renal Cell, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E6397). ASCO Proceedings 23:108 (#1507), 2004.

225. Ford C, Seiferheld W, Choucair A, Hansen J, Dabbas B, Schultz C, Schulsinger A, Mehta MP, Curran W: Evaluation of Expression of DNA Repair Molecules as a Prognostic Factor for Long-term Survivors with Glioblastoma Multiforme (GBM) Treated on RTOG Protocols with Irradiation and Nitrosoureas. ASCO Proceedings 23:109 (#1509), 2004.

226. Robins HI, Won M, Schultz C, Choucair A, Brachman D, Demas W, Mehta MP: A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021, ASCO Proceedings 23:114 (#1529), 2004.

227. Chakravarti A, Seiferheld W, Robins HI, Guha A, Brachman D, Curran W, Choucair A, Mehta M; An Update of Phase I Data from RTOG 0211: A Phase I/II Clinical Study of ZD 1839 + Radiation for Newly-Diagnosed Glioblastoma Patients. ASCO Proceedings 23:124 (#1571), 2004.

228. Moots P, O'Neill A, Barger G, Mehta M, Gilbert M: Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor risk medulloblastoma/PNET and disseminated ependymoma; a preliminary report of ECOG 4397. ASCO Proceedings 23:125 (#1573), 2004.

229. Choucair A, Seiferheld W, Ford C, Hansen J, Dabbas B, Schultz C, Schulsinger A, Curran W, Mehta M: Long-term Survivors with GBM Treated with Irradiation and Nitropsurea have Higher Initial Expression of Ki-67. ASCO Proceedings 23:871 (#9661), 2004.

230. Zhang T, Jeraj R, Keller H, Lu W, Olivera G, McNutt T, Mehta M, Mackie T, Paliwal B: Four Dimensional Tomotherapy. Med Phys 31:1713 (SU-CC-BRA-04), 2004.

231. Jaradat H, Tome W, Paliwal B, Mehta M: Semi-automated Method for Segmenting MRI, Perfusion and Diffusion Images. Med Phys 31:1819 (WE-D-315-04), 2004.

232. Jaradat H, Soisson E, Manon R, Mehta M, Paliwal B: Tomotherapy vs. IMRT Planning on Dose Uniformity and NTDmean to Normal Tissue in Maximum Inspiratory Breath Hold for Lung Cancer. Med Phys 31:1924 (PO-T-355), 2004.

233. Werner-Wasik M, Seiferheld W, Michalski J, Gilbert M, Purdy J, Simpson J, Kresl J, Curran WJ, Diaz A, Mehta M: Phase I/II Conformal Three-Dimensional Radiation Therapy Dose Escalation Study in Patients with Supratentorial Glioblastoma Multiforme: Report of the Radiation Therapy Oncology Group 98-03 Protocol. Int J Radiat Oncol Biol Phys 60: S163-4 (abstract # 58), 2004.

234. Howard A, Mehta MP, Ritter MA, Bradley KA, Tome WA, Chappell RJ, Manon RR, Allen GW: The Value of PET/CT in Gross Tumor Volume Delineation in Lung and Esophagus cancer. Int J Radiat Oncol Biol Phys 60: S536-7 (abstract # 2335), 2004.

235. Mehta MP: Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced NSCLC? Combined Modality Treatment. Proceedings of the University of North Carolina Symposium on Advancing Treatment Options for Non Small Cell Lung Cancer, 2004.

236. Mehta MP: NSCLC Trials: University of Wisconsin dose-per-fraction escalation trial.

Proceedings of the University of North Carolina Symposium on Advancing Treatment Options for Non Small Cell Lung Cancer, 2004.

237. Berk L, Seiferheld W, Rich T, Hrushesky W, Blask D, Gallagher M, Kudrimoti M, McGarry R, Suh J, Mehta M: RTOG BR-0119: Chronobiological Study of the Addition of Melatonin to Radiotherapy for Brain Metastases. Neuro-Oncol 6: 359 (abstract RT01), 2004.

238. Robins H, Won M, Seiferheld W, Schultz C, Choucair A, Brachman D, Demas W, Mehta MP: A Phase II Trial of Conventional Radiation Therapy plus High-Dose Tamoxifen for the Treatment of Supratentorial Glioblastoma Multiforme: RTOG Protocol BR-0021. Neuro-Oncol 6: 363 (abstract RT-19), 2004.

239. Chakravarti A, Seiferheld W, Robins HI, Guha A, Brachman D, Curran W, Choucair A, Mehta M: An Update of Phase I Data from RTOG 0211: A Phase I/II Clinical Study of ZD 1839 (Gefitinib) + Radiation for Newly Diagonsed Glioblastoma Patients.

Neuro-Oncol 6: 372 (abstract TA-12), 2004.

240. Mehta M, Ford JM, Suh J, Phan S: Cumulative Dose of Motexafin Gadolinium and Survival in Newly Diagnosed Glioblastoma Multiforme. Neuro-Oncol 6: 378 (abstract TA-35), 2004.

241. Wen PY, Yung WKA, Lamborn K, Peng B, Dahia P, Abrey L, Raiser J, Cloughsey T, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine H, Mehta M, Robins HI, DeAngelis LM, Hess K, Groves M, Puduvalli VK, Levin V, Conrad C, Kuhn J, Maher E, Hayes M, Silberman S, Letvak L, Capdeville R, Kaplan R, Murgo A, Stiles C, Prados MD: Phase I/II Study of Imatinib Mesylate (ST1571) for Patients with Recurrent Malignant Gliomas (NABTC 99-08). Neuro-Oncol 6: 385 (abstract TA-63), 2004.

242. Miller P, Turek M, Forrest L, Mackie T, Jaradat H, Vail D and Mehta M. Ocular sparing using intensity modulated radiation therapy (IMRT) in a canine model of spontaneous sinonasal cancer: proof-of- principle of conformal avoidance. Invest Ophthalmol Vis Sci 46: 2005.

243. Mehta MP: Therapeutic Management for Metastatic Brain Tumors. Proceedings of the 3rd International Conference on Future Trends in the Treatment of Brain Tumors, Padua, Italy, March 2005.

244. Mehta MP: Should Concomitant and Adjuvant Treatment with Temozolomide Transfer as Standard Therapy in Anaplastic Gliomas? Proceedings of the 3rd International Conference on Future Trends in the Treatment of Brain Tumors, Padua, Italy, March 2005.

245. Knisely JPS, Berkey BA, Chakravarti A, Yung WKA, Curran WJ, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP: RTOG 0118: A Phase III Study of

Conventional Radiation Therapy Alone vs. Conventional Radiation Therapy Plus Thalidomide for Multiple Brain Metastases. J Clin Oncol 23 (16S): 114s (abstract # 1500), 2005.

246. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M: A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boosts for Supratentorial Glioblastoma Multiforme.

RTOG-0023. J Clin Oncol 23 (16S): 116s (abstract # 1511), 2005.

247. Vogelbaum MA, Berkey B, Peereboom D, Giannini C, Suh J, Brown P, Blumenthal D, Biggs C, Schultz C, Mehta M: RTOG 0131: Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligodendrogliomas. J Clin Oncol 23 (16S): 119s (abstract # 1520), 2005.

248. Shapiro WR, Smith JA, Patchell RA, Glantz MJ, Recht LD, Mehta MP, Phen SC, Renschler MF: Validation of Blinded Events Review Committee (ERC)-Determined Time to Neurologic Progression (TTNP) Demonstrates Correlation with Survival, Radiologic Progression, and Functional Independence Endpoints. J Clin Oncol 23 (16S): 122s (abstract # 1534), 2005.

249. Tome W, Mehta M: Technical and Biological Aspects of Optically Guided Extra Cranial Stereotactic Radiotherapy for Periphereal T1/T2NOMO NSC Lung Tumors.

Lung Ca 49 (S2): S314 (abstract P-743), 2005.

250. Shaw EG, Won M, Brachman D, Schultz C, Suh J, Buckner JC, Barger GR, Coons SW, Bullard DE, Mehta M: Preliminary Results of RTOG Protocol 9802: A Phase II Study of Observation in Completely Resected Adult Low-Grade Glioma. Neuro Oncol 7: 284 (abstract # 7), 2005.

251. Renschler MF, Smith JA, Shapiro WR, Patchell RA, Glantz MJ, Recht LD, Mehta MP, Phan SC: Validation of Blinded Events Review Committee-Determined Time to Neurologic Progression Demonstrates Correlation with Survival, Radiologic Progression, and Functional Independence End Points. Neuro-Oncol 7:288 (abstract #24), 2005.

252. Mehta MP: Malignant Glioma: Advances In Radiation Therapy. Neuro Oncol 7:289 (abstract # 27), 2005.

253. Mehta M: SRS and SRT for Malignant Glioma. Proceedings of the 14th Annual Meeting of Japanese Society of Stereotactic Radiosurgery: 28, 2005.

254. Mehta M: Radiosurgery and Radiotherapy for Brain Metastases. Proceedings of the 14th Annual Meeting of Japanese Society of Stereotactic Radiosurgery: 29, 2005.

255. Mehta M: Evidence supporting the use of radiosurgery in brain metastases.

Proceedings of the 7th International Society for Stereotactic Radiosurgery, BS8-1, 2005.

256. Mehta M: Brain Metastases: Data Blitz. Proceedings of the 7th International Society for Stereotactic Radiosurgery, PS3-1, 2005.

257. Tome W, Fenwick J, Mehta M: How Can Tumor Effect and Normal Tissue Effect be Balanced in Stereotactic Body Radiotherapy? Proceedings of the 7th International Society for Stereotactic Radiosurgery, OS29-4, 2005.

258. Soisson E, Richards G, Mehta M, and Tome, W. Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy for treatment of skull-base tumors. Proceedings of the 47th Annual Meeting of the AAPM, Med Phys 32:1964-5, (abst SU-FF-T-67), 2005.

259. Westerly D, Aoyama H, Patel R, Jaradat H, Olivera G, TomĂŠ W, Ritter M, Mehta M, and Mackie T. Non-Tumor integral dose in conformal, external beam radiation therapy. Proceedings of the 47th Annual Meeting of the AAPM, Med Phys 32:1968, (abst SU-FF-T-82), 2005.

260. Jaradat H, Paliwal B and Mehta M. Tomotherapy daily quality assurance phantom.

Proceedings of the 47th Annual Meeting of the AAPM, Med Phys 32:1989, (abst SU-FFT-170), 2005.

261. Jaradat H, TomĂŠ W, and Mehta M. The feasibility of using tomotherapy Hi-Art machine for stereotactic radiosurgery. Proceedings of the 47th Annual Meeting of the AAPM, Med Phys 32:2045-6, (abst SU-FF-T-412), 2005.

262. Fox S, Berkey B, Michalski J, Purdy J, Simpson J, Kresl J, Curran W, Diaz A, Mehta M, Movsas B: Health-Related Quality of Life and Cognitive Status in Patients with Glioblastoma Multiforme Receiving Escalating Doses of Conformal ThreeDimensional Radiation on RTOG 9803. Int J Radiat Oncol Biol Phys 63:S78 (abstract 128), 2005.

263. Aoyama H, Westerly DC, Mackie TR, Bentzen SM, Olivera G, Patel RR, Jaradat H, Tome W, Ritter MA, Mehta MP: Integral Radiation Dose to Normal Structures with Conformal External Beam Radiation. Int J Radiat Oncol Biol Phys 63:S559 (abstract 2546), 2005.

264. Tome W, Orton N, Zhang T, Jaradat H, Mehta M: Optically Guided Stereotactic Radiotherpy for T1/T2N0M0 NSC-Lung Cancer, Radiother Oncol, 76:Supp2, Page S36 (abstract 5), 2005.

265. Jaradat H, Tome W, Mehta M: Image Guided Extracranial Stereotactic Radiotherapy of Non Small Cell Lung Cancer with Tomotherapy. 91st Annual RSNA Proceedings, SST 19-04, 581, 2005.

266. Mehta MP: RTOG Brain Tumor Trials. Asilomar Brain Tumor Meeting Proceedings pg 7, 2006.

267. Shaw E, Berkey B, Coons SW, Brachman D, Buckner J, Stelzer KJ, Barger GR, Brown PD, Gilbert M, Mehta M: Initial Report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective Studies in Adult Low-Grade Glioma, JCO 24:58s (abstract # 1500), 2006.

268. Li J, Bentzen S, Renschler M, Mehta MP: Improvement in Neurocognitive Function (NCF) Correlates with Tumor Regresion After Whole Brain Radiation Therapy (WBRT) for Brain Metastases (BM), JCO 24:59s (abstract # 1504), 2006.

269. Lieberman F, Tsien C, Berkey B, Curran WJ, Werner-Wasik M, Smith R, Grossheim L, Hug E, Mehta M: Phase II Trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary Results of RTOG 04-20, JCO 24:60s (abstract # 1510), 2006.

270. Vogelbaum MA, Berkey B, Peereboom D, Giannini C, Jenkins R, Suh J, Brown P, Blumenthal D, Biggs C, Mehta M: RTOG 0131: Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligodendrogliomas: Relationship between 1p/19q status and progression-free survival, JCO 24:62s (abstract # 1517), 2006.

271. Chakravarti A, Berkey B, Robins I, Guha A, Curran W, Brachman D, Shultz C, Mehta M: An Update of Phase II Results from RTOG 0211: A Phase I/II Study of Gefitinib with Radiotherapy in Newly-Diagnosed Glioblastoma Multiforme, JCO 24:64s (abstract # 1527), 2006.

272. Mehta MP, Gervais R, Chabot P, Shapiro W, Patchell R, Glantz M, Recht L, Phan S, Smith JA, Renschler MF: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a Phase 3 trial, JCO 24:367s (abstract # 7014), 2006.

273. Fox S, Berkey B, Knisely J, Chakravarti A, Yung WA, Curran W, Robins HI, Brachman D, Henderson R, Mehta M, Movsas B: Prospective Neurocognitive Effects and Quality of Life (QOL) in Patients with Multiple Brain Metastases Receiving Whole Brain Radiation (WBRT) +/- Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118, JCO 24:490s (abstract # 8589), 2006.

274. Bradley K, Mehta M, Adamson P, Ames M, Jackacki R, Vezina G, Ingle A, Ivy P, Blaney S, Pollock I: Phase I Study of Motexafin-Gadolinium (MGd) with Radiation Therapy (RT) for Children with Newly-Diagnosed Brain Stem Gliomas (BSG): A Childrensâ&#x20AC;&#x2122; Oncology Group Study, JCO 24:505s (abstract # 9014), 2006.

275. Mohammed N, Mehta MP, Bentzen SM, Khuntia D, Tome WA: Daily Set Up Variation in Patients Receiving Radiation with Tomotherapy for Lung Tumors, JCO 24:667s (abstract # 17005), 2006.

276. Siker M, Mehta MP, Tome W: Tumor volume changes on serial imaging with megavoltage CT for non-small cell lung cancer during conformal radiotherapy, JCO 24:670s (abstract # 17041), 2006.

277. Hodge W, Khuntia D, Tome W, Jaradat H, Mehta MP: Feasibility Report of Stereotactic Body Radiotherapy with Tomotherapy for Early Stage Medically Inoperable Lung Cancer using Extreme Hypofractionation, JCO 24:674s (abstract # 17097), 2006.

278. Mehta MP, Carrie C, Mahe A, Roa W, Nieder C, Ung Y, Eble M, Phan S, Smith JA, Renschler MF: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung

cancer (NSCLC) patients with brain metastases: Results of a Phase 3 trial, Int J Radia Oncol Biol Phys, 66:S23 (abstract # 41), 2006.

279. Li J, Bentzen SM, Renschler M, Mehta MP: MRI response after whole brain radiation therapy in patients with brain metastases and its association with change in neurocognitive function, Int J Radia Oncol Biol Phys, 66:S87 (abstract # 155), 2006.

280. Siker M, Berkey B, Nelson D, Curran W, Michalski J, Souhami L, Chakravarti A, Yung W, DelRowe J, Coughlin C, Mehta M: Age as an Independent Prognostic Factor in Patients with Glioblastoma: a Radiation Therapy Oncology Group Analysis, Int J Radia Oncol Biol Phys, 66:S196 (abstract # 1115), 2006.

281. Petereit D, Mehta M, Kaur J, Govern F, Coleman NC, Ritter M, Koscik R, Moser A, Burhansstipanov L, Rogers D, Helbig P, Guadagnolo A, Roberts C, Molloy K LeBeau R, Reiner M, Spotted Tail C, Cina K, Conroy P, Rost C: Methods to Address Cancer Disparities in Special Populations, Int J Radia Oncol Biol Phys, 66:S136 (abstract # 1014), 2006.

282. Suh J, Mehta MP, Dagnault A, Chabot P, Chang E, Fortin M, Grecula J, Nabid A, Souhami L, Renschler MF: Motexafin Gadolinium-Based Treatment Planning MRI Identifies Occult Brain Metastases Amenable to Stereotactic Radiosurgery: Results of a Phase II trial of Motexafin Gadolinium and Whole Brain Radiotherapy with Stereotactic Radiosurgery, Int J Radia Oncol Biol Phys, 66:S193-4 (abstract # 1110), 2006.

283. Forrest LJ, Lawrence JA, Miller PE, Jaradat HA, Mackie TR, Dubielzig RR, Bentzen SM, Mehta MP: Ocular Sparing Using Image-guided Helical Tomotherapy (IGHT) in Spontaneous Sino-nasal Tumors in Dogs Int J Radia Oncol Biol Phys, 66:S425 (abstract # 2387), 2006.

284. Jaradat H, Mehta M, Nelson K, Schmidt D: Dynamic Delivery Quality Assurance for IMRT to Account for Target Motion. Int J Radia Oncol Biol Phys, 66:S711 (abstract # 2886), 2006.

285. Siker ML, Berkey B, K Porter, Nelson D, Curran W, Michalski J, Souhami L, Chakravarti A, Yung AW, DelRowe J, Coughlin C, Mehta MP: Age as an independent prognostic factor in patients with glioblastoma: an RTOG and ACoS National Cancer Data Base Comparison, NeuroOncol 8:408 (abstract # EP-11), 2006.

286. Li J, Bentzen S, Li J, Renschler M, Mehta MP: Relationship between neurocognitive function and quality of life following whole brain radiation therapy in patients with brain metastasis, NeuroOncol 8:481 (abstract # QL-26), 2006. Quality of Life Award, Society of NeuroOncology.

287. Blumenthal DT, Berkey B, Nelson D, Curran W, Leibel S, Souhami L, Michalski J, Corn B, Chakravarti A, Rogers L, Mehta M: "Short" Delay in Initiation of Radiotherapy May Not Affect the Outcome of Patients with GBM. A Secondary Analysis from the RTOG database, NeuroOncol 8:483 (abstract # RO-02), 2006.

288. Jaradat H, Khuntia D, Johnson S, Richards G, Tome W, Rowley H, Mehta M: Whole brain radiation treatment with hippocampal sparing using tomotherapy, NeuroOncol 8:487 (abstract # RO-16), 2006.

289. Shapiro WR, Mehta MP, Patchell RA, Glantz MJ, Recht L, Sur R, Fortin A, Ung Y, Souhami L, Phan S, Smith JA, Renschler MF: Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in nonsmall cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials), NeuroOncol 8:489 (abstract # RO-25), 2006.

290. Shaw EG, Berkey B, Coons SW, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M: Radiation Therapy Oncology Group (RTOG) Protocol 9802: Radiation Therapy (RT) Alone versus RT + PCV Chemotherapy in Adult Low-Grade Glioma (LGG), NeuroOncol 8:489-90 (abstract # RO-26), 2006.

291. Chakravarti A, Berkey B, Robins I, Guha A, Curran W, Brachman D, Shultz C, Mehta M: An Update of Phase II Results from RTOG 0211: A Phase I/II Study of Gefitinib with Radiotherapy in Newly-Diagnosed Glioblastoma Multiforme, NeuroOncol 8:439 (abstract # TA-08), 2006.

292. Glass J, Schultz C, Brat DJ, Berkey BA, Mehta M: Phase I/II study of pre-irradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma, NeuroOncol 8:443 (abstract # TA-21), 2006.

293. Lieberman FS, Berkey B, Tsien C, Curran W, Werner-Wasik M, Smith R, Grossheim L, Hug E, Mehta M: Phase II trial of concomitant low dose temozolomide with external beam radiation(EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma(GBM): Preliminary Results of RTOG 04-20, NeuroOncol 8:445 (abstract # TA-30), 2006.

294. Robins HI, Oâ&#x20AC;&#x2122;Neill A, Sapiente R, Olsen M, Gilbert M, Mehta M: A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy (XRT) on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM): A Trial of the Eastern Cooperative OncologyGroup (ECOG) E1F01, NeuroOncol 8:450-51 (abstract # TA-49), 2006.

295. Shaw EG, Berkey B, Coons SW, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M: Update of a RTOG Prospective Study of Observation in Completely Resected Adult Low-Grade Glioma), NeuroOncol 8:452 (abstract # TA-54), 2006.

296. Wen PY, Chang S, Kuhn J, Lamborn K, Robins HI, Cloughesy T, Gilbert M, Yung WKA, Mehta M, DeAngelis L, Kesari S, Drappatz J, Dancey J, Prados MD: Phase I Study of Erlotinib (Tarceva) and Temsirolimus (CCI-779) For Patients With Recurrent Malignant Gliomas (NABTC 04-02), NeuroOncol 8:454 (abstract # TA-65), 2006.

297. Wen PY, Yung WKA, Lamborn K, Cloughesy T, DeAngelis LM, Fine HA, Chang SM, Robins HI, Fink K, Abrey L, Lassman A, Mehta M, Kesari S, Kim L, Stiles C, Egorin M, Capdeville R, Kaplan R, Murgo A, Prados MD: Phase II study of imatinib mesylate (STI571) for patients with recurrent meningiomas (NABTC 01-08), NeuroOncol 8:454 (abstract # TA-66), 2006.

298. Bigley J, Bierau K, Hegi M, Diserens AC, Mehta M, Aldape K, Berkey BK, Gilbert M: MGMT Methylation Testing as a Pharmacogenomic Biomarker in a Large,

International Clinical Glioma Treatment Trial.

Conference, Philadelphia, PA, 2006.

Epigenetic Cancer Therapy

299. Mehta MP, Carrie C, Mahe A, Roa W, Nieder C, Ung Y, Eble M, Phan S, Smith JA, Renschler MF: Motexafin Gadolinium (MGd) Combined with Prompt Whole Brain Radiation Therapy (RT) Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases: Results of a Phase 3 Trial.

Proceedings of the Radiological Society of North America, (abstract # SSG25-08), 2006.

300. Jakacki R, Zhou T, Holmes E, Packer R, Goldwein J, Mehta M, Pollack I: Outcome for Patients with Pineoblastoma Treated with Carboplatin as a Radiosensitizer During Radiotherapy Followed by Adjuvant Cyclophosphamide and Vincristine: Preliminary Results Of COG 99701, Neuro-Oncol 9:200 (abstract 150), 2007.

301. Smith AM, Chinnaiyan P, Ray S, Mehta MP, Harari PM, Cezar GG: Metabolomics of Glioma Cell Lines in Response to Ionizing Radiation, AACR, 2007.

302. Jakacki R, Burger P, Zhou T, Holmes E, Packer R, Goldwein J, Mehta M, Pollack I: Outcome for Metastatic (M+) Medulloblastoma (MB) Treated with Carboplatin During Craniospinal Radiotherapy (CSRT) Followed by Cyclophosphamide (CPM) and Vincristine (VCR): Preliminary Results of COG 99701. J Clin Oncol 25(S): 2017, 2007.

303. Cannon GM, Jaradat HA, Tome WA, Khuntia D, Mehta MP, Bentzen SM: Acute Radiation Esophagitis in a Phase I Dose-Escalation Trial Evaluating Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 25(S): 7694, 2007.

304. Shapiro WR, Mehta MP, Langer C, Bezjak A, Timmerman R, Brachman D, Suh J, Smith JA, Phan S, Renschler MF: Motexafin Gadolinium (MGd) Combined with Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in NonSmall Cell Lung Cancer (NSCLC) Patients with Brain Metastases: Pooled Analysis of Two Randomized Phase III Trials. J Clin Oncol 25(S): 2010, 2007.

305. Mehta MP, Dagnault A, Chabot P, Suh J, Chang E, Fortin M, Timmerman R, Grecula J, Eubank L, Renschler MF: Identification of Occult Brain Metastases Amenable to Stereotactic Radiosurgery by Motexafin Gadolinium (MGd) Based on Treatment Planning MRI: Results of a Phase II Trial of Mgd and Whole Brain Radiotherapy (WBRT) with Stereotactic Radiosurgery (SRS). J Clin Oncol 25(S): 2037, 2007.

306. Ghia AJ, Tome W, Thomas S, Cannon G, Mehta M, Kuo JS: Distribution of Brain Metastases in Relation to the Hippocampus. AANS, 2007.

307. Tome W, Ghia A, Thomas S, Cannon G, Mehta M, Kuo JS: Distribution of Brain Metastases in Relation to the Hippocampus. ISRS, 2007.

308. Jaradat H, Paliwal B, Tome W, Mackie TR, Mehta M: Validation of Tomotherapy Machine Matching Procedure at the University of Wisconsin. AAPM, 2007.

309. Soisson E, Mehta M, Harari P, Ritter M, Welsh J, Khuntia D, Patel R, Paliwal B, Tome W, Jaradat H, Limmer J, Schubert L, Westerly D, Gutierrez A, Bentzen S, Jeraj R, Mackie T: Five Years of Experience with Helical Tomotherapy, CARO, 2007.

310. Renschler MF, Phan SC, Smith J, Mehta M: Risk of Central Nervous System Bleeding in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) Following Whole Brain Radiation Therapy (WBRT) is Low. IASLC, 2007.

311. Bradley KA, Kruser TJ, Bentzen SM, Anderson BM, Gondi V, Khuntia D, Perlmann S, Mehta MP: A Prospective Study Comparing CT-Based to PET/CT Based radiation Treatment Planning. Int J Radiat Oncol Biol Phys, 69(3); S68 (abstract 121), 2007.

312. Adkison JB, Cannon GM, Khuntia D, Jaradat H, Tome W, Walker W, Huang B, Mehta M: Image-Guided Intensity-Modulated Hypofractionated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Phase I Dose Escalation Study. Int J Radiat Oncol Biol Phys, 69(3); S88 (abstract 155), 2007.

313. Kwok Y, Won M, Regine WF, Mehta M, Schmitt F, Patchell RA, Watkins-Bruner D: Neurocognitive Impact of Whole Brain Radiation on Patients with Brain Metastases: secondary Analysis of RTOG BR 0018. Int J Radiat Oncol Biol Phys, 69(3); S103 (abstract 184), 2007.

314. Anderson B, Khuntia D, Tome WA, Bentzen S, Hayes L, Mehta MP: Single Institution Experience Treating 100 Vestibular Schwannomas with Fractionated Stereotactic Radiation Therapy or Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys, 69(3); S121 (abstract 218), 2007.

315. Hodge CW, TomĂŠ WA, Khuntia D, Weigel T, Palazzi-Churas KL, Tan I, Mehta MP: IMRT-Based 4D Stereotactic Radiotherapy for Early Stage Inoperable Lung Cancer: Initial Clinical Validation of a Radiobiologic Model. Int J Radiat Oncol Biol Phys, 69(3); S487 (abstract 2516), 2007.

316. Vonk DT, Jaradat HA, Mehta MP, Khuntia D: Adaptive Tomotherapy Planning for Integrated Boost Doses in Rapidly Responding Lung Cancers. Int J Radiat Oncol Biol Phys, 69(3); S525 (abstract 2579), 2007.

317. Cannon GM, Jaradat HA, Rasmussen K, Tome WA, Tanumihardjo I, Walker W, Mehta MP, Bentzen SM, Khuntia D: Dosimetric Evaluation of Helical IMRT, Traditional IMRT, and 3-D Conformal Radiation for Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 69(3); S632-3 (abstract 2783), 2007.

318. Thomas SR, Jaradat H, Mehta MP, Tome WA, Galavis PE, Khuntia A: Can MVCT be used for adaptive radiotherapy? A feasibility study. Int J Radiat Oncol Biol Phys, 69(3); (abstract 2816), 2007.

319. Giannini C, Burger P, Won G, Cairncross G, Jenkins R, Mehta M, Curran W, Aldape K: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in intergroup radiation therapy oncology group trial 9402. Neuro-Oncol 9:528 (MA51), 2007. Neuro-Oncol 9:548 (PA27), 2007.

320. Lieberman FS, Moughan J, Tsien C, Curran W, Werner-Wasik M, Smith R, Grossheim L, Hug E, Mehta M: Phase II trial of concomitant low dose temozolomide with radiotherapy (RT) followed by 12 months of temozolomide and irinotecan for newly

diagnosed glioblastoma (GBM): Updated Results of RTOG 04-20. Neuro-Oncol 9:528 (MA51), 2007.

321. Tsien C, Moughan J, Lieberman FS, Curran W, Werner-Wasik M, Smith R, Grossheim L, Hug E, Mehta M: Phase II trial of concurrent temozolomide with radiotherapy followed by adjuvant temozolomide and irinotecan for 12 cycles in newly diagnosed glioblastoma: Updated Results of RTOG 04-20. Perspectives in CNS Malignancies IV, Poster Presentation, Berlin, Germany, # 209, 2008.

322. Adkison JB, Bentzen S, Khuntia D, Cannon GM, Tome WA, Jaradat H, Walker W, Mehta M: Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer. Proceedings of the 1st European Lung Cancer Conference. J Thor Onc. S89. Abs 248O. Geneva, Switzerland. April 23-26, 2008.

323. Cannon GM, Hodge CW, TomĂŠ WA, Khuntia D, Weigel T, Palazzi-Churas KL, Tan I, Mehta MP: IMRT-based 4D-Stereotactic Radiotherapy for Early Stage Inoperable Lung Cancer: Updated outcomes and initial clinical validation of a radiobiologic model. .

Proceedings of the 1st European Lung Cancer Conference. J Thor Onc. S90. Abs 252P. Geneva, Switzerland. April 23-26, 2008.

324. Shaw E, Wang M, Coons S, Brachman D, Buckner J, Stelzer K, Barger G, Brown P, Gilbert M, Mehta M: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG), J Clin Oncol 26 (15S): 90s (abstract 2006), 2008.

325. De Groot JF, Wen PY, Lamborn K, Chang S, Cloughsey T, Chen AP, DeAngelis LM, Mehta MP, Gilbert MR, Yung WK, Prados MD: Phase II Single Arm Trial of Aflibercept in Patients with recurrent Temozolomide-Resistant Glioblastoma: NABTC 0601, J Clin Oncol 26 (15S): 94s (abstract 2020), 2008.

326. Hodge CW, Legnne P, Wissel P, Schiller JH, Mehta MP: Phase II Trial of Twice Daily Oral Topotecan in Combination with Hyperfractionated Radiotherapy for Limited Stage Small Cell Lung Cancer, J Clin Oncol 26 (15S): 402s (abstract 7522), 2008.

327. Allen J, Donahue B, Mehta M, Miller D, Rorke L, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Dothage J, Muraszko K, Puccetti D, Prados M and Chan K: Childrensâ&#x20AC;&#x2122; Cancer Group protocol 9931: Pre-radiotherapy chemotherapy followed by hyperfractionated craniospinal radiotherapy for newly diagnosed high risk medulloblastoma and PNET. Asilomar Brain Tumor Meeting, 2008.

328. Allen J, Donahue B, Mehta M, Miller D, Rorke L, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G Dothage J, Muraszko K, Puccetti D, Prados M, Chan K: Final Report of the Phase II CCG Protocol 9931 for High Risk Medulloblastoma/PNET: Neoadjuvant Chemotherapy followed by Hyperfractionated Craniospinal Radiotherapy, ISPNO, 2008.

329. Cairncross G, Wang M, Chang S, Shaw E, Jenkins R, Scheithauer B, Buckner J, Fink K, Mehta M, Curran W: A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for Anaplastic Oligodendroglioma (RTOG 9402): The perspective of longer follow-up, Int J Radiat Oncol Biol Phys 72:1(S): S7-8, 2008 (Abstract 16).

330. Chakravarti A, Wang M, Mischel P, Robins HI, Guha A, Machtay M, Curran W, Roach M, Mehta MP, Dicker A: An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients. Int J Radiat Oncol Biol Phys 72:1(S): S9-10, 2008 (Abstract 20).

331. Sperduto P, Sneed P, Bhatt A, Schwer A, Fiveash J, Chiang V, Knisely J, Zhu Y, Gaspar LE, Mehta M: A Multi-Institutional Validation Study of a New Prognostic Index (Graded Prognostic Assessment, GPA) for Patients with Brain Metastases. Int J Radiat Oncol Biol Phys 72:1(S): S51, 2008 (Abstract 111).

332. Kruser T, Tome WA, Seo S, Chappell RJ, Scrimger RA, Mehta MP: Prognostic Factors for Complete Obliteration of Arteriovenous Malformations Treated with LINACbased Stereotactic Radiosurgery, Int J Radiat Oncol Biol Phys 72:1(S): S202, 2008 (Abstract 2074).

333. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang K, Zhang H, Hammond E, Curran W, Mehta MP: The Prognostic Value of Nestin Expression in Newly Diagnosed GBM: Report from the RTOG, Int J Radiat Oncol Biol Phys 72:1(S): S206, 2008 (Abstract 2083).

334. Li J, Bentzen SM, Allen PK, Renschler M, Mehta MP: Primary Histology is Associated with Volumetric Response Following Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases (BM), Int J Radiat Oncol Biol Phys 72:1(S): S206, 2008 (Abstract 2084).

335. Traynor AM, Wassenaar TR, Weigel TL, Campbell TC, Mehta M, Khuntia D, Mathiason MA, Oettel KR: Increasing knowledge about lung cancer in primary care providers (PCPs): Effects of a multidisciplinary lecture series. J Thorac Oncol 3:11(S): S292-3, 2008 (Abstract 158) 336. Kuhn J, Robins HI, Mehta M, Fine H, Cloughesy T, Wen P, Chang SM, De Angelis L, Lieberman F, Reardon D, Abrey LE, Lassman AB, Aldape K, Yung WKA, Dancey J, Lamborn K, Prados M: Tumor Sequestration of Lapatinib (NABTC 04-01), NeuroOncology, 2008 (Abstract ET-05).

337. Chakravarti A, Wang M, Mischel P, Robins HI, Guha A, Machtay M, Curran W, Roach M, Mehta M, Dicker A: An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma, Neuro-Oncology, 2008 (Abstract ET-12).

338. Wen P, Kuhn J, Chang S, Lamborn K, Robins HI, Cloughesy T, Lieberman F, Mehta MP, Gilbert M, Cooper J, Drappatz J, Kesari S, Norden A, Groves M, Aldape K, Yung WKA, Dancey J, Prados M: Phase I/II Study of Erlotinib and Temsirolimus (CCI-779) For Patients With Recurrent Malignant Gliomas (NABTC 04-02), Neuro-Oncology, 2008 (Abstract MA-29).

339. Lassman AB, Wang M, Gilbert MR, Aldape K, Wright J, Wagner H, Brachman DG, Malkin MG, Mehta M: Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma (RTOG 0627) Neuro-Oncology, 2008 (Abstract MA-30).

340. Chang S, Wang M, Cairncross G, Gilbert M, Bahary JP, Dolinskas C, Aldape K, Chakravarti A, Curran W, Schiff D, Jaeckle K, Barger G, Werner-Wasik M, Shipley W, Brachman D, Mehta MP: Toxicity Results of RTOG 9813- A Phase III Randomized Study of Radiation Therapy (RT) and Temozolomide (TMZ) versus RT and Nitrosourea (NU) for Anaplastic Astrocytoma (AA) and Mixed Anaplastic Oligoastrocytoma (MAOA), Neuro-Oncology, 2008 (Abstract MA-36).

341. Choucair AK, Moughan J, Ford CD, Hansen J, Schultz CJ, Schulsinger A, Hammond EH, Mehta MP, Curran WJ Jr.: Predictive Value of hMLH1 after Adjusting for RPA Class in Patients with GBM Treated on RTOG Protocols, Neuro-Oncology, 2008 (Abstract PA-06).

342. Thomas SR, Kaur S, Kuo J, Robins HI, Khuntia D, Mehta MP: Driving Restrictions for Patients with Primary and Metastatic Brain Tumors: Results of a Multi-Institutional Survey, Neuro-Oncology, 2008 (Abstract QL-24).

343. Shaw EG, Wang M, Coons S, Brachman D, Buckner J, Stelzer K, Barger G, Brown P, Gilbert M, Mehta M: Radiation Therapy (RT) versus RT + Procarbazine, CCNU and Vincristine (PCV) Chemotherapy for Adult Low-Grade Glioma (LGG) grade glioma (LGG), Neuro-Oncology, 2008 (Abstract RO-10).

344. Brachman DG, Wang M, Ashby LS, Stea B, Thomas T, Mehta M: Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma: Results of RTOG 0513 Phase I Dose Escalation Toxicity Analysis. Neuro-Oncology, 2008 (Abstract RO27).

345. A. Chakravarti, M. Wang, P. Mischel, H. I. Robins, A. Guha, M. Machtay, W. Curran, M. Roach, M. Mehta, A. Dicker: Correlative molecular endpoints from RTOG 0211: Phase I/II study of Gefitinib + radiation for newly diagnosed glioblastoma (GBM) ASCO-NCI-EORTC Molecular Markers in Cancer Meeting, 2008.

346. Mehta MP: Alchemy, Early Detection, Precision Guidance, and Radiotherapy. Annual Oration in Radiation Oncology, RSNA Annual Program, pp 63, 2008 347. Chi K, Liao CS, Chang CS, Ko HL, Tsang YW, Yang KC, Mehta MP: Angiogenic blocade and radiotherapy (RT) in hepatocellular carcinoma (HCC) - a retrospective analysis. Control/Tracking Number: 09-AB-10120-ASCOGI ASCO Gastrointestinal Cancers Symposium, 2009.

348. Gilbert M, Wang M, Aldape K, Lassman A, Sorensen AG, Mikkelson T, Groves M, Werner-Wasik M, Regine W, Mehta MP: RTOG 0625: A Phase II Study of Bevacizumab with Irinotecan in Recurrent Glioblastoma, J Clin Oncol, 27:(15S) 89s, 2009.

349. Aldape K, Jones G, Wang M, Hegi M, Janzer R, Stupp R, Mehta M, Gilbert M: MGMT Methylation Testing in RTOG 0525: A Phase III Trial of Newly Diagnosed Glioblastoma, J Clin Oncol, 27:(15S) 99s, 2009.

350. Schiller JH, Dahlberg SE, Mehta M, Johnson DH: A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiation Therapy With or Without Thalidomide in Patients

with Stage 3 Non-Small Cell Carcinoma of the Lung (NSCLC): E3598, J Clin Oncol, 27:(15S) 382s, 2009.

351. Westerly D, Cannon G, Khuntia D, Bentzen S, Mehta MP: Potential for increased pneumonitis risk with IMRT as compared to 3D-CRT for patients receiving adjuvant chemotherapy: a radiobiological modeling study. AAPM, 2009.

352. Kuo JS, Mehta M, Ramamurthy R, Shenker Y: Multidisciplinary management of a cabergoline-resistant giant prolactinoma, 11th International Pituitary Congress, Washington DC, June, 2009.

353. Thomas SR, Westerly D, Gondi V, TomĂŠ WA, Zhang M, Mehta MP, Bentzen SM, Mackie TR, Khuntia D: Dosimetric comparison of stereotactic body radiotherapy for early-stage non small cell lung cancer (NSCLC) with intensity-modulated proton therapy (IMPT) and helical tomotherapy (HT), Int J Radiat Oncol Biol Phys, 75:S704 (abstract 3162), 2009.

354. Gondi V, Tome W, Marsh J, Struck A, Ghia A, Bentzen S, Kuo J, Khuntia D, Mehta M: Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Comprehensive multi-institution review of 371 patients with 1133 brain metastases. Int J Radiat Oncol Biol Phys, 75:S236 (abstract .2121), 2009.

355. Hodge CW, Tome WA, Bentzen SM, Mehta MP: Rib Fracture Incidence After Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer: Latency and DoseResponse. Int J Radiat Oncol Biol Phys, 75:S456 (abstract 2610), 2009.

356. Dunn EF, Gondi V, Tome W, Bentzen S, Khuntia D, Jeraj R, Ritter M, Harari P, Pyzalski R, Mehta MP: Target definition with FLT-, CuATSM, and FDG-PET/CT in head and neck cancer. RSNA, 2009 357. Lawrence YR, Wang M, Dicker A, Andrews D, Curran WJ, Michalski JM, Souhami L, Yung A, Mehta M: Acute neurological toxicity (NT) and long-term outcomes in highgrade glioma RTOG trials. J Clin Oncol, 28:15s ASCO, (abstract 2037), 2010.

358. Chakravarti A, Wang M, Robins HI, Guha A, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Lautenschlaeger T, Dicker AP, Mehta M: Determinants of Therapeutic Resistance in Glioblastomas: Lessons learned from RTOG 0211 and Beyond. J Clin Oncol, 28:15s ASCO, (abstract 2062), 2010.

359. Petereit D, Moser A, Hahn J, Boylan A, Kanekar S, Ritter M, Bentzen S, Koop D, Kaur J, Mehta M: Ataxia telangiectasia mutated (ATM) Gene Variants in American Indians, Int J Radiat Oncol Biol Phys, 78:S90, ASTRO, (abstract 192), 2010.

360. Cannon DM, Adkison JB, Chappell RJ, Perumal D, Tome WA, Bentzen SM, Cannon GM, Tolakanahalli R, Mehta MP: Interim Results of a Phase I Risk-Stratified Dose Escalation Study Using Hypofractionated Helical Tomotherapy for Non-Small Cell Lung Cancer, Int J Radiat Oncol Biol Phys, 78:S107-108, ASTRO, (abstract 229), 2010.

361. Chakravarti A, Wang M, Robins HI, Guha A, Curran WJ, Brachman DG, Choucair A, Dolled-Filhart M, Lautenschlaeger T, Mehta M: Determinants of Therapeutic

Resistance in Glioblastomas: Lessons learned from RTOG 0211 and Beyond. Int J Radiat Oncol Biol Phys, 78:S257, ASTRO, (abstract 2117), 2010.

362. Gilbert MR, Wang M, Aldape K, Sorenson GA, Mikkelsen T, Bokstein F, Woo SY, Chumra SJ, Choucair AK, Mehta M: RTOG 0625: A Randomized Phase II Trial of Bevacizumab with either Irinotecan or Dose-Dense Temozolomide in Recurrent Glioblastoma. Neuro-Oncol, 12:iv39 (abstract NO14), 2010.

363. Chakravarti A, Wang M, Robins HI, Guha A, Curran WJ, Brachman DG, Schultz C, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Lautenschlaeger T, Dicker A, Mehta M: Determinants of Therapeutic Resistance in Glioblastomas: Lessons learned from RTOG 0211 and Beyond. Neuro-Oncol, 12:iv105 (abstract RT-01), 2010.

364. Vogelius, I. R.; Westerly, D. C.; Aznar, M. C.; Cannon, G. M.; Korreman, S. S.; Mackie, T. R.; Mehta, M. P.; Bentzen, S. M. Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta Oncol 50:772-776, 2011.

365. Gilbert M, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran W, Mehta MP: RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM), J Clin Oncol 29: (abstract 2006), 2011.

366. Aldape KD, Wang M, Sulman EP, Hegi M, Colman H, Jones G, Chakravarti A, Mehta MP, Andrews DW, Long L, Diefes K, Hetahcock L, Jenkins R, Schultz CJ, Gilbert MR: RTOG 0525: Molecular Correlates from Randomized Phase III Trial of Newly Diagnosed Glioblastoma (GBM), J Clin Oncol 29: (abstract LBA 2000), 2011.

367. Wang M, Dignam J, Won M, Curran WJ, Mehta MP, Gilbert MR: Variation over time and inter-dependence between disease progression and death among patients with glioblastoma (GBM) on RTOG 0525, J Clin Oncol 29: (abstract 2017), 2011.

368. Mehta M, Wang M, Aldape K, Stupp R, Jaeckle KA, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Curran WJ, Gilbert M.R; On Behalf of RTOG, NCCTG and EORTC: RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-Dense (dd) Schedule for Glioblastoma (GBM), Int J Radiat Oncol Biol Phys, 81(S): S128-9 (Abstract # 259), 2011.

369. Brachman D, Wang M, Ashby L, Khuntia D, Mehta M: Phase I/II Trial of Temozolomide (TMZ), Motexafin gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513, Int J Radiat Oncol Biol Phys, 81(S): S129-130 (Abstract # 261), 2011.

370. Camphausen K, Wang M, Graves C, Corn BW, Muanza TM, Howard S, Mahadevan A, Schultz CJ, Haas M, Mehta MP: Predictive Value of Tumor Recurrence Using Urinary VEGF Levels in Patients Receiving Radiation Therapy for Glioblastoma, Int J Radiat Oncol Biol Phys, 81(S): S181, (Abstract # 1052), 2011.

371. Gondi V, Eickhoff J, Tome WA, Kozak KR, Mehta MP: Absence of survival benefit from early adjuvant radiotherapy (EART) for resected supratentorial low-grade glioma (SLGG) in adults: A SEER database analysis, Int J Radiat Oncol Biol Phys, 81(S): S270 (Abstract # 2120), 2011.

372. Gondi V, Hermann B, Mehta MP, Tome WA: Predicting Neurocognitive Function (NCF) Impairment Following Fractionated Stereotactic Radiotherapy (FSRT) for Benign or Low-Grade Adult Brain Tumors, Int J Radiat Oncol Biol Phys, 81(S): S285-6, (Abstract # 2153), 2011.

373. Akgun Z, Perumal K, Tolakanahalli R, Lin Y, Paliwal B, Mehta M: Pre-Treatment Mean Standardized Uptake Value (SUV) of Non-Small Cell Lung Cancer (NSCLC) is Associated with Subsequent Development of Brain Metastases, Int J Radiat Oncol Biol Phys, 81(S): S597, (Abstract # 2806), 2011.

374. Mehta M, Wang M, Aldape K, Stupp R, Jaeckle KA, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Curran WJ, Gilbert M.R; On Behalf of RTOG, NCCTG and EORTC: RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-Dense (dd) Schedule for Glioblastoma (GBM), EJC, 47, S2:10 (abst 18LBA), 2011.

375. Mehta M: Glioblastoma, Clinical Trials Radiotherapy Advances, ECCO/ESMO 2011.

376. Gondi V, Hermann B, Mehta MP, Tome WA: Predicting Neurocognitive Function (NCF) Impairment Following Fractionated Stereotactic Radiotherapy (FSRT) for Benign or Low-Grade Adult Brain Tumors, ECCO/ESMO 2011.

377. Gilbert M, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran W, Mehta MP: RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM), Neuro-Oncol, 13:S3:51, NO-46, 2011. Award for Excellence in Clinical Research, Society for Neuro-Oncology.

378. Gondi V, Eickhoff J, Tome WA, Kozak KR, Mehta MP: Assessing the Survival Impact of Early Adjuvant Radiotherapy (EART) for Resected Supratentorial Low-Grade Glioma in Adults using the Surveillance, Epidemiology, and End Results (SEER) Database, Neuro-Oncol, 13:S3:26, EP-03, 2011.

379. Vogelbaum MA, Hadjipanayis C, Wang M, Wong M, Mehta M, Gilbert M: The Relationship Between Extent of Resection and Outcome in Newly Diagnosed GBM: Results from RTOG 0525, Neuro-Oncol, 13:S3:162, ST-41, 2011.

380. Lassman AB, Wang M, Gilbert MR, Aldape KD, Beumer JJ, Wright J, Takebe N, Puduvalli VK, Hormigo A, Gaur R, Werner-Wasik M, Mehta MP: Phase II Trial of Dasatinib for Recurrent GBM (RTOG 0627), Neuro-Oncol, 13:S3:64, NO-102, 2011.

381. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Iwanami A, Tanaka K, Gini B, DeJesus J, Lisiero DD, Huang T, Prins R, Wen P, Robins HI, Prados M, DeAngelis L, Mellinghoff I, Mehta M, James CD, Chakravarti A, Cloughesy T, Tontonoz P, Mischel P: Targeting

EGFR/PI3K/AKT Regulated SREBP-1/LDLR Mediated Cholesterol Metabolism To Treat Glioblastoma, Neuro-Oncol, 13:S3:70, MP-09, 2011.

382. Wefel JS, Armstrong TS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta MP, Gilbert MR: Clinical Utility of Neurocognitive Function as a Prognostic Factor for Survival and Measure of Differential Between-Arm Treatment Effects in RTOG 0525, MP-09, Neuro-Oncol, 13:S3:74, NC-05, 2011.

383. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta MP: The Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment (GPA) for Patients with Breast Cancer and Brain Metastases, Neuro-Oncol, 13:S3:82, OM-27, 2011.

384. Sulman EP, Cahill DP, Wang M, Won M, Hegi ME, Mehta MP, Aldape KD, Gilbert MR: A Combined Molecular Clinical Predictor of Survival Validated with the RTOG0525 Cohort, Neuro-Oncol, 13:S3:83, OM-30, 2011.

385. Aldape KD, Gilbert M, Cahill D, Wang M, Won M, Hegi M, Colman H, Mehta M, Sulman E: Clinical Utility of G-CIMP and IDH1 Status as Dual Prognostic Markers in Glioblastoma, Neuro-Oncol, 13:S3:84, OM-35, 2011. Award for Excellence in Translational Research, Society for Neuro-Oncology.

386. Armstrong T, Wefel JS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M, Gilbert MR: Clinical Utility Of Quality Of Life (QOL) and Symptom Assessment as Prognostic Factors for Survival and Measures of Treatment Effects on RTOG 0525, Neuro-Oncol, 13:S3:121, QL-03, 2011. Award for Excellence in Quality of Life Research, Society for Neuro-Oncology.

387. Stell BV, Jacobs DI, Grimm SA, Rademaker A, Rice L, Schwartz M, Chandler J, Muro K, Helenowki IB, Marymont MH, Wagner LI, Mehta M, Raizer J: Incongruity on Quality of Life Scores Between Patients with Malignant Gliomas and Caregivers: Updated Data, Neuro-Oncol, 13:S3:125, QL-17, 2011.

388. Cahill D, Wang M, Won M, Aldape K, Maywald R, Hegi M, Mehta M, Gilbert M, Sulman E, Vogelbaum M: Extent Of Resection In Glioblastoma â&#x20AC;&#x201C; Variation Between Molecular Risk Groups In RTOG-0525, Neuro-Oncol, 13:S3:160, ST-34, 2011.

389. Vogelbaum MA, Wang M, Hadjipanayis CG, Won M, Mehta MP, Gilbert MR: The Relationship Between Extent of Resection and Outcome in Newly Diagnosed Glioblastoma: Results From RTOG 0525, ST-41, SNO 2011.

390. Wang M, Dignam J, Won M, Curran W, Mehta M, Gilbert MR: Variation Over Time and Inter-dependence Between Disease Progression and Death among Patients with Glioblastoma (GBM) on RTOG 0525, Neuro-Oncol, 13:S3:28, EP-11, 2011.

391. Sperduto PW, Wang M, Robins HI, Schell M, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski M, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry GA, Suh JH, Mehta MP: RTOG 0320: A Phase III Trial Comparing Whole Brain Radiation (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus with Temozolomide (TMZ) or

Erlotinib for Non-Small Cell Lung Cancer (NSCLC) and 1-3 Brain Metastases. AACR 2012.

392. Kruser TJ, McCabe BP, Mehta MP, Khuntia D, Geye MS, Cannon GM. Reirradiation for locoregionally recurrent non-small cell lung cancer using fractionated IMRT: clinical outcomes at a single institution. Proceedings of American College of Radiation Oncology Annual Meeting, 2012.

393. Mehta MP, Curran W, Wang D, Wang F, Klienberg L, Brade A, Mostafa N, Zhou X, Qian J, Leahy T, Desai B, Giranda V: Phase 1 safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. J Clin Oncol 30(S):2013, 2012.

394. Chakravarti A, Wang M, Aldape KD, Sulman EP, Bredel M, Magliocco AM, Klimowicz AC, Hegi M, Stupp R, Gilbert MR, Curran WJ, Werner-Wasik M, Mahajan A, Schultz CJ, Mehta MP: A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles. J Clin Oncol 30(S):2001, 2012.

395. Cairncross G, Wang M, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Curran W, Mehta M: A Phase III Trial of Radiotherapy (RT) versus Chemotherapy plus RT for Pure and Mixed Anaplastic Oligodendroglioma (RTOG 9402): an Intergroup Trial by the RTOG, NCCTG, SWOG, NCIC CTG and ECOG. J Clin Oncol 30(S):2008b, 2012.

396. Prabhu RS, Won M, Shaw EG, Wang M, Brachman D, Mehta MP: The effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low grade glioma: Secondary analysis of RTOG 98-02. J Clin Oncol 30(S):2047, 2012.

397. Mehta MP, Curran W, Wang D, Wang F, Klienberg L, Brade A, Mostafa N, Zhou X, Qian J, Leahy T, Desai B, Giranda V: Phase 1 safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. IASLC 2012.

398. Brown PD, Shook S, Laack NN, Choucair A, Wefel JS, Meyers CA, Suh JH, Shouhami L, Kavadi V, Mehta M, Watkins-Bruner D: Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (WBRT): First Report of RTOG 0614, a Placebo-Controlled, Double-Blind, Randomized Trial. Int J Radiat Oncol Biol Phys 84:S1 (abstract 2; plenary session presentation) 2012.

399. Chakravarti A, Wang M, Aldape K, Sulman E, Bredel M, Hegi M, Gilbert M, Curran W, Werner-Wasik M, Mehta MP: A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles. Int J Radiat Oncol Biol Phys 84:S4 (abstract 9) 2012.

400. Cairncross G, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Mehta M, Curran W: IDH status predicts benefit from PCV+RT in anaplastic oligodendroglioma-RTOG 9402. Int J Radiat Oncol Biol Phys 84:S5 (abstract 10) 2012.

401. Platta CS, Kruser TJ, Weigel TL, TomĂŠ WA, Das RK, Geye H, Khuntia D, Mehta MP, Cannon GM: Sublobar Resection with Intraoperative 125I Brachytherapy vs Stereotactic Body Radiation Therapy for Treatment of Clinical Early Stage Non-Small

Cell Lung Cancer in Patients not Eligible for Lobectomy. Int J Radiat Oncol Biol Phys 84:S46 (abstract 116) 2012.

402. Kalakota K, Helenowski I, Schumacher A, Marymont MH, Gradishar W, Chandler J, Raizer J, Grim S, Sperduto PW, Mehta MP: Validation of the Breast Cancer Specific Graded Prognostic Assessment (GPA) for Patients with Breast Cancer with Brain Metastases. Int J Radiat Oncol Biol Phys 84:S117 (abstract 291) 2012.

403. Sperduto PW, Shanley R, Kased N, Roberge D, Chao S, Jensen A, Shih H, Kirkpatrick J, Gaspar LE, Mehta, M: The Effect Of Tumor Subtype On The Time From Primary Diagnosis To Development Of Brain Metastases And Survival In Women With Breast Cancer. Int J Radiat Oncol Biol Phys 84:S142 (abstract 352) 2012.

404. Mehta MP, Curran W, Wang D, Wang F, Klienberg L, Brade A, Mostafa N, Qian J, Leahy T, Desai B: Phase 1 safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. Int J Radiat Oncol Biol Phys 84:S269-70 (abstract 2135) 2012.

405. Nam B, Platta C, Sales VL, Kruser T, Khuntia D, Mehta M, Cannon G, Weigel T: Comparison of Stereotactic Body Radiation Therapy vs Sublobar Resection with Intraoperative 125I Brachytherapy vs VATS lobectomy for the Treatment of Clinical Early Stage Non-Small Cell Lung Cancer. 49th Annual STS Meeting, 2012.

406. Platta CS, Kruser TJ, Weigel TL, TomĂŠ WA, Das RK, Geye H, Khuntia D, Mehta MP, Cannon GM: Wedge Resection with Intraoperative 125I Brachytherapy vs Stereotactic Body Radiation Therapy for Treatment of Clinical Early Stage Non-Small Cell Lung Cancer in Patients not Eligible for Lobectomy. Chicago Multidisciplinary Thoracic Symposium, 2012.

407. Wefel JS, Shook S, Brown PD, Laack NN, Choucair A, Suh JH, Roberge D, Kavadi V, Mehta MP, Watkins-Bruner D: Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (WBRT): First Report of RTOG 0614, a Placebo-Controlled, Double-Blind, Randomized Trial, Neuro-Oncol, 14 (S6), abstract NC-08, 2012.

408. Sperduto PW, Shanley R, Luo X, Kased N, Sneed P, Roberge D, Chao S, Weil R, Suh J, Bhatt A, Jensen A, Brown PB, Shih H, Kirkpatrick J, Gaspar LE, Fiveash J, Chiang V, Knisely J, Sperduto CM, Lin N, Mehta, M: Evidence Of Interaction Between Her2 And Estrogen/Progesterone Status In Patients With Breast Cancer And Brain Metastases, Neuro-Oncol, 14 (S6), abstract NO-11, 2012.

409. Vogelbaum MA, Wang M, Peereboom D, MacDonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP: RTOG 0131: Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligodendrogliomas â&#x20AC;&#x201C; Updated Survival and Progression Free Survival Analysis, Neuro-Oncol, 14 (S6), abstract NO-56, 2012.

410. Chakravarti A, Wang M, Aldape K, Sulman E, Bredel M, Hegi M, Gilbert M, Curran W, Werner-Wasik M, Mehta MP: A Revised Recursive Partitioning Analysis Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles. Neuro-Oncol, 14 (S6), abstract MR-02, 2012.

411. Robins HI, Wang M, Gilbert M, Chakravarti A, Grimm S, Penas-Prado M, Chaudhary R, Anderson PJ, Elinzano H, Gilbert RA, Mehta M: Phase I Results from RTOG 0929, a Randomized Phase I/II Study of ABT-888 (Veliparib) in Combination with Temozolomide (TMZ) in Recurrent, TMZ-Resistant Glioblastoma. Neuro-Oncol, 14 (S6), abstract NO-14, 2012.

412. Kalakota K, Offor O, Patel R, Dess R, Schumacher A, Helenowski I, Marymont MH, Sperduto PW, Chmura SJ, Mehta M: Validation of the Breast Cancer Specific Graded Prognostic Assessment (GPA) for Patients with Breast Cancer with Brain Metastases: A Multi-Institutional Experience. Neuro-Oncol, 14 (S6), abstract RT-32, 2012.

413. Mehta M, Curran W, Wang D, Wang F, Kleinberg L, Brade A, Mostafa N, Qian J, Leahy T, Desai B, Giranda V: Phase I Study of Veliparib in Combination with Whole Brain Radiation Therapy in Patients with Brain Metastases, J Thorac Oncol 7: S5, S40: P1-086, 2012.

414. Raparia K, Villa C, Mehta M, Cagle P: Clinical, Pathological and Molecular Predictive Factors for the Development of Brain Metastasis in Patients with Lung Adenocarcinoma. USCAP Abstract 1930, 2013.

415. Mehta MP, Curran W, Wang D, Wang F, Klienberg L, Brade A, Qian J, Leahy T, Desai B, Giranda V: Phase 1 study of veliparib with concurrent whole brain radiation therapy (WBRT) in patients (pts) with brain metastases (mets). ESMO 2012.

416. Kim IA, Peereboom D, De Los Santos J, Sperduto P, Winter K, White J, Mehta MP: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from Her2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG, AACR 2013.

417. Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, Brachman D, Werner-Wasik M, Komaki R, Sulman EP, Mehta MP: RTOG 0825: Phase III Double-blind Placebo-controlled Trial Evaluating Bevacizumab (Bev) in Patients (Pts) with Newly Diagnosed Glioblastoma (GBM), J Clin Oncol 31(15) S1:1 May 2013 (Plenary Presentation) 418. Wefel J, Pugh S, Armstrong T, Gilbert M, Won M, Wendland MM, Brachman D, Komaki R, Crocker I, Robins HI, Lee R, Mehta, M: Neurocognitive Function (NCF) Outcomes in Patients with Glioblastoma (GBM) Enrolled in RTOG 0825, J Clin Oncol 31(15) S1:2004 May 2013.

419. Fisher B, Liu J, MacDonald D, Lesser G, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary J, H Chen, Mehta M: Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas: Preliminary Results of RTOG 0424, J Clin Oncol 31(15) S1:2008 May 2013.

420. Armstrong TS, Won M, Wefel J, Gilbert MR, Pugh S, Kavadi V, Brachman D, Komaki R, Crocker IJ, Robins HI, Lee R, Mehta M: Comparative Impact of Treatment on Patient Reported Outcomes (PROs) in Patients with Glioblastoma (GBM) Enrolled in RTOG 0825, J Clin Oncol 31(15) S1:2013 May 2013.

421. Glass J, Won M, Schultz C, Brat DJ, Bartlett NL, Suh J, Fisher B, Liepman M, Mehta MP: Treatment of Primary Central Nervous System Lymphoma with Pre-irradiation Temozolomide, Rituximab and Methotrexate, Hyperfractionated Radiation Therapy and Post-irradiation Temozolomide: RTOG 0227 Phase II Study Results, J Clin Oncol 31(15) S1:2033 May 2013.

422. Chinnaiyan P, Won M, Wen PY, Rojiani AM, Kavadi VS, Dipetrillo TA, Corn BW, Mehta MP: RTOG 0913: A Phase I Study of Daily Everolimus (RAD001) In Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma, J Clin Oncol 31(15) S1:2047 May 2013.

423. Yoon H, Helenowski IB, Perumal K, Marymont MH, Chandler J, Bendok BR, Rosenow JM, Mehta MP: Prognostic factors and outcome of atypical and anaplastic meningioma with and without radiation, J Clin Oncol 31(15) S1:2083 May 2013.

424. Sulman EP, Won M, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, Komaki R, Gilbert M, Mehta MP, Aldape KD: Molecular Predictors of Outcome and Response to Bevacizumab (BEV) Based on Analysis of RTOG 0825, a Phase III Trial Comparing Chemoradiation (CRT) with and without Bev in Patients with Newly Diagnosed Glioblastoma (GBM), J Clin Oncol 31(15) S1:LBA 2010 May 2013.

425. Sperduto P, Shanley R, Luo X, Andrews D, Werner-Wasik M, Valicenti R, Bahary J, Souhami L, Won M, Mehta M: Secondary Analysis of RTOG 9508, a Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) versus WBRT plus Stereotactic Radiosurgery (SRS) in Patients with 1-3 Brain Metastases; Post-stratified by the Graded Prognostic Assessment (GPA), Int J Radiat Oncol Biol Phys 87 (2S):5152, abstract 123, October 2013.

426. Kalakota K, Rakhra SS, Hideki O, Helenowski I, Marymont MH, Kalapurakal JA, Chandler JP, Mehta MP: Time to Intracranial Failure Following Post-resection Cavity Radiosurgery for Patients with a Single Intracranial Metastasis, Int J Radiat Oncol Biol Phys 87 (2S):160-61, abstract 1033, October 2013.

427. Mishra MV, Regine W, Mehta M: An Evaluation of Worldwide Proton Beam Therapy Clinical Trials, Int J Radiat Oncol Biol Phys 87 (2S):178, abstract 1078, October 2013.

428. Sours C, Mistry N, Zhang H, Kwok Y, Mehta M, Regine W, D'Souza W, Gullapalli R: Feasibility Study Testing the Incorporation of Resting State fMRI Data in Radiation Therapy Planning to Limit Dose to Cognitive Function Networks in Patients with Primary Brain Tumors, Int J Radiat Oncol Biol Phys 87 (2S):254-5, abstract 2131, October 2013.

429. Yoon H, Helenowski IB, Bhandari R, Raparia K, Marymont M, DeCamp M, de Hoyos A, Chandler J, Bendok B, Mehta M: Predictive Factors for Brain Metastases and Relapse and Prognostic Factors for Survival in Stage III-IV Non-Small Cell Lung Cancer (NSCLC), Int J Radiat Oncol Biol Phys 87 (2S):525, abstract 2844, October 2013.

430. Cui Y, Tome W, Gondi V, Mehta MP, Manfredi D, Galvin JM, Xiao Y: Report of Hippocampal Contouring Credentialing in RTOG 0933, Int J Radiat Oncol Biol Phys 87 (2S):576, abstract 2980, October 2013.

431. Gondi V, Mehta M, Pugh S, Tome W, Corn B, Caine C, Kanner A, Rowley H, Kundapur V, Greenspoon JN, Konski AA, Bauman GS, Wenyin S, Kavadi V, Kachnic L: Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy for patients with brain metastasis: Preliminary results of RTOG 0933. ASTRO October 2013. Plenary session presentation.

432. Lautenschlaeger T, Perry J, Peereboom D, White J, Steeg P, Mehta M, Chakravarti A: Cilengitide Inhibits Proliferation and Shows Combined Effects with Radiation in Breast Cancer Cell Lines, Int J Radiat Oncol Biol Phys 87 (2S):658, abstract 3193, October 2013..

433. Cahill DP, George A, Gilbert MR, Chakravarti A, Stupp R, Hegi M, Brown P, Jaeckle KA, Corn B, Sulman E, Souhami L, Werner-Wasik M, Anderson BM, Mehta M, Aldape KD: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: a report from the RTOG-0525 trial, AACR-NCI-EORTC Molecular Markers Meeting, A110, PO.35, October 20 2013.

434. Yoon H, Offor O, Helenowski I, Bhandari R, Raparia K, Marymont M, DeCamp M, deHoyos A, Chandler J, Bendok B, Chmura S, Mehta M,: Predictive Factors for Brain Metastases and Relapse and Prognostic Factors for Survival in Stage III-IV Non-Small Cell Lung Cancer, NeuroOncol 15(3):EP-022, 36, 2013.

435. Fisher B, Hu C, Macdonald D, Lesser G, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary JP, Mehta M: RTOG 0424: Phase II Study of a Temozolomide (TMZ)-Based Chemo-Radiotherapy (RT) Regimen for High Risk Low-Grade Gliomas Preliminary Results Including Quality of Life (QOL) and Neurological Function (NCF), NeuroOncol 15(3):MR-009, 77, 2013.

436. Gondi V, Mehta M, Pugh S, Tome W, Kachnic L: Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy (WBRT) for patients with brain metastasis: Preliminary results of RTOG 0933. NeuroOncol 15(3):NC-012, 94, 2013. Plenary Presentation and Recipient of the Adult Quality of Life Award.

437. Wefel JS, Pugh S, Armstrong TS, Gilbert MR, Won M, Wendland M, Brachman D, Brown PD, Crocker I, Robins HI, Lee R, Mehta, M: Longitudinal Analysis of Neurocognitive Outcomes in Patients with Glioblastoma (GBM) Enrolled in RTOG 0825, NeuroOncol 15(3):NC-021, 97, 2013.

438. Gilbert MR, Pugh S, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Dignam J, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Brachman D, Werner-Wasik M, Tremont-Lukats I, Sulman EP, Mehta MP: RTOG 0825: Primary Outcome Results from a Phase III Randomized, Placebocontrolled Trial Evaluating Bevacizumab in Newly Diagnosed Glioblastoma NeuroOncol 15(3):NC-046, 109, 2013. Plenary Presentation and Recipient of the Adult Clinical Research Award.

439. Nayak L, DeAngelis LM, Wen PY, Brandes AA, Soffietti R, Peereboom DM, Lin NU, Chamberlain M, MacDonald D, Galanis E, Perry J, Jaeckle K, Mehta M, Stupp R, van den Bent M, Reardon D: The Neurologic Assessment in Neuro-Oncology (NANO)

Scale: A Tool to Assess Neurologic Function for Integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria. NeuroOncol 15(3):NO-101, 123, 2013.

440. Sulman E, Won M, Ezhilarasan R, Sun P, Blumenthal D, Vogelbaum M, Colman H, Jenkins R, Chakravarti A, Jeraj R, Brown P, Jaeckle K, Schiff D, Dignam J, Atkins J, Brachman D, Werner-Wasik D, Gilbert M, Mehta M, Aldape K: A Molecular Predictor of Response to Bevacizumab Based on Analysis of RTOG 0825, a Phase III Trial Comparing Chemoradiation with and without Bevacizumab in Patients with Newly Diagnosed Glioblastoma. NeuroOncol 15(3):OM-067, 152, 2013.

441. Perry A, Pugh S, Rogers L, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Mehta M: Pathology Concordance Levels for Meningioma Classification and Grading in RTOG Trial 0539. NeuroOncol 15(3):PA023, 161, 2013.

442. Mahajan A, Manfredi D, Rogers L, Palmer M, Hillebrandt E, Bilton S, Robinson G, Velasco K, Mehta M: Class Solution IMRT Planning, Blinded Comparison to RTOG 0539, NeuroOncol 15(3):RT-027, 184, 2013.

443. Armstrong TS, Won M, Wefel J, Gilbert MR, Pugh S, Wendland MM, Brachman D, Brown PD, Crocker IJ, Robins HI, Lee R, Mehta M: Comparative Impact of Tumor and Treatment on Patient Reported Outcomes (PROs) in Patients with Glioblastoma (GBM) Enrolled in RTOG 0825, NeuroOncol 15(3):SM-003, 226, 2013.

444. Gondi V, Mehta M, Pugh S, Tome W, Corn B, Caine C, Kanner A, Rowley H, Kundapur V, Greenspoon JN, Konski AA, Bauman GS, Wenyin S, Kavadi V, Kachnic L: Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy for patients with brain metastasis from Non-Small Cell Lung Cancer: Preliminary results of RTOG 0933. IASLC 2013 (accepted).

445. Mehta MP, Curran W, Wang D, Wang F, Kleinberg L, Brade A, Zhou NX, Qian J, Zhu M, Leahy T, Holen K, Giranda V: Results of a Phase I Study of Veliparib in Combination with Whole Brain Radiation Therapy in Patients with Brain Metastases.

EORTC Brain Metastasis Conference, 2013 (submitted Jul 2013).

446. Zhang H, Prado K, Langen KM, Mehta M, Regine W, Dâ&#x20AC;&#x2122;Souza W: Achieving Optimal Patient Setup Imaging and Treatment Workflow Configurations in Multi-Room Proton Centers via Monte Carlo Simulation, RSNA 2013 (accepted, December 2013).

447. Caine C, Mehta M, Deshmukh S, Gondi V, Tome W, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Raben A, Shi W, Kavadi V, Kachnic L: CogState computerized memory tests in patients with brain metastases: secondary endpoint results of RTOG 0933 (submitted October 2013 to ESTRO 2014).

448. Tome W, Mehta M, Deshmukh S, Gondi V, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Raben A, Shi W, Kavadi V, Kachnic L: Memory preservation in patients with brain metastases following hippocampal avoidance whole-brain RT. (submitted October 2013 to ESTRO 2014).

449. Palmer M, Mahajan A, Manfredi D, Rogers L, Hillebrandt E, Bilton S, Robinson G, Velasco K, Mehta M: Building Optimal Plans with Dosimetry Power ToolsStandardized Class Solutions + Plan Quality Metrics (RTOG 0539 Secondary Analysis), AAMD, 2014 (submitted November 2013).

PUBLICATIONSâ&#x20AC;&#x201C;BOOK CHAPTERS/MONOGRAPHS/ONLINE PUBLICATIONS: 1.

Mehta MP: Special applications of radiation therapy. In: Current Therapy in Hematology Oncology, Brain and Carbone (eds), 4th edition, B.C. Decker, Philadelphia, Pennsylvania, pp 464-468, 1991.

2.

Mehta MP, Turski PA, Petereit DG, Strother CM, Levin AB, Kinsella TJ: Assessment of arteriovenous malformations pre and post stereotactic radiosurgery using magnetic resonance angiography. In: Stereotactic Radiosurgery Update, Lunsford L.D. (ed), Elsevier Press, New York, New York, pp 129-138, 1992.

3.

Mehta MP, Anderla D, Gehring MA, Mackie TR, Kinsella TJ: Dose optimization for stereotactic radiosurgery. In: Stereotactic Radiosurgery Update, Lunsford L.D. (ed), Elsevier Press, New York, New York, pp 229-234, 1992 .

4.

Levin AB, Mehta MP, Mackie TR, Rozental JM, Kubsad SS: Stereotaxic focused radiation in metastatic lesions to the brain. In: Stereotactic Radiosurgery Update, Lunsford L.D. (ed), Elsevier Press, New York, New York, pp 445-451, 1992.

5.

Mehta MP: Radiosurgery for brain metastases. In: Stereotactic Surgery and Radiosurgery, DeSalles AF, Goetsch SJ (eds), Medical Physics Publishing Corporation, Madison, Wisconsin, pp 353-368, 1993.

6.

Mehta MP, Speiser BL, Macha H: High dose-rate brachytherapy for lung cancer. In: Textbook on High Dose-Rate Brachytherapy, Nag (ed), Futura Publishing Company, Mount Kisco, New York, pp 295-319, 1994.

7.

Mehta MP: Role of brachytherapy-the American experience. In: Minimally Invasive Techniques in Thoracic Medicine and Surgery, Hetzel (ed), Chapman and Hall Medical, London, UK, pp 205-216, 1995.

8.

Mehta MP, Rozental JM: Radiotherapy of pituitary hypothalamic tumors. In: Principles and Practice of Endocrinology and Metabolism, 2nd edition, Becker (ed), J.B. Lippincott Publishing Company, Philadelphia, Pennsylvania, pp 229-237, 1995.

9.

Behal R, Cummings BJ, Ratko T, Bova FJ, Friedman W, Larson, D, Lunsford, LD, Matuszewski K, Mehta MP: Technology Report: Stereotactic Radiosurgery. University Hospital Consortium Clinical Practice Advancement Center, Oakbrook, Illinois, 1995.

10.

Mehta MP, Kinsella TJ: Superior vena cava syndrome. In: Thoracic Oncology, Roth, Ruckdeschel and Weisenburger (eds), W.B. Saunders Company, pp 239-258, 1995.

11.

Noyes WR, Auchter RM, Craig B, French MC, Johnson MN, Lamond JP, Levin AB, Kinsella TJ, Mehta MP: Cost analysis of radiosurgery versus resection for single brain

metastases. In: Radiosurgery 1995, Kondziolka D (ed), S. Karger Publishers, Basel, Switzerland, pp 172-179, 1996.

12.

Mehta MP: Endobronchial radiation therapy. In: Lung Cancer, Pass, Mitchell, Johnson and Turrissi (eds), J.B. Lippincott Publishing Company, pp 741-750, 1996.

13.

Mehta MP: Radiosurgery: Primary and metastatic malignant brain tumors. In: Minimally Invasive Therapy of the Brain, De Salles AF, Lufkin R (eds), Thieme Medical Publishers, pp 213-224, 1996.

14.

Mehta MP, Noyes WR: Solitary brain metastases. In: Tumor Board Case Management, Winchester DP, et al (eds), Lippincott-Raven Publishing Company, Philadelphia, PA, pp 640-648, 1996.

15.

Mehta MP, Sneed PK: Interstitial radiation therapy for brain tumors. In: Principles and Practice of Brachytherapy, Nag S (ed), Futura Publishing Company, Mount Kisco, New York, pp 247-268, 1997.

16.

Mehta MP, Lamond J, Nori D, Speiser B: Brachytherapy of lung cancer. In: Principles and Practice of Brachytherapy, Nag S (ed), Futura Publishing Company, Mount Kisco, New York, pp 323-350, 1997.

17.

Mehta MP: Role of chemotherapy and radiation therapy in the treatment of locally advanced non-small cell lung cancer. In: Updates on Advances in Lung Cancer, Schiller JB (ed), S. Karger Publishers, Basel, Switzerland, pp. 35-55, 1997.

18.

Boyd T, Mehta MP: A comprehensive review of the role of radiosurgery in patients with intracranial metastases. In: Radiosurgery 1997, Kondziolka D (ed), S. Karger Publishers, Basel, Switzerland, pp. 31-50, 1998.

19.

Mehta MP, Boyd T, Loeffler J: Linear accelerator stereotactic radiosurgery using single and fractionated treatment schemes for cerebral metastases. In: Advanced Techniques in Central Nervous System Metastases, Maciunas RJ (ed), AANS, pp 135-154, 1998.

20.

Mehta MP: Radiation Pneumonitis: The Clinical Syndrome, Pathophysiology, and Molecular Basis. In: Volume & Kinetics In Tumor Control and Normal Tissue Complications; Paliwal, Fowler, Herbert, Mehta (eds), Medical Physics Publishing, pp 264-276, 1998.

21.

Mehta MP, Kinsella TJ: Superior vena cava syndrome: Clinical features, diagnosis and treatment. In: General Thoracic Surgery, Shields, LoCicero and Ponn (eds), Williams and Wilkins, pp 2149-2166 , 2000.

22.

Mehta MP, Harari PM: Altered Fractionation Schedules for Lung Cancer. In: Lung Cancer Principles and Practice, 2nd edition; Pass, Mitchell, Johnson, Turrisi, Minna (eds), Lippincott Williams & Wilkins, pp 843-852, 2000.

23.

Mehta MP, Schiller JH: Diagnosis and Management of Stage III NSCLC. Clinical Oncology Update, 3(3)1-15, 2000.

24.

Sahel J, Polans A, Mehta MP, Auchter R, Alberts D: Intraocular melanoma. In: Principles and Practice of Oncology, DeVita (ed), 6th edition, Lippincott-Raven, pp, 20702090, 2001.

25.

Mehta MP: Radiotherapy of pituitary hypothalamic tumors. In: Principles and Practice of Endocrinology and Metabolism, 3rd edition, Becker (ed), J.B. Lippincott Publishing Company, Philadelphia, Pennsylvania, pp 243-254, 2001.

26.

Kesslering C, Mehta MP: Neural tumors. In: Management of Metastatic Disease to the Musculoskeletal System. Heiner JP, Kinsella TJ and Zdeblick TA (eds), Quality Medical Publishing, St. Louis, MO, pp 295-302, 2002.

27.

Mehta M, Treont-Lukats I: Evaluation and Management of Brain Metastases. In: American Society of Clinical Oncology Educational Book. Perry MC (ed), ASCO, Alexandria, VA, pp 375-382, 2002.

28.

Mehta M: Low Grade Glioma: Early vs. Delayed Radiotherapy. In: Fifth Congress of the European Association of Neuro-Oncology Educational Book. Carapella CM (ed), EANO V, Florence, Italy, pp 137-140, 2002.

29.

Guha A, Perry J, Mehta M: Role of Temozolomide in the Management of Brain Tumors – an Update: A CME Monograph adapted from a series of teaching lectures delivered in India, Dec 2002), 2003.

30.

Mackie TR, Olivera GH, Kapatoes JM, Ruchala KJ, Balog JP, Tome WA, Hui S, Kissick M, Wu Chuan, Jeraj R, Reckwerdt P, Harari PM, Ritter MA, Forrest L, Welsh J, Mehta MP: Helical Tomotherapy. In: Intensity Modulated Radiation Therapy A State of the Art, eds J Palta and T Mackie, Medical Physics Publishing Corporation, Madison WI, pp 247-272, 2003.

31.

Mehta MP, Hong T: Current Issues in the Management of Metastatic Cancer: Brain Metastases. Monograph, 2003.

32.

Mehta MP, Tremont I: Brain Metastases. In: Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment, Furie B, Cassileth P, Atkins MB, Mayer RJ, (eds), Churchill Livingstone, Philadelphia, PA pp. 1062-1076, 2003.

33.

Mehta M: Management of Brain Tumors – Past, Present and Future. (A CME Monograph adapted from a series of teaching lectures delivered in India, April 2003), 2003.

34.

Mehta MP: Fractionated Radiation Therapy for Malignant Brain Tumors. In: Youman’s Neurological Surgery (Chapter 9.4.1), H. Richard Winn MD (ed), ISBN 072168291X, W. B. Saunders Company, pp 4015-4026, 2003.

35.

Mehta MP, Tremont-Lukats I: Radiosurgery for Single and Mutliple Brain Metastasis.

In: Intracranial Metastases: Current Management Strategies, Sawaya R (ed), ISBN: 1405116463, Blackwell Publishing, Futura Division, Malden, MA, pp 139-164, 2004.

36.

Hong TS, Tomé WA, Hayes L, Yuan Z, Badie B, Rao R, Mehta MP: Acute Sequelae of Stereotactic Radiosurgery. In: Radiosurgery vol 5, Kondziolka D, McDermott M, Regis J, Smee R, Flickinger JC (eds), S. Karger Publishers, Basel, Switzerland, pp 38-45, 2004.

37.

Bradley KA, TomĂŠ WA, Resnick DK, Mehta MP: Treatment of Trigeminal Neuralgia Using Linear Accelerator-based Radiosurgery. In: Radiosurgery vol 5, Kondziolka D, McDermott M, Regis J, Smee R, Flickinger JC (eds), S. Karger Publishers, Basel, Switzerland, pp 171-180, 2004.

38.

Mehta MP, Gilbert M: Malignant Gliomas: Impacting Survival with new Treatment Strategies. Enduring PowerPoint National Grand Rounds Project (CME Approved) MedComm, 2004.

39.

Mehta MP, Gilbert M: When Cancer Goes To Your Head: Treatment Approaches for Brain Metastases. Enduring PowerPoint National Grand Rounds Project (CME Approved), MedComm, 2004.

40.

Patel RR, Tome WA, Mehta MP: Radiation Therapy for Cerebral Nervous System Tumors (Chapter 45). In: Principles of Neurosurgery, 2nd edition, Rengachary SS, Ellenbogen RG (eds), ISBN 0 7234 3222 8, Elsevier Mosby, London, UK, pp. 719-728, 2004.

41.

Mehta MP, Patel R: Radiotherapy and Radiosurgery for Brain Metastases (Chapter 48). In: Cancer of the Nervous System, 2nd edition, Black PM, Loeffler JS, (eds), ISBN 0 7817 3731 1, Lippincott, Williams and Wilkins, Philadelphia, Pennsylvania, pp. 657672, 2004.

42.

Bradley K, Mehta MP: Basic Concepts Underlying Radiation Therapy (Chapter 10).

In: Textbook of Neuro-Oncology, Berger MS, Prados MD (eds), ISBN 0 7216 8148 4, Elsevier Saunders, Philadelphia, Pennsylvania, pp. 70-74, 2004.

43.

Mehta MP, Langer C, Meyers CA, Patchell RA, Regine WF: WBRT for the Management of Brain Metastases: Novel Approaches to Improving the Therapeutic Index, A Multimedia program Based on a CME Symposium held during the ASTRO 2004 Annual Meeting, American Academy of CME, Inc, 2004.

44.

Albert DM, Auchter RM, Avery RB, Mehta MP: Intraocular Melanoma. In: Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds), 7th edition, Lippincott-Raven, pp, 1809-1825, 2005.

45.

Mehta MP, Bradley K: Radiation Therapy for Leptomeningeal Cancer. In: Leptomeningeal Cancer, Abrey L, Chamberlain M, Engelhard HH (eds), ISBN 0 387 24198 1, Springer, New York, New York, pp. 147-158, 2005.

46.

Mehta MP, Bradley K, Trask D: Treatment of a Patient with Non-Small-Cell-Lung Cancer and Multiple Brain Metastases with Motexafin Gadolinium. Case Studies in Lung Cancer 5: 3-6, 2006.

47.

Mehta MP: Gliomas: Setting New Standards and Developing New Therapeutic Approaches. In Physical, Chemical and Biological Targeting in Radiation Oncology. Mehta M, Paliwal BR, Bentzen SM (eds), Medical Physics Publishing, Madison, WI, pp 166181, 2006.

48.

Gondi V, Jeraj R, Mehta M: The Use of PET and PET-CT in Radiation Oncology, Discussions in PET Imaging 2006.

49.

Mehta MP: Radiation and Cancer Biology Practice Examination for Dosimetrists.

Editor-in-Chief and Author, Advanced Medical Publishing, Madison, WI, 2006.

50.

Mehta MP: Novel Agents and Strategies for Management of Malignant Glioma, Physicians Education Resource, AMA PRA Category 1 Educational Activity, www.cancerpublications.com/newsletter/other/schering_slide/august_06/index.ht ml, 2006.

51.

Shah H, Mehta MP: Radiation Therapy. In: High-Grade Gliomas: Diagnosis and Treatment Barnett G (ed), EISBN 159745-185-1 Humana Press, Totowa, NJ, pp 231-244, 2006.

52.

Khuntia D, Suh J, Tome W, Mehta MP: Stereotactic Irradiation: Linear Accelerator and Gamma Knife. In Clinical Radiation Oncology 2nd Edition, Gunderson LL and Tepper JE (eds), ISBN-13: 978-0-443-06840-9, Churchill Livingstone/Elsevier, pp 331-342, 2006.

53.

Mehta MP, Gilbert MR, Lassman AB, Regine WF, Stieber VW: Metastatic Brain Tumor Concepts and Controversies: A Roundtable Conversation. A CME Monograph, Medical Communications Media, 2006.

54.

Forouzannia A, Hayes LL, Trask DD, Mehta MP: A Patient with Brain Metastases From a Lung Primary: The Role of Motexafin Gadolinium ith Whole Brain Radiation Therapy, In Case Studies in Lung Cancer ISSN: 1539-8234, Physicians’ Education Resource, Dallas, TX, vol 5, pp 1-6, 2006.

55.

Mehta MP: Combinations of Ionising Radiation and Other Sensitising Agents. In MEDICAL RADIOLOGY – Radiation Oncology.

Multimodal Concepts for Integration of Cytotoxic Drugs and Radiation Therapy. Brown, Mehta and Nieder (eds): SpringerVerlaag, (ISBN 978-3-642-06505-7), 2006.

56.

Bradley K, Robins HI, Mehta MP: Nervous System Toxicity. In: Principles and Practice of Chemoradiation, John M, Legha S (eds), Lippincott, (ISBN:9780781741057), 2006.

57.

Mehta MP, Robins I, Kuo J, Rowley H, Salamat S, Hayes L, O’Connor N: Case Studies in Glioblastoma Multiforme, University of Wisconsin, 2007.

58.

Siker M and Mehta MP: Advances in the Treatment of Brain Metastases. In Lung Cancer: Translational & Emerging Therapies. Pandya, Brahmer, and Hidalgo (eds): Taylor and Francis, NY, NY, pp 207-230, 2007.

59.

Siker M, Mehta MP: “Radiation Therapy for Brain Metastases” In Brain Metastases, Raizer J and Abrey L (eds), Springer, Norwell, MA, pp 91-116, (ISBN 978-0-387-692210), 2007.

60.

Siker M, Donahue B, Vogelbaum, M, Tome, W, Gilbert M, Mehta MP: Primary Intracranial Neoplasms. In Principles and Practice of Radiation Oncology, 5th edition.

Halperin E, Perez CA, Brady LW (eds) pp 717-750, (ISBN 978-0-7817-6369-1) 2007.

61.

Mehta MP, Gilbert MR, Chakravarti A: Malignant Gliomas, Hope and Life: A Forward-Looking Discusion, CME Monograph, 2007.

62.

Govindan R, Siker M and Mehta MP: Recent Advances in the Treatment of Brain Metastases in Non-Small Cell Lung Cancer. eUpdate Series, 2007 (http://www.cancernetwork.com/lung-cancer/content/article/10165/62373).

63.

Mehta MP, Buckner J, Sawaya R, Cannon G: “Neoplasms of the Central Nervous System” In Cancer: Principles and Practice of Oncology, 8th edition, Devita, Lawrence, Rosenberg (eds), Lippincott Williams and Wilkins, Baltimore, MD, pp1975-2032, (ISBN 13: 978-0-7817-7207-5, 2008.

64.

Wong G, Manon R, Tome W, Mehta MP: Stereotactic Body Radiation TherapyFractionated Radiation Therapy Perspective. In Principles and Practice of Stereotactic Radiosurgery, Chin and Regine (eds), Spinger, New York, NY, pp 635-642, (ISBN: 9780-387-71069-3, 2008.

65.

Mehta MP, Tsao MN: Cost Effectiveness and Quality of Life. In Principles and Practice of Stereotactic Radiosurgery, Chin and Regine (eds), Spinger, New York, NY, pp 663672, (ISBN: 978-0-387-71069-3, 2008.

66.

Khuntia D, Matthew BS, Meyers C, Johnson S, Mehta MP: Effects of Cancer and Treatments on Cognition: Brain Metastases. In Cognition and Cancer, Meyers C, Perry J (eds), Cambridge University Press, pp 170-186, (ISBN: 978-0-521-85482-5), 2008.

67.

Love N, Vredenburgh J, Batchelor T, Cloughsey TF, Mehta MP, Mikkelson T, Peereboom D, Weingart JD, Wen PY: Malignant Glioma Update (Audio CME Production), 2009.

68.

Mehta MP: Current advances in glioma therapy: Congress of Neurological Surgeons University. Audiovisual CME, internet-based program, 2009.

69.

Khuntia D, Chakravarti A, Robins HI, Palanichamy K, Mehta MP: Radiosensitizers in Neuro-oncology, In Textbook of Stereotactic and Functional Neurosurgery, Lozano AM, Gildenberg PL, Tasker RR (eds), Springer, pp 987-1006, (ISBN: 978-3-540-69959-0), 2009.

70.

Young N, Batchelor T, Cloughsey T, Mehta MP, Mikkelsen, Peereboom D, Vredenburgh J, Weingart, Wen P: Research to Practice, Malignant Glioma Thinktank, Audio CME, 2009.

71.

Nieder C and Mehta MP: Dose-escalated high precision radiotherapy: a method to overcome variations in biology and radiosensitivity limiting the success of conventional approaches? In: The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies, Medical Radiology Book Series, eds Molls M, Vaupel P, Nieder C, Anscher MS, ISBN 978-3-540-74385-9, pp 336-344, 2009.

72.

Mehta MP: “Introduction I” In Spine Radiosurgery, Gerszten P, Ryu S (eds), pp xiv, (ISBN 978-1-58890-509-3), 2009.

73.

Margolin K, Chen M, Cannon G, Mehta M: Multidisciplinary Management Of CNS Melanoma Metastases In Cutaneous Melanoma, Balch CM, Houghton AN, Sober AJ, Soong SJ, Atkins MB, Thompson JF (eds), Chapter 32, 2009.

74.

Mehta MP, Adkison J: Innovative Advances in Thoracic Radiation Therapy In Healthcare Bulletin, 2009.

75.

Mehta MP: Coming of Age: Personalized Cancer Care: Using Theragnostic Radiation Oncology to Deliver Individualized Treatment Plans. Imaging Economics, September 2010.

76.

Mehta MP, Patel D, Chakravarti A: Bevacuzimab Plus Radiotherapy in Malignant Glioma: Is There a Role? In Controversies in Neuro-Oncology, Avastin and Malignant Gliomas, Chen T, Chamberlain M (eds) (ISBN 978-1-60805-132-8), Bentham Books pp 33-39, 2011.

77.

Siker M, Mehta MP: “Anaplastic Gliomas” In Principles and Practice of Neuro-Oncology, 1st edition, Mehta, Vogelbaum, Chang, Guha, Newton (eds), Demos, pp 752-9, (ISBN 978-1-933864-78-5), 2011.

78.

Anderson B, Mehta MP: “Vestibular Schwannoma” In Principles and Practice of NeuroOncology, 1st edition, Mehta, Vogelbaum, Chang, Guha, Newton (eds), Demos, pp 808-817, (ISBN 978-1-933864-78-5), 2011.

79.

Siker M, Mehta MP: “Hemangioblastoma and Hemangiopericytoma” In Principles and Practice of Neuro-Oncology, 1st edition, Mehta, Vogelbaum, Chang, Guha, Newton (eds), Demos, pp 818-19, (ISBN 978-1-933864-78-5), 2011.

80.

Kruser T, Gondi V, Mehta MP: “Pituitary Tumors and Craniopharyngioma”. In Principles and Practice of Neuro-Oncology, 1st edition, Mehta, Vogelbaum, Chang, Guha, Newton (eds), Demos, pp 861-873, (ISBN 978-1-933864-78-5), 2011.

81.

Cannon GM, Mehta MP: Fractionated Radiation Therapy for Malignant Brain Tumors.

In Youman’s Neurological Surgery 6th Edition, H. Richard Winn MD (ed), W. B. Saunders Company, (ISBN 978-1-4160-5316-3), 2011.

82.

Nieder C, Grosu AL, Mehta MP: Brain Metastatases Reirradiation. In Reirradiation: New Frontiers; Medical Radiology - Radiation Oncology Series Springer, (ISBN 978-3-64212467-9), 2011.

83.

Mehta MP: Current Management of Patients with Metastatic Brain Tumors.

Medscape CME publication available at www.MedscapeCMe.com, http://www.medscape.org/viewarticle/742360, May 26 2011.

84.

Gilbert M, Aldape K, Armstrong T, Mehta MP: Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment. Medscape Ocology Education CME Monograph, http://www.medscape.org/viewarticle/747183, August 17 2011

85.

Gilbert M, Aldape K, Armstrong T, Mehta MP: Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment. HemOnc today EducationLab CME Monograph, http://www.hemonctoday.com/cmecenter/activity.aspx?aid=76921, Sepember 28 2011

86.

Kris M, Mehta MP, Marshall MB, Hirsch FR: Virtual Tumor Board: Multidisciplinary Management of Non Small Cell Lung Cancer, MCM CME Video Virtual Tumor Board, http://www.cmecorner.com/programs.asp?ProductID=907, October 19 2011.

87.

Khuntia D, Mehta M: Technological Advances in Lung Cancer: Tomotherapy. In Advances in Radiation Oncology of Lung Cancer (2nd edition), Jeremic B (ed), ISBN 978-3642-19925-7, Springer-Verlag, pp 725-734, 2011.

88.

McHaffie DR, Khuntia D, Tome W, Mehta MP: Stereotactic Irradiation: Linear Accelerator and Gamma Knife, Chapter 16. In Clinical Radiation Oncology 3rd Edition, Gunderson LL and Tepper JE (eds), ISBN 978-1-4377-1637-5, Churchill Livingstone/Elsevier, October 2011.

89.

Mehta MP: CNS Tumors: Overview.

In Clinical Radiation Oncology 3rd Edition, Gunderson LL and Tepper JE (eds), ISBN 978-1-4377-1637-5, Churchill Livingstone/Elsevier, 2011.

90.

Mehta MP, Vogelbaum M, Chang S, Patel N: “Neoplasms of the Central Nervous System”, Chapter 121. In Cancer: Principles and Practice of Oncology, 9th edition, Devita, Lawrence, Rosenberg (eds), Lippincott Williams and Wilkins, Baltimore, MD, pp 1700-1749, (ISBN), 2011.

91.

Gilbert M, Aldape K, Armstrong T, Mehta MP: Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment. HemOnc Today (CME Supplement) May 25 2012.

92.

Shirazi H, Lassman A, Khuntia D, Mehta MP: Central Nervous System Case 1: Anaplastic Oligodendroglioma. In Radiation Oncology Difficult Cases and Practical Management, Small W, Williams TR, Donnelly ED (eds), ISBN 978-1-936287-37-6, Demos, pp 191-197, 2013.

93.

Mehta MP, Shirazi H, Barani, I, Khuntia D: Central Nervous System Case 2: Elderly Patient with Newly Diagnosed Glioblastoma. In Radiation Oncology Difficult Cases and Practical Management, Small W, Williams TR, Donnelly ED (eds), ISBN 978-1-93628737-6, Demos, pp 198-206, 2013.

94.

Mehta MP, Shirazi H, Barani, I, Khuntia D: Central Nervous System Case 3: Low Grade Glioma. In Radiation Oncology Difficult Cases and Practical Management, Small W, Williams TR, Donnelly ED (eds), ISBN 978-1-936287-37-6, Demos, pp 207-214, 2013.

95.

Gondi V, Vogelbaum MA, Grimm S, Mehta MP: Central Nervous System Tumors: Primary Intracranial Neoplasms . In Principles and Practice of Radiation Oncology, 6th edition. Halperin E, Perez CA, Brady LW (eds), LWW, ISBN 978-1-4511-1648-0, pp 649-676, 2013.

96.

Chung C, Mehta M: CME Expert Column on CNS Metastases, Neuro-Oncology Learning Portfolio on Medscape Oncology, 2013 (in press).

97.

Ahluwalia, MS, Garje R, Wen PY, Mehta MP: Adjuvant Therapies (Chemotherapy and Radiation Therapy) for Atypical and Anaplastic Meningiomas, In Controversies in Neuro-Oncology, Best Evidence Medicine for Brain Tumor Surgery, Quiñones-Hinojosa A and Raza SM (eds), Thieme Medical Publishers, ISBN 978-1-60406-755-2, pp 283-290, 2013.

98.

Khuntia D, Mohindra P, Mehta, MP: Lung Cancer, In Clinical Radiation Oncology: Indications, Techniques, and Results, 3rd Edition. Small W (ed), pp, (ISBN ???-?-????????-?), 2014 (in press).

PUBLICATIONS–EDITOR: 1.

Paliwal BR, Fowler JF, Herbert DE, Mehta MP (editors): Volume and Kinetics In Tumor Control and Normal Tissue Complications; Medical Physics Publishing, Madison, WI, 1998.

2.

Mehta MP (Education Editor): Treatment Options for Non Small Cell Lung Cancer: Current Research and Expert Commentary, Medical Education Network, New York, New York, 2001.

3.

Paliwal BR, Fowler JF, Herbert DE, Mehta MP (editors): Biological and Physical Basis of IMRT and Tomotherapy. 6th International Conference on Dose, Time and Fractionation, Medical Physics Publishing, Madison, WI, 2002.

4.

Mehta MP (editor): Optimizing Radiation Therapy: Cytoprotection and Chemotherapy. 12th European Cancer Conference Monograph, Schering Plough, Kenilworth, NJ, 2003.

5.

Brown JM, Mehta MP and C. Nieder (editors): MEDICAL RADIOLOGY – Radiation Oncology.

Multimodal Concepts for Integration of Cytotoxic Drugs and Radiation Therapy. Springer-Verlaag, 2006.

6.

Mehta M, Paliwal BR, Bentzen SM (editors): Physical, Chemical and Biological Targeting in Radiation Oncology. 7th International Conference on Dose, Time and Fractionation in Radiation Oncology, AAPM Symposium Proceedings No.14, Medical Physics Publishing, Madison, WI, 2006.

7.

Bentzen S, Harari P, Mackie R, Mehta MP (editors): Advances In Radiation Oncology.

2007.

8.

Mehta MP, Chang S, Vogelbaum M, Guha A, Herbert N (editors): Principles and Practice of Neuro-Oncology: A Multidisciplinary Approach. Demos Medical Publishing, 2010.

9.

Mehta MP: CNS Tumors: Section Editor In Clinical Radiation Oncology 3rd Edition, Gunderson LL and Tepper JE (eds), ISBN, Churchill Livingstone/Elsevier, 2011.

10.

Mehta MP: CNS Tumors: Section Editor In Difficult Cases in Radiation Oncology, Small W (ed), ISBN, Demos, pp 190-214, 2013.

INVITED PRESENTATIONS: 1.

Childhood meningitis: State-of-the-Art, 1981. Arthur Davison Childrens’ Hospital Pediatric Grand Rounds, Ndola, Zambia, 1981.

2.

Detailed Analysis of the Incidence, Clinical Features, Management and Complications of Gunshot Injuries in Ndola, Zambia, 1979-81. Surgical Grand Rounds, Ndola Central Hospital, Ndola, Zambia, 1981.

3.

Hemobilia: Presentation and Management. Surgical Grand Rounds, Ndola Central Hospital, Ndola, Zambia, 1981.

4.

Traumatic Diaphragmatic Herniation. Surgical Grand Rounds, Ndola Central Hospital, Ndola, Zambia, 1981.

5.

"Radioimmunotherapy, the Magic Bullet". Wisconsin Society of Radiation Oncology, Oconomowoc, WI, February 1987.

6.

Report of a Pilot Study of Endobronchial Irradiation. Wisconsin Society of Radiation Oncologists, Oconomowoc, WI, February 1988.

7.

Endobronchial Irradiation for Malignant Airway Obstruction. Human Oncology Grand Rounds, UWCCC, Madison, WI, April 1988.

8.

An in vivo Model for Dosimetric Analysis of Radiolabeled Monoclonal Antibodies.

American Association for Cancer Research, New Orleans, LA, May 1988.

9.

Non-small Cell Lung Cancer: Radiotherapeutic Perspectives. Human Oncology Grand Rounds, UWCCC, Madison, WI, August 1988.

10.

Time dose fractionation overview. Third International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison, WI, September 1988.

11.

Radiation osteolysis. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison, WI, September 1988.

12.

Endobronchial brachytherapy for malignant airway obstruction. 30th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, New Orleans, LA, October 1988.

13.

Stereotactic radiotherapy for arteriovenous malformations. Radiology Grand Rounds, University of Wisconsin Hospital & Clinics, Madison, WI, January 1989.

14.

Radiotherapy in the management of lung and esophageal malignancies. Thoracic Surgery Grand Rounds, University of Wisconsin Hospital & Clinics, Madison, WI, March 1989.

15.

Non-small cell lung cancer: Overview and focus on brachytherapy. 4th Annual Comprehensive Management of Chronic Respiratory Problems, Madison, WI, March 1989.

16.

Endobronchial radiation therapy for malignant airway obstruction. Annual Meeting of the Wisconsin Thoracic Society, Milwaukee, WI, March 1989.

17.

The curative potential of radiation therapy in the management of non-small cell lung cancer. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison, WI, March 1989.

18.

Radiotherapy applications and developments. University of Iowa/Mercy Hospital Cancer Conference, Davenport, IA, June 1989.

19.

CT based dose-volume analysis of small bowel during pelvic external radiation therapy. Kubsad SS, Mehta MP, Gehring MA, Shanahan TG, Paliwal BR, Kinsella TJ. 31st Annual Meeting of the American Association of Physicists in Medicine, Memphis, TN, July 23-27 1989.

20.

Radioimmunotherapy: Dosimetric and biological analysis. 31st Annual Meeting of the American Society of Therapeutic Radiology and Oncology, San Francisco, CA, October 1989.

21.

Innovative radiotherapy: Stereotaxic radiotherapy. Fall Meeting of the Radiation Therapy Technologists of Wisconsin, Madison, WI, October 1989.

22.

Stereotaxic radiotherapy: Initial experience using a linear accelerator. Notre Dame, IN, February 1990.

23.

Radiotherapeutic innovations in the management of non-small cell lung cancer.

University of Wisconsin Regional Lung Cancer Conference, Madison, WI, March 1990.

24.

The evolving role of radiotherapy in the management of small cell carcinoma of the lung. University of Wisconsin Regional Lung Cancer Conference, Madison, WI, March 1990.

25.

Stereotactic radiosurgery for brain metastases. University of Wisconsin, Medical Physics Seminar, Madison, WI, April 1990.

26.

Stereotactic radiosurgery for brain metastases, the early experience. University of Wisconsin Colloquium in Human Cancer Biology, Madison, WI, May 1990.

27.

Brain tumor response following stereotactic radiotherapy. 26th Annual Meeting of the American Society for Clinical Oncology, Washington, DC, May 1990.

28.

Brain neoplasms: Current limitations and future prospects. Wausau Regional Cancer Center, Wausau, WI, May 1990.

29.

Stereotactic radiation: Evaluation of early brain tumor response. Harvard Radiosurgery Update, Chestnut Hill, MA, June 1990.

30.

The role of stereotactic radiosurgery in the management of pituitary tumors.

University of Wisconsin Endocrine Grand Rounds, Madison, WI, August 1990.

31.

A review of stereotactic radiosurgery for brain metastases. 3rd Midwest NeuroOncology Conference, Madison, WI, August 1990.

32.

Stereotactic radiation: Evaluation of early brain tumor response. 32nd Annual American Society of Therapeutic Radiology Oncology Meeting, Miami Beach, FL, October 1990.

33.

Hyperfractionated high dose rate endobronchial irradiation. 13th Annual American Endocurietherapy Society Meeting, San Diego, CA, December 1990.

34.

Urgent management of high airway obstruction. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison, WI, January 1991.

35.

Treatment of brain metastasis with stereotactic radiation. Levin AB, Mehta MP, Mackie TR. Linde Winter Neurosurgical Meeting, Snowbird, UT, February 1991.

36.

Medical issues in stereotactic radiosurgery. Workshop on Stereotactic External Beam Radiation Therapy, University of Wisconsin, Madison, WI, February 1991.

37.

High dose rate endobronchial radiation: technical and clinical parameters. Petereit DG, Mehta MP, Fowler JF, Shahabi S, Thomadsen BR, Kinsella TJ. Wisconsin Society of Radiation Oncology, Oconomowoc, WI, February 1991.

38.

Management of CNS Neoplasms with stereotactic radiosurgery. Human Oncology Grand Rounds, UWCCC, Madison, WI, March 1991.

39.

Stereotactic focussed radiation in metastatic lesions to the brain. Levin AB, Mehta MP, Rozental JM, Mackie TR, Kubsad SS. American Association of Neurological Sciences Meeting, New Orleans, LA, April 1991.

40.

The management of pelvic recurrence of rectal cancer: Radiotherapeutic intervention for pelvic recurrence: preoperative, intraoperative and postoperative. 26th Annual Cincinnati Cancer Symposium, Cincinnati, OH, April 1991.

41.

Assessment of arteriovenous malformations pre and post stereotactic radiosurgery using magnetic resonance angiography. International Stereotactic Radiosurgery Symposium, Pittsburgh PA, June 1991.

42.

Dose optimization for stereotactic radiosurgery.

Radiosurgery Symposium, Pittsburgh, PA, June 1991.

43.

A stereotactic radiosurgery treatment planning and simulation system. Gehring MA, Mackie TR, Mehta MP, Sanders CL, Reckwerdt PJ, Kubsad SS, Kinsella TJ. International Stereotactic Radiosurgery Symposium, Pittsburgh, PA, June 1991.

44.

Identification of an optimal subgroup of patients with brain metastases suitable for stereotactic radiation. Levin AB, Mehta MP, Mackie TR, Rozental J, Kubsad SS. International Stereotactic Radiosurgery Symposium, Pittsburgh, PA, June 1991.

45.

Strategies to enhance radiosurgical responses. 9th International Conference on Brain Tumor Research and Therapy, Pacific Grove, CA, October 1991.

International

Stereotactic

46.

Acute changes in brain tumor metabolism after treatment with stereotactic radiotherapy. Rozental JM, Mehta MP, Levine RL, Kinsella TJ, Levin AB. 9th International Conference on Brain Tumor Research and Therapy, Pacific Grove, CA, October 1991.

47.

Radiosurgery for brain metastases. 33rd Annual American Society of Therapeutic Radiology Oncology Meeting, Washington, DC, October 1991.

48.

Stereotactic radiation therapy at the University of Wisconsin. Tufts University, Boston, MA, January 1992.

49.

Stereotactic irradiation for high-grade gliomas. Bastin K, Mehta MP, Levin AB, Kinsella TJ. Wisconsin Society of Radiation Oncology, Oconomowoc, WI, February 1992.

50.

Radiation therapy of lung cancer. Pulmonary Conference University of Wisconsin, Madison, WI, March 1992.

51.

New approaches to radiation therapy. Freeport Memorial CME Program, Freeport IL, March 1992.

52.

Special procedures in radiation therapy. State Medical Society Annual Meeting, Milwaukee WI, April 1992.

53.

1H MR spectroscopy of human brain tumors in vivo using optimized RF pulses.

Thomas AM, Rodriguez R, Ryner L, Mehta MP, Brown P, Rozental JM, Turski PA. 11th Annual Meeting of Society of Magnetic Resonance in Medicine, Berlin, Germany, August 1992.

54.

Evaluation of cerrobend block weight. Paliwal BR, Rieger J, Mehta MP, Kubsad SS. 34th Annual Meeting of American Assn of Physicists in Medicine, Calgary, Alberta, Canada, August 1992.

55.

Radiosurgery for arteriovenous malformations based on magnetic resonance angiography. Kubsad SS, Mehta MP, Petereit DP, Turski PA: International Conference on Medical Physics and Radiation Safety, Bombay, India, September 1992.

56.

Stereotactic radiosurgery using a linear accelerator. Kubsad SS, Mackie TR, Gehring MA, Mehta MP, Paliwal BR, Kinsella TJ. International Conference on Medical Physics and Radiation Safety, Bombay, India, September 1992.

57.

Lung cancer. 38th Annual Fall Cancer Conference, Madison, WI, September 1992.

58.

Brachytherapy in lung cancer. ECOG, Spring Meeting, Atlanta, Georgia, February 1993.

59.

Treatment of malignant glioma with stereotactic radiosurgery. Levin AB, Mehta MP, Masciopinto JE, Rohde B. Linde Winter Neurosurgical Meeting, Snowbird, UT, February 1993.

60.

Preliminary analysis of multivoxel 1H MR spectroscopic imaging for CNS neoplasms.

41st Annual Meeting of Radiation Research Society, Dallas, TX, March 1993.

61.

Colony Stimulating Factors: From Laboratory to Clinical Applications. St. Luke's Medical Center Symposium, Milwaukee, WI, April 1993.

62.

Update on radiation oncology for lung cancer. Lung Cancer Seminar, St. Vincent's Hospital, Green Bay WI, April 1993.

63.

Surgery vs. radiosurgery for brain metastases. 1st Congress of the International Stereotactic Radiosurgery Society, Stockholm, Sweden, June 1993.

64.

Recent advances in radiation oncology. Clinical Oncology Seminar, Wisconsin Rapids WI, June 1993.

65.

Compensation of opposing lung fields with a 3-D dose compensation system. Wendt R, Brock L, Haney P, Paliwal BR, Jursinic P, Mehta MP, Kinsella TJ. 18th Annual Meeting of American Association of Medical Dosimetrists, Atlanta, Georgia, June 1993.

66.

Management of brain metastases with stereotactic radiosurgery: "Hands-On" Stereotactic Surgery and Radiosurgery Workshop. Los Angeles, CA, August 1993.

67.

A review of endobronchial HDR brachytherapy. 7th Annual Brachytherapy Symposium, Columbus, OH, September 1993.

68.

Clinical Neuro-Oncology: UW Experience. Wisconsin Radiological Society/Wisconsin Radiation Oncology Society. 1993 Fall Scientific Program, Madison, WI, October 1993.

69.

Glioblastoma treated with external beam radiotherapy and stereotactic radiosurgery boost. 35th Annual Meeting of American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1993.

70.

Compensation of opposing lung fields with a 3-D dose compensation system. Wendt R, Brock L, Haney P, Paliwal B, Jursinic P, Mehta MP, Kinsella TJ. 35th Annual Meeting of American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1993.

71.

Five-year experience with linear-accelerator based stereotactic radiosurgery. ADAC Users' Group Meeting at the 35th Annual Meeting of American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1993.

72.

Stereotactic radiosurgery for glioblastoma: An update. Levin AB, Masciopinto JE, Mehta MP. The Congress of Neurologic Surgeons. Vancouver, Canada, October 1993.

73.

Stereotactic radiosurgery for glioblastoma multiforme. Levin AB, Masciopinto JE, Mehta MP. The World Society for Stereotactic and Functional Neurosurgery, Ixtapa, Mexico, October 1993.

74.

Preliminary analysis of CO 9052, a Phase II study of Cisplatin, Vinblastine and WR 2721 with external beam radiotherapy and WR 2721 for advanced, unresectable, nonmetastatic non-small cell lung cancer. U.S. BioSciences Annual Meeting, Philadelphia, PA, November 1993.

75.

Combined modality management of cancer of the esophagus. Surgical Grand Rounds, University of Wisconsin, Madison WI, October 1993.

76.

Acute morbidity of the upper aerodigestive tract during radiotherapy. Annual Conference of the Wisconsin Diatetic Association, Madison WI, November 1993.

77.

Stereotactic radiosurgery: Clinical, biological and technical ramifications. Cleveland Clinic, Cleveland OH, November 1993.

78.

Current status of stereotactic radiosurgery. Neurosurgical Grand Rounds, University of Wisconsin, Madison WI, January 1994.

79.

Future strategies to improve outcome in childhood malignant gliomas. CCG Glioma Working Group, Philadelphia PA, January 1994.

80.

Radiosurgery applications: Metastatic brain lesions: Fourth Annual Course on Minimally Invasive Therapy of the Brain, Santa Monica CA, August 1994.

81.

Radiosurgery limitations: Response of vascular and nervous tissue to radiosurgery: Fourth Annual Course on Minimally Invasive Therapy of the Brain, Santa Monica CA, August 1994.

82.

Can we justify randomized studies using radiosurgery for patients with metastatic disease and, if so, what should be done? The Preuss Foundation seminar on Stereotactic Radiation Treatment of Brain Tumors, Boston MA, September 1994.

83.

What are the costs of radiosurgery and can society afford these costs? The Preuss Foundation seminar on stereotactic radiation treatment of brain tumors, Boston MA, September 1994.

84.

Cost comparison of radiosurgery and surgery for the treatment of brain metastases.

36th Annual Meeting of American Society for Therapeutic Radiology and Oncology, San Francisco CA, October 1994.

85.

Current issues in stereotactic radiosurgery for brain tumors. Current status of radiosurgery in the United States for malignant and benign tumors. Loyola University Medical Center, Chicago IL, November 1994.

86.

Second neoplasms after successful therapy for initial malignancy in childhood.

Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison WI, November 1994.

87.

Radiosurgery versus Brachytherapy for malignant glioma. 17th Annual Mid-Winter Meeting of the American Brachytherapy Society, Sanibel Island FL, December 1994.

88.

Cost comparison of stereotactic radiosurgery versus surgical resection for brain metastases. Noyes WR, Mehta MP. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1995.

89.

The potential promise of radiosurgery. Eastern Cooperative Oncology Group, Denver CO, April 1995.

90.

Imaging techniques for radiosurgery: Pre- and post-radiosurgery. The 2nd Congress of the International Stereotactic Radiosurgery Society, Boston MA, June 1995.

91.

New strategies for malignant glioma management. Beloit Hospital Tumor Board, Beloit WI, June 1995.

92.

An overview of the current status of outcomes measures in therapeutic radiology.

37th Annual Meeting of the American Association of Physicists in Medicine, Boston MA, July 1995.

93.

Management of acute neuro-oncologic conditions. Neurology Grand Rounds, University of Wisconsin, Madison WI, August 1995.

94.

Radiosurgery for metastatic brain tumors. UCLA Fifth Annual Workshop on Minimally Invasive Therapy of the Brain, Santa Monica CA, September 1995.

95.

Malignant brain tumors; the role of radiosurgery. Gamma Knife Workshop on Stereotactic Radiosurgery, San Diego CA, October 1995.

96.

Technology report: Stereotactic radiosurgery. University Hospital Consortium and the Clinical Practice Advancement Center, Miami FL, October 1995.

97.

An overview of radiosurgery. 37th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Miami FL, October 1995.

98.

Brain cancer. St. Francis Medical Center Grand Rounds, La Crosse WI, October 30, 1995.

99.

Human experience with meningioma. University of Wisconsin, School of Veterinary Medicine Grand Rounds, Madison WI, December 1, 1995.

100. Metastases: Conventional radiation and radiosurgery. LINAC Radiosurgery 1995, University of Florida, Orlando FL, December 1995.

101. Radiosurgery versus surgery: A cost benefit analysis. LINAC Radiosurgery 1995, University of Florida, Orlando FL, December 1995.

102. Endobronchial brachytherapy: LDR vs HDR? 18th Annual Mid-Winter Meeting of the American Brachytherapy Society, Scottsdale AZ, December 1995.

103. Clinical trials in Neuro-Oncology I: An Introduction. University of Wisconsin, Neurosurgery Grand Rounds, Madison WI, February 1996.

104. Clinical trials of amifostine and radiation therapy. Tannehill SP, Mehta MP. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1996.

105. The physical, biological and clinical basis for radiosurgery. University of Wisconsin, Neurosurgery Grand Rounds, Madison WI, March 1996.

106. Clinical trials in Neuro-Oncology II: A review of current trials. University of Wisconsin, Neurosurgery Grand Rounds, Madison WI, March 1996.

107. The current and future management of metastatic tumors: The role of fractionated radiation therapy with or without radiosurgery. The Joint Section on Stereotactic and Functional Neurosurgery and the 46th Annual Meeting of the Congress of Neurological Surgeons, Montreal Canada, September 1996.

108. Stereotactic radiation: Indications for metastatic tumors. 38th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Los Angeles CA, October 1996.

109. Refresher Course: High dose rate brachytherapy for endobronchial and endoesophageal tumors. 38th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Los Angeles CA, October 1996.

110. The evolving role of chemotherapy in adult brain tumors: Innovative cancer therapy for tomorrow. Chemotherapy Foundation Symposium XIV, Mount Sinai School of Medicine, New York NY, November 1996.

111. Radiation therapy and radiosurgery for brain metastases. LINAC Radiosurgery 1996, University of Florida Orlando, FL, December 1996.

112. Economics of radiosurgery. LINAC Radiosurgery 1996, University of Florida, Orlando FL, December 1996.

113. Innovative management strategies for malignant glioma. Loyola University Radiation Oncology Grand Rounds, Chicago IL, January 1997.

114. An ECOG Phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer. Tannehill SP, Mehta MP. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1997.

115. Outcomes research and analysis in radiotherapy. University of Wisconsin Human Oncology Retreat. Madison WI, March 1997.

116. Amifostine and Radiation therapy: Past, Present and Future. Amifostine Advisory Board Scientific Session, Atlanta GA, April 1997.

117. Impact of WWW-aided tools on Neoplastic Diseases Course learning. University of Wisconsin Medical Education Day, Madison WI, April 1997.

118. New radiotherapeutic developments for lung cancer. University of Wisconsin Thoracic Surgery Grand Rounds, Madison WI, April 1997.

119. Malignant tumors-Radiosurgery for metastases. Scientific Session, 3rd Congress of the International Stereotactic Radiosurgery Society, Madrid Spain, June 1997.

120. Brain Metastases: Current Status and role of Radiosurgery. University of Wisconsin Cancer Center Grand Rounds, Madison WI, July, 1997.

121. RTOG Clinical trials for adults with primary malignant brain tumors. Sharing Hope: American Brain Tumor Foundation Symposium, Chicago IL, July 1997.

122. Radiation Pneumonitis: Clinical spectrum, molecular pathophysiology, treatment and prevention. University of Wisconsin Human Oncology Retreat. Madison WI, August 1997.

123. ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for nonsmall cell lung cancer (NSCLC): Early results and RT quality assurance (QA). 8th World Conference on Lung Cancer Dublin Ireland, August, 1997.

124. Combined modality therapeutic approaches for malignant CNS neoplasms.

University of Wisconsin Neurosurgery Grand Rounds, Madison WI, September 1997.

125. Radiation Pneumonitis: An evolving understanding of the clinical syndrome, molecular genesis, factors influencing incidence and possible protection. Fifth International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison WI, September 1997.

126. What is the clinical role of WR-2721? Spokane-area CME Symposium. Couer dâ&#x20AC;&#x2122;Allen, WA, October 1997.

127. Protection of normal tissue from the cytotoxic effects of radiation therapy: role of amifostine. Symposium on Advances in Therapy: Protecting Against the Toxicities of Radiotherapy, Orlando FL, October 1997.

128. Refresher Course: High dose rate brachytherapy for endobronchial and endoesophageal tumors. 39th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Orlando FL, October 1997.

129. Experience with the functional assessment of cancer therapy-lung (FACT-L) in ECOG 4593, a Phase II hyperfractionated accelerated radiation therapy (HART) trial. 39th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Orlando FL, October 1997.

130. A randomized assessment of the value of web-based education for teaching second year medical students. 31st Annual Meeting of the American Association for Cancer Education, Atlanta GA, October 1997.

131. Clinical and economic advances in cytoprotection: fole on amifostine. 1997 Annual Meeting of the American College of Clinical Pharmacy, Phoenix AZ, November 1997.

132. Advances in the treatment of lung cancer. Lung Cancer Awareness Day, University of Wisconsin, Madison WI, November 1997.

133. Stereotactic Imaging. LINAC Radiosurgery 1997, University of FL, Orlando FL, December 1997.

134. Gliomas - Does Radiosurgery Help? LINAC Radiosurgery 1997, University of FL, Orlando FL, December 1997.

135. Advances in the Management of Inoperable Lung Cancer, ASTRO Satellite Symposium, 1998.

136. Cytotoxic protection by Amifostine against the toxicities of combined chemoradiotherapy. National Seminar on Amifostine, Puerto Rico, January, 1998.

137. Update in advances in the management of non-small cell lung cancer. Scientific Symposium, Radiation Therapy Oncology Group Meeting, Houston TX, February 1998.

138. State of the Art Treatment Options for State III NSCLC: Radiation Therapy Advances; a UW-CME video conference sponsored by Bristol Myers Squibb, Madison WI, March 1998.

139. Ethyol as a radioprotector; the American experience. French seminar on Ethyol, Paris France, March 1998.

140. Web-based multimedia modules for Oncology Grand Rounds. University of Wisconsin Medical Education Day, April 1998.

141. There is no role for CNS brachytherapy. 21st Annual Meeting of the American Brachytherapy Society, Albuquerque, NM, June 1998.

142. Primary brain tumors: Role of radiosurgery. 17th Annual UICC Meeting, Rio de Janeiro Brazil, August 1998.

143. Current strategies for improving the therapeutic index of radiation therapy: Radiotherapy in lung cancer. 40th Annual Meeting of ASTRO symposium, Phoenix AZ, October 1998.

144. Endobronchial and endoesophaegeal high dose rate brachytherapy for malignant airway and digestive tract obstructions. 40th Annual Meeting of ASTRO, Phoenix AZ, October 1998.

145. Management of brain metastases. 40th Annual Meeting of ASTRO, Phoenix AZ, October 1998.

146. Gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer for primary and metastaic brain tumors. Society for Neuro-Oncology 3rd Annual Scientific Meeting, San Francisco CA, November 1998.

147. The role of whole brain radiotherapy: Is it necessary? LINAC Radiosurgery 1998, Orlando FL, December 1998.

148. Is radiosurgery cost effective? LINAC Radiosurgery 1998, Orlando FL, December 1998.

149. Review of clinical experience with amifostine. ALZA Multidisciplinary Oncology Board Meeting, Atlanta GA, January 1999.

150. Malignant lesions: Role of radiation therapy and radiosurgery in brain metastases. 4th Congress of the International Stereotactic Radiosurgery Society, Sydney Australia, February 1999.

151. Glial tumors: Role of radiosurgery. 4th Congress of the International Stereotactic Radiosurgery Society, Sydney Australia, February 1999.

152. Sanghavi S, Mehta M: Amifostine as a radioprotector. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1999.

153. Kesslering C, Mehta M: Gadolinium texaphyrin, a novel radiosensitizer. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1999.

154. What have we learned about lung cancer from randomized trials over the last two decades? Dubuque IA, March 1999.

155. Preliminary results from the run-in phase of randomized Phase III trial of Gd-Tex in the management of brain metastases. San Francisco CA, April 1999.

156. Management of brain metastases: does aggressive therapy improve the outcome?

Gadolinium-Texaphyrin Clinical Investigator Meeting. San Francisco CA, April 1999.

157. Pediatric Brain Tumors: Innovative therapeutic approaches-radiotherapy.

4th International Symposium on Special Aspects of Radiotherapy, Berlin Germany, April 1999.

158. Tomotherapy: Where are we going? Radiation Oncology and Medical Physics Visiting Professor Lecture Series, Stony Brook University Hospital, Stony Brook NY, May 1999 (Visiting Professor) 159. Does radiosurgery have a place in the management of malignant glioma? Radiation Oncology and Medical Physics Visiting Professor Lecture Series, Stony Brook University Hospital, Stony Brook NY, May 1999 (Visiting Professor).

160. Current status of radiosensitizers for pediatric CNS tumors, CCG, Denver CO, May 1999.

161. Incorporating high dose rate brachytherapy in the management of lung cancer. The Regional Cancer Center, Erie PA, July 1999.

162. Current role of radiation therapy in lung cancer. The Regional Cancer Center, Erie PA, July 1999.

163. Current recommendations in the management of brain metastases. CNI Khadiwala Memorial Lecture, Denver CO, September 1999.

164. Advances in radiation oncology for brain tumors. CNI Khadiwala Memorial Lecture, Denver, CO, September 1999.

165. Use of Amifostine with Radiation Therapy. Cleveland Clinic Cancer Center Dinner Meeting, Cleveland, OH, September 1999.

166. Introduction to advances in the management of non-small cell lung cancer.

ASTRO/ACR Fall Conference, , Washington, DC. September 1999.

167. Overview of Radioprotection with Specific Emphasis on Amifostine. Rush Presbyterian Hospital, Chicago, IL, October 1999.

168. Use of Amifostine in Radiotherapy and Combination Chemoradiotherapy. Northern Illinois Cancer Center. Chicago, IL, October, 1999.

169. Radioprotection with Amifostine. Alza Pharmaceuticals Dinner Meeting, Chicago, IL, October 1999.

170. Use of Amifostine in Clinical Radiation Oncology. Southern California Radiation Oncology Society, Los Angeles, CA, October 1999.

171. Results of the lead-in phase of the randomized trial of Motexfin-Gadolinium in brain metastases. ASTRO Satellite Symposium: Pharmacyclics Investigators Meeting, San Antonio TX, November 1999.

172. Radiation Oncologyâ&#x20AC;&#x201C;Sensitizers and New Modalities of Therapy. State of the Art Therapy for Children with Brain Tumors. Pediatric Neuro-Oncology Symposium, University of Minnesota, Minneapolis MN, November 1999.

173. Outcomes, measures and cost-effectiveness for radiosurgery. LINAC Radiosurgery 1999, Orlando FL, December 1999.

174. Evolving technologies: Tomotherapy. LINAC Radiosurgery 1999, Orlando FL, December 1999.

175. Review of management approaches for brain metastases. Schering-Plough Temozolomide Brain Metastases Advisory Board. Keystone, CO. February 2000.

176. A multi-center database analysis predicting survival benefit for brain metastases patients treated with radiosurgery. 82nd Annual Meeting of the ARS, London, England, April 2000.

177. Radiation Pneumonitis: The syndrome, pathogenesis, and prevention. University of Wisconsin, Division of Pulmonary Medicine Grand Rounds, April 2000.

178. The Role of Radiotherapy and Evolving Advances for the Management of Primary CNS Tumors. American Association of Neurology, Annual Meeting, San Diego, CA, April 2000.

179. The Future of Imaging and Radiation Sciences. Joint Centers for Radiation Therapy, Harvard Medical School, Boston, MA, May 2000, (Visiting Professor).

180. The Current Status of Combination Chemoradiotherapy in Non Small Cell Lung Cancer. 36th Annual ASCO meeting, New Orleans, LA, May 2000.

181. High Dose Rate Brachytherapy for Endobronchial Lung Lesions. University of Iowa Radiation Oncology Symposium, Iowa City, IA, June 2000, (Visiting Professor).

182. Tomotherapy. Universitiy of Iowa Radiation Oncology Symposium, Iowa City, IA, June 2000 (Visiting Professor).

183. The Impact of Tomotherapy on CNS Tumors. RTOG Semi-Annual Meeting , Montreal Canada, June 2000.

184. Radioprotection with Ethyol. Medical Education Resources/ALZA Pharmaceuticals “Treating and Protecting Your Cancer Patients” Symposium, Salt Lake City, UT, July 2000.

185. Combined Modality Treatment of Locally Advanced Non-Small Cell Lung Cancer.

Gundersen Lutheran Clinic Medical Education Program, LaCrosse, WI, July 2000.

186. The Clinical Implementation of Tomotherapy. University of Wisconsin Comprehensive Cancer Center Grand Rounds Program, Madison, WI, July 2000.

187. Radiotherapy Advances for Pediatric Tumors. University of Wisconsin Childrens’ Hospital, Caring for Children with Brain Tumors Program, Madison, WI, September 2000.

188. Xcytrin™ (Motexafin Gadolinium) and Whole Brain Radiation for Patients with Brain Metastases: Lead-In Phase to Randomized Trial – Final Results., 42nd Annual Meeting of ASTRO, Boston MA, October 2000.

189. Radiotherapy for Brain Metastases. Society for Neuro-Oncology 5th Annual Scientific Meeting, Chicago, IL, November 2000.

190. Whole Brain Radiotherapy: Why is it Standard? LINAC Radiosurgery-2000 Meeting, Orlando, FL, December 2000.

191. Low Grade Glioma: Case Discussions: LINAC Radiosurgery-2000 Meeting, Orlando, FL, December 2000.

192. Metastatic Brain Tumors: Case Discussions: LINAC Radiosurgery-2000 Meeting, Orlando, FL, December 2000.

193. Tomotherapy: McGill University, Oncology Grand Rounds, Montreal, Canada, March 2001 (Visiting Professor).

194. Brain Metastases: Current Issues: McGill University, Oncology Grand Rounds, Montreal, Canada, March 2001 (Visiting Professor).

195. Non-Small Cell Lung Cancer: Role of Radiotherapy: Royal Victoria Hospital, McGill University, Oncology Grand Rounds, Montreal, Canada, March 2001 (Visiting Professor).

196. Brain Metastases: Current Issues: Radiation Oncology Conference, Hospital Notre Dame, Montreal, Canada, March 2001 (Visiting Professor).

197. Primary Brain Tumors: ASTRO Spring Refresher Course, Chicago, IL, March 2001.

198. Phase I trial of Motexafin-Gadolinium and radiotherapy for intrinsic pontine glioma.

NCI/CTEP Drug Development Phase I meeting, NCI, Bethesda, MD, March 2001.

199. The Future of Imaging and Radiation Sciences: Colorado Cancer Research Institute, Denver, CO, March, 2001.

200. Tomotherapy: Radiation Oncology Grand Rounds, University of Pennsylvania, Philadelphia, PA, April, 2001. (Visiting Professor).

201. The Future of Imaging and Radiation Sciences: Cancer Center Grand Rounds, University of Pennsylvania, Philadelphia, PA, April, 2001. (Visiting Professor).

202. Utilizing Tomotherapy to Test New Radiotherapy Processes. Mayo Clinic Tumor Biology Seminar, Rochester, MN, May 2001.

203. Activities of the RTOG Brain Tumor Committee, 1996-2001. 14th International Conference on Brain Tumor Research and Therapy, Asheville, NC, May 2001.

204. Recent Activities of the ECOG Brain Tumor Committee. 14th International Conference on Brain Tumor Research and Therapy, Asheville, NC, May 2001.

205. Temozolomide for the Treatment of Brain Metastases from Soild Tumors. ScheringPlough Advisory Board Meeting, Chicago, Il, June 2001.

206. Brain Metastases: Where Are we Going? University of Wisconsin, Neurology Grand Rounds, Madison, WI, June 2001.

207. Current Clinical Research Opportunities for CNS Tumors. RTOG New Investigators Meeting, Philadelphia, PA, July 2001.

208. Role of Radiotherapy in Brain Tumors. American Brain Tumor Association, Chicago, IL, July 2001: Results of trials with an oral chemotherapy agent for the treatment of brain metastases: Breakthroughs in the Treatment of Brain Metastases: Oral Chemotherapy. A CME Web Conference, September 2001.

209. Lung Cancer: Dose Escalation Matters. Sixth International Conference on Time Dose and Fractionation, Madison, WI, September, 2001.

210. Clinical Implementation of Tomotherapy.

Milwaukee, WI, October 2001.

WISRO/AAPM Conference on IMRT,

211. Clinical Research Opportunities with Tomotherapy. 50th Anniversary for the first Use of the Cobalt 60 Radiotherapy Symposium, London, Ontario, Canada, October 2001.

212. Biologically and Physically Targeted Treatment for Lung Cancer. Scientific Panel.

43rd Annual Meeting of the American Society for Therapeutic Radiation Oncology, San Francisco, CA, November 2001.

213. Impairment of neurocognitive function in brain metastases patients: baseline results from the Phase III trial with Motexafin Gadolinium. American Society of Therapeutic Radiation Oncology, San Francisco, CA, November 2001.

214. ECOG Clinical Trials: Potential Role for Ethyol.

Board Presentation, Sonoma, CA, November 2001.

MedImmune Medical Advisory

215. Clinical Trials with Motexafin Gadolinium. Redox Modulation: A Novel Approach to Potentiate the Effect of Radiation Therapy. ASTRO Satellite Symposium, San Francisco, CA, November 2001.

216. CNS Tumor Clinical Trials Addressing Resistance to Radiation Therapy. Education Day, Society for Neuro-Oncology, Washington DC, November 2001.

217. Impaired Neurocognitive Function in Brain Metastases Patients Is Strongly Correlated With Worse Quality Of Life: Baseline Results From The Phase III trial of Motexafin Gadolinium. 1st World Federation of Neuro-Oncology/Society for Neuro-Oncology Meeting, Washington D.C., November, 2001.

218. Glioblastoma Multiforme: The Phase II RTOG Experience. 1st World Federation of Neuro-Oncology/Society for Neuro-Oncology Meeting, Washington D.C., November, 2001.

219. Alchemy, Detection, Precision Guidance and Radiotherapy. The 15th Annual Simon Kramer Lecture, Jefferson Medical College, Philadelphia, PA, December 2001.

220. Radiosurgery for benign disorders: results. treatment planning and complications.

Neurosurgical Grand Rounds, University of Wisconsin, Madison, WI, February 2002.

221. Integrated CT/Linear Accelerator. Finding the Cures- Part II, 4th Annual Cleveland Clinic Neuro-Oncology Symposium, Naples, FL, February 2002.

222. Brain Metastases: Current Treatment: Temozolomide Investigators’ Meeting, Carlsbad, CA, February 2002.

223. Brain Metastases: Future Directions with Temozolomide: Investigators’ Meeting, Carlsbad, CA, February 2002.

Temozolomide

224. Use of Temozolomide in Brain Metastases and Lung Cancer: Panel. Temozolomide Investigators’ Meeting, Carlsbad, CA, February 2002.

225. Future Directions in Radiation Oncology: The Integration of Biology, Technology and Medicine, MD Anderson Cancer Center, Houston, TX, March 2002 (Visiting Professor).

226. Current Role of Radiation Therapy in Locally Advanced Lung Cancer, MD Anderson Cancer Center, Houston, TX, March 2002 (Visiting Professor).

227. Radiation Oncology in the New Millennium. Wayne State University, Detroit, MI, March 2002 (Visiting Professor).

228. Locally Advanced Non Small Cell Lung Cancer. Wayne State University, Detroit, MI, March 2002 (Visiting Professor).

229. Evolving role of Temozolomide: Brain Metastases, Glioma and Lung Cancer.

Schering-Plough Temozolomide Training Conference, San Diego, CA, March 2002.

230. Low Grade Gliomas: Role of Radiotherapy. Neurosurgical Grand Rounds, University of Wisconsin, Madison, WI, March 2002.

231. Evolution in Medulloblastoma Treatment. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.

232. Non Small Cell Lung Cancer: Dose Escalation Matters. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.

233. Radiosurgery for Brain Metastases. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.

234. New Approaches in the Treatment of Malignant Glioma. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.

235. Tomotherapy. North Central Chapter of the American Association of Physicists in Medicine, Spring Semi-Annual Meeting, Wausau, WI, May 2002.

236. What is Tomotherapy? Wisconsin Oncology Network, Annual Meeting, Madison, WI, May 2002.

237. Evaluation and Management of Brain Metastases.

Orlando, FL, May 2002.

38th Annual ASCO meeting,

238. Results from the Phase III Trial of Motexafin Gadolinium (MGd) in Brain Metastases.

38th Annual ASCO meeting, Orlando, FL, May 2002.

239. Temozolomide for Brain Metastases: Temozolomide Investigators’ Satellite Meeting at the 38th Annual ASCO meeting, Orlando, FL, May 2002.

240. A Review of the Treatment of Brain Metastases: Schering Plough Advisory Board Meeting at the 38th Annual ASCO meeting, Orlando, FL, May 2002.

241. Limited Disease Small Cell Lung Cancer: Current Therapies. GSK Topotecan Investigators’ Meeting, Chicago, IL, June 2002.

242. Topotecan as a Radiosensitizer for Small Cell Lung Cancer.

Investigators’ Meeting, Chicago, IL, June 2002.

GSK Topotecan

243. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Hartford, CN, June 2002.

244. The Scientific Strategy of the RTOG Brain Tumor Research Group. RTOG Summer Meeting, Keynote Speaker, Philadelphia, PA, June 2002.

245. Overview of Current and Future Treatment Strategies for Brain Metastases. Schering Plough International Investigators’ Meeting. Monte Carlo, Monaco, June 2002.

246. Discussion on Clinical Trial Strategies for Brain Metastases. Schering Plough Global Investigators’ Meeting. Monte Carlo, Monaco, June 2002.

247. Phase I/II Lung Cancer Brain Metastases Clinical Trials with Temozolomide. Schering Plough Advisory Board Meeting at the Third International Lung Cancer Conference.

Kona, HA, June 2002.

248. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Long Island College Hospital, Brooklyn, NY, July 2002.

249. Overview of Current and Future Treatment Strategies for Brain Metastases.

Physicians’ Education Resource, CME, Huntington Station, NY, July 2002.

250. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Long Island Jewish Medical Center, New Hyde Park, NY, July 2002.

251. Treatment modalities for Primary Brain Tumors. South African National Oncology Meeting, Bakubung Bush Lodge, South Africa, July 2002.

252. Treatment of Brain Metastasis. South African National Oncology Meeting, Bakubung Bush Lodge, South Africa, July 2002.

253. Background of Temozolomide in Primary Brain Tumor Treatment and Update on Brain Mets Data. Schering Plough Advisory Board Presentation, Kenilworth, NJ, August 2002.

254. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Memorial City Hospital, Houston, TX, August 2002.

255. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Phyicians’ Education Resource, CME, Houston, TX, August 2002.

256. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Deke Slayton Cancer Center, Houston, TX, August 2002.

257. Emerging Strategies for Brain Metastases. European Association for Neuro-Oncology, Annual Meeting, Florence Italy, September 2002.

258. Early vs Delayed Radiotherapy for Low Grade Glioma. European Association for Neuro-Oncology, Annual Meeting, Florence Italy, September 2002.

259. Clinical Brain Tumor Research Strategies from the RTOG. European Association for Neuro-Oncology, Annual Meeting, Florence Italy, September 2002.

260. Temozolomide in the Treatment of Newly Diagnosed Gliomas. Singapore Society of Oncology & Clinical Neuroscience Society, Singapore, September 2002.

261. Emerging Role of Temozolomide in the Treatment of Brain Metastases. Singapore Society of Oncology & Clinical Neuroscience Society, Singapore, September 2002.

262. Overview of Current and Future Treatment Strategies for Brain Metastases.

Temozolomide Roundtable Meeting, Singapore, September 2002.

263. Temozolomide in the Treatment of Newly Diagnosed Gliomas.

Malaysian Oncological Society Annual Scientific Meeting, Kuala Lumpur, September 2002.

264. Emerging Role of Temozolomide in the Treatment of Brain Metastases. Malaysian Oncological Society Annual Scientific Meeting, Kuala Lumpur, September 2002.

265. Motexafin Gadolinium Prolongs Time to Neurologic Progression in Lung Cancer Patients with Brain Metastases: Results of a Randomized Phase III Trial. ASTRO, New Orleans, LA, October 2002.

266. Chemotherapy and Chemo-Radiation Therapy in the Treatment of Brain Metastases. ASTRO CME Symposium, Current Approaches in the Treatment of Brain Metastases, New Orleans, LA, October 2002.

267. Dose Escalation in Non Small Cell Lung Cancer: Still Relevant. UWCCC Annual CME Symposium, Madison, WI, October 2002.

268. RTOG Brain Tumor Research Achievements and Plans. The Pancer Lecture, University of Toronto and Princess Margaret Hospitalâ&#x20AC;&#x2122;s Pancer Brain Tumor Institute, Toronto, Canada, October 2002.

269. Radiosensitizers. National Neurosciences Center, Kolkata, India, October 2002.

270. Radiation Therapy: Past, Present and Future.

Kolkata, India, October 2002.

National Neurosciences Center,

271. Emerging Strategies in the Management of Brain Metastases.

October 2002.

New Delhi, India,

272. Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases. Pharmacyclics Global Investigator Meeting, San Francisco, CA, November, 2002.

273. CNS Tumors: Dose Modifiers of Radiation Response. Education Day, Society for Neuro-Oncology, San Diego, CA, November 2002.

274. Watching Biology in Action: Smart Targeting for Radiotherapy: Non-invasive Imaging of Nervous System Tumors. Society for Neuro-Oncology, San Diego, CA, November 2002.

275. Neurocognitive Changes Following Whole Brain Radiation Therapy for the Treatment of Brain Metastases. Society for Neuro-Oncology, San Diego, CA, November 2002.

276. Other Agents/Other Trials in Glioma. Zarnestra Glioma Advisory Board Meeting, Society for Neuro-Oncology, San Diego, CA, November 2002.

277. Stereotactic Radiosurgery for Intracranial Metastases. LINAC Radiosurgery-2002 Meeting, Orlando, FL, December 2002.

278. Tomotherapy – An Update. LINAC Radiosurgery-2002 Meeting, Orlando, FL, December 2002.

279. Role of CT-PET in Radiotherapy Processes.

Waukesha, WI, December 2002.

UW-GE Strategic Scientific Meeting,

280. The RTOG’s Brain Tumor Research Strategies. 4th Annual Cleveland Clinic NeuroOncology Symposium, Orlando, FL, January 2003.

281. Tomotherapy – An Update. 4th Annual Cleveland Clinic Neuro-Oncology Symposium, Orlando, FL, January 2003.

282. Advances in the Treatment of CNS Tumors. MD Anderson Cancer Center, Orlando, FL, January 2003.

283. New Advances in Oral Alkylating Agents for the Treatment of CNS Malignancies.

Phyicians’ Education Resource, CME, Houston, TX, January 2003.

284. Significance of Clinical Trials. 21st Annual Leland R. Cowan Cancer Symposium: Neuro-Oncology, an Eye to the Future. Brigham Young University, LDS Hospital, Salt Lake City, UT, February 2003.

285. Radiotherapeutic Approaches to Primary Brain Tumors. 21st Annual Leland R. Cowan Cancer Symposium: Neuro-Oncology, an Eye to the Future. Brigham Young University, LDS Hospital, Salt Lake City, UT, February 2003.

286. Modern Radiotherapy for Gliomas in Adults. Advances in the Management of Glioma, the Glioma Update Meeting of the Canadian Brain Tumour Consortium, Lake Louise, Canada, February 2003.

287. Contemporary Approaches in the Management of Brain Metastases and Primary CNS Tumors. 5th Annual Perspectives in Cancer Care – 2003, Jupiter, FL, March 2003.

288. Dose Escalation for Lung Cancer: Rationale and Approaches. University of Texas, San Antonio, TX, March 2003 (Visiting Professor).

289. Glioblastoma Multiforme: Current Standard and Future Approaches. University of Texas, San Antonio, TX, March 2003 (Visiting Professor).

290. State of the Art in the Treatment of Brain Metastases. VIII Congress of the Spanish Radiosurgery Society Pamplona, Spain, March 2003.

291. An Update on the Management of Brain Tumors. Gujarat Cancer Research Institute, Ahemdabad, India, April 2003.

292. An Update on the Management of Gliomas.

Mumbai, India, April 2003.

Tata Memorial Cancer Hospital,

293. Management of Brain Tumors: Past, Present and Future. CME Presentation, Jaslok Hospital and Research Center and Nanavati Hospital, Mumbai, India, April 2003.

294. Management of Brain Tumors.

Bangalore, India, April 2003.

CME Presentation, Kidwai Memorial Hospital,

295. Management of Brain Tumors: Past, Present and Future. CME Presentation, MNJ Cancer Hospital and Medwin Hospital, Hyderabad, India, April 2003.

296. Management of Brain Tumors: Past, Present and Future. CME Presentation, Kolkata, India, April 2003.

297. Management of Brain Tumors: Past, Present and Future. CME Presentation, All India Institute of Medical Sciences, New Delhi, India, April 2003.

298. Tomotherapy: An Emerging Radiotherapy Technology. American Association of Neurosurgeons, Joint Tumor Section Special Symposium: Advances in Molecular Neurosurgery, San Diego, CA, April 2003.

299. Glioblastoma: Today and Tomorrow. University of Arizona, Tucson, AZ, May 2003 (Visiting Professor).

300. The Future of Radiation Oncology. University of Arizona, Tucson, AZ, May 2003 (Visiting Professor).

301. Radiation Oncology at the University of Wisconsin.

Executive Board, June 2003.

Group Health Cooperative

302. Radiosurgery for Brain Metastases: Role of Whole Brain Radiotherapy. 6th Congress of the International Stereotactic Radiosurgery Society, Kyoto, Japan, June 2003.

303. Radiosurgery for brain metastases: Where are we today and where next? General Scientific Session, Keynote speaker. 6th Congress of the International Stereotactic Radiosurgery Society, Kyoto, Japan, June 2003.

304. Radiosurgery Update; Brain and Body. Plenary Lecture. 6th Congress of the International Stereotactic Radiosurgery Society, Kyoto, Japan, June 2003.

305. Glioblastoma Multiforme: The RTOG Phase III Experience. 6th Congress of the International Stereotactic Radiosurgery Society, Kyoto, Japan, June 2003.

306. Whatâ&#x20AC;&#x2122;s New in Radiation Oncology at the University of Wisconsin? University of Wisconsin Hospital Authority Board, July 2003.

307. Combining Molecular Advances in the Understanding of Malignant Gliomas with Radiation Therapy. University of Kyoto, July 2003 (Visiting Professor).

308. Radiation Therapy with Targeted Molecular Approaches for Glioblastoma Multiforme. 2nd Biennial Cleveland Clinic International Summit for Finding the Cure for Glioblastoma. Cleveland, OH, July 2003.

309. The Latest Treatments for Malignant Brain Tumors: Radiation Therapy. American Brain Tumor Association Annual Meeting, Lincolnshire, IL, July 2003.

310. Brain Tumor Clinical Trials: RTOG. Meeting, Lincolnshire, IL, July 2003.

American Brain Tumor Association Annual

311. An Innovative Technological Radiation Therapeutic Approach for Lung Cancer: Radiotherapy Innovations. X World Conference on Lung Cancer, Vancouver, Canada, August 2003.

312. Impact of Whole Brain Radiation Therapy and Motexafin Gadolinium on Neurologic and Neurocognitive Progression in Non-Small Cell Lung Cancer Patients with Brain Metastases: Results of a Randomized Phase III Trial. X World Conference on Lung Cancer, Vancouver, Canada, August, 2003.

313. Combined Modality Treatment of Malignant Glioma. European Congress of Clinical Oncology Satellite Symposium, Copenhagen, Denmark, September 2003.

314. Gliomas and Metastases: Current Therapy and Future Possibilities. University of Louisville Brown Cancer Center, September 2003 (Visiting Professor).

315. Current Management and Future Strategies for Non Small Cell Lung Carcinoma.

Medical College of Virginia, October 2003 (Visiting Professor).

316. The Current and Future Role of Whole Brain Radiation Therapy in Management of Brain Metastases: Evidence-Based Medicine and the Treatment of Brain Metastases Satellite Symposium of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Salt Lake City, UT, October 2003.

317. Tumors of the Central Nervous System (Adult): Refresher Course Session #106; American Society of Therapeutic Radiology and Oncology Annual Meeting, Salt Lake City, UT, October 2003.

318. Induction Chemotherapy Followed by Standard Thoracic Radiotherapy Vs. Hyperfractionated Accelerated Radiotherapy for Patients with Unresectable Stage IIIA & B Non-Small Cell Lung Cancer: Phase III Study of the Eastern Cooperative

Oncology Group (ECOG 2597). American Society of Therapeutic Radiology and Oncology Annual Meeting, Salt Lake City, UT, October 2003.

319. Therapeutic strategies in Managing Glioblastomas: Satellite Symposium (Exploring Advances in the Management of Gliomas) of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Salt Lake City, UT, October 2003.

320. Tomotherapy for Lung Cancer: 3rd Annual Tomotherapy Usersâ&#x20AC;&#x2122; Group Meeting at the American Society of Therapeutic Radiology and Oncology Annual Meeting, Salt Lake City, UT, October 2003.

321. Meningiomas: Non-surgical Treatments.

Oncology, Keystone, CO, November 2003.

Education Day, Society for Neuro-

322. Imaging/Radiation/Radiobiology of Nervous System Tumors. Society for NeuroOncology, Keystone, CO, November 2003.

323. Arguments in Radiation: Conformal Methods and Radiosurgery: Satellite Symposium (Controversies in Primary Brain Tumor Management). Society for Neuro-Oncology, Keystone, CO, November 2003.

324. Current Approaches to Managing Gliomas. 25th Annual Conference of the Association of Radiation Oncologists of India, Kochi, India, November 2003.

325. Tomotherapy: Revolutionizing Radiotherapy. Keynote Address. 25th Annual Conference of the Association of Radiation Oncologists of India, Kochi, India, November 2003.

326. Approach to Brain Metastases. Special Lecture. 25th Annual Conference of the Association of Radiation Oncologists of India, Kochi, India, November 2003.

327. Optically Guided Stereotactic Radiotherapy for AVMs. LINAC Radiosurgery-2003 Meeting, Orlando, FL, December 2003.

328. Hypofractionation for Prostate Radiotherapy. LINAC Radiosurgery-2003 Meeting, Orlando, FL, December 2003.

329. Tomotherapy Clinical Trials. LINAC Radiosurgery-2003 Meeting, Orlando, FL, December 2003.

330. Newly Diagnosed Malignant Glioma. Neuro-Oncology Group of India, Hyderabad, India, January 2004.

331. Newly Diagnosed Malignant Glioma. Neuro-Oncology Group of India, New Delhi, India, January 2004.

332. What have we learned from the RTOG Clinical Trials on Tumors of the Central Nervous System? MD Anderson Cancer Center, Houston, TX, January 2004 (Visiting Professor).

333. Stage III Unresectable and Superior Sulcus Tumors: Current Trends in Lung Cancer.

CME Symposium, New York, NY, January 2004.

334. Chemoradiotherapy in Patients with Brain Tumors, "3rd Symposium on Concomitant Chemoradiotherapy" Irving, TX, April 2004.

335. Using Tomotherapy to Ask and Answer Important Radiobiological Questions.

University of North Carolina Grand Rounds, Chapel Hill, NC, April 2004 (Visting Professor).

336. The Impact of Clinical Trials in Gliomas. 9th United Taiwanese Cancer Convention, Taipei, Taiwan, May 2004.

337. Brain Metastases: Radiosensitizers: MGd; 2004 ASTRO Educational Symposium: Brain Tumors: Evidence-Based Decision Making in the New Millenium. Washington DC, May 2004.

338. The Merits of Dose-per-Faction Escalation and Schedule shortening in Lung Cancer.

University of Indiana, Indianapolis, IN, May 2004.

339. ASCO Clinical Problems in Oncology: CNS Disease in Women with Breast Cancer: Optimal Management for a Problem on the Rise. Whole Brain vs SRS, Whole Brain + SRS vs Whole Brain Alone and New Approaches in Managing Brain Mets. ASCO, New Orleans, LA, May 2004.

340. ASCO Meet the Professor Session: Application of New Radiation Techniques for Lung Cancer. ASCO, New Orleans, LA, May 2004.

341. RTOG Scientific Session Discussant: An Intergroup Randomized Controlled Clinical Trial of Chemotherapy plus Radiotherapy versus RT alone for Pure and Mixed Anaplastic Oligodendroglioma: Initial Report of RTOG 94-02. Washington, DC June 2004.

342. Integration of Novel Agents with Radiation Therapy in Combined Modality Pograms.

5th International Lung Cancer Congress, Kauai, HA, June 2004.

343. Integrating Novel Agents with Radiotherapy in the Treatment of Solid Tumors Conference: Brain Tumors. Lake Tahoe, NV, July 2004.

344. Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: Summary of Recent Clinical Trials: Is this the new Standard of Treatment for Glioblastoma Multiforme? Malaysian Oncological Society, Kuala Lumpur, July 2004.

345. How should we Approach the Other Newly Diagnosed High Grade Gliomas?

Malaysian Oncological Society, Kuala Lumpur, July 2004.

346. Current Status of Anaplastic Astrocytoma: RTOG 9813. Schering-Plough Advisory Meeting. Brugge, Belgium, September 2004.

347. Anaplastic Oligodendroglioma: RTOG 9402. Schering-Plough Advisory Meeting.

Brugge, Belgium, September 2004.

348. Chemical Modifiers of the Radation Response to Brain Metastases.

ASTRO Presidential Symposium, American Society of Therapeutic Radiology and Oncology Annual Meeting, Atlanta, GA, October 2004.

349. ASTRO Technology Assessment Experience: From 3-D Conformal Radiotherapy to Stereotactic Radiosurgery.

ASTRO Educational Session, American Society of Therapeutic Radiology and Oncology Annual Meeting, Atlanta, GA, October 2004.

350. Adult Brain Tumors: Refresher Course Session #401; American Society of Therapeutic Radiology and Oncology Annual Meeting, Atlanta, GA, October 2004.

351. Anaplastic Oligodendroglioma: Is Combination Chemo-radiotherapy the New â&#x20AC;&#x153;GoldStandardâ&#x20AC;? in Managing Gliomas? ASTRO Satellite Symposium, American Society of Therapeutic Radiology and Oncology Annual Meeting, Atlanta, GA, October 2004.

352. Adjuvant Radiotherapy for Brain Tumors. 11th Biennial Conference of the Indian Society of Oncology. Banagalore, India, October 2004.

353. Pearls in Management of Vestibular Schwannomas: Role of Radiotherapy and Radiosurgery. World Federation of Neurosurgical Societies, Jaipur, India, October 2004.

354. Pearls in Radiation and Radiation Biology: Advances in XRT. World Federation of Neurosurgical Societies, Jaipur, India, October 2004.

355. Radiotherapy of Gliomas: Recent Advances in Management of Gliomas. World Federation of Neurosurgical Societies, Jaipur, India, October 2004.

356. Fulford Seminar on Malignant Gliomas: Role of Radiation. World Federation of Neurosurgical Societies, Jaipur, India, October 2004.

357. Management of CNS Metastasis: Role of Radiosurgery, XRT and Sensitizers. World Federation of Neurosurgical Societies, Jaipur, India, October 2004.

358. Future Directions in Radiation/Chemotherapy. World Federation of Neurosurgical Societies, Jaipur, India, October 2004.

359. Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced NSCLC? University of North Carolina Symposium, St. Thomas, US Virgin Islands, November 2004.

360. The University of Wisconsin Dose-per-Fraction Escalation Approach. University of North Carolina Symposium, St. Thomas, US Virgin Islands, November 2004.

361. Brain Metastases: Where Are We Today?

November 2004 (Visiting Professor).

Yale University, New Haven, CT,

362. Malignant Gliomas: The Management Challenges in View of the Recent Temozolomide Data. Yale University, New Haven, CT, November 2004 (Visiting Professor).

363. Do the EORTC/NCIC Findings Apply to All Malignant Gliomas? Combined Chemoradiation: Indications, Complications, and Implications. Satellite Symposium, 9th Annual Meeting of the Society for Neuro-Oncology, Toronto, Canada, November 2004.

364. RTOG BR-0119: Chronobiological Study of the Addition of Melatonin to Radiotherapy for Brain Metastases. 9th Annual Meeting of the Society for Neuro-Oncology, Toronto, Canada, November 2004.

365. Cumulative Dose of Motexafin Gadolinium and Survival in Newly Diagonsed Glioblastoma Multiforme. 9th Annual Meeting of the Society for Neuro-Oncology, Toronto, Canada, November 2004.

366. Conventional Radiotherapy in the Management of Benign, Atypical and Malignant Meningiomas. LINAC Radiosurgery-2004 Meeting, Orlando, FL, December 2004.

367. Metastatic Tumors: Radiation Oncology Strategies for Intracranial and Extracranial Lesions. LINAC Radiosurgery-2004 Meeting, Orlando, FL, December 2004.

368. The Clinical Relevance of Recent Randomized Controlled Trials in Glioma Management. Grand Rounds, Department of Neurological Surgery, University of Wisconsin, Madison, WI, December 2004.

369. Role of Radiotherapy for GBM. Schering Plough National POA Symposium, Orlando, FL, January 2005.

370. Advances in Glioma Management.

January 2005.

St. Louis Radiological Society, St. Louis, MO,

371. Advances in Chemo Radiotherapy of Brain Tumors. Grand Rounds, Medical Oncology, Missouri Baptist Medical Center, St. Louis, MO, January 2005.

372. Innovations in Glioma Therapy, Grand Rounds. Medical Oncology, University of Missouri, Columbus, MO, January 2005.

373. The Role of Radiation Therapy for Gliomas. 7th Annual Neuro-Oncology - Current Concepts Symposium, Orlando, FL, January 2005.

374. Therapeutic Management for Metastatic Brain Tumors. 3rd International Conference on Future Trends in the Treatment of Brain Tumors, Padua, Italy, March 2005.

375. Should Concomittant and Adjuvant Treatment with Temozolomide Transfer as Standard Therapy in Anaplastic Gliomas? 3rd International Conference on Future Trends in the Treatment of Brain Tumors, Padua, Italy, March 2005.

376. Xyctrin for the Treatment of Brain Metastases. Pharmacyclics Meeting, New York, NY, April 2005.

377. Radiation Therapy and Concomittant Temozolomide for Glioblastoma Multiforme.

US Temozolomide Investigatorsâ&#x20AC;&#x2122; Meeting, Chicago, IL, April 2005.

378. Combination Chemoradiotherapy for Malignant Glioma: Are we Making Progress Yet? Vanderbilt University Medical School Grand Rounds, Nashville, TN, April 2005 (Visiting Professor).

379. State-of-the-Art Treatment Approaches for Brain Metastases. Vanderbilt University Medical School Grand Rounds, Nashville, TN, April 2005. (Visiting Professor).

380. Whatâ&#x20AC;&#x2122;s New for Malignant Gliomas & Brain Metastases? Charleston, NC, April 2005.

381. Malignant Glioma: Advances In Radiation Therapy. Plenary Session, World Federation of Neuro-oncology/EANO, Edinburgh, Scotland, May 2005.

382. Optimizing Combined Modality Treatment for First-Line High-Grade Gliomas.

Satellite Symposium, World Federation of Neuro-oncology/EANO, Edinburgh, Scotland, May 2005.

383. Cognition and Cancer: Cognitive Deficits in Patients with Brain Metastases, University of Toronto, Toronto, Canada, May 2005.

384. Malignant Gliomas: A New Dawn in Therapeutic Choices? Grand Rounds, Thomas Jefferson University, Philadelphia, PA, May 2005 (Visiting Professor).

385. Brain Metastases: Recent Developments. Grand Rounds, University of Texas-SW, Dallas, TX, May 2005.

386. New Strategies for Brain Metastases. Grand Rounds, University of Texas-SW, Dallas, TX, May 2005.

387. New Developments in Treatment of Brain Metastases. 6th International Lung Cancer Congress, Kauai, Hawaii, June 2005.

388. Perspectives in Central Nervous System Malignancies: The Increasing Incidence of Brain Metastases in Breast Cancer Patients: Prophylaxis and Treatment, Prague, Czech Republic, June 2005.

389. Glioblastoma Multiforme: The Multidisciplinary Approach to Treatment: San Francisco, CA, July 2005.

390. Current Treatments for Brain Metastatic Disease: Radiation Therapy (WBRT/SRS) GLIADELÂŽ Wafer Metastatic Advisory Board San Francisco, CA, July 2005.

391. Novel Targeted Agents in Gliomas: Fourth International Congress on Targeted Therapies in Oncology, Washinton DC, August 2005.

392. SRS and/or SRT of Malignant Glioma. Educational Lecture, 14th Annual Meeting of the Japanese Society of Stereotactic Radiosurgery, Osaka, Japan, September 2005.

393. Radiosurgery and Radiotherapy for Brain Metastases. 14th Annual Meeting of the Japanese Society of Stereotactic Radiosurgery, Osaka, Japan, September 2005.

394. New Advances in Malignant Glioma. Mito Gamma House Anniversary Celebration, Tokyo, Japan, September 2005.

395. Role of Radiation Dose-Intensification with Molecularly-Targeted Therapies in NonSmall Cell Lung Cancer. Hokkaido University, Sapporo, Japan, September 2005.

396. Evidence supporting the use of radiosurgery in brain metastases. 7th Congress of the International Society for Stereotactic Radiosurgery, Brussels, Belgium, September 2005.

397. Brain Metastases: Data Blitz. 7th Congress of the International Society for Stereotactic Radiosurgery, Brussels, Belgium, September 2005.

398. Radiation combined with Drugs in CNS Tumors: 7th International Conference on Dose, Time and Fractionation in Radiation Oncology: Physical, Chemical and Biological Targeting in Radiation Oncology, Madison, WI, September 2005.

399. New Agents in Gliomas. 9th Fall Oncology Conference, Hilton Head, SC, September 2005.

400. How, Why, & When to Treat Brain Metastases: A Case-Based Symposium. 47th Annual ASTRO Meeting, Satellite Symposium, Denver, CO, October 2005.

401. Oligodendroglioma: The Status of Combination Chemoradiotherapy Oligodendroglioma. 47th Annual ASTRO Meeting, Denver, CO, October 2005.

in

402. Integrating Systemic Therapy with Radiotherapy for Brain Metastases, 10th Annual Persepctives in Thoracic Oncology Conference, New York, NY, November 2005.

403. New Perspectives in Glioblastomas. X National Meeting and Residential Course of Italian Association of Neuro-Oncology, Naples, Italy, November 2005.

404. Emerging Concepts in the Management of Brain Metastasis. X National Congress and Course of Italian Association of Neuro-Oncology, Naples, Italy, November 2005.

405. Imaging and Radiation Sciences. UWCCC Grand Rounds Series, University of Wisconsin, Madison, WI, November 2005.

406. Glioblastoma Multiforme: The Minneapolis, MN, November 2005.

Multidisciplinary

Approach

to

Treatment:

407. Advancement in Radiation Oncology: Cancer 2006 Preferred Treatment and Management Options Meeting, Hoag Cancer Center, Huntington Beach, CA, January 2006.

408. New Advances in Managing Gliomas, 36th Annual Radiation Oncology Outcomes Tracking Seminar, Gainesville, FL, February 2006 (Visiting Professor).

409. New Advances in Managing Gliomas, 36th Annual Radiation Oncology Outcomes Tracking Seminar, Gainesville, FL, February 2006 (Visiting Professor).

410. Advanced Technology Applications in Lung Cancer, 36th Annual Radiation Oncology Outcomes Tracking Seminar, Gainesville, FL, February 2006 (Visiting Professor).

411. Theragnostic Dose Painting in Lung Cancer, Tomotherapy Inc Lecture Series, Madison, WI, March 2006.

412. Surgery vs. Radiosurgery for Brain Metastases: Perspectives in CNS Malignancies, Budapest, Hungary, April 2006.

413. Radiosensitizers: Advances in Surgery and Radiotherapy: Perspectives in CNS Malignancies, Budapest, Hungary, April 2006.

414. Management of Brain Metastases: Concepts & Controversies, Northwestern University Hospital, Chicago, IL, April 2006.

415. Malignat Gliomas: TEAM Program, Chicago, IL, April 2006.

416. Mehta MP: RTOG Brain Tumor Trials. Asilomar International Brain Tumor Meeting, April 2006.

417. Malignat Gliomas: TEAM Program, Los Angeles, CA, May 2006.

418. Innovative Radiotherapeutic Approaches for GBM, Health Sciences Centre Foundation Lectureship, 12th Biennial Canadian Neuro-Oncology Meeting, May 2006.

419. Whatâ&#x20AC;&#x2122;s Hot in Thoracic Radiation Oncology?

Atlanta, June 2006.

Meet the Professor Series, ASCO,

420. Brain Metastases---Whole Brain Radiotherapy, Surgery, and Radiosurgery. Meet the Professor Series, ASCO, Atlanta, June 2006.

Stereotactic

421. Motexafin gadolinium combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer patients with brain metastases: Results of a Phase 3 trial, ASCO, Atlanta, GA, June 2006.

422. Integrating signal transduction inhibitors and other targeted agents in the management of gliomas, ASCO Satellite Symposium, Atlanta, June 2006.

423. Role of GammaKnife/CyberKnife in NSCLC: 7th International Lung Cancer Congress, Maui, HI, July 2006.

424. Twice-a-day Thoracic Radiotherapy for SCLC: 7th International Lung Cancer Congress, Maui, HI, July 2006.

425. Planned Phase III trial exploring the role of concurrent and adjuvant temozolomide plus radiotherapy in anaplastic glioma without 1p/19q loss: the CATNON trial.

Schering-Plough Oncology North American Temodar Investigators Advisory Board, Chicago, IL, July 2006.

426. Management of Grade 3 Astrocytoma. Okura Symposium, Tokyo, Japan, July 2006.

427. Current Advances in the Management of Glioblastoma Multiforme. University of Arizona, Tucson, AZ (Visiting Professor), September 2006.

428. Management of Glioblastoma Multiforme.

September 2006.

TEAM presentation, Phoenix, AZ,

429. Controversies in the Management of Brain Metastases, Barrows Neurological Institute, Phoenix, AZ, September 2006.

430. Management of Stage III Unresectable Disease; Integration of Various Modalities, Los Angeles Comprehensive Lung Cancer Review, Los Angeles, CA, October 2006.

431. New Advances in Managing Glioblastoma: Update 2006: Management of Central Nervous System Tumors, City of Hope Cancer Center, Duarte, CA, October 2006.

432. Adult Brain Tumors: Refresher Course Session #206; 48th Annual Meeting of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Philadelphia, PA, November 2006.

433. Motexafin Gadolinium (MGd) Combined with Prompt Whole Brain Therapy (RT) Prolongs Time to Neurologic Progression in Non-Small Cancer (NSCLC) Patients with Brain Metastases: Results of a Phase 3 Annual Meeting of the American Society of Therapeutic Radiology and Philadelphia, PA, November 2006.

Radiation Cell Lung Trial. 48th Oncology,

434. Theragnostic Radiation Therapy for Lung Cancer; Tomotherapy Users’ Group Meeting, 48th Annual Meeting of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Philadelphia, PA, November 2006.

435. Improving Outcomes in Non Small Cell Lung Cancer Using Tomotherapy: New Horizons in the Fight on Cancer with TomoTherapy” Symposium at Fundacion Areces, Fundación Grupo IMO, Madrid, Spain, November 2006.

436. Motexafin Gadolinium (MGd) Combined with Prompt Whole Brain Radiation Therapy (RT) Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases: Results of a Phase 3 Trial. Annual Meeting of the Radiological Society of North America, Chicago, IL, November 2006.

437. Dose Limiting Toxicities in the CNS: Workshop on Advanced Technologies in Radiation Oncology: Evaluating the Current Status and Future Potential of Proton and Other Heavy-Charged Particle Radiation Therapy, Intensity-Modulated/ImageGuided Radiation Therapy, and Stereotactic Radiation Therapy, National Cancer Institute, Division of Cancer Treatment & Diagnosis, Radiation Research Program, November 2006.

438. UW Development & Application of Tomotherapy, UWCCC Retreat, Keynote Lecture, Madison, WI, January 2007.

439. Applying Advanced Technology in Managing Lung Cancer, University of Michigan, Ann Arbor, MI, (Visiting Professor), January 2007.

440. Advances in Radiation Oncology: Cancer 2007 Preferred Treatment and Management Options Meeting, Hoag Cancer Center, Huntington Beach, CA, February 2007.

441. Managing CNS Tumors, ASTRO Spring Refresher Course, Chicago, IL, March 2007.

442. IGRT Keynote: Physicianâ&#x20AC;&#x2122;s Perspective: 2007, ASTRO Image Guided Radiotherapy (IGRT II) Symposium, St. Petersburg, FL, April 2007.

443. Transitioning from 3-D/IMRT to IGRT: CNS and Head & Neck: 2007, ASTRO Image Guided Radiotherapy (IGRT II) Symposium, St. Petersburg, FL, April 2007.

444. Overcoming Temozolomide Resistance, Schering Plough Global Advisory Board Meeting, Nerola, Italy, May 2007.

445. Malignant Gliomas: Using Biology to Refine Treatment, University of Colorado Grand Rounds, Aurora, CO, May 2007.

446. Her2-neu Status, Trastuzumab, and Brain Metastases from Breast Adenocarcinoma, ASCO, Chicago, IL, June 2007.

447. Tomotherapy for Non Small Cell Lung Cancer, Past, Present and Future, First Italian National Tomotherapy Conference, Aviano, Italy, May 2007.

448. Advanced Technology Applications in Non Small Cell Lung Cancer. Scripps Clinic, La Jolla, CA, June 2007.

449. Gliomas: Progress or Mirage? Scripps Clinic, La Jolla, CA, June 2007.

450. Malignant Brain Tumors: Review of Current Treatment and Future Directions.

Grossmont Center for Cancer Treatment, La Mesa, CA, June 2007.

451. Glioblastoma Multiforme: The Multidisciplinary Approach to Treatment. Irvine, CA, June 2007.

452. Tomotherapy for Non Small Cell Lung Cancer, Past, Present and Future, First Taiwanese Tomotherapy Conference, Taipei, Taiwan, July 2007.

453. Radiotherapy for Malignant Glioma. Current Trends in the Management of Malignant Gliomas, Schering Plough Latin/South America International Conference, Acapulco, Mexico, September 2007.

454. Brain Metastases: Expert Review; Integrated Medical Learning, Annual Meeting of the Congress of Neurological Surgeons, San Diego, CA, September 2007.

455. Maliganant Glioma Grand Rounds, University of Maryland, Baltimore, MD, September 2007. (Visiting Professor).

456. Gliomas: Promise, Progress and Hope: Franklin Square Hospital Tumor Board Speaker, Baltimore, MD, September 2007.

457. Technical Advances in Radiation Therapy: 2007 Symposium on Gliomas and Secondary Brain Tumors, New York, NY, September 2007.

458. Brain Metastases: Whole Brain Radiotherapy/Radiosurgery: 2007 Symposium on Gliomas and Secondary Brain Tumors, New York, NY, September 2007.

459. Radiotherapy in Early Stage Non-Small Cell Lung Cancer, Gundersen Clinic Grand Rounds, La Crosse, WI, October 2007.

460. Risk Based Dose Escalation: Non-Small Cell Lung Cancer, QUANTEC Workshop, Madison, WI, October 2007.

461. Implementing Tomotherapy in Clinical Practice: Aizawa Comprehensive Cancer Center Inaugural Tomotherapy Symposium, Miyamoto City, Japan, October 2007.

462. Adult Brain Tumors: Refresher Course Session #411; 49th Annual Meeting of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Los Angeles, CA, October 2007.

463. Gliomas: Promise, Progress and Hope: St. Francis Hospital Tumor Board Speaker, Cleveland, OH, November 2007.

464. Gliomas: Strategies for Improving Outcomes: Cleveland Clinic Grand Rounds, Cleveland, OH, November 2007.

465. Glioblastoma: Where Next? Genentech Advisory Board Meeting, Dallas, TX, November 2007.

466. Controversies in Neuro-Oncology: A Case-Based Discussion on Managing Primary and Metastatic Brain Tumors, Satellite Symposium, 12th Annual SNO Meeting, Dallas, TX, November 2007.

467. Brain Metastases: Epidemiology, Management and Toxicities, Israel Oncology Symposium, Tel Aviv, Israel, November 2007.

468. Malignant Gliomas: Progress and Future Directions, Israel Oncology Symposium, Tel Aviv, Israel, November 2007.

469. New Directions in the Management of Gliomas: Association of Radiation Oncologists of India Annual Meeting, Chennai, India, November 2007.

470. Round Table Glioma Discussion: Apollo Hospital, Chennai, India, November 2007.

471. Progress in Glioma Therapy: Gujarat Cancer Physicians’ Roundtable, Ahemdabad, India, December 2007.

472. Anaplastic and Low Grade Gliomas in Adults: Evidence-based Decision Making, Childrens’ Hospital of Los Angeles, USC Oncology Grand Rounds, Los Angeles, CA, January 2008 (Visting Professor).

473. Glioblastoma: New Therapeutic Options- Are they for real? Childrens’ Hospital of Los Angeles, USC Research Seminar, Los Angeles, CA, January 2008 (Visting Professor).

474. Brain Metastases Research: NCI Workshop on the Biology of Brain Metastases, Bethesda, MD, January 2008.

475. An Insight Into Brain Tumor Management. New Delhi, India, February, 2008.

476. Optimal chemoradiotherapy schedules for high grade gliomas. 6TH Tata Memorial Centre Evidence Based Management Of Cancers In India Meeting (EBM 2008) on Central Nervous Tumours, Role of Molecular Diagnostics & Interventional Radiology in Oncology, Mumbai, India, February, 2008.

477. Should we treat anaplastic oligodendrogliomas differently than high grade astrocytomas? 6TH Tata Memorial Centre Evidence Based Management Of Cancers In India Meeting (EBM 2008) on Central Nervous Tumours, Role of Molecular Diagnostics & Interventional Radiology in Oncology, Mumbai, India, February, 2008.

478. Tomotherapy: A Success Story Integrating Academia with Entrepreneurship.

Tomotherapy Inauguration, Advanced Center for Technology, Research and Education in Cancer, Navi Mumbai, February, 2008.

479. Efficacy for modern radiotherapeutic approaches in the management of brain tumours. 6TH Tata Memorial Centre Evidence Based Management Of Cancers In India Meeting (EBM 2008) on Central Nervous Tumours, Role of Molecular Diagnostics & Interventional Radiology in Oncology, Mumbai, India, February, 2008.

480. Transitioning From 3-D/IMRT to IGRT: CNS and Head & Neck, 2008 ASTRO Image Guided Radiotherapy (IGRT III) Symposium Newport Beach, CA, March 2008.

481. Glioma Management and Research Opportunities, Abbott Research Seminar, Abbott Park, IL, April 2008.

482. Radiotherapy for Malignant Gliomas, Current Trends in the Management of Malignant Gliomas II, Rio de Janeiro, Brazil, May 2008.

483. Tomotherapy Clinical Trials: NSCLC, 2nd European Tomotherapy Usersâ&#x20AC;&#x2122; Group Meeting, Antalya, Turkey, May 2008.

484. Management of Lung Cancer with Tomotherapy, TomoTherapy Regional Meeting â&#x20AC;&#x201C; North East, New York, NY, May 2008.

485. Optimal Management of Stage III Non-Small Cell Lung Cancer, Meet the Professor Session, ASCO, Chicago, IL, May 2008.

486. Current Management of Gliomas: University of Wisconsin Grand Rounds, Madison, WI, July 2008.

487. The Combination of Chemotherapy and Radiotherapy in Newly Diagnosed Glioma: 2008 Brain Tumor Multimodality Treatment Forum, Guangzhou, China, August 2008.

488. Current and Future of Primary Brain Tumor Multimodality Treatment, 2008 Chinese Society of Clinical Oncology (CSCO) 18th Annual Meeting, Shanghai, China, August 2008.

489. The RTOG Experience in Clinical Trials in Brain Tumors, 1st Sino American Network in Therapeutic Radiation Oncology (SANTRO) Symposium, Beijing, China, August 2008.

490. Intensity Modulated Radiotherapy in Lung Cancer, 1st Sino American Network in Therapeutic Radiation Oncology (SANTRO) Symposium, Beijing, China, August 2008.

491. Practice Consensus and Treatment Recommendations for Primary and Metastatic CNS Tumors, 1st Sino American Network in Therapeutic Radiation Oncology (SANTRO) Symposium, Beijing, China, August 2008.

492. Challenges and Future of Brain Tumor Treatment, 1st Sino American Network in Therapeutic Radiation Oncology (SANTRO) Symposium â&#x20AC;&#x201C; Schering Plough Satellite Meeting, Beijing, China, August 2008.

493. Adult Glioblastoma: Strategies, Challenges and Opportunities: Allegheny Cancer Center Grand Rounds, Pittsburgh, PA, September, 2008.

494. Adult Brain Tumors: Refresher Course; 50th Annual Meeting of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Boston, MA, September 2008.

495. Anaplastic Gliomas: Clinical and Translational Advances; 50th Annual Meeting of the American Society of Therapeutic Radiology and Oncology Annual Meeting, Boston, MA, September 2008.

496. Neuropsychological Efects of Brain Tumors: Brain Tumor Caregiver Training Workshop, University of Wisconsin, Madison, WI, October 2008.

497. Indications and Radiotherapy Techniques for High Grade Gliomas: 10th Congress of the Brazilian Society of Radiotherapy, Recife, Brazil, October 2008.

498. Doses and Radiation Volume by Clinical Stage in Lung Cancer: 10th Congress of the Brazilian Society of Radiotherapy, Recife, Brazil, October 2008.

499. Current Approach in the Treatment of Brain Metastases: 10th Congress of the Brazilian Society of Radiotherapy, Recife, Brazil, October 2008.

500. Approaches for Treating Secondary Brain Tumors: Radiation; 2nd Annual Symposium on Malignant Gliomas and Brain Metastases, Washinton DC, November 2008.

501. Adult Gliobastoma: Strategies, Challenges and Opportunities: Methodist Hospital, Cancer Grand Rounds, Houston, TX, November 2008.

502. Management and Clinical Research in Glioblastoma: University of Virginia, Cancer Grand Rounds, Charlottesvile, VA, November 2008.

503. The RTOG Experience in Managing Brain Metastases: 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, co-sponsored by ASTRO/ASCO/IASLC, Chicago, IL, November 2008.

504. Radiotherapy Posters Discussion, Society of Neuro-Oncology, 13th Annual Meeting, Las Vegas, NV, November 2008.

505. Advanced Radiotherapy Technologies: Role of Protons and Carbon Ions in CNS Tumors, Society of Neuro-Oncology, 13th Annual Meeting, Sunrise Session, Las Vegas, NV, November 2008.

506. Alchemy, Early Detection, Precision Guidance, and Radiotherapy: RSNA, Annual Oration, Chicago, IL, December, 2008.

507. Management of Anaplastic Gliomas: Visiting Lecturer Series, University of Texas Southwestern, Dallas, TX, February 2009 (Visiting Professor).

508. Radiosurgery and Fractionated Stereotactic Radiotherapy for Vestibular Schwannoma, Cleveland Clinic Stereotactic Body Radiotherapy and Stereotactic Radiosurgery Symposium, Orlando, FL, February 2009.

509. Management of Early Stage Non-Small Cell Lung Cancer with Stereotactic Body Radiotherapy, Cleveland Clinic Stereotactic Body Radiotherapy and Stereotactic Radiosurgery Symposium, Orlando, FL, February 2009.

510. Management of Malignant Glioma, American College of Radiation Oncology Annual Symposium Keynote, Las Vegas, NV, February 2009.

511. Motexafin Gadolinium and Whole Brain Radiotherapy in Breast Cancer Brain Metastases, Brain Metastases in Breast Cancer Workshop (NCI/RTOG/Komen Foundation), Arlington, VA, February 2009.

512. Cognitive Evaluation and Neuroprotective Strategies, Brain Metastases in Breast Cancer Workshop (NCI/RTOG/Komen Foundation), Arlington, VA, February 2009.

513. Alchemy, Early Detection, Precision Guidance, and Radiotherapy: Ohio State University, Columbus, OH, April 2009 (Visiting Professor).

514. Invading the Sanctuary: Brain Metastases, Role of Radiotherapy: 100th Annual AACR Meeting, Denver, CO, April 2009.

515. Current Trends in The Treatment of Glioblastoma Multiforme: A nationwide, 26-site live broadcast symposium from Velocity Broadcasting, Pittsburgh, PA, April 2009.

516. Helical Tomotherapy Dose Escalation for NSCLC: Mediterranean Tomotherapy Symposium, Keynote Address, Milan, Italy, April 2009.

517. Novel Therapies for Malignant Gliomas: 2nd Annual Update in Neuro-Oncology Symposium, University of Rochester, Keynote Address, Cannaduiga, NY, May 2009.

518. Clinical Trials: Efficiency, Effectiveness and Impact. Pharmacyclics Board of Directors Presentation, June 2009.

519. High Grade Glioma: National, Taiwanese Resident Training Course, Taipei, Taiwan, July 2009 (Visiting Professor).

520. Low Grade Glioma: National, Taiwanese Resident Training Course, Taipei, Taiwan, July 2009 (Visiting Professor).

521. Advanced Stage Non-Small Cell Lung Cancer: National, Taiwanese Resident Training Course, Taipei, Taiwan, July 2009 (Visiting Professor).

522. Small Cell Lung Cancer: National, Taiwanese Resident Training Course, Taipei, Taiwan, July 2009 (Visiting Professor).

523. Recent Advances in Radiotherapy, Shin-Kong Hospital Cancer Grand Round, Taipei, Taiwan, July 2009.

524. Detecting and Managing Early Stage Lung Cancer, 2nd DHO-UWCCC and RTO-SKH Joint Symposium on Cancer Therapy, Taipei, Taiwan, July 2009.

525. Tomotherapy for Lung Cancer, Thai Radiation Oncology Society Special Seminar, Bangkok, Thailand, July 2009.

526. Neurocognition and Radiotherapy, University of Wisconsin, Radiation Oncology Lecture, Madison, WI, August 2009.

527. Recent Advances in Radiation Oncology, Special Lecture, Cedars Sinai Hospital, Los Angeles, CA, August 2009.

528. Brain Metastases, Management and Outcome, Chilean Neurooncology Conference, Santiago, Chile, September 2009.

529. Radiotherapeutic Management of Meningioma, Chilean Neurooncology Conference, Santiago, Chile, September 2009.

530. Radiotherapy: Emerging Trends Toward Personalized Medicine, Northwestern University, Radiation Oncology Seminar, Chicago, IL, September, 2009.

531. Early Detection, Precision Guidance, and Radiation Therapy: Towards Personalized Medicine, University of Wisconsin, 8th International Time, Dose, Fractionation Conference, Madison, WI, September, 2009.

532. Brain Metastases: Effect of Radiotherapy, Metastases Center of Excellence, NCI, Annual Research Retreat, Bodega Bay, CA, October, 2009.

533. Optimizing Radiation Dose Intensification in Non Small Cell Lung Cancer, Yonsei Medical Center Grand Rounds, Seoul, Korea, October 2009.

534. Tomotherapy Evolution and Clinical Applications, Seoul National University Cancer Center Grand Rounds, Seoul, Korea, October 2009.

535. Tomotherapy: Clinical Applications, and New Frontiers, 2nd annual Tomotherapy Usersâ&#x20AC;&#x2122; Meeting, Seoul, Korea, October 2009.

536. Invading the Sanctuary: Brain Metastases, International Tripartite (Korea, Japan, China) Radiation Oncology Convention Plenary Lecture, Korean Society of Therapeutic Radiation Oncology, Seoul, Korea, October 2009.

537. Towards Personalized Radiotherapy: Dana Farber/Brigham & Womenâ&#x20AC;&#x2122;s Radiation Oncology Grand Rounds, Boston, MA, October 2009 (visiting Professor).

538. Personalized Medicine: Is It the Future Now? Role of Molecular Markers in Clinical Decision Making in Radiotherapy. Education Day Joint meeting of the Society of Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA, October 2009.

539. Tomotherapy and Clinical Trials: Solving Challenging Clinical Tomotherapy International Meeting, Madison, WI, October 2009.

Problems:

540. Clinical Trials with Tomotherapy. Tomotherapy Users Education Forum, Chicago, IL, October 2009.

541. RTOG 0214: A Phase III Comparison of Prophylactic Cranial Irradiation versus Observation in Locally Advanced Non Small Cell Lung Cancer: QOL and Neurocognitive Analysis. Plenary Summary and Perspective. ASTRO 2009 Annual Meeting, Chicago, IL, November 2009.

542. Protons and Heavy Ions. Gildaâ&#x20AC;&#x2122;s Club, Madison, WI, November 2009.

543. Brain Metastases: Breast Cancer, 3rd Annual Symposium on Gliomas and Secondary Brain Tumors, Philadelphia, PA, November 2009.

544. Non Small Cell Lung Cancer: Tumor Volume Delineation, 31st Annual Conference of the Association of Radiation Oncologists of India, ICRO Workshop on Tumor Volume Delineation for IMRT, Hyderabad, India, November 2009.

545. New Technologies: Tomotherapy, 31st Annual Conference of the Association of Radiation Oncologists of India, Hyderabad, India, November 2009.

546. EGFR Inhibitors, Combination with Radiotherapy and Chemotherapy: Merck Satellite Symposium, 31st Annual Conference of the Association of Radiation Oncologists of India, Hyderabad, India, November 2009.

547. Malignant Brain Tumors: Tailoring Therapeutic Choices, 31st Annual Conference of the Association of Radiation Oncologists of India, Hyderabad, India, November 2009.

548. Neuro Symposium: NCCN Guidelines & Case-Based Discussion, 31st Annual Conference of the Association of Radiation Oncologists of India, Hyderabad, India, November 2009.

549. The Clinical Power of Tomotherapy Today and a Vision for the Future, 31st Annual Conference of the Association of Radiation Oncologists of India, Hyderabad, India, November 2009.

550. Evolution of Tomotherapy. Prince Court Hospital Tomotherapy Opening Ceremony and Dedication, Kuala Lumpur, Malaysia, November 2009.

551. Steretotactic Radiosurgery: Linac and Tomotherapy. National Cancer Institute, Natioanl General Hospital, Kuala Lumpur, Malaysia, November 2009.

552. Clinical Applications of Tomotherapy. Malaysian Oncological Society, Putra Jaya, Malaysia, December 2009.

553. Tomotherapy: Present and Future. Penang and Northern Region Oncology Meeting, Penang, Malaysia, December 2009.

554. Radiotherapeutic Management of Astrocytoma: University Interdisciplinary Conference, Madison, WI, February 2010.

of

Wisconsin,

555. Management Options for NSCLC: McGill University Meet-the-Professor Resident Symposium, Montreal, Quebec, Canada, February 2010 (Visiting Professor).

556. Tomotherapy Evolution and Clinical Applications: Intensifying Treatment for Non Small Cell Lung Cancer, Montreal Interhospital Symposium, Montreal, Quebec, Canada, February 2010.

557. Controversies in Neuro-Oncology, An Academic/Community Forum: Controversies in the Management of Cerebral Metastases, AANS/CNS Tumor Section, Online Webinar, March 2010.

558. Molecular Genetic Markers for Personalizing Radiotherapy for Gliomas, Neurosurgery Grand Rounds, University of Wisconsin, Madison, WI, March 2010.

559. Management Strategies for Malignant Gliomas: Chemoradiation for GBM, 4th Multidisciplinary Neuro-Oncology Symposium, Turkish Oncology Society Group, Istanbul, Turkey, April 2010.

560. Brain Metastases: Novel Radiotherapy Approaches, 4th Multidisciplinary NeuroOncology Symposium, Turkish Oncology Society Group, Istanbul, Turkey, April 2010.

561. Tomotherapy Clinical Trials: Americas Tomotherapy Users’ Education Forum, San Diego, CA, April 2010.

562. Advances in Radiation Therapy, Brain Tumor Caregivers’ Conference, University of Wisconsin, Madison, WI, May 2010.

563. The Evidence for Focused Therapies vs. Whole Brain Radiotherapy. 2010, American Association of Neurologic Surgeons’ Meeting, Philadelphia, PA, May 2010.

564. Clinical Trial Advances, European Tomotherapy Users’ Group Meeting, Malaga, Spain, May 2010.

565. Management of Brain Metastases in Lung Cancer Patients, ASCO Annual Meeting, Chicago, IL, June 2010.

566. An Approach to Personalizing Radiotherapy: Molecular Markers, Molecular Imaging, Advanced Delivery Methods, and Theragnostic Radiation Oncology.

Emory University, Atlanta, GA, June 2010.

567. Radiotherapy for Gliomas. MSD Current Trends in Glioma, Tokyo, Japan, July 2010.

568. Psuedoprogression. MSD Current Trends in Glioma, Tokyo, Japan, July 2010.

569. Current Perspectives in Adult Glioblastoma. Robert Michael Educational Institute CME Program, Baylor Medical School-Dallas, TX, August 2010.

570. Management of Adult Low Grade and Malignant Gliomas. Hong Kong Clinical Oncology Training Course, Queen Elizabeth Hospital, Hong Kong, China, September 2010.

571. Options for Advanced Stage III Non Small Cell Lung Cancer. Hong Kong Clinical Oncology Training Course Queen Elizabeth Hospital, Hong Kong, China, September 2010.

572. Brain Metastases. Hong Kong Clinical Oncology Training Course, Queen Elizabeth Hospital, Hong Kong, China, September 2010.

573. Non-Small Cell Lung Cancer-Tumor Volume and Normal Tissue Delineation. Hong Kong Clinical Oncology Training Course, Queen Elizabeth Hospital, Hong Kong, China, September 2010.

574. Case Magement Series: GBM, Anaplastic Oligodendroglioma, Skull Base Chordoma, and Advanced Non Small Cell Lung Cancer. Hong Kong Clinical Oncology Training Course, Queen Elizabeth Hospital, Hong Kong, China, September 2010.

575. IMRT Applications for Lung Cancer. Hong Kong, China, September 2010.

576. Non Small Cell Lung Cancer Treatment Advances. Yonsei University Medical Center, Seoul, Korea, September 2010.

577. Integrating Radiotherapy with Advances in Imaging and Molecular Biology. 1st Samsung Cancer Center Symposium: Shaping Future Cancer Medicine, Samsung Comprehensive Cancer Center, Seoul, Korea, September, 2010.

578. Management of Adult Low Grade and Malignant Gliomas. Samsung Comprehensive Cancer Center, Seoul, Korea, September 2010.

579. ASTRO Brain Metastases Guidelines Panel (Panel 17), ASTRO, San Diego, CA, October 2010.

580. Is More Imaging Better in Radiation Oncology, Point-Counterpoint Panel, RSNA, Chicago, IL, November 2010.

581. Radiation Therapy for CNS Metastases: What Should the Standard Approach Be? 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 2010.

582. Integrating Advanced Technology in the Management of Non Small Cell Lung Cancer, University of Texas, San Antonio, San Antonio, TX, December 2010 (Visiting Professor).

583. Optimizing and Personalizing Radiotherapy for Brain Tumors, Brain Tumor Institute, Northwestern University, Chicago, IL, December 2010.

584. Integrating Advanced Technology in Managing NSCLC, Grand Rounds, Lurie Cancer Center, Northwestern University, Chicago, IL, January, 2011.

585. IMRT: Methods, Evolution and Applications in Radiotherapy.

Hospital, Wonju, S Korea, February, 2011.

Wonju Christian

586. Up-to-date Experience with Helical Tomotherapy. Yonsei Medical Center Special Symposium, Seoul, S Korea, February, 2011.

587. Current Management of GBM: How Did We Get Here?

Scientific Symposium, Wallingford, CT, March 2011.

588. Role of Radiotherapy in Managing Myeloma.

Cancer Center Center, Chicago, IL, March 2011.

Bristol Myers Squibb

Northwestern Hospital and Lurie

589. Brain Metastases Issues Relevant to Medical Oncologists. First Elekta Medical Advisory Board Summit: Brain Metastases Gaps and Opportunities, Chicago, IL, March 2011.

590. Update on Clinical and Dosimetric Trials of Tomotherapy, Americas Usersâ&#x20AC;&#x2122; Education Symposium, Charleston, SC, March 2011.

591. Imaging and Molecular Tools Are Moving us Toward Personalizing Radiotherapy for Brain Tumor Patients: Reality or Pipedream? University of Pittsburgh Neurosurgery Grand Rounds, March 2011.

592. Radiation Oncology: Primer to Promise, Northwestern University Radiology Core Curriculum Lecture Series, Northwestern University, Chicago, IL, March 2011.

593. Radiation for Prevention and Treatment of Brain Metastases in Lung Cancer, Webinar hosted by Global Resource for Advancing Cancer Education and LUNGevity, April 2011.

594. Advanced Technology In Lung Cancer, Chicago Radiological Society, Annual Meeting, Chicago, IL, April 2011.

595. RTOG Brain Tumor Clinical Trials, NCI-CTEP, Brain Tumor Steering Committee Meeting, May 2011.

596. Personalizing Radiotherapy Approaches for Patients with Brain Tumors, Keynote Adress, 2011 Florida Brain Tumor Biomedical Technology Summit, Florida Center for Brain Tumor Research of the University of Florida, Orlando, May 2011.

597. IMRT Evolution and Applications, University of Khon Kaen, Khon Kaen, Thailand, May 2011.

598. Current Experience with IMRT, National Cancer Center, Singapore, May 2011 (Visiting Professor).

599. Stereotactic Body Radiotherapy for Lung Cancer, 15th Congress of the ASEAN Association of Radiology, Singapore, May 2011.

600. Stereotactic Radiosurgery for CNS Tumors, 15th Congress of the ASEAN Association of Radiology, Singapore, May 2011.

601. Brain Metastases: Clinical Trials Outcomes, and Techniques of Radiotherapy, ASCO, Chicago, IL, June 2011.

602. Management of GBM: ASCO 2011 Updates: Chinese Regional Meeting, ASCO, Chicago, IL, June 2011.

603. Lessons learned from IG-IMRT, and the Need for Technology Testing, III Congress of ALATRO Meeting, Panama City, Panama, June 2011.

604. Lung Cancer Oligometastatic Disease: Brain Metastases. 14th World Conference on Lung Cancer, Amsterdam, Netherlands, July 2011.

605. Whole Brain Radiation Therapy after Surgery/Stereotactic Radiosurgery, Second International Symposium on Long-Term Control of Metastases to the Brain and Spine, Cleveland, OH, September 2011.

606. Radiosurgery-Where is the Field Going? A Radiation Oncologistâ&#x20AC;&#x2122;s Perspective, Elekta Expert Forum, Stockholm, Sweden, September 2011.

607. RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-Dense (dd) Schedule for Glioblastoma (GBM), ECCO/ESMO Stockholm, Sweden, September 2011.

608. Glioblastoma, Clinical Trials Radiotherapy Advances, ECCO/ESMO Stockholm, Sweden, September 2011.

609. RTOG 0525: Clinical Data Overview, Merck Oncology Ex-US Primary Brain Tumor Expert Input Forum, Stockholm, Sweden, September 2011.

610. Treatment of Medically Marginal or Inoperable Patients with Early Stage NSCLC, Northwestern University Thoracic Oncology Symposium 2011, Chicago, IL, October 2011.

611. Unresectable Disease: Combined Modality Therapy: Chemo/Radiation/Targeted Therapy - Northwestern University Thoracic Oncology Symposium 2011, Chicago, IL, October 2011.

612. Oligometastatic Disease: Brain Metastases, Northwestern University Thoracic Oncology Symposium 2011, Chicago, IL, October 2011.

613. Current Treatment Strategies and Outcomes After Radiosurgery for Brain Metastases, 6th Annual Northwestern University Radiosurgery Symposium, Chicago, IL, October 2011.

614. Personalizing Radiotherapy for Brain Tumor Patients, MD Anderson Cancer Center, Visiting Professor Lecture, Houston, TX, October 2011.

615. Case-Based Evidence-Driven Decision Making in Low Grade Gliomas, MD Anderson Cancer Center, Visiting Professor Lecture, Houston, TX, October 2011.

616. Case-Based Evidence-Driven Decision Making in Brain Metastases, MD Anderson Cancer Center, Visiting Professor Lecture, Houston, TX, October 2011.

617. Non-Surgical Management of Early Stage Non-Small Cell Lung Cancer, MD Anderson Cancer Center, Visiting Professor Lecture, Houston, TX, October 2011.

618. Role of Radiosurgery in the Management of Brain Neoplasms, St. Mary Hospital CME Lecture, Chicago, IL, November, 2011.

619. The Impact of New Data on Optimizing the Standards of Care in Newly Diagnosed Glioblastoma: Expert Perspectives on Current Standards of Care and Novel Approaches, a priME Oncology Satellite Symposium, Society of Neuro-Oncology Annual Meeting, Garden Grove, CA, November 2011.

620. Treatment Considerations for a Patient with Newly Diagnosed Glioblastoma: Expert Perspectives on Current Standards of Care and Novel Approaches, a priME Oncology Satellite Symposium, Society of Neuro-Oncology Annual Meeting, Garden Grove, CA, November 2011.

621. Treatment Considerations for a Patient with Recurrent Glioblastoma: Expert Perspectives on Current Standards of Care and Novel Approaches, a priME Oncology Satellite Symposium, Society of Neuro-Oncology Annual Meeting, Garden Grove, CA, November 2011.

622. RTOG Brain Tumor Clinical Trials, Society of Neuro-Oncology Annual Meeting, Garden Grove, CA, November 2011.

623. Lessons from Radiation Oncology Clinical Trials: CNS, NCI Clinical Trials Workshop, Rockville, MD, December, 2011.

624. Management Issues in Brain Metastases Patients, Northwestern University Gynecologic Onocology Seminar, Chicago, IL, December 2011.

625. Role of Radiotherapy in Managing Gliomas, Northwestern Brain Tumor Institute Outreach Lecture, Lake Forest Hospital, Lake Forest, IL, January 2012.

626. Regarding the Merits and Challenges of Whole Brain RT and SRS, 2012 SRS/SBRT Scientific Meeting, Carlsbad, CA, February 2012.

627. RTOG 0525: Primary Outcomes and Implications. Current Trends Latin America 2012: Expert Perspectives on Standards of Care and Novel Approaches, Buenos Aires, Argentina, March 2012.

628. Imaging Challenges in Response Assessment. Current Trends Latin America 2012: Expert Perspectives on Standards of Care and Novel Approaches, Buenos Aires, Argentina, March 2012.

629. Utility of the Gamma Knife and Cyberknife in GBM. Current Trends Latin America 2012: Expert Perspectives on Standards of Care and Novel Approaches, Buenos Aires, Argentina, March 2012.

630. Personalizing Treatment Approaches for Brain Tumor Patients.

Chicago, Neurosurgical Grand Rounds, Chicago, IL, March 2012.

University of

631. Integrating Biological and Physical Advances to Improve Radiotherapy Outcomes.

University of Maryland Radiation Oncology Visiting Professor Grand Rounds, Baltimore, MD, March 2012.

632. Changing Therapeutic Perspectives for Early Stage NSCLC. Ohio State University, Radiation Oncology Visiting Professor Grand Rounds, Columbus, OH, April 2012.

633. Radiotherapy for Early Stage Lung Cancer. Chicago Area Radiation Therapistsâ&#x20AC;&#x2122; 35th Annual Conference, Chicago, IL, April 2012.

634. Updated Results of RTOG 9402: RTOG Semi-Annual Sumer Meeting, Plenary Session, Philadelphia, PA, June 2012.

635. Chemoradiotherapy for Anaplastic Oligodendroglioma, ASTRO Journal Club, Chicago, June 2012.

636. Neuroimaging and Radiosurgery: AANS/ASTRO Stereotactic Radiosurgery Course for Neurosurgery and Radiation Oncology Residents, Evanston, IL, August 2012.

637. Breast-to-Brain Working Group Presentation and Discussion: Preclinical and Clinical Development of Radiosensitizers, NCI, NIH, Rockville, MD, August 2012.

638. Multidisciplinary Care in Glioma Patients: Japan Glioma Update Meeting, Tokyo, Japan, August 2012.

639. Radiation Therapy for Malignant Glioma: Japan Glioma Update Meeting, Tokyo, Japan, August 2012.

640. Endpoints in Brain Metastases Trials and Phase I ABT888 Results: Abbott Investigator Meting for Phase II Brain Metastases Trial Launch, Rosemont, IL, September 2012.

641. Radiosurgical Management for Meningiomas: 7th Annual Northwestern Radiosurgery Symposium: Multimodality Approach to Cranial Radiosurgery & Stereotactic Body Radiation Therapy, Chicago, IL, September 2012.

642. Whole Brain Radiation Therapy for Brain Metastasis: 14th Annual Brain Tumor Update and 3rd Annual International Symposium on Long-Term Control of Metastases to the Brain, Las Vegas, NV, September 2012.

643. Controversies in Management of Brain Metastases: Surgery with Whole Brain Radiation Therapy vs. Surgery Followed by Radiosurgery to the Surgical Cavity, 14th Annual Brain Tumor Update and 3rd Annual International Symposium on LongTerm Control of Metastases to the Brain, Las Vegas, NV, September 2012.

644. The Role of the Gamma Knife in an Era of Targeted Therapy: Elekta Users’ Meeting, ASTRO 2012, Boston, MA, October 2012.

645. The Effect of Tumor Subtype on the Time from Primary Diagnosis to Development of Brain Metastases and Survival in Women with Breast Cancer, ASTRO 2012, Boston, MA, October 2012.

646. CNS Tumor Board: Management of Primary Glioblastoma Multiforme, Satellite Symposium, 17th Annual Meeting of the Society of Neuro-Oncology, Washington D.C., November 2012.

647. Gamma Knife Center Tilburg, 10 years and 5000 patients later: Controversies in Radiosurgery: Radiosurgery should be limited to patients with 3 metastases: Yes, Amsterdam, Netherlands, November 2012.

648. Proton Radiotherapy: Is It Worth the Hype? 2012 Annual RSNA Meeting, Chicago, IL, November 2012.

649. Cognitive Sequalae of Brain Radiotherapy.

Chile, December 2012.

650. Management of Brain Metastases.

December 2012.

2012 SONEPSYN Congress, Valdivia,

2012 SONEPSYN Congress, Valdivia, Chile,

651. Fractionated Radiotherapy for Meningioma. 2012 SONEPSYN Congress, Valdivia, Chile, December 2012.

652. “Best of 2012”: CNS and Pediatric Tumors. University of Maryland Annual “Best of” Symposium, Baltimore, MD, January 2013.

653. Tumors of the Central Nervous System. ASTRO Spring Refrsher Course, Chicago, IL, (ABR-certified SAM activity), March 24 2013.

654. What’s New in the Controversy Regarding Whole Brain Radiation Therapy for Multiple Brain Metastasis? Northwestern University, 8th Annual Northwestern Radiosurgery Symposium, May 31 2013.

655. Central Nervous System Metastasis and Lung Cancer: Management Challenges: New Possibilities For Radiation After Initial Treatment, ASCO Meet the Professor Session, Chicago, IL, June 1 2013.

656. Update on NSCLC Brain Metastases Treatment, Abbvie Oncology, Chicago, IL, June 2 2013.

657. Discussant for RTOG 0825, 0424, and 0227: RTOG Semi-Annual Sumer Meeting, Plenary Session, Philadelphia, PA, June 15 2013.

658. Issues in Lung Cancer Radiotherapy, 6TH International Conference on Pulmonary Imaging, Madison, WI, July 19 2013.

659. “Difficult Cases in CNS” ASTRO Educational Session, ASTRO, Atlanta, GA, September 25 2013.

660. CNS Technologies and Debate, New York Roentgen Society meeting, NY, NY, October 11 2013.

661. CNS Cases and Discussion, New York Roentgen Society meeting, NY, NY, October 11 2013.

662. Radiotherapy of Brain Metastases: standards of care and novel approaches, Serono Symposia International Foundation Central Nervous System (CNS) Malignancies Vienna, Austria, October 25 2013.

663. Radiation Therapy for Brain Metastasis: 15th Annual Brain Tumor Update and 4th Annual International Symposium on Long-Term Control of Metastases to the Brain, Las Vegas, NV, November 9 2013.

664. Controversies in Management of Brain Metastases: Surgery with Whole Brain Radiation Therapy vs. Surgery Followed by Radiosurgery to the Surgical Cavity, 15th Annual Brain Tumor Update and 4th Annual International Symposium on LongTerm Control of Metastases to the Brain, Las Vegas, NV, November 9 2013.

665. Proton Therapy for Brain Tumors: 15th Annual Brain Tumor Update and 4th Annual International Symposium on Long-Term Control of Metastases to the Brain, Las Vegas, NV, November 10 2013.

666. CNS Cancer Tumor Board: Clinical Investigators Provide Perspectives on Current Cases from Their Practices, Industry Supported Symposium, 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, San Francisco, CA, November 21 2013.

667. What Have we Learned from Clinical Trials on Radiation Therapy? Brain Metastases, Sunrise Session, 4th Quadrennial Meeting of the World Federation of NeuroOncology, San Francisco, CA, November 24 2013.

668. Clinical Trial Development for CNS Metastatic Breast Cancer: Achievements and Challenges: Breast Cancer Central Nervous System Metastases: A Strategic Approach to Integrating Local and Systemic Therapies, Clinical Problems in Oncology Session, Chicago, IL, ASCO 2014 (5/31/2014 8:00AM - 9:15AM).